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ABSTRACT 
 
Background: Chronic diseases have increased worldwide. Despite the significant advances in 
medical science, the management of chronic diseases continues to be poor.  To meet this 
challenge, we need to try to implement existing chronic illness models of prevention, early 
detection, and risk factor management. This is achievable in part by linking primary health care 
clinicians, such as primary health care nurses (PHCNs) and hospital-based medical specialists.  
This study evaluated a ‘real life’ chronic disease outreach program (CDOP), which assisted 
PHCNs with the early detection and management of chronic illnesses known to cause chronic 
kidney disease (CKD) and cardiovascular disease (CVD). PHCNs are critical in the management 
of chronic illnesses but they require ongoing support of and links with specialists. This will 
ensure that current guidelines reach the people receiving primary health care (PHC) and 
detection of those needing referrals. 
Aims: The study aimed to determine if CDOP was an effective method for the early detection 
and management of diabetic and hypertensive patients at high risk for complications like stroke, 
ischaemic heart disease and CKD. It also aimed to evaluate the PHCNs’ knowledge and 
motivation, and to elucidate the challenges facing the current health system in the management 
of patients with chronic conditions.  
Methods: Patients at risk for complications were enrolled for increased monitoring and clinical 
support and management, at 20 clinics in Soweto, South Africa (SA). CDOP used a paper-based 
support and patient care system, modelled on the Wagner Chronic Illness Care Model (CICM).  
The components for evaluation included: (i) Focus on monitoring functional and clinical 
outcomes  (ii) Health system interventions, such as increased ‘decision support’ and the 
development of a ‘prepared motivated health care team’ and (iii) Enhancing PHCNs’ knowledge 
and motivation. The evaluation followed the various elements of the Wagner CICM, as well as 
drawing on the WHO Innovative Care for Chronic Conditions (ICCC) Framework. A cohort 
analysis of functional and clinical outcomes in enrolled patients was conducted. PHCN 
knowledge and motivation was assessed through self administered questionnaires. Health 
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worker knowledge was evaluated through the use of case scenarios and multiple choice 
questions. On the theme of health worker motivation, Franco’s model, with Penn-Kekana’s 
adaptation, was used to develop the questions and analyse diary recordings. Diary recordings of 
PHCNs and meetings with regional and provincial health managers’ discussions were collected 
by CDOP staff during follow-up focus groups and feedback meetings. Diaries were analysed 
thematically.  The CDOP evaluation is thus a triangulated analysis of clinical and functional 
outcomes, diary recordings, and the self-administered questionnaire.  
Results: The CDOP ran from 2003-2006, during which time 618 patients (61% females, 39% 
males) deemed at risk of CKD or CVD were enrolled; 55% had uncontrolled hypertension (HTN), 
45% DM with HT and/or proteinuria. Patients were followed for 2 years. In total, 108 patients 
completed 2 years of follow up, most of whom were referred for specialist support (n=69, 11%), 
more intensive medication regimes or because were not available in the PHC system. Most did 
not require referral (515, 82%), 35 (6%) were referred but never arrived at the hospital and 6 
(1%) died. Twelve percent had advanced CKD, 2% required dialysis, 6.9% required medications 
not available to primary care clinics, and 1% died. As a tool to detect those needing referral, the 
program was successful. The sensitivity and specificity for detecting those needing referral was 
95% and 100%, respectively.. However, although PHCNs were able to detect high risk patients, 
not all those referred arrived at the hospital.  Hypertension, blood glucose, cholesterol and 
proteinuria control significantly improved in those followed (p<0.01) over 2 years, but no 
improvement was noted with weight control. Importantly, proteinuria and kidney function, in 
patients with static stable renal function, measured by estimated GFR equations and urine 
dipstick or albumin creatinine ratio (ACR), did not worsen significantly. Of the remaining 510 
patient enrolled but not followed up, 213 (35%) were reabsorbed into the routine clinics, and a 
further, 123 (20%) of patients enrolled were lost to follow up completely. The diary recording 
thematic analysis revealed the problem of poor patient follow up, attributed to the poor existing 
health system in the clinics, competing demands on PHCNs, staff shortages, high staff turnover, 
and the low motivation and morale of clinicians. The analysis of the health worker questionnaire 
showed improved motivation and statistically better knowledge in those PHCNs involved with 
CDOP compared to those who were not exposed to the program (p<0.0034). 
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 Conclusions: CDOP was successful in supporting PHCNs, detecting patients with advanced 
disease and ensuring their early referral. Such programs are able to correctly detect people with 
disease, but this is dependent on the health and program systems being intact. It also improved 
patient risk factor control in the sub-set of referred patients and impacted on PHCNs’ existing 
knowledge and motivation for caring for patients. Its weaknesses were related to the poor 
existing health systems and infrastructure, and the poor integration of chronic illness care in the 
region. The PHC clinics had poor follow up compared with that in the hospital setting. The study 
also revealed an overworked, poorly supported, and frustrated primary health care team. This 
was despite the fact that the PHCNs were willing and motivated to deliver a good service.  
 
  
vii 
PREFACE  
The Chronic Disease Outreach Program (CDOP) began its life in a highly specialised 
renal unit of a tertiary hospital, located in Soweto, South Africa. The program was driven by the 
fact that many patients developing end stage renal failure (ESRD) in Soweto are not offered 
dialysis or transplantation. This is because of the scarce resources and an established protocol 
that limits access onto renal replacement therapy (RRT) programs. After learning about an 
Australian program for Indigenous populations, and recognising similarities between the 
communities, it was decided to establish an early detection strategy in Soweto. This program 
aimed to provide nephrologists with an alternative to refusing people dialysis and intervening 
downstream from the problem. Its focus on primary and secondary prevention, aimed to prevent 
people developing ESRD, or to facilitate early detection of ESRD and provide appropriate 
interventions to prevent early death from cardiovascular disease (CVD). The Chronic Disease 
Outreach Program (CDOP) would also link the primary and tertiary care systems.  
 The program was established jointly with the Directorate for Chronic Disease of the 
Johannesburg Metropolitan Health Department (JMHD) in 1999. It was inspired by, modelled on 
and motivated by the CDOP in Australia, but its introduction in Soweto required adaptation and 
significant scaling up. The Australian CDOP was developed in response to an ‘epidemic’ of 
chronic kidney disease and cardiovascular disease in indigenous Australians. This same 
epidemic was suspected as being a problem in communities in South Africa, particularly in 
disadvantaged communities such as in Soweto and Southern Gauteng. This was confirmed by a 
pilot CDOP study (Phase 1), conducted from 1999 to 2003, known as the Primary Prevention 
Program (PPP). The pilot program informed this study, known as the ‘paper based’ version of 
CDOP or Phase 2. The program has since developed into a ‘web based’ version, Phase 3, not 
discussed in this thesis (https://www.medicaldatabanks.net/cidoppp/).  
Initially, as indicated above, the program was referred to as the Primary Prevention Program, 
where the term ‘primary’ referred to the primary health care setting where the program was 
implemented. In public health terms, the program was developed around secondary prevention 
but did include some aspects of primary prevention with respect to patient education. However, 
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the motivation of CDOP was not only about prevention among indigenous people in Australia 
and South Africa (SA) who could not afford expensive technologies. Instead it provided an 
opportunity to establish an argument for good secondary prevention, which is a good practice in 
any health system.   
The program in SA was tailored around resource realities, and included the use of simple 
diagnostic techniques for early detection and vigorous treatment to prevent the development of 
ESRD. A screening method to detect people with CVD and CKD, and attempting to arrest the 
disease process among an African population, needed to be developed, implemented and 
evaluated. Soweto and its surroundings reflect a typical setting of Black Africans. Like Australian 
Aboriginal people, black South Africans have suffered under colonialism, discrimination, 
marginalisation and inequality.  
The impetus to start this program, for South Africans in Soweto, began in 1996 when I 
met Wendy Hoy, the Australian CDOP creator, at an African Association of Nephrology (AFRAN) 
meeting in Abidjan, Ivory Coast. At this meeting Professor Hoy presented compelling evidence 
indicating the effectiveness of her program in reducing deaths and dialysis starts (Hoy et al., 
2000, Hoy et al., 2003b). The program took place in a small Australian Aboriginal community of 
2000 people on the Tiwi Islands of the Northern Territory. Compared with European Australians, 
Aboriginal Australians in the Northern Territory require a disproportionate amount of dialysis. 
The program aimed to reduce the number of people requiring dialysis, an expensive treatment 
for the ‘end stage’ of chronic kidney disease (CKD). Prevention strategies had not been 
developed in these areas and, at least, secondary prevention strategies were an attractive 
option. Hoy’s program not only resulted in a decrease in the number of people starting dialysis 
but also in a reduction of ‘all cause’ mortality from cardiovascular disease (CVD), such as 
strokes and heart failure, because it targeted the primary causes of ESRD i.e. diabetes  (DM) 
and hypertension (HTN). The benefits of renoprotection have the benefit of all risk 
cardiovascular protection. The program has since expanded elsewhere in Australia, an outreach 
program, run in a  context of disadvantage and social transition, similar to that of most black 
South Africans (Hoy et al., 2003a). 
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The possibility of a similar program in Soweto was even more compelling because of the 
sophisticated primary health infrastructure developed around Chris Hani Baragwanath Hospital 
(CHBH). This hospital is a tertiary, academic teaching hospital on the outskirts of Soweto. The 
latter is an extensive collection of suburbs to the Southwest of Johannesburg, established as a 
result of the forced removal Apartheid policies of the former Nationalist Government. The clinics 
were developed following the 1976 ‘uprising,’ with the aim to win back ‘the hearts and minds’ of 
the local black population. Although the ‘uprising’ was concerned firstly with the language policy 
in schools, it was interpreted more generally as a rise against Apartheid policies. After the 
protest the government sought to create a façade of improving the quality of life and living 
conditions of people in Soweto.  As a result, numerous primary health care clinics were 
established. The Soweto-based South African CDOP program took advantage of this fact.  
A major challenge was whether a program such as Wendy Hoy’s could be scaled-up in 
Soweto, with a population of between one to two million and an average chronic disease clinic 
population (HTN and DM) of 2000 to 4000 people per clinic, compared with the total Tiwi 
population of 2000 people. The Soweto program aimed also to develop the program using 
established chronic illness models, and to draw on the knowledge and experiences of 
nephrologists running CKD prevention and early detection programs elsewhere in the world. 
This thesis is an evaluation of this experience to establish a CDOP program in Soweto and 
Southern Gauteng. 
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1 INTRODUCTION 
Rationale and Approach for Chronic Disease Outreach Program 
No nephrologist working in a developing world setting can provide care for all those 
people in the community who develop end stage renal disease (ESRD). Many people developing 
ESRD in South Africa  are offered neither dialysis nor transplantation, i.e. renal replacement 
therapy (RRT), because of scarce resources and established protocols for accepting only 
patients without significant co-morbid disease onto the RRT programs (Moosa and Kidd, 2006, 
Dirks and Levin, 2006). When the program on which this thesis is based was conceptualised, 
there was a need to establish an early detection and prevention strategy to provide 
nephrologists with an alternative to prevent people developing ESRD or early death from CVD. 
CDOP provided the opportunity of early detection through screening high risk patients with HTN 
and DM. It provided a link between the primary and tertiary care health systems. The initiation of 
this program was an attempt to start changing the approach of managing chronic illnesses in 
Soweto. This included highlighting the future challenges of initiating similar programs, which 
includes scaling up a program and motivating primary health care clinicians to participate..  The 
improved recognition of kidney disease globally can be attributed to some important 
developments, which included re-defining and re-classifying CKD, culminating in a coherent 
conceptual model of kidney disease (National Kidney Foundation, 2002, Levey et al., 2003, 
Levey et al., 2005) (As illustrated in Figure 1). 
A key reason for the new definition of kidney disease and the model is that CKD 
encompasses a range of conditions, including its early forms and final failure. This definition 
highlights the natural history of CKD, providing a systematic description of the course of the 
disease over time unaffected by treatment. CKD staging highlights the phases of susceptibility 
and increased risk. It has brought focus on the pre-clinical phases, where kidney disease has 
begun but is asymptomatic. The earlier manifestations may include HTN, proteinuria or reduced 
kidney function, but the presence of disease may not be identified unless a clinician screens for 
it. Unfortunately, when a person reaches the ‘clinical phase’ of kidney disease, it is usually too 
late to impact on its progression. 
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Figure 1. Conceptual Model of Chronic Kidney Disease 
Note: The model covers the course of CKD and the therapeutic strategies. Shaded ellipses represent 
stages of CKD; unshaded ellipses represent potential antecedents or consequences of chronic kidney 
disease. Thick arrows between ellipses represent risk factors associated with the initiation and 
progression of disease that can be affected or detected by interventions. Interventions for each stage are 
given beneath the stage. ‘Complications’ refer to all complications of chronic kidney disease and its 
treatment, including complications of decreased GFR (HTN, anaemia, malnutrition, bone, and mineral 
disease) and cardiovascular disease. Increasing thickness of arrows connecting later stages to 
complications represents the increased risk of complications as kidney disease progresses (Levey et al., 
2007a). 
 
 
At the final stages, a person may present in a ‘uraemia’ state, with symptoms of vomiting, 
confusion and fluid overload.  In this state, the chances of recovery or remission are unlikely and 
the person will require preparation for dialysis or transplantation. These expensive therapies are 
often unavailable in developing countries and are very costly in general (Barsoum, 2006).   
This new knowledge of the development and progression of kidney disease served to  highlight 
the problem, leading to greater awareness of the burden of kidney disease and understanding of 
factors influencing its progression and outcome (Coresh et al., 2003, El-Nahas, 2004).  Most 
kidney disease specialists have focussed on kidney disease phases specifically. To a large 
extent, this is driven by funding from pharmaceutical companies or Kidney Foundations, but also 
by the general lack of awareness that kidney disease is fundamentally a genuine public health 
problem  (Schoolwerth et al., 2006, El Nahas and Bello, 2005, Levey, 2006). Some programs 
have focussed on screening people at highest risk for CKD, which would include those with DM 
Healthy 
Population
Risk or
Initiation
Factor
Progression Factors Disease
CKD as a risk factor for adverse outcomes
of chronic disease e.g. HTN, DM, HIV
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and HTN, but also other susceptibility and risk factors such as obesity, dyslipidaemia and race. 
However, in general these programs have failed to cross the divide to true integrated prevention 
and cure. They have not been able to highlight the closeness of the challenge facing chronic 
non-communicable and communicable diseases, both of which require ongoing treatment. They 
have also not highlighted the close link between CVD and CKD. 
 Whilst these studies have detected those at risk, highlighted the problem and shown us 
what can be done, they have not necessarily answered the challenge of implementation and 
delivery on a large scale, especially in developing countries. They have also not elucidated the 
necessary changes required to existing health systems. The improved focus on CKD as a public 
health problem and better detection of those with disease should be met with an improved 
system of integrating prevention and treatment within the existing health system. This type of 
integration needs to find its way into the mainstream practices of kidney disease management. 
Unfortunately, in chronic illness care primary and secondary preventive roles tend to be 
separated. Clinicians continue to see their role as treating those already sick, rather than 
preventing illnesses. An associated problem includes the fact that the definition of prevention 
has also become quite confusing (Starfield et al., 2008), often incorporating established disease 
and this includes kidney disease. An integrated system has good communication and 
coordination between different components of care (Bachmann, 2007). Vertical integration is 
about linking the different levels of care, linking primary care, the first point of first contact with 
the health service e.g. clinic or general practitioner, with secondary care,  the first level of care to 
which problematic cases are referred, e.g. regional hospital. If disease progresses or requires 
the next level of care, then patients are referred to the tertiary care level. In the case of severe 
renal dysfunction or end stage kidney failure, higher specialist care level referral to the regional 
dialysis unit would be required. An amalgamation of the conceptual model of CKD and its 
integration with the different levels of care in the health system is discussed further in Chapter 2.  
Figure 2 demonstrates its amalgamation with the public health levels of care and 
prevention strategies. This figure highlights the fact that any program hoping to tackle a chronic 
illness requires a well functioning health system,   including clear referral protocols and a sharing 
of clinical information.  Importantly horizontal integration of different curative and preventative 
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services is imperative.  Success in the area of coronary artery disease has been shown in 
Australia, England and the United States (Rose, 1981), yet despite the benefit of integration 
being clear, the approach has not been adapted to other settings. 
 
 
Figure 2. Linking Levels of Care and Prevention Strategies for CKD 
Adapted from KDIGO and Cuban conceptual models (Levey et al., 2007a, Almaguer et al., 2005). 
CKD – chronic kidney disease, GFR – glomerular filtration rate ml/min; ESRD – End Stage Kidney 
Disease or CKD stage 5 
 
 
Advances in medications and improved technical developments in dialysis have failed to 
resolve the growing burden of kidney disease. Countries around the world are challenged with 
problems of inadequate resources and treatments are extremely expensive. Figure 3 
demonstrates the low rate of acceptance onto RRT programs. 
Globally, there continues to be an increasing burden of chronic illnesses like HTN and 
DM. This means a greater number of people succumb to ESRD or die of cardiovascular 
complications with kidney disease (El Nahas and Bello, 2005). Developing countries have a dual 
burden of chronic non-communicable diseases like HTN and DM, and ‘chronic’ communicable 
diseases associated with kidney disease like HIV/AIDS. In the United States, HIV renal diseases 
is a common cause of ESRD in African Americans (Szczech et al., 2003). While no data exists 
for South Africa, HIV/AIDS is widely perceived by nephrologists to already be or soon to become 
the largest cause of ESRD in this country. The true numbers are difficult to determine, however, 
Population
Intervention
Strategy
Health 
Promotion
Primordial 
Prevention
Welfare Health Disease
Premature
Death
Primary 
Prevention
Secondary
Prevention
Tertiary
Prevention
Individual Intervention Strategy
Healthy
Population
Behaviour
Risk
Factors
Biological
Risk
Factors
CKD
Stage
1
GFR
>90
CKD
Stage
2
GFR
60-89
CKD
Stage
3
GFR
30-59
CKD
Stage
4
GFR
15-29
CKD
Stage
5 or 
ESRD
GFR
<15
Person
Family
Community
Hereditary – Social – Economic –
Environmental- Psychological -
Physical
Health Service and
Health Team
  
5 
because many patients with HIV are not referred for RRT because of restrictions on resource 
allocation (Fabian et al., 2007).   
 
Figure 3. Select Countries ESRD Prevalence, Incidence and Acceptance to RRT 
Note: Figure taken from Barsoum et al. NEJM, March 2006 
 
In developing countries, these problems are aggravated by higher rates of malnutrition 
and primary risk factors for chronic illnesses, e.g. obesity and smoking. So despite 
improvements in the early detection of kidney disease and our greater knowledge of treatment of 
established kidney disease, we are far from achieving any real success in reducing the burden 
of disease. 
A number of studies have highlighted that CKD is not only an unrecognised public health 
problem, but a marker of an even greater and also more recognised problem; cardiovascular 
disease (CVD) (Go et al., 2004, de Zeeuw et al., 2005, Parikh et al., 2006). In reality, these two 
major causes of morbidity and mortality are closely linked. Epidemiological surveys have 
highlighted that CKD and CVD share common susceptibilities and risk factors (Coresh et al., 
2007, Fox et al., 2004a) such as race, obesity, and proteinuria, HTN, DM and HIV.  Although the 
principles of prevention need to be tailored according to available resources, the emphasis in all 
settings needs to include simpler diagnostics, early detection with appropriate screening 
approaches, and vigorous treatment using primary health care clinicians rather than dialysis or 
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transplantation (Epping-Jordan, 2005). Kidney disease program strategies have highlighted that 
an integrated prevention strategy may have a major impact to improve outcomes for CKD and 
CVD (Rossert and Wauters, 2002, Hallan et al., 2006c). However, because CKD and CVD are 
so closely linked, it would be more sensible to focus more broadly on improving management of 
the chronic illnesses (Epping-Jordan, 2005, Beaglehole et al., 2007).   
There is, therefore, a need to move away from an organ specific focus and rather, to 
focus on all organs and specialities associated with a higher risk of CVD and CKD. This 
integrated strategy must be shared by all specialists involved in chronic disease care (e.g. 
cardiologists, nephrologists, endocrinologists and HIV specialists) and by primary health care 
clinicians (doctors and nurses). If we focus upstream of the end organ damage, then we will 
focus on the same problems. Risk factors like obesity, HTN and DM are as important to treat as 
the end point.  Certain medications, like angiotensin converting enzyme inhibitors (ACEi) and 
lipid lowering agents like statins, have proven particularly valuable for managing risk factors and 
diseases associated with CKD and CVD (Ruggenenti et al., 2001b, de Jong and Brenner, 2004).  
However, prevention and good primary health care  is not established without a cost, and 
programs for primary and secondary prevention require organizational skills and human skills to 
be established (Barsoum, 2006, World Health Organization, 2008). A first step is to establish the 
networks and build alliances among all clinicians addressing the problem of chronic illnesses at 
different levels in the health system. To achieve this we have to look to existing systems and 
models for managing chronic illnesses. The World Health Organization (WHO) has highlighted 
the approach of starting with simple strategies and adding to these with improved resources and 
skills. This comprises an initial focus on lifestyle measures (reducing tobacco smoking and 
obesity), and then moving to more specific measures such as proteinuria detection and 
ultimately dialysis and transplantation (Epping-Jordan, 2005, Epping-Jordan et al., 2005) . 
Immediate integration of the primary, secondary and tertiary health care sectors provides the 
links, support and integrated strategies for managing chronic disease, rather than focusing on 
one sector of public health as more important than another. 
One popular model adopted predominantly in the developed world, specifically by  the 
United States Family Medicine fraternity, is the Wagner Chronic Illness Care Model (CICM)  
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(Figure 4) (Wagner, 2004, Wagner et al., 2001). However, other models in developing countries 
have been successfully implemented for combating chronic infectious diseases. Such models 
include those used in Cambodia which integrated the management of HIV, diabetes and 
hypertension and improving PHC response to chronic NCDs (Janssens et al., 2007, Coovadia 
and Bland, 2008). The development of chronic care services that cut across conventional 
categories of infectious diseases and NCDs (Setel et al., 2004), and the incorporation of 
indicators of program outcomes and access to service are components used to measure 
program success.  Strategies for managing tuberculosis and HIV have included the use of 
evaluation and reporting treatment outcomes (Harries et al., 2008), and these models can be 
adapted for all NCDs, including CVD and CKD.  
 
 
 
 
Figure 4. Wagner Chronic Illness Care Model (CICM)  
 
This Chronic Illness Chronic Care Model  adds to the stepwise approach by 
acknowledging a health system paradigm shift when approaching ongoing chronic care. It 
recognises that the current dominant reactive health system – waiting for people to present with 
disease – does not deal with this contemporary challenge of chronic illnesses. In the Innovative 
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Care for Chronic Conditions Framework (ICCC), the WHO highlights the importance of the 
correct support for a health system, which includes better resources and policies to support 
chronic disease management.  CICM and ICCC, in essence, call for the same advances, an 
improved integrated method for managing chronic illnesses.  These models potentially provide a 
platform for the Rose Philosophy (Rose, 1981) of integrating prevention and treatment into a 
single platform, resulting in  improved knowledge to detect and manage CKD, and a better 
understanding of its close links with CVD. We have the skills to manage both problems by 
chronic illnesses programs for prevention, detection and management (Hoy et al., 2003c, de 
Jong et al., 2003, Brown et al., 2003b), We also need to tackle the problems of implementation 
and scaling up programs for managing chronic illnesses. This includes linking the tertiary 
specialist systems (hospitals) with the primary health system to develop a comprehensive 
strategy to manage chronic illnesses.  
Health systems have developed around the specific need of diseases prevalent at the 
time (World Health Organization, 2000a), primarily communicable, infectious diseases like 
measles, smallpox, malaria and poliomyelitis. Infant and child mortality and maternal mortality 
rates were, until the last 5-6 decades, very high. Health systems tended to develop around the 
typical and health care management, the ‘find it and fix it’ model (Epping-Jordan et al., 2004, 
Epping-Jordan, 2005), in which health providers waited for people to present with an acute 
illness to a hospital, clinic or general practitioner . This model acknowledges that our existing 
health system focuses far too much on specific specialised problems. The CICM model goes 
further, by arguing the need to reorganise our health systems, and improve decision support, 
communication and information to facilitate the management of chronic disease. These 
improvements would result in both the patient and health care team being more empowered to 
manage chronic diseases. Enabled, knowledgeable patients and health workers are essential 
requirements to improved patient adherence, follow up and clinical outcomes, as illustrated in 
the WHO Innovative Care for Chronic Conditions (ICCC) Framework (World Health 
Organization, 2002a) (Figure 5). 
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Figure 5.  Innovative Care for Chronic Conditions Framework 
Note: This model was developed by the World Health Organization based on the Wagner CICM model 
 
 
Contemporary societies face new burdens associated with lifestyle problems around 
tobacco use and poor nutrition and the development of chronic, non-communicable diseases 
(NCD). The shift was assumed to be from a high prevalence of infectious diseases (tuberculosis, 
malaria), in poorer societies, to a high prevalence of NCDs (hypertension, diabetes, cancers, 
obesity and cardiovascular disease) with economic development. ‘Health transitions’ are 
dynamic, complex and not easily simplified (Manderson, 2008), as evidenced by declining 
survival and deteriorating health conditions in some countries e.g. Zimbabwe, and the existence 
of high burdens of non-communicable diseases like diabetes, hypertension and obesity in 
communities in developed countries e.g. Aboriginal Australians.. Chronic illnesses currently are 
best defined as non-communicable diseases like heart disease, hypertension, diabetes, asthma 
and epilepsy (Couper, 2007), but now communicable disease like HIV/AIDS and TB could be 
included in the overall framework of chronic illnesses. Chronic illnesses are broadly defined as 
health problems that require ongoing management over a period of years or decades (World 
Health Organization, 2002a), or more specifically as illnesses that last longer than 3 months and 
are not self-limiting (Wagner et al., 2001). The transition from primarily communicable acutely 
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treatable disease to chronic illnesses requires a more integrated health system, able to deliver 
high quality care over time.  
The emergence and re-emergence of disease is often related to poor infrastructure, poor 
socioeconomic and physical conditions and where there has been an inability to provide 
accessible health services and sustainable disease control (Manderson, 2008). Over the past 
century, health systems have undergone overlapping generations of reforms but definitions and 
conceptual models of disease lag behind existing knowledge and practice.  
Kidney disease is not seen as part of the CVD continuum like coronary artery disease or 
stroke, nor is it seen as part of the continuum of chronic illnesses. It would be advisable to 
ensure that all chronic disease, like chronic kidney disease,  are included in order to achieve the 
goals of improved detection, management and outcomes (Schneider et al., 2006, Si et al., 2008, 
World Health Organization, 2000a) (see Figure 7). Health systems are defined as comprising all 
the organizations, institutions and resources devoted to producing health actions. A health action 
is defined as any effort, whether in personal health care, public health services or through 
intersectoral initiatives, whose primary purpose is to improve health (World Health Organization, 
2000a). We have to evolve these early health systems from their ‘radar’ like approach to a 
chronic ongoing integrated care model. Figure 6 explains the relationships and relatedness 
between the various chronic diseases and their early risk factors, which needs to be understood 
when developing services tackling these illnesses (Beavers and World Health Organization, 
2003). This figure highlights the commonality of risk factors such as hypertension, diabetes and 
obesity on the risk of developing chronic illnesses like chronic kidney and cardiovascular 
disease, with the resultant complications which could include ESRD and or a stroke. 
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Figure 6. An Integrated Model of Chronic Disease 
Note: The kidney is an organ which illustrates this ‘interactive model’ of chronic illnesses. Adapted from 
‘Healthcare Decision making in the Western Pacific Region:  diabetes and the care continuum in the 
Pacific Island Countries (Beavers and World Health Organization, 2003). 
 
Figure 6 also highlights the need for integrated and intersectoral initiatives which require 
health systems to be developed in a horizontal manner, focusing on common risk factors, 
preferably at the source, rather than vertically on specific illnesses or ‘organ systems’. Ideally, 
disease should be prevented in the community, through health education and other 
interventions, e.g. discouraging smoking or poor lifestyle resulting in obesity. It is often the case 
that a problem occurs before prevention can occur and a person’s first point of contact with the 
health service will be a primary health care (PHC) clinic. In these cases, interventions will be 
required to prevent the disease worsening, i.e. secondary prevention. In the case of DM, for 
example, good primary DM glucose control should prevent HTN or proteinuria. Either of these 
complications could increase the chances of disease progressing to CVD (strokes) or CKD (end 
stage renal disease). Secondary prevention intervention will also be required to prevent 
proteinuria progressing, such as initiating treatment with an angiotensin converting enzyme 
inhibitor (ACEi). The most cost effective method for secondary prevention would include a 
screening program in the community or clinic, and the education of primary health care 
providers. Often the knowledge and skills for best treatment reside in the tertiary specialist 
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referral centres, but the greatest impact for treatment rests at the first point of contact at the PHC 
clinic and with the primary care clinician.  
 
Background to Study Site 
This section provides an argument for the need to evaluate the extent of the burden of 
chronic illnesses in South African in general and specifically in Soweto. It highlights the 
importance of the PHC sector in dealing with this problem, providing the appropriate skills and 
support to PHC clinicians and an argument for developing a chronic disease outreach program.  
 In South Africa, and especially in Soweto, the nurses working in PHC clinics are known 
as the Primary Health Care Nurse (PHCN). They are most often the primary source of contact 
for most people who are ill and they form the backbone of primary health care in South Africa 
(Health Systems Trust et al., 1999). It was recognised in 1988, by Edelstein in Soweto, that  
nurses were not adequately or appropriately trained to meet the needs of primary care services. 
One of the most obvious gaps was the small number of nurses with post basic training in skills to 
diagnose and treat common complaints. To meet these needs, a number of post basic courses 
and in-service training programs were developed in South Africa (Health Systems Trust et al., 
1999). Many of these programs were highly effective, including the program developed by the 
Primary Health Care School in Soweto (Pein et al., 1999), which bridged the knowledge-skills 
gap left from basic training. The nurses trained with this skill, were referred to as Primary Health 
Care (PHC) nurses, or later known as the ‘PHCN’. Although most people working in South Africa 
use and understand this term, many prefer “nurse clinicians” or “nurse practitioners” and the 
official Nursing Council term is not PHCN. 
The need to evolve health systems requires a move away from a reactive model towards 
an early prevention and treatment model. Models like the CICM or ICCC provide the tools to link 
primary care to specialist care, and offer an opportunity to investigate how to best link specialists 
with primary health workers. Early disease management can be achieved by providing better 
communication, knowledge and motivation for primary care clinicians. Acknowledging the key 
role played by the PHCN in managing chronic diseases, and what would be required to improve 
their knowledge and motivation, remains largely unaddressed. Evaluating the impact of the 
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chronic disease program on improving kidney and cardiovascular outcomes, by utilising the 
PHCN as an important link in the health system, requires investigation. 
In 1999, a Chronic Disease Outreach Program (CDOP) began in Soweto, South Africa. 
Soweto is an acronym for “south western townships”.  Soweto is on the outskirts of 
Johannesburg, and was established as a result of the Apartheid system whereby black South 
Africans were forcibly moved since the 1930s. Soweto remains a largely black urban township, 
of crowded houses, backyard rooms, shacks and hostels, situated 20km from Johannesburg 
(Rispel et al., 1996).   For political and practical reasons,  the population has never been 
counted accurately, but an official figure of one million was given in 1996 and it is now possibly 
1.6-2 million or higher (Doherty et al., 1996).  After the 1976 uprisings, some people believed 
that improved primary health care service were established to try and win over community 
support, others thought it due to doctors feeling unsafe. No evidence exists for either assertion. it 
appears that the PHC services were primarily driven by the need to diagnose and treat common 
complaints instead of referring them to directly to Chris Hani Baragwanath hospital (Health 
Systems Trust et al., 1999).  The resultant PHC clinics and nurses allowed the primary care 
service to be linked with the only hospital in the vicinity. Chris Hani Baragwanath Hospital is 
Soweto's only regional hospital and was established in 1941 as the Royal Imperial Hospital, 
Baragwanath, in what is today Diepkloof, for convalescing British and Commonwealth soldiers 
(Wikipedia Contributors, 2008, Brodie, 2008). The hospital was named after John Albert 
Baragwanath, who owned the land at the time, and changed to Chris Hani Baragwanath Hospital 
(CHBH) in 1996, in memory of the murdered anti-apartheid activist. Today it has 2800 beds, 
serving the needs of the Soweto population and others in the South Western Gauteng area, the 
nearby North West Province and even regional Southern African neighbouring countries such as 
Botswana, Mozambique and Zimbabwe. The hospital acts as both a local referral hospital for the 
clinics in South Western Gauteng province, but also has a regional, tertiary and even quaternary 
service. The local or secondary hospital function results in it accepting first referrals from the 
surrounding primary health care centres and it is the primary referral centre for primary health 
care nurses and doctors working in the public health clinics and for private general practitioners 
in Soweto and the region. CHBH and its primary health service development mirrored that of 
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primary health care development taking place worldwide in the 1970s (Segall, 2003).  Although it 
is the only regional hospital, the care provided in Soweto has remained largely fragmented, with 
multiple health authorities, local regional and government health departments, taking on the 
responsibility for the provision of care to the population (Rispel et al., 1996). A newer clinic 
system, with some improvements in regional management and upgrading of some clinics to 
community health centres, was developed in 1996 after South Africa’s liberation, but the hospital 
today remains largely unchanged (Rispel et al., 1996, Doherty et al., 1996). The referral system 
has remained the same for the past 20 years, and there is no secondary hospital in the area, so 
CHBH receives referrals directly from PHC clinics to its casualty department. Patients are then 
triaged to a specialist clinic at the discretion of the casualty doctors. 
There is a lack of information regarding the disease burden, population size and health 
service needs and utilisation in Soweto (Doherty et al., 1996). Like other parts of sub-Saharan 
Africa, Soweto residents’ face multiple burdens of CVD and CKD risk, non-communicable 
disease such obesity, HTN and DM, and communicable diseases like HIV and TB (White and 
Dalby, 2008, Sliwa et al., 2008, Beran and Yudkin, 2006). In 1999, CDOP was established in a 
number of primary care clinics in Soweto (Figure 7). 
 
Figure 7. Location of Chronic Disease Outreach Programs 
City of Soweto (South Western Township ).
An ‘apartheid’ city established South West of Johannesburg 
comprising of a predominantly black ‘Transitional’ Community of 2 
million people
Soweto
CDOP
established
mainly in
clinics
in Soweto
and also in
clinics
South of
Township
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The approach by CDOP in Soweto has been to stratify the  high risk population groups 
within the DM and HTN population (Katz, 2005b).  This recognises the lack of resources to 
screen all people attending chronic clinics. This strategy, in keeping with that followed by others 
(Hallan et al., 2006a, Hallan et al., 2006c, Brown et al., 2003a, Naicker, 2003), recognizes those 
at highest risk of CVD and CKD are patients with uncontrolled HTN or with DM, HIV and 
proteinuria. The approach of focussing on early risk factors, common to both CKD and CVD, like 
uncontrolled hypertension and albuminuria supports the emphasis of developing integrated, 
rather than disease-specific, surveillance programs. It also supports a unified approach for 
primary and secondary prevention. The Chronic Illness Care Model (CICM), discussed earlier, 
served as a good model in Soweto for the Chronic Disease Outreach Program, as screening for 
CKD matched the processes carried out by the PHCN when managing hypertension, diabetes 
and HIV. It also provided an opportunity to focus on PHC clinicians as the ‘prepared and 
proactive team’ (Wagner et al., 2001), who manages the risk factors associated with CKD and 
CVD  and specifically the PHCNs in Soweto, who are the foundation on which the service is run. 
 
These chronic illness care models measure both the progress and outcomes of care, 
encourage follow up, and can enable ‘‘stepping up’’ or ‘‘stepping down’’ care from PHC to 
specialist care (Gask, 2004). Deciding where patients can be best managed is not always well 
researched. An effective health care system relies on all components being intact, and those 
clinicians working in the PHC sector have to be able to recognize and implement appropriate 
strategies for managing disease, and if disease is advanced, to refer the patient to the next tier. 
Chronic disease programs also facilitate the long-term social processes that involve 
capacity building of both the communities and health workers. The strengthening of health 
systems in developing countries remains a key challenge, especially in the wake of the existing 
epidemics of “chronic” infectious illnesses like HIV and TB together with chronic non-
communicable diseases, often co-occurring. CKD and HIV share similarities in that their risk 
factors can be effectively detected and treated, but their treatment is complex and often, at some 
point in the course of the illness, will require specialist support to ensure effective management. 
The major constraint with chronic illnesses is that life- long therapy is required, often with 
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multiple drugs. The aims of establishing Outreach Programs should not be to develop a program 
specific for kidney disease but rather to integrate kidney disease management horizontally into 
established chronic disease systems within the existing PHC services. Programs for HIV and 
antiretroviral (ARV) therapy in South Africa demonstrate the difficulty in establishing and 
integrating into the existing poor health systems. Programs for HIV are developed in parallel 
within health systems, and this weakens rather than strengthens the overall health system 
(Victora et al., 2004, Schneider et al., 2006). Whilst a focus of the study is to highlight CKD 
amongst chronic illnesses, it is not the aim to achieve this to the detriment of other chronic 
illnesses. It is recognised that the improvement of CKD and CVD as a whole will rely on 
improved primary health care services. This is clearly supported by evidence that countries, with 
good health policies and organization and with a strong service for primary care have better 
health outcomes at a lower cost (Rawaf et al., 2008). Both Couper (2007) and Rawaf (2008) 
highlight the importance of certain key principles and a person orientated approach to deal with 
the overlapping problems associated with chronic illness, and this approach is supported.  
The need for integration and more broad-based improvements in population health, such 
as preventive measures, primary care services, and health workforce development (‘horizontal 
programming’) (De Maeseneer et al., 2008), is endorsed, despite the fact that CDOP was 
initiated in a vertical manner. The need for integration is supported by most but it is 
acknowledged that the implementation of this framework remains a challenge (De Maeseneer et 
al., 2008, van Weel et al., 2008, Couper, 2007, De Maeseneer et al., 2007), and this is 
evidenced by the desire to implement such a strategy as part of the ‘15 by 2015’ campaign (De 
Maeseneer et al., 2008). It is envisaged that CKD would be detected and managed as part of an 
overall approach to a patient with the risk factors for chronic illnesses (hypertension and 
diabetes), and that this would include screening for proteinuria and an estimated the glomerular 
filtration (eGFR) rate at the PHC consultation. This thesis acknowledges that decreasing the 
chronic non-communicable disease (NCD) burden requires the implementation of the 
multisectoral policies aimed at decreasing population-level risks for NCDs, and effective and 
affordable delivery of primary care interventions for patients with chronic NCDs. This framework 
for a public health approach is informed by experience of scaling up interventions for chronic 
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infectious diseases (tuberculosis and HIV) (Couper, 2007). However, as was commented by 
Couper (2007), page 4; “unfortunately a major opportunity was lost, in planning this vertical 
program” for HIV. The ultimate integration of CKD screening would have to take this into 
account, and ensure that it is part of the overall management of patients at high risk for CKD and 
CVD, and falls under the gambit of chronic illnesses.While focusing on the technical and 
structural aspects of the health systems is important, supporting and developing staff, is a key 
element of all chronic illness programs. Continuing care needs to be delivered by a well 
functioning team (Epping-Jordan, 2001).The Wagner CICM and WHO ICCC models both call for 
an informed, activated and motivated health care team. Unfortunately there is little investment in 
the development of staff (Franco et al., 2002). This sentiment was expressed by Hongoro and 
McPake (2003), who have found health workers in developing countries to be underpaid, 
demoralised and underproductive, and noted problems with health worker training, deployment, 
and retention. In order to achieve the successful delivery of chronic disease care, attention to the 
conditions of health workers needs to be addressed.  
 In Soweto, there was a need and motivation to establish an early detection and 
prevention strategy, to provide nephrologists with an alternative to refusing people RRT, and to 
prevent people developing ESRD or early death from CVD. However, prevention strategies are 
costly, require a degree of sophistication and expertise to establish, and are seen by many as a 
long term rather than a short term solution (Kober and Van Damme, 2004, Dirks and Levin, 
2006). CDOP was established to try and answer some of these questions. 
  
Soweto a Transitional Community 
   ‘Transitional communities’, through colonisation, urbanisation and western dietary 
influences, have undergone dramatic changes over very short periods of time, who, prior to 
these developments, had lived very different life styles (Figure 8). We are reminded by 
Manderson that the epidemiological shifts in disease, termed health transition, cannot be 
explained so simply (Manderson, 2008). The Soweto community, like industrialised and 
urbanised societies, show a concurrent increase in non-communicable illnesses and in Soweto 
also new infectious diseases. These variations in patterns of disease and life expectancy reflect 
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the complexity of factors affecting health transition and include the social, cultural, and 
behavioural factors, belief systems and practices, geography and economic factors (Manderson, 
2008).  It has been suggested that biological factors may play a role in chronic disease 
prevalence (Burrows et al., 2008), as whilst their lifestyles and diet have been altered in many 
ethnic populations, bodies and genetics adaptation may differ in response to the same transition 
(Karter et al., 2002, Hsu et al., 2003, Hong et al., 2004). Findings have suggested that the 
genetic difference between racial or ethnic groups seem to relate more to differences in 
susceptibility to factors which promote CKD. The result of these factors is a higher burden of 
CVD and CKD in black or indigenous communities discussed earlier (Cass et al., 2004, Lea et 
al., 2008).  Such dramatic societal transitions are behind the high burdens of CVD and CKD in 
black or indigenous communities discussed earlier. Transitional communities and the changes in 
their ‘way of life’ form part of a greater worldwide problem, reflected in the metabolic syndrome 
(see also figure 13). 
 
Figure 8. “Transitional” Communities and the risk of Chronic Diseases 
Note: Developing world and ‘minority’ communities appear to be at particular risk for cardiovascular (CVS) 
and chronic kidney disease (CKD).   
 
 
Overweight and obesity, central obesity, sedentary lifestyle, higher visible fat intake, and 
higher social class were significantly associated with DM in an Indian study (Ram et al., 1998). 
Traditional lifestyle
Community Disrupted
e.g. Colonialistation
Westernised diets & lifestyles
High risk for Chronic Illnesses
e.g. Obesity, HT, DM,HIV
“Transitional” Community Develops
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In SA, data from the THUSA study (Transition and Health during Urbanisation in South Africa) 
showed increases in overweight, obesity and several risk factors for NCD (Vorster et al., 2005, 
Vorster, 2002, THUSA study et al., 2007). The changes in dietary habits amongst poorer rural 
and urban Africans have been documented for some time in Southern Africa (Walker, 1995, 
Steyn et al., 2005). In city dwellers, prevalence of obesity, HTN, and DM have risen and remain 
true for ‘transitional communities’ like Soweto (Katz et al., 2006b). The ‘way of life’ of these 
communities has changed significantly. With increasing smoking, excessive drinking, and 
impoverishment, these factors remain potent continuing health challenges.  
 
The higher risk for CKD and CVD among ‘minority’ disadvantaged communities like 
African Americans and Australian Aborigines is influenced by poverty and other structures of 
violence (Ward, 2008, Burrows et al., 2008, Cass et al., 2004, Spencer et al., 1998). African 
Americans have a 3-7 times greater risk of kidney disease than Euro-Americans, even for the 
same diagnosis (Lopes et al., 1994, Brancati et al., 1992, Cass et al., 2004). Disparities in HTN 
and DM control also exist in disadvantaged and minority communities (Duru et al., 2008, 
Mainous et al., 2004), and disparities between rural and urban areas are well documented 
internationally (LuXia et al., 2008, Abdul-Rahim et al., 2001, Ram et al., 1998) and locally 
(Walker, 1995, Vorster et al., 2005). In these studies risk factors and morbidity of CVD and CKD 
differed in rural and urban areas, and often in relation to poverty and gender. The association of 
CVD-CKD and HTN with DM was greater in urban than rural subjects.  
Unfortunately the greatest burden of non-communicable chronic disease is also felt by 
countries with a high burden of infectious diseases (Global Forum for Health Research, 2002, 
Abegunde et al., 2007, Strong et al., 2005), leading to additional and aggravating effects on non-
communicable diseases e.g. HIV and HIV associated kidney disease can cause ESRD, and HIV 
is a cause of heart disease. Research has highlighted this epidemiological transition from 
infectious diseases to NCDs experienced in middle-income countries with growing economies, 
but in South Africa, this transition has been joined by the HIV/AIDS epidemic (Manderson, 2008, 
Vorster and Kruger, 2007). The impact of this double burden is on health resources and services 
with increased demands on the clinicians facing these epidemics, the interpretation of trends of 
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morbidity and mortality have been difficult. However, the recent study in rural Agincourt in South 
Africa by Tollman et al. (2008) was able to demonstrate this impact and concluded that mortality 
from NCDs was prominent despite the increase in deaths from chronic infectious disease.  
The high prevalence of obesity, DM, HTN and other kidney diseases like infectious 
glomerulonephritis and HIV glomerular diseases, suggests that like other “transitional” and 
minority communities around the world, South Africans have an increased susceptibility to 
kidney disease and its aggressive course. Hemodynamic and metabolic factors, perhaps 
aggravated by existing poverty and the high prevalence of low birth weight (related to intra-
uterine malnutrition), are also factors to be considered (Barker et al., 1989, Huxley et al., 2000). 
This strong causal relationship between DM  and the resultant lethal CVD complications leads to 
an underestimation of the primary importance of CKD and, hence, under-reporting in official 
mortality statistics (Pugsley et al., 2003).  
The epidemiological transition in CVD in Soweto is evident in statistics of hospital 
admission. In 1993 at Baragwanath Hospital, Soweto, only 42 cases of CVD (coronary artery 
disease or myocardial infarction) were diagnosed from a total of 23,000 hospital admissions 
(Walker, 1995). In a recent follow up evaluation of 4162 patients, the presence of CVD  and its 
risk factors was found to be high, including 616 cases of coronary artery disease (Sliwa et al., 
2008). This health transition, including the significant burden of non-communicable disease, 
despite the growing infectious disease burden, was recently described in a rural community in 
South Africa (Tollman et al., 2008). The implication of this transition is the need for the delivery 
of effective primary health care. Almost all the studies call for the establishment of programs that 
are holistic, integrated, but trans-disciplinary and multisectoral. This is required to break the 
vicious circle of poverty and under-nutrition and the long-term prevention of CVD and CKD. 
 
Soweto Chronic Disease Outreach Program  
 
CDOP was initiated as the Primary Prevention Program (PPP), as a pilot secondary 
prevention strategy, in June 2001. As already indicated, the program was modelled on an 
outreach program run with remote indigenous communities in Australia (Kondalsamy-
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Chennakesavan et al., 2004, Katz et al., 2006a, Hoy and Kondalsamy-Chennakesavan, 2004). 
PPP was established to detect people at high risk for CKD and CVD, but also to curb the high 
incidence of end stage renal disease (ESRD). The pilot program aimed to compare progression, 
morbidities and rates of dialysis and death in two separate regions in Johannesburg. The CDOP 
pilot program ran in Soweto Wits Health Region B of Gauteng Province, which included Chris 
Hani Baragwanath Hospital (CHBH) and another region, Region C. These Region C clinics are 
closer to central Johannesburg and have a different specialist referral hospital, Johannesburg 
Academic Hospital. The pilot program aimed to compare progression, morbidities and rates of 
dialysis and death in the two regions. Chris Hani Baragwanath hospital was chosen for this 
study, as it is the tertiary ‘specialist referral’ facility for PHC clinics in the region. This allowed the 
two regions to run independently and be compared.  
The people enrolled into the pilot CDOP, PPP, had the same profile of underlying chronic 
diseases as those who participated in the current study i.e. HTN (BP>140/90) or DM and HTN or 
proteinuria. They were enrolled at 12 intervention clinics (IC) and 4 control clinics (CC). The IC 
clinics used CHBH as their referral hospital and CC clinics did not. At the intervention clinics, the 
patients were managed with the early use and quicker up titration of an ACE inhibitor and a 
diuretic, and received specific health education. BP targets were set at a lower value of 
120/70mmHg. The health education included information about HTN, DM, CKD and the 
appropriate lifestyle and management for these diseases. The treatment targets, developed from 
existing established guidelines, were also simplified. Instead of providing clinicians with 
algorithms of management, nurses were requested to focus on a specific target for a CVD or 
CKD risk factor. In HTN, where different targets exist for HTN alone compared with DM and 
proteinuria, we chose a single blood pressure target. In DM management, targets were also 
divided into three different zones e.g. HbA1c level <7 is optimal; 7-8 acceptable and if >8 
additional action. This target was simplified to <8. This strategy was taken in view of the poor 
control in the pilot project at baseline where glucose serum levels were >10mmol/L (Figure 9).   
  
22 
 
Figure 9. Glucose levels on Pilot CDOP (PPP*) 
HGT – haemoglucotest (finger prick serum glucose mmol/L);M0=baseline; M1=month one;M2=month two; 
M3 = month three; M6= month six 
Note: Treatment group patients with HGT>10mmol/L at baseline. At 6 months nearly 75% had finger prick 
HGT of less than 10mmol/L; *Primary Prevention Program 
 
 
Control clinics (CC) managed their patients according to established ‘normal’ practice 
guidelines and were also monitored, but there was no assistance with management or 
interference in care, unless advanced disease was detected. Here BP was managed primarily 
with a thiazide diuretic and goals were standard (<140/90mmHg). In the IC clinics PHCNs could 
contact the program director at any time, they visited the referral centre every 4 weeks for 
reports on progress, individual cases were discussed, and patients needing specialist care were 
referred. Before and after data were collected and compared between intervention and control 
sites. A total of 871 patients (527 females, 268 males) were enrolled onto the pilot program at 
baseline (645 IC, 226 CC). Age distribution was significantly different between IC and CC clinics, 
with more people >60 years in the IC clinics. Gender distribution was similar. Control clinics also 
had significantly more DM patients and IC clinics had more HTN patients. Comparisons of 
baseline characteristics are shown in Table 1.  
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Table 1. Baseline Parameters of Patients enrolled on the Pilot PPP 
 
Parameters Control Clinics Intervention Clinics p 
 N  N   
Age * 219 51.4 (10.0) 625 57.5 (11.9) <0.001 
Male 226 78 (34.5%) 645 201 (31.2%) 0.353 
Diabetics * 226 110 (48.7%) 645 234 (36.3%) 0.001 
Hypertensive * 226 178 (78.8%) 645 622 (96.4%) <0.001 
Smokers * 201 19 (9.5%) 577 86 (14.9%) 0.051 
Alcohol 201 24 (11.9) 569 98 (17.2) 0.078 
Height, cm * 165 161.9 (12.8) 583 158.1 (10.5) <0.001 
Weight, kg 219 78.1 (14.6) 631 80.3 (19.0) 0.083 
Hips, cm 192 109.5 (13.7) 587 111.1 (19.1) 0.218 
Waist, cm 189 96.2 (14.3) 583 97.5 (18.8) 0.366 
BMI, kg/m2 * 162 31.0 (8.3) 581 32.7 (8.6) 0.026 
Obese by WHR 187 86 (46.0%) 583 256 (43.9%) 0.619 
SBP * 221 147.8 (22.2) 619 153.0 (21.6) 0.002 
DBP 221 93.4 (12.6) 619 93.6 (12.5) 0.826 
MAP 221 111.5 (14.8) 619 113.4 (14.1) 0.094 
Data are Mean (SD) or proportions; * Significant difference between the 2 groups 
BMI – body mass index, WHR – waist-hip-ratio 
 
Significant differences in some parameters at baseline indicate the non-homogeneity of 
the different regions, making direct comparisons of the intervention difficult. In the Soweto IC 
clinics, there were significantly more smokers, alcohol users, and patients had higher systolic 
blood pressures (SBP). There was also a slightly higher BMI and obesity by waist hip ratio, 
although it was not significant. No significant difference could be noted in blood glucose level, 
haemoglobin and serum creatinine levels. However, the proportion with proteinuria by dipsticks 
was significantly higher in CC group (53%), compared with 32% in IC group; p<0.001. This 
probably related to the greater number of DM in the CC group. However, the median levels of 
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the protein to creatinine ratio (PCR) did not differ in the two groups, but blood lipid levels 
(cholesterol and LDL) were significantly higher (Table 2).  
Table 2. Baseline Urine and Blood Lipid Profile 
 
Parameters Control Clinics Intervention Clinics p 
 N  N   
Urinary Dipstick ≥1+ 200 106 (53%) 604 192 (31.8%) <0.001 
PCR# 62 0.02 290 0.02  
Serum Creatinine* 51 79.5 (74.2-85.3) 424 84.9 (81.6-88.3) 0.270 
Total Cholesterol 111 4.7 (1.0) 331 5.2 (1.2) <0.001 
HDL 107 1.3 (0.4) 321 1.2 (0.5) 0.240 
LDL 107 2.7 (1.0) 315 3.2 (1.1) <0.001 
Triglycerides 111 1.5 (1.1) 323 1.6 (1.0) 0.098 
#PCR - Median for Protein Creatinine Ratio *Geometric mean (CI) for Serum Creatinine 
HDL – high density lipoproteins; LDL – low density lipoproteins 
 
In the pilot phase of CDOP, nearly 90 percent of participants were overweight or obese 
by either BMI or waist circumference (Kondalsamy-Chennakesavan et al., 2004). Women were 
more likely to be in the higher categories of all parameters of body weight and fat than men. The 
average waist circumference was in the obese range for both CC and IC participants. More 
participants were classified obese by waist circumference than by either BMI or waist-hip ratio 
alone. As in other transitional populations, waist circumference has proven to be a better 
indicator marking obesity than BMI and better association with CVD, CKD risk (Alberti and 
Zimmet, 1998, International Diabetes Federation, 2005). 
Using clinical outcomes and after 6 months of follow up, evaluation of the pilot phase of 
the PPP showed that the control of risk factors had improved. The program was successful in 
reducing risk factors and after a short period of follow up, achieved better treatment targets (Katz 
et al., 2006a, Katz et al., 2006b). Significant phase I reductions in blood pressure, blood glucose 
and proteinuria were achieved at intervention sites (Katz et al., 2002). Changing people’s eating 
habits and lifestyle was more difficult than just adding medication to achieve a blood pressure 
target in HTN. A non-significant reduction in proteinuria was achieved in the intervention group 
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(0.057 to 0.049 g/mmol; p=0.45 NS), indicating that increased use of ACEi and improving blood 
pressure control may have had additional effects. An important finding was that hyperlipidaemia 
was more common in both the treatment and control sites than previously believed, suggesting 
that the lifestyle of Soweto people is continuing to change. It could also reflect an increase in the 
availability and consumption of cheap fast foods and high sugar carbonated soft drinks over the 
past few decades. This was particularly worrying given current restrictions and essential drug 
guidelines, whereby lipid lowering medications are not available in most primary care clinics.  
Although PPP was found to be a simple and effective means of ensuring better risk factor 
control, this was for a very short follow up period, and its sustainability had not been tested. 
There was also a large drop-out rate of patients enrolled. These results must be considered 
against the poor overall follow up of patients. These facts prompted a more comprehensive 
approach and evaluation of CDOP. The challenge was to see if this could be improved and 
scaled up into the paper-based version, Phase II of the project, i.e. the component of CDOP 
used for this project. This resulted in the implementation of Phase II the ‘nurse coordinator’ and 
‘paper based’ phase.  
 
2 KIDNEY DISEASE AS A PUBLIC HEALTH PROBLEM 
This chapter will argue that kidney disease is globally both a significant public health 
problem and  should be considered part of an integrated approach to chronic diseases in the 
primary health care setting. It highlights the links between CKD and CVD, and establishes an 
argument for both improved management in patients with diabetes and hypertension and the 
early detection of serious risk factors and/ or complications in order to prevent strokes, coronary 
heart disease, development and progression of CKD. It also establishes a link between the 
global rise of chronic illnesses and the metabolic syndrome and its cluster of risk factors 
including the association between metabolic syndrome (MetS) and CKD. Finally it will provide an 
overview of key kidney disease prevention programmes established in various regions 
worldwide. 
 
Global Epidemiology of Kidney Disease  
Chronic kidney disease (CKD) is increasingly recognised as a global public health 
problem, as a result of key developments in our understanding and detection of kidney disease. 
The evaluation of kidney disease using an estimated glomerular filtration rate (eGFR), as well as 
the ability to monitor proteinuria easily with a single urine sample, has greatly improved 
awareness of the problem. These developments, coupled with existing methods for assessing 
risk and progression, resulted in conceptual models outlining the definition and classification of 
CKD which have been used to highlight the existing burden of kidney disease (National Kidney 
Foundation, 2002, Levey et al., 2003, Levey et al., 2005, Coresh et al., 2002, Coresh et al., 
2005, El-Nahas, 2004, Schoolwerth et al., 2006) (see figures 1 and 2). These developments 
have allowed doctors, researchers, and public health specialists to focus on risk factors for CKD 
and CVD, and to encourage earlier diagnosis and better follow up people with CKD. The models 
have also enabled researchers to better determine background precursors to CKD, to identify 
risk factors for its development, progression and outcomes, and to test strategies for its early 
detection, evaluation, and management.  
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CKD is poorly recognised. It is not mentioned in the 2005 WHO Report on ‘preventing 
chronic illness: a vital investment’ as a chronic disease requiring prevention (World Health 
Organization, 2005c). This is despite the fact that  CKD is common in people with CVD and with 
CVD risk factors (HTN, DM and obesity), and that the presence of CKD multiplies the risk for 
adverse outcomes in these conditions, and is often a precursor to CVD (Sarnak et al., 2003, Go 
et al., 2004, Zoccali, 2006) (discussed below). CKD is also a risk factor for adverse outcomes in 
other acute and chronic diseases such as infections (Hepatitis B and C, HIV)(Fabian et al., 
2007). In the period 1985 to 1999, the percentage of haemodialysis centres providing care to 
patients with HIV in the United States increased from 11% to 39%, and the percentage of 
dialysis patients with HIV infection increased from 0.3% to 1.4% (Ahuja et al., 2002) (Figure 9). 
This information remains unknown for sub-Saharan countries most affected by infectious 
diseases and especially HIV/AIDS. Despite the link between CVD and CKD, and the high and 
growing levels of CKD associated with HIV, CKD remains unrecognised as an important chronic 
disease. In most cases, stroke and coronary artery disease are considered part of this 
continuum, but kidney disease is not. Equally, HIV/AIDS is still not considered by most countries 
to be part of the chronic illness continuum.  
 
Figure 9 ESRD, Deaths and HIV Nephropathy 
ESRD and AIDS Nephropathy and Deaths in black patients with AIDS 
ESRD = End Stage Renal Disease, HAART – highly active antiretroviral therapy 
Note: Information is for and Deaths in black patients with AIDS 
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In the United States, HIV renal diseases represent the third commonest cause of ESRD 
in African Americans between 24 and 60 years (Szczech et al., 2003). The incidence of HIV in 
South Africa is one of the highest in the world, and given this, it is possible that HIV/AIDS is a 
significant cause of ESRD, but no data exists currently. People with HIV do not easily qualify for 
dialysis or transplantation, and there is therefore no way to determine its impact on ESRD 
(Fabian et al., 2007). It has been advised that all HIV patients be screened regularly for CKD, 
but this is not being carried out1. Fabian et al. (2007) continue to suggest that an integrated 
management, similar to other high risk groups like HTN and DM, should be implemented to 
reduce the progression to ESRD. If one recognizes the conceptual framework of kidney disease, 
by which renal disease is initiated and then progresses (see figure 1), it is possible to develop 
the same framework for HIV CKD, as for the other chronic illness and risk factors (HTN, DM, 
obesity etc). This framework developed by the Kidney Disease: Improving Global Outcomes 
(KDIGO) group allows for the recognition of susceptibility factors2, possible initiation factors and 
the progression factors associated with the development and deterioration of kidney disease 
(Figure 10). The greatest burden of NCD is felt by countries which also have a high burden of 
infectious diseases (Global Forum for Health Research, 2002), leading to additional and 
aggravating effects on the NCD burden e.g. HIV related renal diseases causing ESRD such as 
HIV associated nephropathy (HIVAN). There is a greater realisation amongst health workers 
who have a specific interest in CKD, that we must have a more realistic approach to the existing 
and increasing burden of CKD. This means changing the focus to earlier detection rather than 
trying to provide dialysis and transplantation for all patients. 
                                               
 
 
 
1
 The Infectious Diseases Society of America (IDSA) published guidelines in 2005, recommending that all individuals 
be assessed for CKD at the time of diagnosis of HIV infection, with a screening urinalysis for proteinuria and a 
calculated estimate of renal function. Therefore any patient with persistent proteinuria, persistent haematuria or 
(glomerular filtration rate) GFR <60mL/min per 1.73m2 should be referred to an institution where a specialist can 
evaluate this patient for further investigations Gupta SK et al., 'Guidelines for the Management of Chronic Kidney 
Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases 
Society of America', Clinical Infectious Diseases, 40 (2005), 1559–85. 
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Initiation Factors
DM/ HTN/ Obesity /Infections e.g. 
HIV
 
Figure 10. Initiation Factors of CKD 
.  
Note: The susceptibility and initiation factors of CKD and CVD which form part of the KDIGO CKD 
conceptual framework which is a screening, risk reduction and management model.  
DM - diabetes, HTN – hypertension, HIV – Human Immunodeficiency Virus  
 
 
The implications of our ability to detect kidney disease  is seen in the study of CKD in the 
United Kingdom (UK), revealing that the trend for CKD, as in other developed countries, is 
expected to continue to rise at an annual rate of around 5–8% (Lysaght, 2002). The factors 
influencing this rise include ageing populations, as the incidence of ESRD is higher in elderly 
people (United States Renal Data System, 2003), i.e. incidence of ESRD >1200/million per 
annum >65 years. The increased incidence of type 2 DM, which is closely linked to CKD will also 
directly impact on the development of CKD (Wild et al., 2004, Rossing et al., 2004, Friedman 
and Friedman, 2007), as is the rise of CKD from HIV in sub-Saharan countries like South Africa 
(Fabian et al., 2007).  
Studies from Europe, Australia, and Asia confirm a global trend in the high prevalence of 
CKD (de Zeeuw et al., 2005, Chen et al., 2005 , Hallan et al., 2006b, Chadban et al., 2003, Iseki 
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et al., 2007). For example, screening surveys of representative samples of the whole population, 
using eGFR measurements, in Australia (Chadban et al., 2003), Japan (Iseki et al., 2007), and 
Holland (Hillege et al., 2001), identify between 6% and 11% as having some degree of CKD. 
The prevalence of CKD increases to 50–60% when at-risk individuals are screened (Brown et 
al., 2003b). In the United States, 9.6% of adults in the general population are estimated to have 
CKD (Stevens et al., 2006, Coresh et al., 2007) and kidney failure is being shown to be 
increasing. In general the outcomes remain poor, and the costs of managing end stage renal 
disease are high. The number of persons in the United States with kidney failure who are treated 
with dialysis and transplantation is projected to increase from 340 000 in 1999 to 651 000 in 
2010 (United States Renal Data System, 2000).  
Disparities in the incidence of ESRD (CKD stage 5) are strongly influenced by the racial 
and ethnic differences as well as by biological and social differences. In Australia and the USA, 
the annual incidence of ESRD is substantially lower in wealthier European populations 
compared with their poorer counterparts, i.e. indigenous Australians and African-Americans 
(United States Renal Data System, 2003, McDonald and Russ, 2003) (see Table 3). Studies 
have pointed to both biological and social causes for the differences (Hsu et al., 2003, Ward, 
2008, Cass et al., 2004, Burrows et al., 2008, Karter et al., 2002). Some of these factors include 
difficulties with HTN and proteinuria control, and genetic differences between blacks and whites 
related to differences in susceptibility and likelihood of progression (Hsu et al., 2003, Karter et 
al., 2002, Ward, 2008).  While the incidence of ESRD has been found to be greater in 
geographic areas with less educated populations and lower household incomes (Cass et al., 
2001), studies that controlled for these factors found that African Americans DM had a higher 
likelihood of ESRD than European Americans with DM (Karter et al., 2002, Brancati et al., 1992). 
The persistence of ethnic disparities after adjustment again suggests a possible genetic origin, 
the contribution of unmeasured environmental factors, or a combination of these factors. 
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Table 3.  Incidence and prevalence of ESRD, select regions and populations 
 Incidence of 
ESRD 
(per million 
per year) 
Prevalence of ESRD 
(per million) 
Europe   
UK 101 626 
European average 135 700 
Russia 15 79 
Australia   
White people 94 658 
Aboriginal people 420 1895 
USA   
Overall 336 1403 
White people 256 1004 
African-American 982 4432 
Less Developed Countries   
India 34-240 Unknown 
South Africa 99 Unknown 
Nigeria Unknown Unknown 
Adapted from (El Nahas and Bello, 2005, Naicker, 2003) 
 
Differences in the access to dialysis and transplantation, the incidence of ESRD, and the 
number of people who require dialysis and transplantation (prevalence of end stage CKD) are 
largely determined by the availability of resources. There  is a clear and direct relation between a 
country’ s gross national product and the availability of RRT, with less developed countries 
unable to meet the increasing demand (De Vecchi et al., 1999). This huge inequality also stems 
from current differences in health-care resource allocation to programs of RRT. Disparities are 
also likely to reflect the racial and ethnic mix (El Nahas and Bello, 2005). These socioeconomic 
discrepancies are seen in South Africa, and with rationing of resources, these discrepancies 
make it difficult to ensure equity (Moosa and Kidd, 2006). Improvements in access to RRT and 
better quality care has been seen in previously disadvantaged racial groups, and this is 
suggested to be related to early detection and management of kidney disease (Burrows et al., 
2008). Improvements in care stem from improved control of DM, HTN and other risk factors for 
kidney failure, as well as new pharmacologic agents (Burrows et al., 2008).  
Overt kidney disease is only the tip of the iceberg of covert CKD.  Although this is better 
recognised in the developed world by academics and possibly health services, the challenges in 
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the developing world are greater. Around 85 percent of the world’s population lives in low-
income or middle-income countries, and here the clinical, epidemiologic, and socioeconomic 
effects of CKD and CVD are the greatest. International comparisons of disease are therefore 
difficult. Data of people receiving dialysis and transplantation are better known in developing 
countries compared with all stages of CKD, so international comparisons must be based on 
ESRD (Barsoum, 2005). Drawing on mostly recently published data (Lamiere et al., 2005, Hallan 
et al., 2006b, Iseki et al., 2007, Horl et al., 1999), the prevalence of ESRD, or patients on 
dialysis, is higher than 2000 pmp (per million population) in Japan, about 1500 pmp in the United 
States, and about 800 pmp in the European Union. In developing countries, despite similar rates 
of incidence, the figures vary from less than 100 pmp in sub-Saharan Africa and India to about 
400 pmp in Latin America and more than 600 pmp in Saudi Arabia (Barsoum, 2006). Differences 
in prevalence are largely a matter of survival made possible by RRT (dialysis and 
transplantation), which in turn depends on health care expenditures and the economic strength 
of different countries. The credibility of statistics from many developing countries is questionable, 
but some experts have suggested a low incidence of 150 pmp as the average for people who 
are receiving dialysis and transplants i.e. ESRD (Barsoum, 2005). This lower incidence more 
likely reflects poor data collection and fewer people receiving RRT in these countries. In 
countries like Australia, where resources are available to collect information, the rates of ESRD 
in the ‘minority’ Aboriginal populations are as high as 2000 pmp (Spencer et al., 1998). In the 
United States, incidence rates and progression rates of CKD to ESRD are higher among black 
and Hispanic compared with their white counterparts (United States Renal Data System, 2006, 
Volkova et al., 2008, Hsu et al., 2003, Burrows et al., 2008, Karter et al., 2002). The difference, 
discussed in chapter one, reflect ethnic origins, genetic and environmental factors (Barsoum, 
2005).  
In addition to placing an unaffordable financial burden on poor countries, RRT has 
negative social, economic and psychological effects on communities. In most developing 
countries, patients receiving regular dialysis are only partially rehabilitated, since dialysis is often 
delivered sub-optimally due to limited availability of dialysis machines, equipment to provide and 
purify the water, and people with skills for managing ESRD and its co-existing diseases 
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(Barsoum, 2006). This is aggravated by the challenges of transportation of people from their 
homes to treatment centres. These difficulties, together with household socio-economic burdens, 
often result in poor adherence to therapies (Moosa and Kidd, 2006, Dirks and Levin, 2006). In 
the words of Barsoum (2006; page 999), “families must often cope with a chronically depressed, 
sometimes aggressive, unemployed relative who must be escorted regularly to a possibly distant 
dialysis centre to receive care”. The great challenges of managing ESRD includes making health 
authorities in developing countries recognise the extent of the problem, and then to detect and 
treat CKD at the earliest possible stage.  
   
Linking Kidney and Cardiovascular Disease 
CKD is far more common in people suffering from CVD, and CKD is a risk factor for the 
development of CVD. CKD patients have a risk of CVD that is 10 to 30 times that of people 
without kidney disease (Sarnak et al., 2003). The likelihood of developing CVD is classically 
assessed on risk factor profiles that include age, gender, blood pressure, cholesterol, smoking, 
body weight, type 2 DM, physical inactivity, insufficient fruit and vegetables, and alcohol 
consumption (de Zeeuw et al., 2005, Dirks et al., 2006, Manjunath et al., 2003). These 
recognised risk factors account for 90% of CVD events, and the metabolic syndrome has been 
identified as a multidimensional risk factor for CVD. There is also a socio-economic gradient in 
the risk factors for CVD using, as examples, India and China (Liu, 2007). A study within 10 
industries in India showed a direct correlation between educational status and five risk factors for 
CVD, namely smoking, regular physical activity, DM, HTN, and the metabolic syndrome (Reddy, 
2004).  
The specificity of risk factors allows clinicians the opportunity to initiate the most 
appropriate therapy. There is an overlap of therapies targeting CVD and CKD, as lowering blood 
pressure (BP) or controlling DM has an impact on both diseases. There is now also an overlap 
of methodologies to assess risk, which include an estimated GFR (eGFR) and determining the 
level of albuminuria.  Considering that patients in all stages of CKD are at high risk of CVD, it is 
important to screen all those people at risk for both the traditional risk factors (obesity, 
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cholesterol, hypertension, diabetes) and non-traditional risk factors like albuminuria and eGFR 
(Menon et al., 2005). In a study by Go et al (2004), from the United States, there was a graded 
risk of developing a CVD event; this rose sharply for people with an eGFR less than 45 ml per 
minute per 1.73 m2.  
Recent data from several large, diverse populations have associated progressive 
decreases in kidney function (eGFR) with increased chance of death, cardiovascular events, and 
hospitalization (Go et al., 2004, Manjunath et al., 2003). People with CKD are more likely to be 
hospitalised and to die principally from CVD, than they are to develop kidney failure (Keith et al., 
2004, Go et al., 2004), and have a greater likelihood of dying from co-morbidities of kidney 
disease than progressing to ESRD (Keith et al., 2004, Menon et al., 2005). In addition to 
reducing lifespan, CKD substantially reduces quality of life, yet it is often not recognised as a 
serious health problem. A person’s baseline eGFR, the amount of proteinuria, the cause of 
kidney disease, race and gender, are more likely to result in kidney failure developing or 
progressing further, rather than resulting in their death. This is true, until a person is older than 
65 years; at this age and beyond, death is more likely.  Therefore, in patients with a lower risk of 
dying from CVD, screening is even more compelling to prevent the progression of CKD to ESRD 
(Menon et al., 2008). At older ages the clinician is also likely to prevent early death. 
 
Major Breakthroughs in Kidney Disease Management 
CKD Prevention and Early Detection Strategies 
 
Some key initiatives and discoveries have resulted in health practitioners being in a 
position to have an impact on chronic illnesses like CKD and CVD. CKD prevention involves the 
early identification of individuals at risk, detection and treatment, so that adverse outcomes of 
CKD are prevented or delayed (National Kidney Foundation, 2002). The K/DOQI framework fits 
closely into the chronic illness models, as it recognises the need for early detection and good 
follow-up with appropriate interventions in PHC, but also highlights  an integrated response 
between PHC and specialist care (Table 4) (National Kidney Foundation, 2002). In under-
resourced health systems, the focus has to move from expensive ‘end of the road’ interventions 
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to early intervention and primary prevention strategies by integrating care between specialists, 
primary care clinicians and the community. 
Because CKD and chronic illnesses are closely linked, a single initiative to combat them 
is convincing. Risk factors for CKD include an age of more than 60 years, HTN, DM, CVD, and a 
family history of CKD. Linking these risk factors with the determination of serum creatinine  and 
a spot urine  for albumin–creatinine ratio (ACR) are sufficient to detect CKD and evaluate risk for 
CVD (K/DOQI, 2002, de Jong et al., 2003, de Zeeuw et al., 2005)(figure 10, above). As CVD and 
CKD share similar risk factors, common preventative strategies may extend beyond the kidney 
itself. 
 
Table 4. Chronic Kidney Disease and Clinical Action Plan 
 
Stage Description GFR 
or eGFR 
mL/min/1.73m2 
Action* 
 At increased 
risk 
>90 
(with CKD risk 
factors) 
Screening 
CKD CVD risk reduction 
In PHC sector 
1. Kidney damage 
with normal or 
 
GFR 
> 90 Diagnosis and treatment 
of co-morbid conditions, 
Slow progression, 
CVD risk reduction 
2. Mild CKD  
 
60-89 Estimating progression 
3. Moderate  
GFR 
30-59 Evaluating and treating 
complications 
4. Severe  GFR 15-29 Preparation for dialysis 
and transplant 
Referral to a kidney 
specialist 
5. End Stage 
Renal Disease 
(ESRD) 
<15 
(or dialysis) 
RRT started if uraemia 
present 
Note: Chronic kidney disease is defined as either kidney damage or GFR <60 mL/min/1.73 m2 for 3 
months. Kidney damage is defined as pathologic abnormalities or markers of damage, including 
abnormalities in blood or urine tests or imaging studies. Minor adaptations have been made to the original 
table (K/DOQI 2002) 
 ** Includes actions from preceding stages. GFR - glomerular filtration rate; CKD - chronic kidney disease; 
CVD - cardiovascular disease; RRT – renal replacement therapy 
 
 
 
It is now possible to track CKD progression as well as the risk for further progression, 
and including the risk of CVD. The most sensitive test for early CKD is albuminuria. The earliest 
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stage of low-grade albumin leakage into urine is microalbuminuria. The clinical diagnosis of 
CKD, by measuring proteinuria and kidney function, is now simplified, with spot urine albumin-
creatinine ratio (ACR) and an estimated Glomerular Filtration Rate (eGFR), carried out at the 
primary point of contact with people at risk. The GFR (the major kidney function test) can be 
reasonably estimated from serum creatinine using an equation validated in a large number of 
people with CKD in combination with the variables of age, sex, and race (Levey et al., 1999, 
Stevens et al., 2006, Cockcroft and Gault, 1976a).Therefore, CKD refers to a person with either 
proteinuria (protein leakage measure with urine ACR) or reduced functioning of any of the 
kidney’s normal functions, such as toxin clearance, erythropoietin production, or acid-base 
balance, but is measured clinically by an eGFR, using these standard established formulae.  
Clinical manifestations of kidney dysfunction may be HTN or anaemia, although there are 
often no symptoms until kidney disease is well advanced. Clearly CKD, HTN, DM and other CVD 
risk factors, if uncontrolled and undetected, can result in stroke, heart failure and/or progression 
of CKD to ESRD. As discussed above, people with a reduced GFR are particularly prone to CVD 
(Go et al., 2004), and are more likely to be hospitalised and/or die of CVD before requiring 
dialysis or transplantation.  While chronic diseases such as HTN, DM and CKD tend to be 
separated by organ systems by specialists, this is not the case for PHC clinicians.  However, 
chronic illnesses are generally poorly managed by PHC clinicians and a framework to approach 
these conditions is needed together with improved structures to manage these conditions 
(Couper, 2007), and CKD is one of those which needs to be integrated into PHC management. . 
Current preventive care practices include maintaining stringent control of blood pressure 
to a target of 120/80 mmHg, using angiotensin-converting enzyme inhibitors (ACEi) and 
angiotensin II receptor blockers (ARBs) in both diabetic and non-diabetic kidney disease, 
maintaining good glycaemic control in individuals with DM, and following a low-protein diet (de 
Jong and Brenner, 2004, Hebert, 2006, International Society of Nephrology, 2005, Ruggenenti et 
al., 2001a, Rossert and Wauters, 2002). Treating dyslipidaemia, losing weight and quitting 
smoking, may also help to delay progression of early CKD (de Jong and Brenner, 2004, 
Ruggenenti et al., 2001a, Rossert and Wauters, 2002).  
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One study conducted in the Netherlands  indicated that in the general population, the 
presence of albuminuria predicted both cardiovascular and non-cardiovascular mortality (Hillege 
et al., 2001). Amongst Australian Aborigines, there is an epidemic of type 2 DM, HTN, CKD, and 
CVD, and the incidence rates of people entering treatment programs for ESRD in some remote 
areas were – in the  mid 1990s -  20 to more than 60 times those of non-Aboriginal Australians 
(Spencer et al., 1998). In response to this massive rise in CKD and ESRD, in one area of the 
Northern Territory, a CDOP was instituted to reduce the number of Aboriginal Australians 
starting dialysis. The Australian CDOP substantially reduced the number of people needing 
dialysis (end stage kidney failure) through ‘CVD’ risk factor control and all cause mortality, 
predominantly through a reduction in CVD such as heart failure and stroke (Figure 11) (Hoy et 
al., 2005b, Katz et al., 2006a). This was an integrative approach, focused on detecting and 
treating common risk factors for CKD (Hoy et al., 2005a).  The program used random spot urine 
(ACR) to measure proteinuria, and this was shown to be a stable and robust marker of CKD, and 
determinant for other chronic disease morbidities. The broad base of shared risk factors 
probably explained the simultaneous emergence of the excessive CKD and CVD morbidities 
from which these populations suffer. Thus, albuminuria was a unifying marker for the harmful 
effects of the spectrum of chronic diseases. However  Hoy and McDonald also argued that 
dipstick urine protein could be used as a surrogate for ACR when resources were constrained 
(Hoy and McDonald, 2004). This fits into the WHO models where a step-wise approach would 
be to use a cheaper urine dipstick measurement before progressing to ACR (Epping-Jordan, 
2005).  
 
Primary prevention depends on a multitude of changes, including socioeconomic 
advancement to changes in health care. However, even if these changes are successfully 
implemented, they will take time to modulate disease incidence, and therefore initiatives need to 
be implemented early on. The modification of existing disease is feasible. In the CDOP program 
carried out in this Australian high-risk community, it was demonstrated that systematic 
management with ACEi helped reduce ESRD and CVD deaths, with huge estimated cost 
savings (Hoy et al., 2005a). Albuminuria, both micro and macro, may simply be the renal 
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manifestation of a generalized abnormality of vascular function (Jensen et al., 1995), and 
therefore if targeted with simple measures can have a major impact. 
 
 
 
 
 
 
 
 
 
 
Figure 11 Impact of Integrated Approach in Australian CDOP 
Dialysis Starts and Natural Deaths in Adults (18+ yr) being managed on Australian integrated CDOP 
measuring #Annual Rolling Average, to mid 2003. *Dialysis starts = patients starting dialysis, @Natural 
deaths = all cause morbidity, main factors affecting all cause mortality were strokes, heart failure and 
kidney failure (Katz et al., 2006a, Hoy et al., 2005b). 
 
 
There is evidence that using an ACEi to treat individuals who are identified from 
screening as having microalbuminuria, or are at risk for CVD, results in a reduction in 
albuminuria, and reduces both progressive renal disease and cardiovascular events (Asselbergs 
et al., 2004, ADVANCE, 2007). Unfortunately, many patients with CKD still receive suboptimal 
care. Despite DM associations and CKD guidelines, ACEi or  ARB are not used in patients with 
DM and co-morbid HTN or CKD (Cooke and Fatodu, 2006). CKD is both under diagnosed and 
under treated. The reasons for this suboptimal care are likely complex. The important aspects 
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highlighted here are that people at risk because of DM or HTN are often unaware that CKD can 
be caused by these conditions and are not made aware of the link between urine protein 
‘leaking’ and kidney dysfunction, easily measured by an eGFR.  
 
Global Rise of Chronic Illnesses 
 
The impact of chronic illnesses is being felt in developing countries for two main reasons: 
the population is ageing as a result of social and medical improvements, but also rapid social 
and environmental changes is leading to an increase in common, preventable risk factors 
associated with chronic disease prevalence (World Health Organization, 2005c, Strong et al., 
2005)Organization. In 2005, low-income and middle-income countries accounted for around 
80% of the total burden of chronic disease mortality in developing countries, and in these 
countries, chronic diseases (including persistent communicable diseases such as HIV/AIDS and 
TB) were responsible for 50% of the total disease burden (Abegunde et al., 2007). In low- and 
middle-income countries, the increase in chronic non-communicable diseases (HTN and DM) is 
concurrent with unresolved communicable diseases (HIV/AIDS) (Strong et al., 2006).  By 2020, 
the burden of DM and CVD will have increased by 130% in Africa alone, affecting nearly 21 
million and 1.3 million people respectively, with concomitant increases in the prevalence of CKD, 
especially ESRD (also known as stage 5 CKD) (Schena, 2000).  
The Australian Outreach program has documented that most people with chronic disease 
have more than one morbidity, overlapping morbidity, justifying integrated rather than disease 
specific programs (Hoy et al., 2005a) (Figure 12). The risk factors for CVD and CKD can be 
clustered into the metabolic syndrome (visceral obesity, dyslipidaemia, hyperglycaemia and 
HTN) or considered as separate entities. The paper by Hoy et al (2006) focuses on the value of  
screening people for multiple cardiovascular risk factors or if it is better to assess risk according 
to the metabolic syndrome definition (Hoy et al., 2006). It was found that an integrated approach, 
including primary and secondary prevention of all elements of the syndrome, rather diseases 
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specific approach was better. They also found that albuminuria had an important risk in non-
renal risk, and these issues and the metabolic syndrome are discussed below.  
 
 
Figure 12. Overlapping morbidities of chronic disease 
Note: Adults screened in a single Aboriginal Community in the Australian Chronic Disease Outreach 
Program 
 
 
The Metabolic Syndrome and Chronic Disease 
For the past two decades the metabolic syndrome (MetS) has referred to a constellation 
of diseases, and highlights the risk for developing type 2 DM and an increased risk for 
cardiovascular disease (Ballantyne et al., 2008).  Metabolic Syndrome as an entity is recognised 
as a major public health challenge worldwide (Editor, 2005).  It is a cause of both CVD and CKD 
but this term was originally recognised to help us understand how insulin resistance links with 
vascular disease, and if it could predict risk for developing CVD and type 2 DM (Sattar et al., 
2008). There is no specific cause of this syndrome, but it includes cardiovascular risk factors and 
chronic conditions including visceral obesity, dyslipidaemia, HTN, and glucose intolerance or 
hyperglycaemia. The definition has undergone a series of changes over the last four decades, 
most recently by the  International Diabetes Federation (International Diabetes Federation, 
2005). This definition of Metabolic syndrome includes central obesity plus any two of the 
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following four factors: raised triglyceride levels or treatment for this lipid abnormality, raised 
cholesterol or treatment for this lipid abnormality, raised blood pressure (>130/85mmHg) or 
treatment of previously diagnosed hypertension, and raised fasting blood glucose (>5.6mmol/L) 
or previously diagnosed type 2 diabetes. Crucial to the IDF definition, to be defined as having 
metabolic syndrome, a person must have central obesity (waist circumference of a certain size 
which is ethnicity specific). No normal data for waist circumferences are available for Africa, and 
so European targets are used (>102cm for men and >88cm for women). The first published 
working definition was from the WHO and included the same cluster but also microalbuminuria 
(Alberti and Zimmet, 1998). Because of the regular re-evaluations of this syndrome, the central 
causative factor of insulin resistance has been challenged (Yudkin, 2007). The argument put 
forward is that central obesity, lack of exercise and tissue inflammation should be considered as 
the causative factors, resulting in the cascade of disease and complications. However, the 
clinical diagnosis of metabolic syndrome has always been in contention, since it was described 
by Gerald Reaven in 1988 (Reaven, 1988). 
The pathogenesis of the metabolic syndrome is multi-factorial, with the major underlying 
risk factors being central obesity and insulin resistance (Reaven, 1988).  Most patients with type 
2 DM have insulin resistance, and most but not all are obese. A major contributor and possible 
cause is an excess of circulating fatty acids and an associated rise in cardiovascular 
inflammatory markers e.g. C-reactive protein (Festa et al., 2000, Ridker et al., 2003, Rutter et al., 
2004). Inflammation affecting the vascular endothelium associated with dyslipidaemia and 
atherosclerosis causes the increase in stroke and coronary artery disease. Albuminuria is an 
early and dominant element of this symptom complex, and strongly predicts all-cause and 
cardiovascular illnesses and deaths.  
The importance of diagnosing the metabolic syndrome is that it highlights the risk 
associated with cardiovascular disease. The combination of risk factors further increases this 
risk (Expert Panel, 2001, Ballantyne et al., 2008, McNeill et al., 2005). This has been examined 
in several large epidemiological studies (McNeill et al., 2005). In the DECODE study (Balkau, 
2000, The Decode Study Group, 2003), European men and women without diabetes, but with 
metabolic syndrome, had increased risk from death from all causes as well as from 
  
42 
cardiovascular disease.  In the United States, in adults 30-70 years of age, the metabolic 
syndrome was associated with an increased risk of coronary heart disease and total mortality. 
Those people with DM and pre-existing CVD had rates that were even higher. Even one or two 
metabolic syndrome risk factors confer increased risks of disease. Metabolic syndrome indicates 
an even worse prognosis than its individual risk factors (Meigs, 2003). Hoy et al. (2006) found 
that CKD and HTN were the most prominent and earliest features of the syndrome. There also 
appears to be gender differences; in the San Antonio Study mortality was more than twice as 
high in women as men (Meigs et al., 2003, Haffner, 2000). In the United States (US) 
Framingham Offspring Study elevated CRP levels were related to insulin resistance and the 
presence of the MetS especially in women (Rutter et al., 2004). In the ARIC study, again in the 
US which followed a cohort with low rates of coronary heart disease, stroke or DM, the men and 
women with the metabolic syndrome were 1.5 times more likely to develop coronary heart 
disease after adjustment for established risk factors (Ballantyne et al., 2008). Evaluating 
metabolic syndrome in Aboriginal Australians revealed high rates of kidney disease, HTN, and 
DM all increasing with age, and an overlapping of these risk factors (Hoy et al., 2006).   
It is argued that the metabolic syndrome is not better than other models highlighting risks 
for cardiovascular disease. Wannamethee (2005) argues that it was better for predicting type 2 
DM than coronary artery disease, and the Framingham score was a better predictor of disease 
than the metabolic syndrome constellation of risk factors (Wannamethee et al., 2005). The value 
of the metabolic syndrome as a clinical tool remains controversial and others have also added to 
this debate3. Here the conclusions were that the metabolic syndrome had a weak or no 
association with vascular risk in elderly populations, and defining risk for DM and cardiovascular 
disease had little real clinical value. It was felt that the clinical focus should remain on 
establishing optimum risk algorithms for each disease. Ultimately the metabolic syndrome 
serves well as a simple clinical tool for identifying high-risk subjects predisposed to 
cardiovascular disease or type 2 DM..   Risk factors identifying people with the metabolic 
                                               
 
 
 
3
 Sattar et al (2008) argued that it was not as good as traditional algorithms that use continuous or categorical 
measures and which contain the key risk factors for cardiovascular disease: age, LDL cholesterol, and smoking. 
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syndrome may provide opportunities to intervene earlier in the development of shared disease 
pathways that predispose individuals to both CVD and DM.  
 
The Metabolic Syndrome and CKD 
The causes of the increased risk of CVD in CKD are most likely due to shared CVD risk 
factors, including DM, HTN, obesity, lipid abnormalities, and smoking (Manttari et al., 1995, Fox 
et al., 2004a, Muntner et al., 2000, Tozawa et al., 2007, Tozawa et al., 2002, Zoccali, 2006). It 
could therefore be concluded that established cardiovascular disease risk factors, or metabolic 
syndrome risk factors, are associated with the development of new-onset kidney disease and 
progression of CKD. This has been confirmed in a number of studies including among Japanese 
men, African Americans, Chinese and Southeast Asians (Tozawa et al., 2007, Lea et al., 2008, 
Kitiyakara et al., 2007, Chen et al., 2007). Interestingly, in the Southeast Asia study, the 
definition used to define metabolic syndrome influenced the likelihood of predicting risk for CKD, 
suspected to be similar to reasons for developing CVD.  
Detecting and treating metabolic syndrome early on in the community will influence 
kidney disease and may also delay the progression or development both of CKD and CVD. In 
one study, there was a linear relationship between the number of metabolic syndrome risk 
factors and CKD (Tanaka et al., 2006). There is evidence too that the pathogenesis of CKD is 
linked to inflammation, measured by a serum C-reactive protein (Lee et al., 2007, Beddhu et al., 
2005, Zoccali, 2006), and in the studies by Beddhu et al. and Lee et al. the metabolic syndrome 
and high CRP were independently associated with increased prevalence of CKD and the odds of 
CKD increased in the setting of high CRP and metabolic syndrome. Inflammation is increasingly 
prevalent in patients with CKD (Muntner et al., 2004), and the inflammation with associated 
obesity and atherosclerosis is most likely the cause of kidney damage as in other organs 
(Beddhu et al., 2005, Rutter et al., 2004, Zoccali, 2006). The development of insulin resistance, 
DM and HTN further activates the cascade of kidney dysfunction (Figure 13, see also figure 8). 
Thus, associations of inflammation with metabolic syndrome and its component conditions, 
described in the general population, are also present in patients with moderate CKD. Risk 
factors do not act in single organs or compartments and can be targeted with primary prevention 
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strategies. 
 
Figure 13. Metabolic Syndrome and Kidney Disease 
Adapted from a lecture by Dr Valerie Luyckx – Abstract South African Renal Society 2002- “Why poor 
people get kidney disease” (Luyckx, 2002)* 
 
 
CKD and CVD Risk Factor Control 
Hypertension and Diabetes 
Diabetes (DM) and hypertension (HTN), as already clarified, are the most common risk 
factors associated with kidney and cardiovascular disease. Lowering blood pressure (BP) in 
people with DM and HTN is associated with decreases in cardiovascular events and kidney 
failure (U. K. Prospective Diabetes Study Group, 1998, The European Study for the Prevention 
of Renal Disease in Type 1 Diabetes, 2001, Nosadini et al., 2000, ADVANCE, 2007). The 
seventh report of the Joint National Committee on prevention, detection, evaluation, and 
treatment of high blood pressure (JNC VII report) indicated that only 37% of all patients with 
HTN were controlled (BP<140/90mmgHg), and only 59% of patients with HTN are being treated 
(Chobanian et al., 2003), despite the availability of many effective, cost-effective and well-
tolerated drugs in primary care. 
 
DM control, and specifically the prevention of the vascular complications of type 2 DM 
mellitus, is a global health priority. Glycaemic control and the common association with HTN 
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make DM a double challenge. Despite access to diabetic medication like metformin, 
sulfonylurea’s, insulin and newer agents (Turner et al., 1999, Koro et al., 2004), rates of 
glycaemic control have also declined, as defined by HbA1c levels<7%. Control rates were 44.5% 
for the third National Health and Nutrition Examination Survey (NHANES III) (1988–1994) and 
dropped to 35.8% for NHANES 1999–2000.  
The target levels of blood pressure for people with DM have changed in recent years. In 
a review, analysis demonstrated that only 25% of diabetic participants receiving antihypertensive 
drugs had their HTN controlled to the recommended BP of less than 130/85mmHg (Hajjar and 
Kotchen, 2003). With the increased prevalence rate of DM observed in this analysis, 
uncontrolled HTN with DM is an important health problem. Many patients do not have adequate 
blood pressure control, suggesting that inadequate HTN control may be a universal 
phenomenon (Berlowitz et al., 1998, Hajjar and Kotchen, 2003, Wong et al., 2007).
 
 DM and HTN in association with kidney diseases are poorly recognised.  In one 
retrospective study amongst people with evidence of CKD, the disease was only documented in 
10% of patients with DM and less than 13% of hypertensive patients despite the presence of an 
abnormal serum creatinine and proteinuria (McClellan et al., 1997). More than 45% of people 
with ESRD had a diagnosis of DM and 26% had a primary diagnosis of HTN. It has been 
demonstrated that almost 33% of the US adult population has HTN and 75% of those with CVD 
have co-morbidities which include coronary artery disease, stroke, DM, and CKD (Wong et al., 
2007). Despite treatment rates of 75% or greater in many cases, HTN was controlled to goal in 
only 30-50%. Moreover, given recent recommendations to reduce the BP goal to lower than 
before to reduce cardiovascular and kidney disease (Turnbull and Collaboration., 2003), the 
implication of these new targets is that control rates are a greater distance from the desired goal 
(Wong et al., 2007).  However, in the African American Study of Kidney Disease (AASK) a lower 
BP target did not affect progression of kidney disease but ACEi were more effective than other 
classes of anti-hypertensive agents (Wright et al., 2002). Improved diabetes control and any 
treatment for HTN results in benefit, and generally lower blood pressure targets have been 
shown to reduce CVD risk further and the initiation of new onset CKD (ADVANCE, 2007, 
Turnbull and Collaboration., 2003, U.K. Prospective Diabetes Study Group, 1998). Target blood 
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pressure for people with HTN is <140/90mmHg but is lower for persons with high-risk (<125/75 
mm Hg) conditions such as DM and CKD (low GFR or proteinuria) (Chobanian et al., 2003, 
Lenfant et al., 2003) . 
A review of multiple randomised trials evaluating the effects of different blood pressure 
regimens on major cardiovascular events found that ACEi tended to perform better in people 
with high risk factors for CVD, but calcium channel blockers (CCB) were better in people with 
HTN only (Turnbull and Collaboration., 2003). In people with DM and HTN, again ACEi had 
better outcomes compared with people given only a CCB (Estacio et al., 1998). The Modification 
of Diet in Renal Disease Study (MDRD) investigated the role of diet and ACEi dosing in patients 
with CKD. It revealed that 91.5% of patients were on anti-hypertensive medication but only 54% 
had control less than or equal to 140/90 (Buckalew et al., 1996), a threshold above the target 
blood pressure of <130/80mmHg for a person with CKD and proteinuria (Chobanian et al., 
2003). 
This is also true in the general South African population. The South Africa National 
Demographic and Health Survey (Steyn et al., 2008) revealed that HTN was more common in 
less educated individuals and the elderly. HTN risk was lowest in rural blacks and significantly 
higher in obese black women than in women with a normal body mass index. Improved HTN 
control was found in the wealthy, women, older persons, Asians, and persons with medical 
insurance. Poorer, younger men without health insurance had the worst level of HTN control. 
HTN was only controlled in 21% of all adults (Steyn et al., 2001). Levels of HTN awareness, 
adherence with medication and control were also much higher for women compared with men. 
Adherence factors are important in blood pressure control. Factors affecting control may include 
the adherence of clinicians to guidelines for control. Suboptimal control and under-treatment of 
patients with cardiovascular risk factors in the primary care occurs (Zachariadou et al., 2008), 
and adherence remains a major obstacle in public health in South Africa as it is globally. 
Obstacles to adherence seem to be related to issues of the healthcare system,  patients’ 
knowledge about their chronic disease, beliefs and attitudes, and the relationship with healthcare 
professionals (Vermeire et al., 2007). Improvement of documentation of clinical information in 
the medical records, as well as clinicians training for implementation and adherence to clinical 
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practice guidelines, are potential areas of improvement. This problem in some ways may reflect 
that treatment guidelines, usually written by specialists and based on the results of clinical trials, 
do not take into account key issues faced in primary care. These include the amount of time and 
resources available to screen, educate, medicate, and reinforce regular, maintained blood 
pressure and glycaemic control.   
Patient adherence factors involved with management of chronic illnesses like DM and 
HTN is very poorly researched and probably more important and even more complex than 
currently realised (Ingersoll and Cohen, 2008, Chapman et al., 2005, Cramer, 2004, DiMatteo et 
al., 2002). Patient’s medication-taking, matching the prescribed treatment regimen, is influenced 
by many factors. Adherence factors include aspects such as depression, health literacy and the 
complexity of the medication regimen (Ingersoll and Cohen, 2008). Pill burden, regimen 
complexity, side effects, duration of needed treatment, and dosing schedule all further impact on 
patient adherence.  
Adherence, as defined by the WHO, is clearly complex and  is defined as the degree to 
which a person’s behaviour corresponds with the recommendation of the health care provider 
(World Health Organization, 2003) . Adherence can relate to actions such as taking medication, 
following diet, and/or executing lifestyle (World Health Organization, 2003). Researchers have 
identified disease factors such as chronicity, symptom prominence, and response to treatment. 
There are also health care delivery factors such as the wait for appointments or medications, 
convenience of the pharmacy and clinic, in addition to environmental or contextual factors such 
as social support and socioeconomic status. Clinician factors such as clear communication and 
time spent explaining the disease and the treatment, and patient–clinician relationship factors 
such as trust are also documented as being important.  Collaborative management, involving the 
doctor, patient, nurse, pharmacist and support from relatives, is an area which must be 
considered to achieve a significant improvement in treatment success rates with regard to HTN 
and DM. I will discuss this later in the thesis. 
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Obesity Risk Factor Management 
Obesity greatly increases the risk of cardiovascular disease, metabolic syndrome, and DM 
(Yudkin, 2007, Hallan et al., 2006a, Hossain et al., 2007). In South Africa, obesity has a greater 
effect on women than men (Puoane et al., 2002, Vorster, 2002). Obesity is a complex disorder 
that is difficult to control. Lifestyle measures remain the cornerstone of management, but 
maintaining weight loss, even if achieved, is difficult. 
Regulation of body weight is maintained by biological factors which favour weight gain 
and defend the body against weight loss (Sikaris, 2004). People must continually fight against 
biological factors and environmental pressures that encourage weight gain or provide the 
context that facilitates weight loss. Managing obesity firstly requires that a non-overweight 
person does not gain weight: a diet which is eucaloric,  and regular daily exercise of between 30-
60 minutes (Department of Health, 2001). If a person is overweight, this becomes more difficult, 
requiring a hypocaloric diet and 45-60 minutes of daily exercise (Merchant et al., 2006). A 
number of studies have been carried out evaluating obesity management and a person’s ability 
to maintain weight loss. In the United States the Trial of HTN Prevention Phase II (TOHP-II) 
people were assigned to two groups. One involved usual care, diet and exercise, and the other 
was given additional support through group meetings and individual counselling (Stevens et al., 
2001). In this study, if weight loss was maintained after 3 years, there was a 65% reduction of 
developing HTN. However, these positive results were dampened by the fact that reduction was 
only maintained in 12% of people. This challenge was similar in DM prevention studies, where 
considerable effort and resources were needed to achieve and maintain weight loss of around 
4.5kg, although if the weight loss was achieved, it resulted in a 60% reduction of developing type 
2 DM (Lindstrom et al., 2003, Diabetes Prevention Program Research, 2002). Achieving 
sustainable weight reduction in clinical practice remains challenging.  
 
Managing Dyslipidaemia 
Patients with HTN and especially those with type 2 DM have an increased prevalence of 
lipid abnormalities. This  contributes to their high risk of CVD (Neaton and Wentworth, 1992) and  
  
49 
predicts the increased risk of kidney dysfunction. Treatment may impact on the development of 
kidney disease (Muntner et al., 2004). Hyperlipidaemia is also associated with a more rapid loss 
of renal function and the progression of established kidney disease (Manttari et al., 1995, 
Campese and Park, 2007, Ruggenenti et al., 2001b).  For the past decade or more, multiple 
clinical trials have demonstrated significant beneficial effects of pharmacologic HMGCoA4 
reductase inhibitor or statin therapy on diminishing the risk of cardiovascular morbidity and 
mortality in subjects with coronary artery disease or type 2 DM and for primary CVD prevention 
(Baigent et al., 2005, Colhoun et al., 2004, Sever et al., 2005, Collaborators, 2008). Clinicians 
have been urged to regard CKD as a CVD risk equivalent and to manage patients in accordance 
with guidelines from the American National Cholesterol Education Program Adult Treatment 
Panel (Expert Panel on Detection, 2001), and there is evidence supporting these 
recommendations (Nogueira and Weir, 2007). Despite the multiple beneficial effects of statins on 
CVD risk in well resourced settings, only about a third of patients in general, and patients 
specifically with CKD and ESRD, are currently treated for hyperlipidaemia (Fox et al., 2004b, 
Stacy and Egger, 2006).  
Screening for dyslipidaemia is advised annually in most DM and HTN guidelines (Society 
for Endocrinology, 2003, Southern African Hypertension Society, 2003, South African Renal 
Society, 2004, American Diabetes Association, 2008). Although goals for lipid control are similar 
to international guidelines (<5mmol/L) (Society for Endocrinology, 2003), in South Africa the 
target levels for initiating treatment for cholesterol are much higher than other guidelines. It 
should be noted that lipid modifying medications are not available in the PHC setting and are not 
included in the South African National Essential Drug List  (EDL) Primary Care Guidelines 
(National Department of Health, 1998a).The use of lipid modifying drugs like the statins is seen 
to be too costly, and consequently the emphasis is on lifestyle modification, including reduced 
consumption of saturated fats and cholesterol, and increased exercise, until levels of  cholesterol 
are >6.5mmol/L, LDL >4mmol/L or HDL <1mmol/L in men and <1.2 in women (Seedat et al., 
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2006). In developed and developing country guidelines, and especially in relation to diabetes, 
clinicians are encouraged to initiate lipid modifying drug therapy only if patients are at particular 
high risk of cardiovascular disease, have had previous cardiovascular disease, or if their lipid 
levels are very high (Berger and Marais, 2000, American Diabetes Association, 2008).   
As in the metabolic syndrome, the management involves a comprehensive targeting of 
the overall risk factors for CVD and CKD, with prevention focusing on avoidance of tobacco 
smoking, participation in regular exercise, and health-promoting diet, not dissimilar from obesity 
management. The Lipid and Atherosclerosis Society of Southern African goes further and calls 
for primary prevention strategies of CVD and CKD.   It encourages community based public and 
professional education and the provision of community facilities for exercise and recreation. An 
integrated approach for managing dyslipidaemia, like other CVD and CKD risk factors, is 
advised. 
 
Risk Factor Management and CKD Progression 
Control of certain risk factors is important to prevent progressive renal function loss in 
patients with established renal diseases. Here, the primary risk factors to target are high blood 
pressure (Klag et al., 1996) and proteinuria (Locatelli et al., 1996, Ruggenenti et al., 2001b);  
both are associated with a more rapid decline in renal function. Lipid abnormalities have also 
been shown to cause the progression of kidney disease (discussed above). Genetic factors also 
appear to be involved, and people with the ACE DD genotype progress more rapidly to end-
stage renal failure than those without that genotype (van Essen et al., 1996). This beneficial 
effect of angiotensin converting enzyme inhibitors (ACEi) in preventing the progression of 
chronic kidney disease (CKD) is clear from a number of evidence based clinical trials (Parving, 
2001, Lewis et al., 1993, Bakris, 1993, Heart Outcomes Prevention Evaluation Study, 2000, 
Maschio et al., 1996, Kshirsagar et al., 2000). Several studies have demonstrated the potential 
for preventing or delaying the initial onset of diabetic kidney disease by treating patients who 
have DM with ACEi. ACEi prevent the development of microalbuminuria (ADVANCE, 2007, 
Asselbergs et al., 2004). In the early stages of DM, patients may have heightened renal function, 
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which manifests itself as a high GFR, sometimes called hyperfiltration. Such a state may 
precede the development of microalbuminuria in DM (de Jong and Brenner, 2004). 
The specific targets for remission and regression of CKD,  summarised in two publications 
(Hebert et al., 2001, Ruggenenti et al., 2001b), include the following clinical targets:  excellent 
glycaemic control in diabetic patients, aggressive blood pressure control, correction of 
dyslipidaemia; reduction in proteinuria with ACEi and/ or angiotensin receptor blockers, 
reduction in cardiac risk factors, and appropriate diet and lifestyle modifications. These aspects 
mirror those advised in the approach to managing the metabolic syndrome, highlighting its 
commonality with CVD. 
A number of factors are associated with progression of CKD in people with known pre-
existing renal disease. Early detection and the ability to prevent progression are important 
factors motivating the development of kidney and cardiovascular protection programs, where 
standardised treatment strategies, simplified targets and early detection of risk factors can be 
evaluated (Coresh et al., 2003). As discussed above, studies have demonstrated the beneficial 
effects of numerous interventions and simplified targets to prevent or delay the progression of 
CKD.  
Clinical diagnosis of CKD has become simplified. Current recommendations call for 
annual urine testing and monitoring of people with DM, HTN or HIV (de Zeeuw et al., 2005, 
Gupta et al., 2005). Testing for proteinuria in the risk groups of DM and HIV has not been as well 
established as that for HTN, where a simple dipstick method has been calculated to be cost 
effective (de Jong and Brenner, 2004). The Kidney Disease Outcomes and Quality Initiative 
(K/DOQI) Guidelines, discussed earlier and developed by the United States Kidney Foundation, 
have provided a framework for the diagnosis, staging, and evaluation of CKD (Eknoyan and 
Levin, 2002). These Guidelines recommend a stage-appropriate action plan that is independent 
of the type of kidney disease and can be taught to and carried out by non-nephrologists (Table 
2).  Importantly, this framework outlines interventions that address both CKD and CVD, and their 
risk factors; It includes the use of an estimated GFR calculated from a prediction equation, which 
incorporates serum creatinine (as opposed to relying only on serum creatinine), as the best 
measure for assessing kidney function in routine clinical practice. The guidelines acknowledge 
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and recommend the routine provision of an estimated GFR (eGFR) to facilitate identifying and 
staging individuals with CKD  (K/DOQI, 2002). Improving early recognition of patients with CKD 
necessitates laboratory testing of people at increased risk. An albumin-specific method for 
testing spot-urine samples, albumin-creatinine ratio (ACR), will detect kidney damage earlier 
than standard urine-protein tests. Early identification widens the window of opportunity to put 
effective interventions to work, so benefiting patients and reducing costs both for patients and 
health care organizations. The development of this framework has proven to be a critical factor 
to stimulate research and provide a guide to those wishing to start early detection programs. It 
has impacted not only on our ability to affect CKD, but importantly, outcomes in CVD. However, 
the use of these methods to detect CKD and especially the ESRD group (CKD stage 5), has 
limitations. The number of patients with ESRD probably underestimates the entire burden of 
CKD because the numbers with earlier stages of disease (stages 1 to 4, Table 5) are likely to 
exceed by as much as 50 times those reaching ESRD (stage 5) (Coresh et al., 2003). 
 
Table 5. USRDS CKD Staging and Incidence of CKD in each group 
  
Stage Description GFR 
(mL/min/1.73m2) 
Prevalence* 
 At increased risk >90 
(with CKD risk 
factors) 
N(1000s) % 
1. Kidney damage 
with normal or ↑ 
GFR 
90 5,900 3.3 
2. Kidney damage 
with mild ↓ GFR 
60-89 5,300 3.0 
3. Moderate ↓ GFR 30-59 7,600 4.3 
4. Severe ↓ GFR 15-29 400 0.2 
5. Kidney Failure <15 
(or dialysis) 
300 0.1 
 
 
The data derived from the third National Health and Nutrition Examination Survey in the United 
States indicate that up to 11% of the general adult population (19 million) could have some 
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degree of CKD, including more than 8 million individuals with eGFR of less than 60mL per min 
(Coresh et al., 2003). An estimated 5·9 million people could have stage 1 CKD with normal renal 
function. These observations have substantial limitations, including basing prevalence estimates 
on single serum creatinine measurements, which are subject to variations owing to differences in 
calibration systems between laboratories (Clase, 2006, Levey et al., 2007b, Coresh et al., 2002). 
In addition, the data do not indicate which patients will progress to ESRD. Subsequently, the 
estimates based on serum creatinine were converted into estimates based on GFR by use of the 
formula of the Modification of Diet in Renal Diseases study (Hallan et al., 2004).  This has not 
been fully validated in different populations and at different stages of CKD5 (Coresh et al., 2002).  
 A discussion by Chen and Hsu (2003), based on the results of the third American 
National Health and Nutrition Examination Survey (NHANES), has questioned the need to 
change the classification of CKD used by the US National Kidney Foundation’s Kidney Disease 
Outcomes Quality Initiative (NKF DOQI). This classification is continually subject to debate, and 
some have argued that stages 1 and 2 would be better defined by the associated abnormalities 
(e.g. microalbuminuria, haematuria; panel 1) rather being classed as CKD. These improvements 
are believed to assist clinicians with daily clinical practice. Questions remain about the validity of 
using these equations to estimate GFR in population based epidemiological surveys. However, 
an eGFR remains an acceptable tool to evaluate kidney function. 
 
Kidney and Chronic Disease Programs across the globe  
 The early identification of people at risk of CKD, and the prevention of 
progressive CKD, is likely to be key factors in alleviating the future burden of ESRD and the 
associated mortality. Ninety percent of people who develop ESRD and require dialysis in a 
developed world setting will receive it, while most people in developing world communities with 
ESRD will die (De Vecchi et al., 1999). The huge disparity in the prevalence of ESRD between 
                                               
 
 
 
5
 The two most commonly used prediction equations for calculating an estimated glomerular filtration rate (eGFR) are 
the four variable Modification of Diet in Renal Disease (4-v MDRD) (Levey et al. 2000) and Cockcroft-Gault (CG) 
equation (Cockcroft and Gault 1976). The applicability of these equations for black South Africans is unclear. 
However, at the time of this study a ‘South African’ equation had not yet been formulated. 
  
54 
more and less developed countries probably stems from the inadequacy of health-care resource 
allocation to programs of renal replacement therapy (RRT), i.e. dialysis and renal 
transplantation.  
The pattern of ESRD (CKD stage 5) has changed over time. In the 1970s, 
glomerulonephritis and pyelonephritis were the most widespread causes of ESRD. In the last 
decade, the prevalence of these diseases had declined relative to the epidemic increase of type 
2 DM and vascular diseases such as HTN and generalized atherosclerosis. In South Africa HIV 
is also a major factor associated with ESRD. As discussed earlier, CKD and CVD have common 
risk factors and can be detected early by tracking albuminuria and  the GFR (de Jong et al., 
2003). Unfortunately, most patients are referred to a nephrologist only when renal function is 
close to the level where dialysis is required, when conservative reno-protective treatments will 
have little impact. In developing countries, this often means death, as no dialysis or transplant 
facilities are available. Initiatives should be undertaken to make health care providers and the 
general population more aware of the seriousness of CKD, its risk factors, and opportunities for 
screening. People identified with CKD should be provided appropriate educational materials to 
explain the treatment regimens and the benefits of undertaking therapy.  
Currently, there are very few surveillance systems for tracking patients with chronic 
illnesses and especially CKD in stages before dialysis or transplantation. For this purpose, the 
International Society of Nephrology has designed guidelines adapted to the developing world 
(International Society of Nephrology, 2005). Recommendations, are based mostly on consensus 
procedures rather than hard evidence (National Kidney Foundation, 2002), and different 
screening strategies, have not been compared for their ability to detect chronic kidney disease or 
their efficiency. Screening only persons deemed to be at high risk is a viable option when mass 
campaigns are impossible and resources are limited. In one study, 20% of people had estimated 
glomerular filtration (eGFR) rates lower than 30 ml/min/1.73m2, but only 1-2% of those with 
values of 30-60 ml/min/1.73m2 progressed to end stage renal disease over eight years (Hallan et 
al., 2006c). This study helped simplify the screening task by showing that a simple screening 
strategy targeting people with DM, HTN, or age >55 had the highest detection rate for CKD and 
this was combined with a low number needed to be screened (Hallan et al., 2006c). This 
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approach of screening high risk patients for CKD is the approach currently proposed and 
followed by most people who focus on CKD and CVD (Hoy et al., 2003b, Rossert and Wauters, 
2002, de Jong and Brenner, 2004, Ohmit et al., 2003). However, most patients detected had a 
low risk of progression to end stage renal disease. Whether screening is cost effective needs 
further research, as there are limited studies with longitudinal follow up and extending screening 
to people without DM or HTN cannot yet be recommended. Efficient screening might lead to an 
increase in workload for the health services as the patients detected are at high risk and need 
intensive intervention to prevent progression to ESRD and CVD complications. The costs of 
detecting patients and treating them might not be economically balanced in relation to possible 
expenditure on medical care as a whole. For this reason,  control of DM, HTN, smoking, 
overweight, dyslipidaemia, infection, and pollution, and possibly the use of a single daily pill 
(“polypill”) containing generic ACEi, statins, aspirin, and folic acid, should be on the agenda of 
many developing countries (Barsoum, 2006). 
The options when establishing a CKD or CVD prevention program includes either 
screening an entire population, as in the Dutch PREVEND and in the Australian Aboriginal 
studies, or to detect a cohort of people at the highest risk of kidney disease (de Jong et al., 
2003, Hoy et al., 2003c, Katz et al., 2002)(see Figure 14 below). The former approach is costly, 
less likely to be achieved in the developing world, and so is inappropriate.  
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Figure 14. CKD Prevention Strategies  
 
 
Evidence also supports a more focused screening approach. Mass untargeted screening 
appears to capture only a few percent, whereas targeted (e.g. HTN) screening is more effective, 
capturing 50% or more (Brown et al., 2003a, Littenberg et al., 1990, Boulware et al., 2003). 
Screening should target persons most at risk for chronic kidney disease: individuals with a 
personal or family history of DM or HTN, those from poor social circumstances, and high risk 
ethnic groups (Lei et al., 1998). 
In Australia, Wendy Hoy and her team developed a number of programs in Australian 
Aboriginal communities, and had collaborated with teams elsewhere including India, Nigeria and 
South Africa (Katz et al., 2006a, Katz, 2005b). She has outlined the need to work together with 
communities to engage community interest in chronic illness management and prevention 
strategies, to help assess needs in the community, and to develop an agreement with the local 
community or health authority (Hoy et al., 2003a). Once these basic requirements are met, then 
one can proceed to help local staff implement the program, to try to ensure sustainability, and to 
provide a mechanism and skills to evaluate the processes and outcomes. Below, a few specific 
international programs aimed at preventing these diseases are discussed.  
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Kidney Help Trust Rural Project – India  
Indian nephrologists were faced with the same problems as in South Africa. They had the 
expertise to provide dialysis but not the resources to deliver to all (Mani, 2006). The Kidney Help 
Trust was developed in 1985 in Chennai, originally to fund transplantation, and was one of the 
earliest programs tackling the overwhelming CKD problem in India. In India DM and HTN are 
widely prevalent, and the incidence is increasing steadily. The program was established to 
identify all people with DM and HTN as early as possible, detect those at risk, and treat risk 
factors well before the kidneys were damaged, at the least possible expense. It was the first 
non-communicable disease program in India, although programs existed for ‘chronic’ infectious 
diseases like TB and leprosy.  This program focused on proteinuria, HTN and DM and included 
other common local renal diseases, e.g. kidney stones (Mani, 2003); it later included screening 
for kidney function. Persons at risk of renal failure were identified using the MDRD formula. The 
program needed to develop vertically, but was run by local community participants (health 
workers). The success of the project was its simplicity. It involved a cheap mass screening 
campaign, run over a number of years and aimed at early detection of kidney disease, it 
included 25 000 people in a group of villages and hamlets about 50 km from Chennai. It was 
also driven by primary health care nurses (PHCNs), who were trained to detect disease and give 
basic treatment under supervision. The problems of this kidney disease screening program 
included lack of long-term quantitative data and inability to evaluate the impact of the 
intervention. Mani (2003) noted that only 8% took ongoing treatment, indicating problems with 
adherence, and those health workers were only able to visit homes every 18 months. It also 
reflects the weakness of not focusing on those at high risk, as was carried out in other programs 
i.e. rationalising the screening process. However, the program had an impact on the 
communities’ awareness of CKD, and detected and successfully treated people at risk for both 
CKD and CVD. The program’s success was its modest and relatively simple goals, and its focus 
on the primary care setting, detecting people before they presented to hospital.  
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Bolivian Renal Disease Project 
The Bolivian Renal Disease Project, a collaborative project run by Plata and Remuzzi 
with the support of the Bergamo Institute and International Society of Nephrology and 
Commission for the Global Advancement of Nephrology (ISN-COMGAN), involved a population 
based mass screening for urinary disease in ‘healthy’ subjects (Perico et al., 2005, Plata et al., 
1998).The program was motivated for similar reasons to other developing country programs, i.e. 
shortage of resources and access to dialysis and transplantation. However, the purpose of the 
program was not only to detect those people with kidney disease but also to carry out an 
epidemiological survey to determine the extent of kidney disease in the country. About 14 000 
patients were screened and urinary abnormalities were detected in over 4000.  These people 
were referred to local health centres and were to be followed up for three years. Unfortunately 
only 23.9% were followed up (Perico et al., 2005). For those with positive screening for kidney 
disease, further investigations disclosed an array of kidney abnormalities, 1.6% having end 
stage kidney failure. The successes of this project outlined the basis to starting all such 
programs, i.e. gaining a good understanding of local problems using a simple and cheap test. 
This study helped define the incidence of asymptomatic kidney diseases in an unselected 
population. It showed that it is possible to screen a large population at relatively low cost, and 
provided a framework for further action to help prevent and diagnose kidney diseases. Aside 
from its scientific value, this study illustrates how, by rationalizing resources and investing in 
research programs, renal disease progression and cardiovascular risk may eventually improve, 
resulting in less demand for dialysis, and reducing cost of treatment and also death. However, 
the initiators of this program again saw the solution to future programs as in the hands of kidney 
specialists only. I will argue throughout this thesis that solutions need to lie mainly in the primary 
care setting in chronic disease clinics, with the support of kidney specialists. 
 
Cuban Program for Prevention of Chronic Renal Failure 
Cuba faces the same problems, but has greater resource challenges. Most people with 
end stage kidney failure are not offered any dialysis or transplantation. Cuban nephrologists 
have focused their efforts on developing a public health model integrating health promotion and 
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disease prevention (Almaguer et al., 2005). The Ministry of Public Health of Cuba launched the 
National Program for the Prevention of Chronic Renal Failure in 1996. The predominant focus of 
this program is around policy and health system changes rather than specific program 
development. The health ministry has analysed resources and evaluated the burden of kidney 
disease in the country. The program includes education for nephrologists, family doctors, and 
other health professionals, including the orientation of primary health care toward increased 
kidney disease surveillance and treatment. The Cuban program shows an excellent 
understanding of the need to link primary, secondary and tertiary prevention with the progression 
of kidney disease (see figure 2). Although no specific program has been developed, the aim is to 
integrate interventions within the primary health care system and focus on high risk people with 
CVD or CKD risk factors. What is unique about Cuba is that it has an excellent primary health 
care infrastructure with very high doctor to patient ratios.  
 
The United States NKF KEEP  
Moving to programs in developed countries, in the United States the concern over the 
doubling of its ESRD population who will require dialysis by 2010 from 300 to 600 thousand, 
prompted the National Kidney Foundation (NKF) to sponsor the NKF Kidney Early Evaluation 
Program (KEEP). KEEP screenings are conducted across the country, but the majority have 
been in South and Atlantic regions. The program relied on people volunteering to be tested. To 
maximize efficiency, this program also targeted those at high risk group: first order relatives of 
people with HTN, DM or kidney disease and those with a personal history of HTN or DM (Figure 
14). The aims of the program were to encourage at-risk persons to seek evaluation and 
management from a healthcare provider (McGill et al., 2004). 
The KEEP Pilot Screening Program demonstrated that targeted screening is an effective means 
to identify people at risk for kidney disease, and to identify them early enough to allow for 
effective intervention (Brown et al., 2003a). The screening identified risk factors for DM, HTN 
and/or kidney disease in 71.4% of individuals screened. The program also identified that the 
presence of anaemia, an eGFR <60mls/min per 1.73 m2, and microalbuminuria were 
independently associated with CVD, and when all 3 were present, CVD was common and 
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reduced survival (McCullough et al., 2007). The program confirmed the link between CKD and 
CVD (Go et al., 2004), and the results supported the view that screening for CVD would be of 
high yield among people with these risk markers even if they do not admit any history of CVD 
symptoms (McCullough et al., 2007). 
The KEEP program was effective in getting some people screened to see a physician, 
but not all. What was of concern were the findings after the primary care physician’s review. 
Those referred with a possible problem did not know what their clinicians’ management decision 
was nor what the findings were after they had been seen. Some clinicians advised patients not 
to worry about ‘small’ amounts of protein in the urine, or that ‘slightly’ elevated serum creatinine 
levels were not of concern. This highlighted the poor baseline knowledge of CKD by primary 
care clinicians. Education of primary care clinicians and health care providers regarding 
significance of abnormal test values and appropriate interventions emerged as particular areas 
of concern. In view of this, KEEP has since started a third generation version of the program 
which includes multiple interventions for the patient, to improve understanding and motivation to 
better manage their chronic conditions, but also to improve clinicians knowledge and 
management protocols for these conditions. KEEP highlighted the needs for people to embrace 
lifestyle behaviours that reduce risk, and adhere to medical recommendations in managing their 
existing conditions. At the same time, health care providers need to implement the latest 
evidence-based guidelines in diagnosis and treatment (Ohmit et al., 2003).  
 
The Dutch PREVEND Program  
In Holland the PREVEND (Prevention of Renal and Vascular End-stage Disease) study 
to investigated the impact of microalbuminuria in the general population in city of Groningen. The 
study organisers invited a potential 85 000 potential subjects, aged 28-75yrs, to participate and 
41 000 agreed and sent their urine by post for screening. Seven percent were found to have 
significant microalbuminuria, a urinary albumin concentration of 20–200 mg/l.  Amongst these 
3000 subjects with microalbuminuria, 75% were not known to have either DM or HTN. Although 
the prevalence of microalbuminuria was higher in diabetic (16%) and hypertensive (11%) 
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subjects, still 6.6% of subjects without known risk factors appeared to have microalbuminuria 
(Hillege et al., 2001). 
As a result of  the PREVEND program, the authors invited those people screened with high 
normal proteinuria or significant proteinuria into a follow up study. This study also included 
additional people screened. Among this new group of just over 8500 subjects, it was determined 
that males, older age, obesity (Pinto-Sietsma et al., 2000a) and smoking (Pinto-Sietsma et al., 
2000b) were  important predictors for a higher risk for the likelihood of having proteinuria. 
This cohort has been followed up for over ten years, making this a comprehensive screening 
and evaluation program which has shown how risk factors and CVD and CKD outcomes are 
connected (Bello et al., 2007, Halbesma et al., 2006). These findings are further supported by 
results from the same Dutch group, in the PREVEND-IT study. Here they found that when 
screening the general Dutch population for albuminuria, followed by empirical treatment with an 
ACEi (fosinopril), those people who were positive for proteinuria benefitted. The Dutch group 
questioned whether an empirical intervention with an ACEi in high risk patients was more cost-
effective than  screening (Atthobari et al., 2006). This has implications for developing countries 
where supplying appropriate treatment may be more important than screening high risk 
individuals. This last study provides an argument for ‘simply’ treating all high risk patients, and 
suggests screening may be an unnecessary costly exercise. However, this does not address the 
other values of screening which include determining the epidemiological differences which may 
exist in different countries and different population groups.  
 
The Singapore NKF Screening Program  
Singapore is a newly industrialized country with excellent access to dialysis when 
patients develop end-stage renal disease (ESRD). Seventy percent of the country's total ESRD 
population receives subsidized chronic dialysis care at the National Kidney Foundation 
Singapore (NKFS), a unique dialysis provider funded through charitable donations (Ramirez et 
al., 2003). The NKFS developed a comprehensive early detection and treatment of CKD 
because of the expected escalation in the burden of ESRD in the nation and the impact it would 
have on funding. The plan was aimed at ameliorating the continued increase in ESRD through 
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an early intervention and prevention program. This is possible because of the small population 
and geographic size of Singapore, and because renal disease and dialysis, through the NKFS, is 
a very popularly supported charity. The NKFS Prevention Program also incorporated a public 
health approach to the prevention of CKD. The strategy, like other programs described, was 
developed around the ‘conceptual framework of the natural history of progression of kidney 
disease and its predisposing factors (see figures 1 and 2). Singapore has a central data base, 
and collects aggregates and reports data on kidney disease in the Singapore population. The 
NKFS prevention program combined both a population-based and a high-risk prevention 
strategy, educating doctors to screen people with DM and HTN, in order to use the program as 
both a primary prevention and secondary prevention strategy focusing not on all risk factors 
associated with high risk.  This approach was cost-effective for high risk and it could be argued 
as being cost effective for a country like Singapore or Holland (de Jong and Brenner, 2004, de 
Jong et al., 2003), which could afford a population based screening program. However for most 
countries and with current evidence this would not be considered the most cost effective 
approach (Brown et al., 2003a, Sumaili et al., 2009, Hallan et al., 2006c), and a high risk 
approach would be more appropriate. Another criticism is that it did not remove the risk factors 
that lead to disease, and the approach therefore is largely palliative. The NKFS prime focus was 
on broad based general population primary screening, believing that a population-based 
approach would modify the determinants of disease in the population as a whole, and potentially 
have a larger impact on reducing the rates of disease. This latter approach relies heavily on 
public education, but also incorporates activities that remove obstacles to healthy behaviour.  
Factors influencing the choice of program included firstly that Singapore could afford a 
broad based population approach, but the epidemiology of ESRD in Singapore was also a 
significant factor influencing the prevention program. Approximately 50% of incident cases of 
ESRD are attributed to DM and HTN. Surveillance data on the level of blood pressure and 
glycaemic control for patients with DM and HTN also demonstrated sub-optimal control, leading 
the NKFS to follow an approach which targeted these patients at high risk for developing renal 
complications and ESRD. The health care delivery system of Singapore is such that most 
chronic outpatient care is conducted by primary care practitioners paid at the point of contact, 
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and NKFS does not have access or control of these practitioners. This was a major deficiency in 
the program. 
However, 450 000 patients have been screened since 1997. Analysis revealed important 
local information including racial differences in the risk factors among the major communities. 
Differences were found for proteinuria, systolic and diastolic blood pressure levels, which are not 
traditionally classified as elevated and associated with proteinuria. Proteinuria began to occur at 
markedly lower body mass index levels among certain racial groups. Malays were more likely to 
have higher proteinuria than Chinese (Ramirez et al., 2002), consistent with observations that 
Malays exhibit the highest incidence rate of ESRD, compared with other racial groups (Indian 
and Chinese). Differences in birth weights, related to socio-economic status, among these ethnic 
groups might also account for variations in HTN and renal disease (Ramirez et al., 2001). Malays 
are also more likely to be obese and have DM (Hong et al., 2004). Although this program 
focused on kidney disease, the close link of CKD with CVD risk factors helped with future 
approaches to chronic disease management. The National Kidney Foundation of Singapore 
incorporated a stepwise primary, secondary, and tertiary prevention strategy. 
Components of the program included an aggressive public education program, routine 
surveillance for kidney disease and associated chronic diseases. The implementation of a 
disease management program to improve physician practice patterns, and the provision of 
comprehensive services in the community through a network of Prevention Centres was 
developed to optimize the care of patients at risk for kidney disease. The program also provided 
a baseline epidemiological survey against which future interventions could be measured. 
 
The Australian Chronic Disease Outreach Program  
The Australian Outreach Program is a Aboriginal Australian specific, predominantly rural 
based prevention program (Hoy et al., 2003c), with both screening and treatment. It started on 
the Tiwi Islands and has since extended to other Aboriginal areas. It involves mass community 
screening to detect and treat people at high risk (Figure 14). The communities range in size from 
a few hundred to a couple of thousand. These are small, allowing paid program staff the 
opportunity to screen the entire community, compared with at risk communities in Africa, India 
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and South America.  Program nurse coordinators spend long periods of time living with the 
communities and training local health care workers to use algorithms and specific treatment 
targets for chronic illnesses. The program has significantly reduced morbidity and mortality of 
kidney and cardiovascular disease (see figure 11). It has influenced national protocols, 
becoming a government lobby group and galvanizing NGOs in Australia (Hoy et al., 2000). This 
program has been integrated into normal clinic activities in other Aboriginal communities. Its 
protocols have also been incorporated into standard care guidelines for Aboriginal adults in the 
Top End of the Northern Territory.  
A major factor of the programs’ success is the strength of the program management 
team and the funding it secured. These Aboriginal communities exist in a wealthy developed 
country, allowing the Australian CDOP the opportunity to seek out potential sponsors, including 
large mining corporations operating on or near Aboriginal land. The programs still rely on 
Aboriginal community support and in a context of considerable historical mistrust, have not 
always been forthcoming from the local health authorities. This appears to be changing with the 
program’s success. However, it is still slow to influence day-to-day practice throughout Australia.  
Indigenous Australians are disadvantaged, relative to other Australians, over a range of socio-
economic and health measures (Cass et al., 2004). The age- and sex-adjusted incidence of end-
stage renal disease (ESRD) is almost nine times higher amongst Indigenous than it is amongst 
non-indigenous Australians. A striking gradient exists from urban to remote regions, where the 
standardised ESRD incidence is from 20 to more than 30 times the national incidence (Cass et 
al., 2004). Kidney specialists understand kidney disease and ESRD from a traditional, 
biomedical perspective, in which kidney disease is attributed to one of a range of discrete 
primary disease processes. However, work among the Australian Aboriginal communities has 
created the understanding that CKD and CVD is closely related to the social, cultural and 
environmental determinants of health in conjunction with the biology of kidney disease. It has 
highlighted the need for primary prevention strategies which include improved access to 
antenatal services to reduce the prevalence of intrauterine growth retardation, screening and 
intensive management of DM in pregnancy, prevention of obesity in childhood, training 
community members to improve housing, food supply initiatives to improve access to healthy 
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foods, cultural appropriate initiatives to improve nutrition and decrease smoking and physical 
activity programs to reduce obesity and likelihood of DM (Cass et al., 2004, Hoy et al., 2006). 
This research highlights the need for secondary prevention, covering the period from the 
development of albuminuria to ESRD, requiring a coordinated national program to provide 
community based screening and intervention for HTN, DM and albuminuria (Hoy et al., 2000, 
Hoy et al., 2003b). Early use of ACEi and starting oral hypoglycaemic agents and insulin for DM 
management is also recommended. Adequate resources and well supported staff are essential 
for sustaining such programs (Hoy et al., 2005b). This includes constant evaluation to follow 
outcomes and modify strategies in accordance with chronic illness care guidelines (Wagner, 
2004, Wagner et al., 2001).  
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3 STRATEGIES FOR CHRONIC ILLNESSES MANAGEMENT 
The objectives of this chapter are to investigate the current approaches for managing 
chronic illnesses. The discussion will take a critical look at the focus on prevention of risk factors, 
the associated diseases implicated in the chronic illness burden and whether it is appropriate 
and have the greatest impact on public health. It will critically investigate whether the ‘prevention’ 
strategy has lost its way. The argument will also focus on aspects of health systems which could 
have an impact on the chronic illness burden. Thereafter the focus will shift more specifically to 
kidney disease detection and management programs, evaluating the different approaches in the 
context of this discussion.  
Many economically advanced nations have achieved major reductions in the toll of 
chronic diseases, especially of CVD, which researchers tend to attribute more or less equally to 
prevention strategies and health services (Unal et al., 2005, Kuulasmaa et al., 2000). From this 
experience, several evidence-based interventions have emerged for the prevention and control 
of chronic diseases. The global emphasis is on primary prevention, focusing on a few key 
modifiable risk factors e.g. unhealthy diets and physical inactivity resulting in obesity (World 
Health Organization, 2007b, Nestle, 2006) and tobacco use (Lancet., 2007). This appears to be 
both rational and cost effective.   
For the past twenty years, strategies of primary and secondary prevention and treatment  
have been adopted and continue particularly in the areas of paediatrics and obstetrics, in the 
United Kingdom, United States and Australia (Rose, 1981). This combined application of primary 
and secondary prevention is achieved in obstetrics through good antenatal care, immunisation 
against tetanus and supervised delivery, and in paediatrics with childhood immunisation, weight 
monitoring, breastfeeding and other practices. This approach to health care has also been 
introduced in cardiovascular care, where clinicians are searching for ways to prevent deaths 
from stroke or myocardial infarction through early identification and treatment of diseases such 
as hypertension. 
We now have to ensure that the integration of prevention and treatment finds its way into 
the mainstream practices of primary health care and that they include kidney and cardiovascular 
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disease management. It has been estimated that the implementation of integrated strategies in 
cardiovascular disease management in a few key developing countries could prevent around 18 
million deaths globally over the next 10 years (Lim et al., 2007). Achievement of these health 
gains would need an average yearly investment of $4·7 billion or $1·10 per head, depending on 
the country. Medications would account for around two-thirds of this cost, but interventions for 
populations and individuals at high risk would almost meet the global goal for prevention and 
control of chronic diseases.  
 
Failures of Existing Prevention Strategies 
Medical science and public health have progressed appreciably over the past 50 years in 
managing CVD and CKD. We have an extensive understanding of the risks associated with 
these diseases and their complications, the treatment targets for disease control,  and advanced 
medications to achieve these goals (Figure 15) (El-Nahas, 2004). The chronic disease threat 
can be overcome using existing knowledge. Yet we remain unable to control common chronic 
conditions like DM and HTN, which would decrease the incidence of CKD and CVD. Effective 
solutions require comprehensive and integrated action at country level, led by governments and 
involving local NGOs and actors at all levels of the health system. 
 
Figure 15  Treatment Targets and Medication for CKD and CVD 
ACEi – angiotensin converting enzyme inhibitor, ARB- Angiotensin Receptor Blocker, CCB – Calcium 
channel blocker, NCCCB – Non-dihydropyridine calcium channel blocker, b-blocker – beta blocker 
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Life style factors, discussed earlier, impact on CVD and CKD. Prevention aimed at risk 
factors and early diagnosis and treatment have a striking effect on reducing CVD morbidity and 
mortality, but there is still little information to inform systematic implementation, the “how” of 
chronic disease programs (World Health Organization, 2007a). Surveys conducted by the WHO 
over the last five years show some early signs of progress. The proportion of countries with a 
national policy for chronic disease prevention and control rose from 42% to 70% between 2005 
and 2006 (World Health Organization, 2007a). In this period, the proportion of countries with a 
chronic NCD unit or department in the health ministry also increased from 60% to 84%, and the 
proportion of countries with a specific budget line for chronic NCDs increased from 39% to 68% 
(World Health Organization, 2007a). Nevertheless, the proportion of the health budget spent, in 
general, on prevention and control of chronic NCDs remains very small. Although the scientific 
knowledge to achieve the global goals now exists, many low-income and middle-income 
countries must deal with the practical realities of limited resources and a double burden of 
infectious and non-communicable diseases. Integrated strategies, discussed earlier, as 
proposed by the WHO (Epping-Jordan et al., 2005), are always relevant for countries with 
budgetary and resource constraints. WHO has proposed an integrated stepwise approach to 
chronic disease prevention and control (Epping-Jordan et al., 2005), including secondary 
prevention strategies once a country can afford them. The main principle of this approach is a 
phased implementation of interventions, with core, expanded and optimum interventions, based 
on the availability of resources, political and community support, and the configuration of 
national health systems. Ideally, the interventions are comprehensive and balanced at every 
step, covering programs directed at the whole population and at individuals at high risk. As 
additional resources become available and support broadens, an expanded set and ultimately 
an optimum set of interventions can be implemented.  
The concept and understanding of prevention has expanded and changed over the past 
few decades to include the management of risk factors, with risk factors being considered as 
“diseases”(page 580) (Starfield et al., 2008). Prevention has generally been considered as that 
which prevents disease (primary prevention) and that which prevents the progression of existing 
disease (secondary prevention). The World Health Organization did not include prevention as 
  
69 
part of the role of the health system (World Health Organization, 2000a), and prevention 
strategies now include primary, secondary and even quaternary prevention (Starfield et al., 
2008).  For some preventing morbidity on dialysis may not be considered prevention at all. The 
threshold for risk factors being treated and being termed disease is being lowered (Kaplan and 
Ong, 2007), which has implication to costs of healthcare and patient management. This has 
resulted in the treating of risk factors without strong evidence that they will have an overall 
improvement on ‘population health’. It has also resulted in increased expenditure, as 
medications are directed at each risk factor, without clear evidence of its impact on 
cardiovascular outcomes (Ferreira-González et al., 2007) . Starfield (2008) has begun to 
question whether this approach is most appropriate and whether the shift should not focus on 
the ‘population’ as a whole rather than the individual with CVD risk factors. It was Rose (1981), 
who provided evidence for reducing coronary artery disease as a result on focusing on risk 
factors. However it was the intention of Rose to have a population orientation, and not on the 
individual patient focus. An example used for inappropriate use of research findings are when 
anti-lipid medication researched in males was recommended for females, without the supporting 
evidence (Kendrick, 2007). It is not enough to show a medication works in one population group 
and then recommend it for all others (S Ward et al., 2007). Population-based studies 
consistently show lower risk of disease or morbidity from single risk factors compared with 
clinical based studies (Fox, 1996). Prevention has always been to focus on diseases, and risk 
factors are being considered the same as disease. This has resulted in the boundaries between 
prevention and care becoming blurred. Starfield (2008), highlights the major challenges to 
establishing policy for appropriate interventions to reduce the burden of illnesses would be to 
focus on  the success or failure in populations, prioritising inequities in health populations and 
improving health generally in the population, rather than focus ‘disease by disease’. Population-
attributable risk should be the priority over individual (relative) risk, and focus should be on 
defined populations with strong evidence to support an intervention. Interventions should be 
shown to be cost effective and reduce morbidity and not just the ‘disease’. Population-based 
information systems make it possible to merge ‘‘prevention’’ and ‘‘care’’, and the full range of 
options must be considered to achieve the desired outcomes and these should be prioritised 
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according to maximum gain for the population as a whole. A compelling argument now exists for 
carefully reconsidering our approach to improving outcomes for chronic illnesses. 
This WHO stepwise framework offers a flexible and practical approach to assist 
ministries of health in balancing diverse needs and priorities while implementing evidence-based 
interventions (Epping-Jordan et al., 2005). The WHO recognizes the difficulty in achieving the 
above ideal and has proposed that countries adopt a practical or a phased approach, tailored 
according to existing capacity. The WHO outlines the methods for achieving this approach by 
advising the development of a hierarchical framework to unify surveillance and prevention 
program activities, recognising that these should be flexible across a range of risks, conditions, 
ages and areas (Bonita, 2003). Standard methods and tools are adaptable to local settings. The 
aim is to start with primary prevention strategies and then to progress to secondary and tertiary 
level care according to existing resources.   A key aim is to develop basic sentinel surveillance 
and treatment sites, and then to add on to existing systems (Figure 16). 
 
Figure 16. The WHO STEPS Framework 
 
At the national level, government should provide a unifying support role for CD 
prevention and control, so that actions at all levels and by all stakeholders are mutually 
supportive. Broad based action, across different sectors, is necessary at all stages of policy 
Step1: Behaviours
 Tobacco and alcohol use
 Intake fruit and vegetables
 Physical inactivity
Step 2: Physical measures
 Height, weight, waist
 Blood pressure
 Pulse rate
Step 3: Blood samples
 Cholesterol
 Blood glucose 
Next Steps: … Expanded … Optional etc.
Example:….Decision Support….Information System
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formulation and implementation because major determinants of chronic disease burden lies 
outside the health sector. As part of comprehensive public-health action, population-wide and 
individual interventions are combined, and this recognises that most countries will not have the 
resources to immediately do everything set out in the policy. However the implementation of 
these strategies is far more difficult to achieve than suggested and this strategy offers no 
practical approach or processes for implementing the framework. The barriers affecting 
implementation in clinical practice need to be corrected and effort needs to be directed to these 
ideals. It has also been proposed that certain key principles be implemented at the PHC level, 
clinic or family practice, during one on one consultations with patients who have chronic 
illnesses (Couper, 2007). The service needs to both appropriate and of a certain quality and 
certain key principles need to be addressed at this level of care. The “7 habits of highly effective 
carers” (page 6, Couper 2007), highlighted include those proposed by both the Wagner Chronic 
illness Care Model (CICM) and WHO Innovative Care for Chronic Conditions  (ICCC) 
Framework. Fundamental strategies include commitment to the person who is ill, continuity of 
care, collaboration, a comprehension of the patients regarding their illness and how to manage it 
themselves. It also includes the ability of a patient to adapt to change, adhere to their new 
treatment and lifestyle changes. Finally it includes clear and simple guidelines for health 
providers and patients and the capture and tracking of clinical information in order to follow a 
person’s progress.  These overriding principles proposed by chronic illness guidelines are 
applicable on the macro level and micro levels of providing  patient care. It is amongst these 
broader guidelines and PHC ‘key principles’, that collaboration and interaction with a specialist 
should be viewed. This small component of collaboration, amongst the many required to improve 
chronic illness care is the need for improvement of communication between hospitals and 
primary care. Improvement of follow-up of high-risk patients, particularly  those identified to have 
problems and whose disease appears to be treatment-resistant, need to be flagged (Zoccali, 
2006) and maybe even referred. New forms of collaboration between all those health workers 
concerned need to be planned and tested. It is in pilot ‘outreach programs’ that such approaches 
can be tested. 
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This approach suggests the need to move away from a radar approach to managing 
chronic illnesses, discussed earlier. In this model, by which most current health systems run, 
patients are only detected with a chronic disease in the advanced stages when they present to a 
doctor or hospital. Chronic disease management into the future relies on a better-coordinated 
system involving all components of the health care system in an integrated manner. Here 
patients are detected early in a PHC setting, and management support is provided by specialists 
if needed, together with effective systems for referral and an information data base to help 
support these systems. Public health decision-making is critically dependent on the timely 
availability of sound data. The role of health information systems is to generate, analyse and 
disseminate such data (AbouZahr and Boerma, 2005). In practice, health information systems 
rarely function systematically in an integrated fashion.  
Large population based screening studies or programs initially focusing on screening 
should only be undertaken to identify people with disease if the criteria are met for it being a 
public health problem i.e. burden of disease larger or becoming larger, it is unfairly distributed, 
strategies must exist which could alter the course of these diseases, and such strategies are not 
yet in place (Schoolwerth et al., 2006)..  Pilot studies or screening programs can determine the 
scale and nature of the problems and help determine health system requirements.  While this 
approach may not be feasible or cost effective in all developing countries it may be for some 
diseases where prevalence is high. An alternative cost effective and sometimes more 
appropriate approach is to screen within the health system. This would allow for both primary 
prevention, e.g. screening for CKD in people with DM and a family history of CKD before they 
develop the disease, and secondary prevention screening can be followed, e.g. screening for 
microalbuminuria in people with DM and treating aggressively to prevent overt proteinuria or 
advanced CKD. This strategy utilizes the existing PHC system, developing skills and resources 
at the same time. The approach in SA CDOP has been to focus on the high risk population 
groups, as those with uncontrolled HTN or DM with proteinuria are at highest risk for CVD or 
progressive CKD. 
Lifestyle measures remain the key to the epidemic of NCD and HIV, but these have to be 
matched with screening and treatment programs to impact on overall disease. This approach is 
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true for kidney disease too, as it recognises the continuum of CKD. Here we come to the point 
made by Rose (1981), discussed earlier, of the need to integrate prevention and treatment. 
Impacting on the primary care setting will affect the flow to the tertiary system. In our attempt to 
move the ‘mean’ towards improved management of chronic illnesses, specialists need to work 
with primary care clinicians and be involved with public education. This includes a commitment 
and sustained adherence to a healthy lifestyle. An integrated plan is essential, focusing on the 
susceptible and high risk groups along the entire continuum of kidney disease, with effective 
management at all levels of CKD.  
 
 Health Systems and Program Interventions 
Attempting to integrate a kidney disease focus within a chronic disease management 
program is challenging. People’s health status and quality of life will not be improved solely by 
medication and technical advances; and thus healthcare systems have to move away from the 
current dominant  model of ‘‘find it and fix it’’  to a more integrated approach (Katz, 2005b, 
Epping-Jordan, 2005). Such solutions often require cooperation between government, private 
funders and non-governmental organizations. This is in keeping with the WHO definition of a 
‘health system’ which comprises all organizations, institutions and resources devoted to 
producing health actions (World Health Organization, 2000a). Programs often rely on outside 
organizations and appropriate technologies to stimulate their development (Bachmann, 2007), 
but although non-governmental and private-for profit organizations are important players in 
stimulating innovation, they cannot carry out the central activities of the public health sector 
(World Health Organization, 2005a) . This responsibility has to fall on policy makers, government 
departments and the people and institutions that are responsible for public health care. 
Programs like CDOP require the acquisition of skills but also resources and funding. We have to 
balance our enthusiasm to initiate programs with the practical reality and recognition that most 
countries like South Africa, which need prevention and detection programs, are also those in 
which they are most difficult and time consuming to set up. Establishing these intervention 
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programs often require many years from the time of conception to implementation and even 
more time to scale up.  
The strengthening of health systems in developing countries remains a key challenge, 
especially in the wake of the existing epidemics of HIV and chronic diseases. Fragmentation of 
health systems, by developing parallel programs, can lead to chaos (McCoy et al., 2005, 
Sanders and Chopra, 2001, Sanders et al., 2005). The energy and activism around HIV/AIDS 
should be joined with other chronic illness programs, providing an opportunity to strengthen and 
integrate health systems. Integrated programs are more likely to develop health systems 
horizontally across sectors and this will have a positive affect for all chronic illnesses. Chronic 
disease programs facilitate the long-term social processes of capacity building of both 
communities and health workers. CKD and HIV share similarities, their risk factors and 
complications can be effectively detected and treated.  
In South Africa, nephrologists have had significant experience in CKD.  As dialysis and 
transplantation are a scarce resource to which access is limited, great efforts have been made to 
ensure equitable access to this resource and better patient adherence (Dirks and Levin, 2006, 
Moosa and Kidd, 2006). The problems in strengthening health systems and scaling up therapies 
in the face of HIV and CKD include the scarcity of human resources, caused by an inadequate 
supply, maldistribution, the low remuneration health workers receive and the increased migration 
to more favourable environments (Schneider et al., 2006, Victora et al., 2004). Poor productivity 
and culture of service delivery is also a problem (Hongoro and McPake, 2003).  
Another key challenge is insufficient financial investment into already weakened health 
systems. Although global funding has increased, adequate funding has been a challenge with 
scaling up of HIV programs.  Even if there were adequate funding, the human resources 
required to provide treatment falls far short of what is required (Rosen et al., 2005, McCoy et al., 
2005). Health system infrastructure is also inadequate. Such challenges cannot be reversed in 
the short term. 
In chronic disease programs, it is critical to link treatment with prevention. Integrating the 
therapeutic and prevention roles has improved care provided by obstetricians and paediatricians 
(Rose, 1981). Integrating treatment and prevention is shown to have a greater impact on 
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outcomes than treatment alone (Salomon et al., 2005) (see figure 2). Success has been 
achieved in Australia and the United States from the late 1970s where this focus resulted in the 
reduction of mortality from coronary artery disease (Rose, 1981, Lenfant, 2003). For coronary 
artery disease, although both primary and secondary prevention and treatment components are 
necessary to maximise health care, the greatest benefit is seen with primary prevention (Unal et 
al., 2005). This may prove true also for other chronic diseases.  Strategies should focus on 
primary prevention, particularly tobacco control, healthier diets and exercise.  
People with chronic illnesses often present late in the natural history of their disease, 
when the disease is well advanced. An integrated health care system, involving all ‘structures’ 
including prevention and treatment components, is particularly appropriate for the ongoing care 
of any chronic illnesses, such as tuberculosis, DM, HIV (Epping-Jordan, 2005). Prevention 
strategies would include focusing on those at highest risk for disease and utilising a mass 
strategy of prevention and treatment to shift the whole population distribution of that risk variable 
(Rose, 1981). However, many questions have yet to be answered with regard to health systems 
and chronic illnesses: how to ensure the availability of low-cost generic drugs for people at high 
risk of CVD or CKD and their uptake and long-term use without financial burden. Other 
questions include how to identify people at high risk in primary health-care settings and ensuring 
appropriate referral. A simple set of indicators and good information systems for monitoring 
progress in implementing strategies to manage chronic conditions is also needed (Beaglehole et 
al., 2007). 
 In South Africa, chronic disease systems for managing HIV and TB have received a 
greater focus and are better funded and receive more attention for political and emotive reasons. 
But the management of all chronic diseases require a functioning health system and so tackling 
these problems should be integrated under the same banner (Epping-Jordan, 2005, Couper, 
2007). The health system in South Africa requires significant strengthening given the epidemics 
both of non-communicable chronic disease and HIV. Research and evaluation of health systems 
has taken place in developing countries (Joint Learning Initiative, 2003, Sanders et al., 2005), 
and especially with regard to HIV (McCoy et al., 2005, Schneider et al., 2006) but also non-
communicable chronic illnesses (Abegunde et al., 2007, Epping-Jordan, 2005).  
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Health Systems Evaluation 
  The evaluation of a health system is best approached by firstly understanding the 
environment in which it functions and then breaking the health system down into its components. 
The impact of a health system or program depends on socio-economic and social stratification 
factors such as race or ethnicity, gender and age, and because of this, quantitative evaluation of 
the outcomes may not provide all the answers to controlling illness. Despite the existence of 
many programs, a relatively small number of these are evaluated. Program evaluation 
determines which programs are needed, effective and utilised (Potter, 1999). 
A prerequisite for effective implementation of any secondary prevention strategy, 
including early detection and prevention programs, is a functioning and equitable primary health-
care system. The provision of affordable and reliable drugs for chronic disease is a major 
challenge, with many patients missing out on effective and cheap treatments. Proper planning 
and implementation of prevention and control strategies depend on reliable and comparable 
information to monitor the burden of chronic diseases and their risk factors. In the poorest 
countries, the availability and quality of health information systems are often inadequate to 
inform health policies and resource allocation at global, regional, and country levels (AbouZahr 
and Boerma, 2005, Murray et al., 2004). The rapid escalation of demand for chronic care 
services has been poorly documented, and major gaps in the supply of health information for 
developing countries are apparent. An information system allows for evaluation of challenges, 
and quick reaction to new methods to tackle problems. Good examples exist of the use of data 
for evidence-based decision-making leading to better health (Mubyazi and Gonzalez-Block, 
2005). Inadequate health information contributes to the non-recognition of the burden of chronic 
diseases, inadequate resource allocation, improper planning of control strategies, and little 
means of monitoring the effect of health policies (Boerma and Stansfield, 2007).    
The environment includes the policies and politics in which a system must function, the 
economic dynamics which prevail, and the underlying risk of disease in that community. In the 
case of a chronic disease like CKD, this includes risk factors associated with CKD like smoking, 
obesity, DM, HTN and HIV/AIDS. It also includes socio-economic factors. Evaluation has to take 
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into account the various components needed to ensure service delivery such as urine dipsticks 
measurements, blood HbA1c and eGFR measurements. It also includes the existing structures 
required to manage the disease, such as the clinics and PHCN staff. Finally, constant evaluation 
of the processes and outcomes are required, in keeping with the participatory action research 
methodology.  
Models like the Wagner CICM and WHO ICCC recognise these complexities (Epping-
Jordan et al., 2004, World Health Organization, 2002a), highlighting the need for adequate 
resources, appropriate protocols and systems, and for health workers and patients to work 
together. Integration can occur at many levels, including at the level of program management 
(Schneider et al., 2006, Si et al., 2008). This includes integrating the financing, procurement of 
resources and monitoring of the programs at the national level.  
 
Models for Managing Chronic Diseases and Kidney Disease 
Having outlined the great challenge of chronic diseases, the problem of CKD and its link 
to CVD, globally, in SA and in the setting of this study, I now consider some models which have 
been proposed to deal with these challenges. A core focus of this thesis is finding a solution to 
the management of chronic illnesses and developing strategies to deal with the problem. A key 
component to this ‘solution’ is to establish of programs and strategies to combat chronic 
illnesses. This includes primary care facility and clinician approach, and included in this 
approach is the linking of the primary health care and specialist care settings and the effective 
up and down referral. Health care delivery systems are generally poorly focused on dealing with 
chronic illnesses compared to infectious diseases. The approach is often unstructured, lacks 
systematic follow-up and monitoring of chronic clinical care, and provides little information about 
morbidity or mortality. Two key chronic illness models, the Wagner Model and World Health 
Organization Model, discussed earlier, have attempted to provide guiding principles for 
managing chronic diseases and must be considered seriously in any endeavour to tackle the 
problem. I turn to these now. Both are strategies based on reviews of innovative best practice 
and affordable healthcare systems (Wagner, 2004, World Health Organization, 2002a).  
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The Wagner Chronic Illness Care Model (CICM) and WHO Innovative Care for Chronic 
Conditions (ICCC) Framework models were designed to improve management of chronic 
illnesses like DM and HTN (see figure 4 and 5) (Si et al., 2008, Nutting et al., 2007, Solberg et 
al., 2006, Vargas et al., 2007, Tsai et al., 2005).  The models are particularly valuable because 
they focus on clinicians as ‘a prepared and proactive team’ (Wagner et al., 2001, World Health 
Organization, 2002a). CICM and ICCC differ in that they strongly acknowledge the role of PHC 
clinicians, both doctors and nurses, and recognise the interaction required between the health 
care team and patients. They offer an opportunity to provide higher quality care by implementing 
a few fundamental changes. The models recognise the transformation needed in managing 
chronic illnesses from a reactive to proactive one. They acknowledge, although indirectly, the 
need to assist the PHC clinician with evidence-based guidelines, specialist expertise, and an 
information system which can track patients’ clinical progress and outcomes.  
A central role of these models is that they provide a methodology to measure  both the 
progress and outcomes of care through an information system, encourage follow up and enable 
the ‘‘stepping up’’ or ‘‘stepping down’’ of care from PHC to specialist health care (SHC), 
according to criteria determined by data systematically collected (Gask, 2004). This concept of 
deciding where patients can be managed is not well understood by health professionals and 
especially public health care managers.  In primary care settings where  people with DM are 
managed, relatively little clinician effort is required to incorporate the elements of these models 
into daily practice routines (Nutting et al., 2007). Implementing the models has been associated 
with better incorporation of recommended clinical guidelines, reducing CVD risk in patients with 
DM, for instance. In one study (Vargas et al., 2007), over a 1-year interval, a total of 1170 DM 
patients were compared, using the CCM at intervention sites and ‘usual care’ management at 
‘control’ sites. While there were improvements in both groups, at the intervention sites the risk 
factors for CVD, blood pressure, lipid levels and HbA1c were significantly lower than the usual 
care sites. Various other trials provide evidence supporting most of the components of the 
Wagner CICM, and in particular, broadening the care team by including nurses in chronic illness 
management (Peters and Davidson, 1998, Aubert et al., 1998a, Bodenheimer et al., 2005). This 
included involving nurses in patient management activities such as tracking patient care, (The 
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California Medi-Cal Type 2 Diabetes Study, 2004) with telephone follow-up (Nutting et al., 2007, 
Polonsky et al., 2003), and in self management support for patients e.g. glucose monitoring. In a 
meta-analysis of the value of the CICM model, it was found that interventions that incorporated 
one or more elements of the CICM had beneficial effects on clinical outcomes and processes of 
care for patients, with results consistent across various chronic illnesses (Tsai et al., 2005).  
However, most of these studies were conducted in small primary health care practice settings in 
the United States, and in small communities.  It remains unknown if it is suitable in larger 
environments in lower income settings in developing countries. 
Chronic illness care models recognise the importance of involvement of the patient and 
their family in patient care, for the delivery of effective health care for chronic diseases care. 
They however do not provide an effective implementation model or system. The “efficacy” 
(whether an intervention works under ideal circumstances) of these models has to be transferred 
in “effectiveness”(whether the intervention works under the conditions of a health service).  
Research based model are an exciting alternative to traditional randomised control trial (RCT) 
research, on which most chronic illness care is based, because of its pragmatic and ‘real life’ 
implementation. It is here that we should turn to more established primary health care responses 
to chronic conditions.  These responses include the integrated management of chronic illnesses 
with that of chronic communicable diseases, (Coovadia and Bland, 2008) e.g. as demonstrated 
in Cambodia with HIV, diabetes and hypertension (Janssens et al., 2007). Responses to 
problems like HIV and TB has resulted in the incorporation of a regular evaluation of the 
program performance and achievement of outcomes. A standardised guideline for detection and 
treatment has been established. This approach used for the control of tuberculosis (Harries et 
al., 2008) can be adapted for chronic illnesses with simple systems being developed and 
enforced for monitoring and evaluation of outcomes of patients and of program performance. 
There is concern that medical discoveries are not being translated into a measurable 
human benefit and although models like the Wagner CICM and WHO ICC, have attempted to 
provide the frameworks for delivery of evidence-based medicine to the health care team through 
decision support and data information systems, this is not the case. Broad clinical improvement 
requires that a critical mass of participating clinicians in community health services be committed 
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to understanding their patterns of practice and bringing these patterns into alignment with 
evidence-based best practices. This requires leadership, a constant flow of information and 
analyses, and mutual support and problem-solving. However, CICM does not pay enough 
attention to the broader issues of policy, implementation, the organization and equipping of the 
health care team. It also fails to present a clear message about process and resource 
development.  
Some of these deficiencies were recognised by the WHO, and a modified version of the 
CICM was developed, namely the WHO ICCC Framework (see figure 5). The ICCC takes into 
consideration the broader aspects of the chronic disease management and is potentially more 
suitable for larger scale community implementation. The ICCC framework expands on the 
community and policy aspects of improving health care for CD, but also includes components at 
the micro (patient and family), meso (health care organization and community), and macro 
(policy) levels (Epping-Jordan et al., 2004). It takes into account a “systems” activity that is 
difficult to conduct without organizational leadership, support, and good infrastructure. The ICCC 
provides a road map for decision makers who want to improve their health system's capacity to 
manage chronic conditions in accordance with local resources and demands, although as with 
the CICM, it does not offer an approach to implementation.   
The WHO model, like Wagner’s, recognised that the successful management of chronic 
conditions required a team approach. It acknowledges that this could only be achieved when 
patients, community partners, and ‘proactive’ health care teams are informed, motivated, 
prepared and working together (World Health Organization, 2002a).  Proactive care refers to 
care that anticipates patients' needs rather than relying on a patient-initiated interaction that is 
often introduced because of urgent symptoms. Clear treatment plans with scheduled, regular 
follow-up are typical features of proactive approaches. This partnership approach is a significant 
change from traditional health care, in which health care providers are seen as experts, patients 
are viewed as passive recipients of care, and communities are largely ignored. It also recognises 
different levels required for improving health care by separating chronic illness management 
components. Like the Wagner CICM, it acknowledges that especially in developing countries, 
chronic conditions present mainly at the PHC level and need to be handled in these settings 
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(Epping-Jordan, 2005). The ICCC framework therefore encompasses both models. This model 
was used in this thesis, especially when evaluating the program. However, it needed adaptation, 
as it did not provide a method or an approach to the implementation of a chronic illness program. 
To some extent these models have been incorporated into CKD early detection and 
prevention programs, but only one CKD program, not already described above, for American 
and Alaskan Indians, used the CICM to implement and run of its program (Narva, 2007, Narva, 
2008). So there is not much experience of CICM outside of DM management, and very little with 
regard to its application in kidney disease. Most programs and their driving models recognise the 
need for integration, coordinated care, and the complexity of providing health care for chronic 
conditions in an organized way. These models are able to demonstrate that chronic illnesses 
cannot be ‘cured’ with a single initiative but that they require ongoing effort and coordination.  
 
Fundamentals of Chronic Illness Programs  
The program examples above, demonstrate that it is possible to establish outreach 
programs.  Most programs focus on secondary prevention, attempting to either detect disease 
early, or then intervene by improving management of the illness and reducing subsequent 
complications. They demonstrate the need to have clear approach, but not all use an overriding 
health system model to guide their programs. This may be a weakness. They should, according 
to Wagner CCIM and WHO ICCC, have decision support components, an information system, 
and a method of evaluating their impact. Importantly, programs using these models should 
develop a strong focus on developing an ‘informed and proactive health team’ (primary care 
clinicians and specialists), and strong patient and community partnerships. A focus on the team 
delivering health care  remains as important as adequate funding and a functioning health care 
system (Beaglehole and Dal Poz, 2003). Some of these fundamental aspects of establishing a 
program, using a chronic disease model are described in Table 6 (Glasgow et al., 2001). These 
components of a chronic illness or chronic non-communicable disease program are both 
practical and philosophical in approach. They are both derived from on the ground experience 
but should also be linked to a clear framework or model. 
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Table 6. Requirements to establishing a chronic disease model or program 
 
1. The availability and understanding of population-based chronic disease management. 
Strong primary health care focus with the PCC Nurse being critical especially in the 
developing and poorly developed countries. 
 
2.  Support from government, local community organization (NGOs), health workers and 
patients 
3. Funding or research on real-world/practice-oriented issues, systems, and organizational 
change strategies (to be able to translate studies to primary care settings). Securing 
some form of bridging assistance from local government or an NGO, whether financial or 
other, such as equipment, human resources or technical skills.  
 
4. The appropriate health care policies to provide reimbursement for and the incentives to 
create a chronic disease model. 
 
5. Systems-based support for the primary care physician’s (or other staff) implementation of 
behaviour change strategies. 
 
6. An understanding of the personal and social-environmental factors that lead to long-term 
sustained self-directed behaviour change and establishment of a productive interaction 
between health care system managers, program organizers, patients and the health 
practice team. 
7. Adequate integrated information systems and sharing of information across provider 
groups or clinics. Establishment of an organized integrated program as compared with 
the ‘usual’ standard ‘find it and fix it model’ of care existing in most countries.  Organized 
care has shown better outcome compared with standard care programs. 
 
8. Adequate time to address patient-focused issues in an interactive, personally tailored 
manner during office visits. 
 
Adapted from (Katz, 2005a, Glasgow et al., 2001) 
 
 
 
 Whether or not they focus on CKD as a primary element, chronic illness models all 
recognise and acknowledge the role of improving management of chronic illnesses like HTN, 
DM or TB to reduce outcomes. The goal of any model or framework is to reduce the burden of 
morbidity, disability and premature mortality related to chronic illnesses through a primary care 
strategy which has key elements. This would include identifying and addressing risk factors 
which can be managed and changed, screening for these common chronic illnesses and then 
diagnose, treat and follow-up these patients using standard protocols. The proposed models 
could borrow the same elements as those developed for tuberculosis and HIV control. These 
models would include a clear set of goals, a strategy and targets for control, a package of 
interventions for quality care, key operations for national implementation, and indicators to 
measure progress towards increasing the impact of primary care interventions on chronic 
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illnesses. The framework will need regular evaluation and even adaptation in different settings. 
Traditional methods of review focus on measuring and reporting on program effectiveness. The 
challenge will remain that most results often find that the evidence is mixed or conflicting, and 
provide little or no clue as to why the intervention worked or did not work when applied in 
different contexts or circumstances, when deployed by different stakeholders, or when used for 
different purposes (Pawson et al., 2005). While they focus predominantly on ‘functional and 
clinical outcomes,’ they have to a lesser extent focused on evaluating the primary health care 
team and the health system failures and challenges, and the impact of the programs on the 
clinician and health system. It remains critical to evaluate comprehensively the impact of the 
program and not only focus on the bottom line, namely clinical outcomes, but also on why these 
outcomes or failures are occurring. In health systems and other public services, we are dealing 
with complex social interventions, which act on complex social systems, like performance 
measures, regulation and inspection, and inter-departmental interactions. Part of the problem is 
one of complexity, and there are no ‘magic bullets’ which will always hit their target, and effective 
programs are crucially dependent on context and interaction. Traditional methods of review 
focus on measuring and reporting on program effectiveness. Results often find that the evidence 
is mixed or conflicting, and provide little or no clue as to why the intervention worked or did not 
work when applied in different contexts or circumstances, when deployed by different 
stakeholders, or when used for different purposes (Pawson et al., 2005). 
 
Facility and Consult based approach to Chronic Care 
 The key principles of the approach to chronic illness care have been highlighted earlier 
but a more detailed approach is needed if one considers the ‘health care team’ as critical 
component chronic care delivery. Many of the principles have been highlighted earlier, but they 
need to be implemented to achieve these goals. Couper (2007) offers an excellent approach to 
ensure effective PHC clinicians by highlighting commitment to the patient as the fundamental 
principle, but also that it be shared by other health professionals. 
 In all seven principles are proposed, with the next being, ‘continuity of care’ (Couper, 
2007). It is referred to as active and sustained follow up (Von Korff et al., 1997), which arises 
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from a clinicians commitment to the individual, that their interests are considered. The result of 
this type of interaction is that a personal relationship is developed with the individual. Couper 
(2007) argues that the knowledge of a person’s illness, their medication and complications are 
both more efficient and cost effective. The continuity ensures that protocols and management 
plans are followed, and previous problems are addressed at follow up visits. The principle of 
collaboration has particular pertinence to this thesis review and highlights the need for links for 
cardiovascular and kidney care. Although this principle has many levels, it primarily includes 
collaboration between patient and clinician. As outlined in the CICM and ICC models this 
collaboration for chronic illnesses is highlighted by the need for the patient, their family and 
community to also be informed and involved in their care (Wagner, 2004, World Health 
Organization, 2002a). It is also an important focus which is not well taught to health care 
providers (Couper, 2007). Overall, the collaboration of care requires that the patient is informed 
about their illness, its treatment and possible outcomes. The aim of this collaboration, especially 
related to chronic illness is a focus on achieving a healthy lifestyle and also adherence to 
treatment. This type of collaboration is especially pertinent to chronic illnesses like HTN and DM, 
where home blood pressure recordings and blood glucose readings are important. This type of 
collaboration is especially important in the Soweto context, where patient ‘support groups’ 
remain a key factor in patient care. Collaboration for chronic illness care would include many 
specialities involved in kidney and cardiovascular key e.g. endocrinology, cardiology. 
 Further principles covered include a clinicians understanding of the socio-psychological 
components of their chronic illness and the patient’s comprehension of their illness. Evidence 
exists supporting better outcomes for patients who are better informed (Holman, 2004). This 
includes reduced hospitalisation and costs for care (Bodenheimer et al., 2002).  
The ability for a patient to adapt to ‘change’ is considered to be fundamental, which 
embodies the need to visit their PHC clinician regularly and take responsibility for their treatment 
(Couper, 2007). It is especially important with regard to chronic illnesses, where lifestyle and 
ongoing treatment is needed, allowing for extended periods of ‘self care’ i.e. three to six month 
medication repeats, and reduced clinic numbers and visits. Fundamental to the management of 
chronic illnesses is the integration of clinical guidelines. Unfortunately guidelines are often 
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written by researchers out of touch with the ‘coal face’ care of the PHC setting, and a balance 
between the individual need and clinical evidence is required. Outcomes are improved when 
guidelines are followed (Weingarten et al., 2002 ), and so the balance is about finding 
appropriate guideline use and their implementation. Clinical data capture includes the focus on 
individual interaction with the patient and the maintenance of clinical notes. The use of electronic 
databases, has further complicated the process, but provides an opportunity to ensure continuity 
of patient care, and better audit and evaluation of progress and outcomes. Variables which 
should be monitored require good evidence to support their use. A clear rationale needs to be 
considered. It is well shown that using such approaches will improve the management of chronic 
illnesses (Glasziou et al., 2005). 
The implementation of chronic care principles is covered in the WHO Integrated 
Management of Adolescent and Adult Illness Program (IMAI), and has shown to be a useful tool 
(Organization, 2004). This approach includes the ‘5 As’, which assists the clinician during the 
consultation i.e. assessing patients clinical condition, providing Advice, Agreeing to set and 
accept goals of management, ‘assisting’ the patient with the treatment plan, and ‘arranging’ 
follow up. Couper (2007) has added a practical approach by sub-categorising the ‘assessment’ 
to include another four Cs which include evaluating patients ‘complaints or concerns’, ‘control’ of 
the illness, ‘compliance’ or adherence with treatment and finally looking for any ‘complications’.  
 Couper’s paper offers clear approach for the PHC facility or family practice to manage 
people with chronic illnesses, and a template against which facilities can be evaluated. A strong 
argument is provided for its use, but this is guarded with the concern and recognition of the 
challenges of implementation, and especially in the government health sector. 
 
Primary Health Care Clinician Motivation  
 Having a committed PHC clinician is a fundamental requirement to achieve improved 
management of chronic illness (Couper, 2007), and achieving the goals of a health organization 
require a health worker to be motivated (Franco et al., 2002, Wagner, 2004, World Health 
Organization, 2002a). It is for these reasons and because models for chronic illness focus on a 
‘motivated, informed, and active’ health care team that this issue is being covered in this thesis. 
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Amongst the various options of managing chronic illness, the most popular and 
successful is usually nurse driven. Chronic disease programs often have a strong primary health 
care focus involving the PHC nurses (Yawn, 2000). Nurse practitioners are well equipped to 
provide practical education on the everyday activities of people with chronic diseases and have 
been successfully used to manage and coordinate care for patients with chronic illnesses 
(Connelly and Connelly, 1979). Appropriately trained nurses can offer the same value as doctors 
and provide as good outcomes with regard to patient care (Laurant et al., 2005). Nurse 
practitioners have the potential to reduce doctors' workload and direct healthcare costs, but 
achieving such reductions depends on the particular context of care and the skills of the nurse. 
Health systems in developing countries often rely on nurses to deliver health care and for 
success; this requires informed, activated and motivated health workers.  In some instances, the 
nurse has even replaced the doctor with chronic disease management with the same outcomes 
for patients, process of care, resource utilization or cost, but importantly nurses must be 
appropriately trained (Laurant et al., 2005, Si et al., 2008, Nutting et al., 2007, Solberg et al., 
2006, Vargas et al., 2007, Tsai et al., 2005).  However, for health workers to be willing to 
achieve the goals of any organization and deliver high quality work and efficiency, they must be 
motivated (Franco et al., 2002). Motivational issues impacting on care include poor attitudes to 
patients, arriving late at work, absenteeism and burnout (Gilson et al., 1994, Piko, 2006, Van 
Lerberghe et al., 2002). A functional health system relies on its clinicians to examine patients 
quickly and effectively and to provide the appropriate treatment. These actions rely on a clinician 
being both motivated and enthusiastic. Some of this motivation is self-derived (intrinsic 
motivation) but the enabling organization (extrinsic motivation) is also very important. The 
motivation to deliver high quality care has many facets, including the policy environment and 
management styles, resource availability and worker competence. Franco and colleagues 
investigated the ‘determinants’ and the ‘motivational outcomes’ affecting health workers in 
developing world countries. In one  in-depth study evaluating of 500 employees, carried out in 
hospitals in Georgia and Jordan (Franco et al., 2004),  health worker motivation was evaluated 
using three analytical approaches, that included psychometric testing, perceived contextual 
factors and motivational outcomes (feelings, thoughts and behaviours). Despite the countries’ 
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socio-political differences, the study revealed similarities in the areas of self-efficacy (a worker’s 
sense that they can do the job and that the work is under control), pride and satisfaction (related 
to their job environment and organization), management openness (transparent communication 
and attitude to change), and job properties i.e. making the job more interesting (job recognition 
and responsibility, integrating tasks to improve variety and reduce monotony, job rotation 
through different areas). Financial reward was important but was not the only factor influencing 
motivation. Differences between the two sites revolved around local cultural issues and 
highlighted the need to create programs that are both socially appropriate and developed 
specifically for the type of health worker, e.g. nurse or manager. The study highlighted the 
complex nature of health worker motivation, and the need for interventions and comprehensive 
programs to improve motivation. A weakness of this study was that it was conducted among 
predominantly hospital based health workers.  
Another study utilising this type of methodology was that of Penn-Kekana and colleagues 
in South Africa, but here the health workers were nurses from hospital based maternal health 
services, (Penn-Kekana et al., 2005). Although the study focused on maternal health services, it 
reflected the nursing dynamics in the South African health system in general.  This study 
revealed that many nurses expressed a lack of motivation, burn out and an intention to leave the 
nursing service. Reflecting on determinants of motivation, nurses were confident in their ability 
but were concerned with promotion opportunities, inability to support their families and work-
load.  More than half wished they had not become nurses. Nurses felt underpaid, overworked, 
underappreciated and unsupported by management. All these factors strongly impacted on their 
ability to provide a quality service and implement policy interventions.  
Both studies concluded on the need for interventions that addressed changes to policy 
and the organization environment. Other studies also support better organization commitment 
with good support from managers and supervisors and colleagues (Cheng-I et al., 2006) .  Work 
motivation is an important component of achieving the goals of the organization, and this is 
important for achieving targets with chronic disease management (Van Lerberghe et al., 2002). 
The value of the health worker, and specifically nurses, and the need to invest in this vital human 
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resource, with better planning, production, remuneration and management, is well recognised in 
some programs (Schneider et al., 2006, Bodenheimer et al., 2005).  
  Although low levels of worker motivation plague public health systems in developing 
countries, there has been a surprising lack of attention to the human elements of reforms 
required to bring out the best from health workers (Franco et al., 2002). The focus globally is 
more often on technology, infrastructure and health economics than on the people and the 
relationships required to ensure service delivery (Blaauw et al., 2003). Blaauw et al. (2008) 
encourage more complex, multi-disciplinary approaches for a better understanding of the 
motivations of health workers and health managers and improve health system performance. 
Worker motivation depends upon the organizational context in which the worker is situated, the 
organizational structure, resources, processes, and culture, and organizational feedback about 
performance (Franco et al., 2002). The successful functioning of health services requires 
relationships between health workers and their patients, managers and health workers, and 
external organizations e.g. NGOs. Overall public sector, or health service, performance depends 
on successful relationships in all of these areas.  
Franco and Penn-Kekana both developed a conceptual model of health worker 
motivation for their research (Franco et al., 2004, Penn-Kekana et al., 2005) (see figure 25 and 
Appendix 8b). The model looks at the factors interacting between the health worker and the 
organization in which they work.  It takes into account those aspects within the health 
organization and within the society that influence workers’ motivation. It looks at workers as 
individuals, their psychological and internal make up driving them to deliver good care. This is 
the willingness of the worker to achieve the policies of the politicians and managers. This in turn 
is influenced by an individual’s work ethic, internal forces and the external rewards which they 
derive from their work. These internal motivational processes can be viewed as a series of 
measurable inputs (determinants) that lead to certain measurable motivational outcomes or a 
motivated health worker. Individual determinants are influenced by personality and value 
systems. Factors also at play in determining an activated and motivated health worker include 
the way clinicians perceive their working environment. It includes how workers perceive 
themselves as knowledgeable and able to deliver the service, although this is also dependent on 
  
89 
the work environment. These can be defined as behavioural (what workers do); emotional or 
affective (what workers feel) and rational or cognitive (what workers think) (Franco et al., 2004). 
These perceived contextual factors are enabling factors for the worker to be motivated and be 
ready to work. These factors interact with each other and the other factors. The inputs and 
outcomes arising from the individual health worker must operate within the existing social, 
environment and organization context. Ultimately the health workers internalize these factors, 
and from this, produce an output to deliver the required improved functional and clinical 
outcomes. Health systems are social systems, and therefore health system researchers and 
reformers need to pay much more attention to social theory (Blaauw et al., 2003). Natural 
science methods of enquiry are inadequate and inappropriate for understanding social systems. 
Often, reform programs have focused on a very limited number of channels (e.g. financial 
incentives) to influence worker behaviour, and have neglected less tangible incentives such as 
the work itself, achievement, and recognition. Successful initiatives in PHC have often taken 
cognisance of these factors and introduced performance-related incentives, i.e. financial 
incentives, for clinic staff to deal with issues impacting on delivery and improving quality of care 
(McDonald et al., 2007, Roland, 2004, McElduff et al., 2004).  
The conceptual model proposed by Franco et al. (2004), which is particularly relevant to 
South Africa, offers an opportunity for evaluating worker motivation as part of a new program or 
reform. Franco recommended that researchers replicate his evaluation of workers motivation in 
developing countries. This includes validation of scales of motivation used for evaluation 
including evaluating potential interventions. In South Africa the transition from Apartheid has 
brought widespread economic difficulties and the declining value of salaries, coupled with rapid 
and poorly planned health system changes. Rather than embarking on developing a new 
instrument to evaluate motivation, which is often the case (Steiner and Norman, 1994), it makes 
sense to rather validate existing models. The Franco conceptual model has been validated both 
at face value and content by researchers (Franco et al., 2004, Penn-Kekana et al., 2005), and 
has been shown to both appropriate and to reveal reproducible informative data. The only 
criticism is that its domains remain fairly broad and this may result in lack of validation of 
individual concepts.  
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Health workers in South Africa are often criticised for their behaviour towards patients, as 
“harsh and unsympathetic” (Global Forum for Health Research, 2002).This reflects the 
importance of managers paying attention to factors which influence this behaviour and attempts 
should be made to improve working conditions.  It is more often the mechanisms by which 
programs or services are implemented that result in their success (Travis et al., 2003). The 
components outlined here relate to how management looks after its health workers. It also 
relates to how policies are implemented and their impact on health workers environment. 
Managers need to recognise the impact of a policy or program on the health workers 
environment before implementation. 
Health workers also have to understand what needs to be achieved e.g. who should be 
referred. When norms ,standards, and associated processes are clear, it is possible for workers 
to understand how they can help in reaching the goals or targets of disease management 
(Franco et al., 2002). When embarking on initiatives or programs within the public health sector, 
factors need to include the individual, the organization, and society at large. The worker is a 
critical component of health systems performance, and one that is largely understudied. 
Consequently, effective programs will depend on all these aspects taking place within a health 
system.  
 
Linking Primary Health Care and Tertiary Health Care 
An effective PHC system is important. However, the treatment of chronic illnesses is 
complex and will often require specialist support at some point in the life course (Coovadia and 
Bland, 2008, Tollman et al., 2008). The major constraint with chronic illnesses is the continuity of 
care with life-long therapy required, often with multiple drugs. The treatment and continuity of 
care, as outlined above, is clearly best suited for the PHC clinician, but the failure has often been 
to invest in vertical interventions and not focus on the interrelationship of illnesses (Magnussen 
et al., 2004). The late referral, and resultant detrimental morbidity, mortality and cost implications 
are well documented in kidney disease (Roubicek et al., 2000, Levin, 2000). The communication 
and collaborative efforts of the nephrologist and PHC clinician are highlighted as factors 
influencing timely referral (Navaneethan et al., 2008), and effective systems of education and 
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communication need to be enhanced. An effective health care system relies on all components 
being intact, and PHC systems have to be able to recognise and implement appropriate 
strategies for managing disease, and if disease is advanced, to refer the patient on to the next 
tier (see figure 2). District health systems, comprising primary health care and first referral 
hospitals, are the key to the delivery of basic health services in developing countries (Segall, 
2003). Although management of chronic illnesses like HIV and CKD may be complex, the 
complexity lies in the problems and complications and can be addressed with adequate support 
from specialist tertiary services and a systematic approach.  Monitoring and evaluation, on the 
other hand, is relatively simple.   Primary health clinicians have the ability to provide good quality 
and continued care for a range of chronic diseases, as demonstrated for patients with type 2 DM 
(Griffin and Greenhalgh, 1998, Renders et al., 2001) and in the management of HTN (Oakeshott 
et al., 2003, Ornstein et al., 2004). However, not all patients are treated to the correct standards 
(Harris and Zwar, 2007b). Nurse-based intervention to assist with management of HTN and DM 
have been shown to be effective in two different clinical settings: one, a doctor driven HTN 
specialty and the other a doctor-nurse driven primary care setting (Norby et al., 2003). In this 
latter study, Norby and colleagues demonstrated that a doctor-nurse partnership model to 
manage HTN led to improvements in control rates and decreased complications and associated 
morbidity and mortality.  Importantly, better outcomes were more often achieved with an 
organised, decision support and data base driven computerised systems (Ornstein et al., 2004), 
with specialist support integrating with primary health care (Gruen et al., 2002). Optimal care 
often involves some kind of “shared care” arrangement between generalists and specialists, as 
part of an ongoing relationship among the patient, PHC clinician, and specialist (Starfield et al., 
2005) .  
In view of the increased prevalence and broad spectrum of cardiovascular disease in 
developing countries like South Africa (Sliwa et al., 2008), improvements are required for 
primary-care screening, early detection and treatment of CVD and CKD, including prompt 
referral of patients at early stages of disease. However, patients should be referred back to 
primary care when stable, highlighting the need to integrate care. Ensuring these systems are 
working is important. It is often in the tertiary care sector that the latest evidence-based methods 
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are researched, and being able to implement these in the PHC system requires good 
communication between the systems. Although the intellectual capital resides in the academic 
institutions, the focus of these institutions and their research often does not address the needs of 
the health system or the disease. Systems research and primary prevention is often seen as 
mundane and of secondary importance. The defining features of primary care (that is, continuity, 
coordination, and comprehensiveness) are well suited to care of chronic illness (Rothman and 
Wagner, 2003). The proposed solutions to managing chronic illnesses should not consist of 
resting the responsibility primarily in the specialist or PHC clinician, but the effective integration 
of these components of healthcare. For this to be achieved a positive policy environment, 
appropriate health care organization, collaboration and effective clear guidelines highlighting 
when people move up and down a system need to be established and implemented (Wagner, 
2004, World Health Organization, 2002a, Couper, 2007, Si et al., 2008, Nutting et al., 2007, 
Solberg et al., 2006, Vargas et al., 2007, Tsai et al., 2005). 
 
 
Scaling Up Prevention and Disease Management Models 
Chronic illnesses require a functioning public health system. This is not the case in sub-
Saharan Africa and South Africa (McCoy et al., 2005, Sanders et al., 2005, Schneider et al., 
2006). Although South Africa is distinctly better off than other sub-Saharan countries (Van 
Damme and Kegels, 2006), with better doctor to patient ratios and very good nursing ratios, the 
improvement of health systems still remains challenging.  
In order to impact on the morbidity and mortality from chronic illnesses in an 
economically sustainable manner, tobacco control measures, salt reduction strategies, and 
multi-drug strategies to treat patients with high-risk cardiovascular disease and kidney disease, 
are all needed (Gaziano et al., 2007, Schoolwerth et al., 2006). These interventions are cost-
effective interventions now needed to be scaled up to have an impact on reducing chronic 
conditions (Gaziano et al., 2007). We also need to determine their feasibility. Ultimately 
policymakers have to decide on which intervention are most cost effective to scale up to reduce 
the risk of chronic disease and alleviate the existing burden. Although the need for reorientation 
of service delivery towards chronic disease care is suggested, insufficient supply of human 
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resources for health and existing service delivery cultures remain major constraints to scaling up 
health services (Van Damme and Kegels, 2006, Schneider et al., 2006). Many studies are 
focusing on HIV/AIDS and ARV therapy sub-Saharan Africa studies but the challenges are 
similar for other chronic diseases.  
The challenges for scaling up efforts and introducing new health interventions in 
developing countries are well described (Victora et al., 2004, Schneider et al., 2006, Gaziano et 
al., 2007). Constraints to the successful introduction of new interventions in the health system 
includes access to services, the affordability of the treatment, stigma of disease, unsatisfactory 
service delivery infrastructure, weak medication regulatory processes and supply systems, and 
the lack of good management of the required processes. Health system delivery challenges 
related to scale up are similar for HIV and chronic diseases and are described in the WHO report 
on health systems (World Health Organization, 2000a). Treatment has been made more 
affordable for chronic illnesses and especially HIV ARVs but, as outlined earlier, the constraints 
to reaching universal coverage go beyond financial issues (Victora et al., 2004, Schneider et al., 
2006).  
A particular problem has been the lack of investment in people and infrastructure. The 
inadequate supply of skilled, motivated health care workers is now the primary limitation to 
scaling up treatment for chronic illnesses (Kober and Van Damme, 2004, Hongoro and McPake, 
2003, Liese et al., 2003, Chen et al., 2004). The problem has many dimensions and includes 
supply, migration of nurses and doctors, maldistribution, a skills mix imbalance, and also poor 
knowledge (Chen et al., 2004). In South Africa and other sub-Saharan countries, the shortage of 
health professionals, is recognised as important  in HIV and AIDS care, but not in relation to 
other chronic diseases (Department of Health, 2003).  The inadequate supply of health 
professionals is mostly in underserved areas, and posts are not being filled to support any health 
care initiative in the public health sector (Padarath et al., 2004). This is both a reason to develop 
outreach support initiatives and a reason for concern, since they risk failure without adequate 
staffing of public health clinics. Given the skills shortage in South Africa, the focus should be on 
investing in training health workers and preventing the ‘brain drain’ of nurses and doctors 
internationally and  internally within South Africa, with health workers moving away from the 
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primary care sector to tertiary and private sectors, including NGOs (Padarath et al., 2003). 
Response options include increasing the numbers of doctors and nurses or adopting delivery 
models with less reliance on these skills. However, models utilising fewer doctors or nurses 
seem have attracted limited attention (Van Damme and Kegels, 2006). Health professionals 
have had to deal with a decline in their incomes over time (Liese et al., 2003), and if poorly paid, 
are unlikely to be motivated and productive (McPake et al., 1999, Van Lerberghe et al., 2002). 
Community members, know as health promoters are often employed to assist PHC clinicians, 
and an aggravating factor includes the fact that volunteers are also poorly paid and lack 
motivation (Schneider et al., 2006).   
Additional problems include the complex service delivery challenges for chronic illness. 
Chronic diseases often require processes to be simplified, especially if managed in primary care 
sector. Although treatment is available in the early phases of disease, it is time consuming to 
continue close monitoring with laboratory investigations. Unfortunately failure to do so early on 
makes it impossible for the primary care sector to manage the complex later stages of disease 
e.g. dialysis and transplantation. Simple algorithms or clinical targets can be established, but at 
some stage, linking with a ‘specialist’ may be required to manage complications or difficult 
treatment decisions. Here the integration of the primary care worker and specialist becomes 
critical.  
4 METHODOLOGY 
Hypothesis 
The establishment of a chronic disease outreach program in Soweto will assist with the early 
detection and management of chronic kidney disease and cardiovascular disease, including the 
improved and more efficient follow up of patients once detected. The chronic disease outreach 
program will improve management of patients with kidney and cardiovascular risk factors, as 
well as improve referral to a specialist centre of those patients detected to have advanced 
disease, and have an impact on the knowledge and motivation of primary care clinicians, 
predominantly the primary health care nurses, in the primary care clinics involved on the 
program.  
 
Study Aims and Objectives  
The study aim was to establish a chronic disease outreach program (CDOP) and evaluate its 
operation in an existing urban and peri-urban regional primary and specialist health care setting. 
The program was developed to assist the PHC clinicians (PHCNs and doctors) in the primary 
care clinics with the management of high risk patients, those with uncontrolled hypertension 
(HTN) and diabetes (DM) and HTN who were at risk for, or already had kidney and 
cardiovascular disease.  
 
Specifically, the objectives were to determine if CDOP was effective in: 
 
1. Detecting, managing and following a cohort of high risk patients in a primary and tertiary 
setting for two years.  
2. Retarding the development of kidney and cardiovascular disease in high risk subjects by 
intervening if they have uncontrolled hypertension, diabetes and proteinuria or other 
cardiovascular risk factors e.g. obesity, hypercholesterolemia. 
3. Retarding the progression of kidney and cardiovascular disease in subjects already afflicted, 
with the aim of fewer needing dialysis or dying with kidney failure. 
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4. Improving the knowledge and motivation of the clinicians working with chronic illnesses.  
5. Demonstrating a chronic disease management model which aids in improved risk factor 
control, treatment adherence and improved outcomes. 
 
Methodological Approach 
An intervention to improve care can be measured both quantitatively e.g. determining if 
target blood pressures are achieved, or qualitatively e.g. determining why patients miss visits or 
why patients do not return for follow up visits. A study such as this would be referred to as an 
outcome and process evaluation study. Examples of chronic disease and CKD programs, 
described in chapter 2, indicate the complexity of the requirements needed in order to achieve 
successful patient care. Evaluating a program includes evaluating the biological, social, clinical 
and behavioural factors which influence its outcomes. An understanding of the health system or 
program being evaluated is important. It is important to break down the components of the 
health system. This would include the structure (resources, users and organizations), processes 
(actions, services provided and utilised), and outcome (changes in health, behaviour, 
knowledge). The health system designed for managing chronic illnesses in Soweto could be 
described as in Figure 17.  
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Figure 17. The Health System and Chronic Disease Care in Soweto 
(Adapted from Bachmann (2007) CKD – chronic kidney disease, CVD – cardiovascular disease, HTN – 
hypertension, DM – diabetes, CHBH – Chris Hani Baragwanath Hospital, PHCN – primary health care 
nurse, NGOs – non-governmental organizations 
 
Service quality needs to be part of the evaluation of a health system. Four key 
components are described and all these require different methods of evaluation (Bachmann, 
2007). The quality of a program or service includes its ability to achieve what it set out to do, and 
its effectiveness is best evaluated using a randomised control study. However, if this is not 
possible then other designs could be considered.  Efficiency and equity can also be measured 
as part of the quality.  
 
Epidemiological Approach 
No strategy for change is effective under all circumstances, but  multi-faceted strategies 
are more expensive than simply evaluating a single intervention and outcome (Wensing and Van 
der Weijdent, 1998). Public health interventions are complex programs and this complexity 
includes the need to change behaviour in chronic diseases e.g. lifestyle modification (Kelley, 
1996, McLeroy et al., 1988, Winett et al., 1989). Public health often involves the poorest and 
marginalised in societies, and evidence is often gathered from easily accessible subjects, which 
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may exclude these types of peoples. The result is that very little research based evidence exists 
on disadvantaged groups (Rychetnik et al., 2002, Hawe and Sheill, 1995).  
Randomised controlled trails (RCT) provide the most valid approximation of effectiveness 
and provide strong evidence of causation. Their value is in the minimisation of selection bias and 
confounding variables. A RCT can be used to evaluate the effectiveness of an intervention, but 
despite this methodology there is still no good evidence about many types of care (Bachmann, 
2007). The RCT has been used to gather information about drug effectiveness rather than about 
programs. Although simple to allocate people to different drugs or groups, its implementation in 
the ‘real world’ situation is far more challenging. Many evaluation mechanisms, such as 
randomised controlled studies, may be unable to fully evaluate complex public health 
interventions. Validity in quantitative approaches to research relies on rigorous adherence to 
methodological rules and standards, which is not possible in real life interventions. This makes it 
is difficult to apply these same rules to qualitative research (Angen, 2000). In instances where 
poor methods are used, it may be difficult to determine whether it is because the tools of 
evaluation failed or because the program itself failed. In many cases the evaluation of a program 
using clear simple quantitative methods are not sufficient. In cases where a RCT is not 
logistically or ethically possible, then well designed observational studies can still provide useful 
information.  
Observational studies involving a cohort can also provide information about the 
effectiveness of health care. These studies can estimate the needs for health care quantify 
inequity and measure indicators of health quality. A cohort study can identify people and health 
services characteristics associated with worse outcome, determine predicative factors in health 
outcomes, distribution or usage (Bachmann, 2007).Qualitative evaluation may provide the link to 
explain why a clinical health delivery model was successful or not.  
 
Integration of Quantitative and Qualitative Information 
For evidence to be transferred elsewhere it is important not only to measure outcomes 
but also to provide a description of the process of the intervention, as part of this qualitative 
measurement. This means one has to evaluate the context of the program i.e. existing 
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circumstances and processes and not only clinical targets e.g. blood pressure levels.  In 
addition, disentangling the various factors associated with outcomes is best identified utilising a 
range of methods, both quantitative and qualitative. This includes triangulating information from 
various methodologies.  
The chronic disease outreach program’s analysis draws on multi-method approaches 
involving triangulation between methodologies, data sources, time frames and levels of human 
interaction.  The focus for this study is predominantly on the PHCNs as the ‘prepared proactive 
team’ members, the key health workers in the existing health care structure to detect early and 
advanced kidney and cardiovascular disease. The value of utilising multi-method evaluation here 
was to combine the best of quantitative and qualitative data to evaluate the program. The 
qualitative component of this study looked at and evaluated the processes involved in a public 
health intervention of this nature. The clinical component focused on the clinical outcomes over 
time and additional qualitative data focused on the processes and people trying to achieve these 
‘improved functional and clinical outcomes’.  
The qualitative evaluation thus necessitated both a framework analysis approach and a 
grounded theory approach to evaluate all aspects of the program. It looked at how effective the 
intervention was and the processes of professional behaviour change. It tried to identify the 
barriers to changing behaviour, and what personal skills and attributes were needed by the 
primary health clinicians and other health care workers, to effect change 
 
Description of intervention and evaluation 
This study on which this thesis is drawn was conducted from February 2003 to February 
2006. Patients were enrolled at 20 clinics and health centres (11 in Soweto and 9 other regional 
clinics) in the South West Gauteng region, and were followed for 2 years (Figure 18).  
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Figure 18. Chronic Disease Program Clinic Sites 
Note: Eight CDOP sites were outside of the Soweto area and comprised, 2 CHC and 6 clinics; *ROPD - 
renal outpatient department/clinic, CDOP – chronic disease outreach program, CHBH – Chris Hani 
Baragwanath Hospital 
 
All clinics were from the same health region, controlled by the province, and had registered 
PHCN as staff. All patients at risk of kidney disease were referred to a single specialist 
nephrology clinic at Chris Hani Baragwanath Hospital. All clinics were incorporated into a 
program modelled on the Chronic Illness Care Model (CICM) (see figure 4), which utilised 
PHCNs to link primary care and specialist care (Wagner et al., 2001). The evaluation of the 
program and health system environment was further assessed using the WHO ICCC Framework 
(see figure 5). The WHO models’ advantage was its improved acknowledgement of the policy 
environment and health care organization to support chronic care (World Health Organization, 
2002a).  The PHCNs were provided with decision support, escalated scaling up of medication, 
and prompt access to specialist care.  Program nurse coordinators provided this link and they 
were in constant contact and available to the health care team at the clinics, for clinical ‘decision 
support’ and to assist with communication to management if the need arose e.g. medication 
shortages. These interactions took place through telephonic communication and regular visits 
when collecting patients’ data forms, i.e. ‘Annual visit’ and ‘Follow Up’ forms, or when providing 
CHC – Community Health Centre
ROPD* –specialist referral centre
Standard Health care clinic
1 CHC South West of 
Johannesburg
N
5 clinics and 1 CHC south of 
Soweto
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‘feedback reports’ about a patient’s clinical progress and management, and during education 
visits or at the regular focus group meetings with PHCNs (Figure 19). 
 
 
Figure 19. Feedback Report Process 
 
Two program nurse coordinators collected patient visit forms, (generated by the PHCNs), 
and together with a nephrologist, they evaluated and analysed the information and provided 
feedback and decision support to the PHCN (see also figure 20 and figure 21).  
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Figure 20. CDOP Health System Processes
Note: Typical referral pattern - solid open white arrow
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* Patient clinical data is analysed by Program Nurse 
 
Clinical data evaluation included assessment of modifiable CVD and CKD 
body mass index (BMI) and waist circumference, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), random serum glucose, HbA1c, serum cholesterol, proteinuria and an 
estimated glomerular filtration rate (eGFR), using the Cockcroft
1976b) and the abbreviated Modification of Diet in Renal Disease (MDRD) formulas 
al., 2000).  
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Figure 21 Chronic Disease Outreach Program Structure
NPC – nurse program coordinator, PHC 
Note: CDOP was implemented in a vertical manner with the aim of integrating screening 
methodology into chronic disease care practice 
 
PHCNs in the clinic were encouraged to sequentially, enrol adult males and females,  
>18 and <80yrs old, who met the criteria for high risk or established CKD or CVD; women who 
were pregnant were excluded, as were patients not willing to participate 
Consent). Participants included patients with uncontrolled DM with HTN (
proteinuria or uncontrolled DM (random glucose 
Proteinuria was measured by albumin creatinine ratio (ACR) on a spot urine sample, and was 
defined as microalbuminuria (ACR
or nephrotic if >200mg/mmol.  
PHCNs were encouraged to start early treatment with insulin if DM was uncontrolled and 
angiotensin converting enzyme inhibitors (ACEi) for HTN or proteinuria, but no specific treatment 
regimen was enforced. If uncontrolled, then PHCNs were instructed to add other classes of DM 
or HTN medication and increase them to the maximum acceptable levels. Care was free in the 
primary care clinics and ranged from zero to $8 at the specialist centre
employment status or age. Only ‘essential drug list
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calcium channel blocker, thiazide diuretic, beta blocker and aldomet, insulin and oral 
hypoglycaemic agents) were available in the clinics. CDOP authorized the initiation or scaling up 
of medication, where no doctor existed, and ensured medicines were up-scaled faster than was 
normal practice. Most clinical targets were determined by national and international society 
guidelines. For cholesterol management, simvastatin an HMGCoA reductase inhibitor, was the 
only lipid lowering medication available at the specialist clinic. 
Due to resource constraints, referral occurred only if cholesterol was >7mmol/L, despite 
existing guidelines advising referral at >6.5mmol/L. All medications were available at the 
specialist centre to manage HTN and DM, including angiotensin receptor blocking agents. 
Indications for specialist referral included uncontrolled HTN or DM despite at least one year on 
program and on maximal therapy available at primary care centre, uncontrolled HTN or DM with 
other serious CVD risk factors, uncontrolled DM requiring insulin, with no doctor or PHCN 
available or able to initiate treatment,  established kidney disease – eGFR <60mls/min, nephrotic 
range proteinuria ACR>200mg/mol, cardiac disease (heart failure or chest pain requiring an 
evaluation), a new stroke, or if the person required anti-lipid medication not available at the 
clinic.  The existing health system referral process enabled patients to be referred directly to the 
nephrologist specialist clinic, not through the casualty/emergency room as is normal practice 
(Figure 20). The existing chronic disease management and referral system was altered by 
CDOP, attempting to ensure improved health care organization. 
  Components evaluated by CDOP at follow up clinic visits, feedback meetings, and from 
the clinical data and an exit questionnaire, included: (i) functional and clinical outcomes (ii) 
Health systems and (iii) PHCN knowledge and continuing education.  Diary recordings were 
collected by the same three CDOP team members, and underwent thematic analysis using 
Atlas.ti software. All PHCNs working at the clinics were encouraged to participate in the exit 
questionnaire. This questionnaire, besides evaluating motivation, evaluated the continued 
medical education support for clinicians, the existing working conditions of health workers, the 
program itself and the environment in which clinicians worked i.e. equipment and medication. 
The Franco existing conceptual model was used to assess health worker motivation (Franco et 
al., 2002, Franco et al., 2004, Penn-Kekana et al., 2005).  CDOP evaluation was triangulated 
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with the analysis of clinical and functional outcomes, diary recordings, and the questionnaire. All 
participants, patients and PHCNs signed informed consent before enrolment or completing the 
questionnaire, and the study was passed by the University of the Witwatersrand Ethics 
Committee (protocol number 03-10-17). 
Nurse program coordinators were in constant contact and available to the health care 
team at the clinics, for clinical ‘decision support’ and to assist with communication to 
management if the need arose e.g. medication shortages. These interactions took place through 
telephonic communication and regular visits when collecting patients’ data forms, i.e. ‘Annual 
visit’ and ‘Follow Up’ forms, or when providing ‘feedback reports’ about a patient’s clinical 
progress and management, and during education visits or the weekly focus group meetings with 
PHCNs. 
The program maintained an ‘action based’ component, although this could not be 
considered to be participatory action research (PAR), and nurses and doctors were asked to 
critique and make suggestions about the program. The program was based on the actual 
experiences of all participants, and the information collected was based on strict scientific 
method. So in fact the program included some aspects evaluating its ‘efficacy’ under 
experimental circumstances where patients were randomly enrolled into a ‘controlled’ study but 
also included determining its ‘effectiveness’ under conditions of a functioning health service. 
Information about program methodology and evolution change was documented.  In practical 
terms this meant that the clinical enrolment and outcomes evaluation was initially to have a more 
traditional randomised component to its design. However, in keeping with early feedback 
received from nurses, the model was slightly altered, and patients were sequentially enrolled 
who met the inclusion criteria.  This change reflects the more flexible design adopted, which met 
the PHCNs’ needs. All changes were documented in the diary recordings, and both program 
changes and methodology changes were tracked over time and were recorded in the program 
and methodological time lines (see figures 37 and 38 in results).  
The scaling up of the program was not a key focus or aim of the program. However, the 
experiences of implementing the program, and the information gathered from the diary 
recordings and questionnaire provided some insight into the potential challenges for future 
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scaling up of chronic disease programs in Soweto. This issue was therefore addressed in the 
literature review and discussion. 
 
The key practical components of organising CDOP can be described as follows: 
• PHCNs were trained by nurse program coordinators, using standard protocols, on how 
to enrol patients onto the program 
• PHCNs on their own, or with the assistance of a  nurse program coordinators, enrolled 
patients onto the program 
• Nurse program coordinators and I were available for queries every day, providing a link 
between tertiary and primary facilities 
• Weekly visits were undertaken by nurse program coordinators to different clinics, which 
included the delivery of patient the ‘feedback reports’ that outlined the ‘decision 
support’ for patient treatment 
• A usual once weekly visit by the nurse program coordinators and myself was arranged 
and this included a ‘focus group’ meeting with nurses to discuss program and their 
patients 
• Regular tracking took place of the patients lost to follow up on the program 
• Teaching on a requested topic e.g. HTN Management, was conducted at weekly visits 
by the nurse program coordinators and myself 
• Individual patient ‘feedback reports’ for PHCNs, were delivered by nurse program 
coordinators which assisted them with clinical management i.e. decision support 
• 3-4 monthly ‘feedback meetings’ with all PHCNs took place at the tertiary hospital 
(nephrology unit) to provide a report on programs progress and challenges 
• 3-4 monthly ‘feedback meetings’ were arranged with the Johannesburg Metropolitan 
Health Department (JMHD) managers who were responsible for health care delivery in 
the region 
• Intermittent visits to some of the clinics were also arranged with the Assistant Director 
from JMHD responsible for chronic disease management in the Soweto region 
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• A review of individual patient data was undertaken during the focus group discussions 
at the clinics and PHCNs were advised on future treatment and educated about the 
protocols of management. 
 
Enrolment Processes  
Study participants were shown a ‘Health Information and Education Booklet’ by the 
PHCN or the HW, who explained the study, information about HTN, DM and its CVD and CKD 
complications, and investigations that would be carried out in someone with DM, HPTN or CVD 
and CKD (Appendix 2 - Health Education Booklet). The booklet was designed by the CDOP 
team, members of JMHD chronic disease directorate and patients. Every clinic was supplied 
with 2 booklets, and the CDOP PHCN or a health worker trained to provide education assisted 
nurses, and they were asked to spend at least 10-15 minutes going through the booklet with the 
patient. At follow up visits PHCNs and nurse program coordinators were to check that someone 
had gone through the booklet with them, and also when patients were referred to the specialist 
clinic at CHBH. Adherence problems were to be documented in the diary recordings. 
The follow up process included PHCNs filling in the patient’s clinical data on the 
‘Initial/Yearly Visits’ form at enrolment and then yearly (Appendix 3) and then a ‘Follow up visit’ 
form 6 months after enrolment (Appendix 4). The ‘Initial and Yearly visits’ forms were filled in at 
enrolment in the program and then yearly thereafter. The ‘Follow up visit’ forms were completed 
every 4-6 months. A minimum of 2 visits per year were captured, and PHCNs were allowed a 2 
months leeway either side of the 6 month follow up period. All forms were analysed by program 
coordinators, myself or by another specialist in the department. The process was outlined in 
figure 20-22, and the results of this analysis were delivered back to each clinic in the form of a 
‘Feedback Report’ or a ‘decision support process (Appendix 5). A feedback report comprised of 
a summary of the patients’ demographic information and clinical information, including that which 
required attention by the PHCNs. These forms were intended to provide ‘decision support’ for 
PHCNs at the clinics. It helped them to decide on medication which should be used, if clinical 
targets were not achieved, or to advise PHCNs to refer a patient to the renal outpatient 
department (ROPD) for specialist attention, if a patient had advanced disease. These reports 
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were typed by the two nurse program coordinators. PHCNs and health workers were supplied a 
support manual to guide and remind them about the process and investigations (Appendix 6). 
This included basic information on normal tests, investigations required, and basic information 
about DM and HTN management. The ‘Support Manual’ together with the nurse program 
coordinators visits, focus group and ‘feedback’/CME meetings, all served to reinforce CDOP 
protocols.  
The weekly visits to a PHC clinic, included ‘focus group’ discussions, with the 2 nurse 
program coordinators, me and all nurses, doctors and health promoters. These discussions were 
summarised in dairies and were semi-structured, taking on a similar format each week. 
Discussions included feedback on program progress, a review of the program and its 
challenges, and clinical cases.  The patients enrolled were reviewed, focusing on clinical issues 
around management. An educational topic related to DM, HTN, CVD or CKD was usually 
included at the end of the meeting. The average duration of these meetings was 1.5 to 2 hours. 
Discussions informed the protocol changes.  
Feedback meetings, every 4-6 months, were held separately for PHCNs and for 
managers at JMHD. All PHCNs at the clinics participating in CDOP were invited to the renal unit 
at CHBH, where the meetings were held. Here, nurses were presented with patients’ clinical 
data and its analysis. Time was set aside for discussion of the results and to discuss action that 
should be taken to deal with challenges which had arisen from the data and its analysis. Time 
was also allocated to a CME topic. These topics were canvassed during the focus group 
meetings or from detecting shortfalls in patient care during analysis and follow up visits. The 
‘feedback’ meetings with JMBH management had a similar structure, but did not include a CME 
topic. These meetings lasted 2-3 hours. There was single meeting held with the executive 
management committee, comprising of all department directors at the end of phase II. All 
meetings were recorded by me and the nurse program coordinators. 
Patient Follow up 
All patients’ data were captured at baseline (‘Initial/Yearly Visits’ form), and every 6 
months thereafter (‘Follow up visits’ form). The nurse program coordinators collected the data 
forms from the clinic and the forms were brought back for entry onto the computer. 
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The data were analysed and from this analysis, a list of comments and management proposals 
were generated. Analysis took the form of determining whether clinical information was normal 
or abnormal, and especially to determine if risk factor targets were being achieved or were too 
high and required referral e.g. blood pressure was <120/70 if hypertensive; proteinuria  
>0.2g/mmol or >200g/mol. It also included evaluating the number of patients enrolled and the 
enrolment speed. A report comprising of both clinical targets and the ‘decision support’ for each 
patient was delivered to the clinic in the form of a Feedback Report, described earlier. This 
report included management advice about the patients’ chronic illnesses (see Appendix 5). 
The entire process of CDOP enrolment, data capture and follow up process is summarised in 
figure 22. 
 
Figure 22. Enrolment and Follow up Processes 
* Enrolment criteria of ‘decision support’ became criteria 4months after program initiation 
 
 
 Qualitative Data Collection 
At the same time as the quantitative evaluation process (clinical outcomes, e.g. blood 
pressure targets and functional outcomes e.g. follow up and referral of patients), a qualitative 
component also took place. This took the form of informal ‘focus group interviews’ during clinic 
follow up visits, by the CDOP team, as described above. Diary recordings documenting the 
focus group discussions follow up visits and meetings were also reviewed, and these informed 
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changes to the program and determined the continuing medical education topics. All people 
involved in the organization of the health services i.e. PHCNs, doctors, and administrators, were 
invited to participate in these focus group meetings. 
A decision was taken at the outset that patients would not be routinely interviewed nor 
would they participate in organised regular focus groups. This decision was made, due to time 
constraints and that CDOP only had 2 full time nurse program coordinators and one part time 
program director. Although patients were not interviewed, information regarding their challenges 
with the CDOP was documented during follow up visits, the PHCN/doctor focus groups and 
feedback meetings, and was recorded in my and the nurse program coordinators diaries. 
Interviews were unstructured, and attempted to ascertain challenges encountered by clinicians 
and nurse program coordinators. Interviews also covered aspects such as existing levels of 
knowledge and available ongoing CME (continuing medical education). A questionnaire 
(discussed earlier) was also used to assess these components of program delivery and patient 
challenges were noted in an open section of the questionnaire.  
 
Clinical Data Measurement Validity and Reliability  
Clinical data were evaluated at the time of downloading into the data base. The clinical 
data and questionnaire data were recorded by a single data manager throughout the study. For 
the clinical data, a series of queries were generated when necessary, i.e. missing data and 
illegible data. The data queries were followed up by nurse program coordinators when visiting 
clinics. Nurse program coordinators also evaluated data at the time of assessing patients’ risk 
factors and achievement of targets and when writing up a ‘feedback report’ for the clinic. 
Individual diaries were kept by the two program nurse program coordinators and the program 
doctor, and then they transcribed their own diary recordings into word documents for analysis.  
  
Treatment and Management Options 
The medication made available and prescribed for patients with HTN and DM at CDOP 
clinics, was from a National Department of Health Essential Drug List (EDL). The medication 
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available at the clinic differed from that available at the specialist clinic. Medication at the 
specialist clinic was from the Secondary and Tertiary Hospital National Department of Health 
Essential Drug Lists. The use of prescribed medications was based on the normal clinical 
practice protocols available at clinics and hospitals. Standard EDL guidelines and Soweto 
Primary Health School Primary Health Care Manual were used for patients being managed at 
the clinics (National Department of Health, 1998a, Pein et al., 1999). These guidelines were 
used in conjunction with the national EDL guidelines, and the schools guidelines do not have 
any specialist input The Soweto Primary Health School was responsible for training most 
PHCNs who participated in the program (see results section), with one year  training open to all 
professional nurses wishing to specialise as PHCNs. The PHCNs have a tremendous respect for 
the school and its teachers, and tend to use the schools guidelines more than EDL. These 
guidelines were developed recognising the limitation and challenges faced by PHCNs in the 
clinics, and the school continued to provide ongoing education and support by afternoon weekly 
continuing medical education sessions at the school. The school is based at a clinic next to 
CHBH. PHCNs are expected to travel, using government supplied transport and their own if 
transport is not available, to these meetings. 
Patients enrolled on CDOP were given the same medications, but the speed of up-
titration differed from the protocols used by PHCNs at the clinics, and the range of medications 
available at the hospital was much larger. At the specialist clinic, the adult hospital level EDL and 
some quaternary medications were  available (National Department of Health, 1998b). This 
included a broader variety of DM and HTN medication and medication for the management of 
associated risk factors, e.g. angiotensin receptor blockers (telmisartan) and cholesterol lowering 
agents (simvastatin).  
Although CDOP used the same medication, it used established national and international 
HTN, DM and renal society guidelines (Society for Endocrinology, 2003, Southern African 
Hypertension Society, 2003, South African Renal Society, 2004). It also used its ‘decision 
support’ system like ‘feedback reports’ and ‘telephone support’ to achieve treatment targets. Up-
titration of medication was quicker than existing up-titration of medication in the clinics, which 
followed EDL protocols. CDOP patients’ risk factors were aggressively tackled and all patients 
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enrolling onto program required baseline blood and urine investigations, resulting in a more 
aggressive approach to managing their chronic disease and associated risk factors. Risk factor 
targets were simplified for CDOP clinicians to assist with earlier up-titration to achieve these 
targets. The clinic or hospital pharmacies were responsible for the dispensing and the 
accountability of the medication. 
 
Lifestyle Measures 
The lifestyle measures prescribed were derived from two sources, the CDOP Education 
Booklet and Support Manual (see Appendices 2 and 6), which was given to each clinic, and the 
‘Prevention and Management of Overweight and Obesity in South Africa’ guideline, developed 
by the National Department of Health (Department of Health, 2001). Lectures summarising the 
guidelines were given to PHCNs at a feedback meeting and their clinics. Lifestyle measures 
centred on the PHCNs measuring a person’s body mass index (BMI) and waist circumference, 
and then advising them on appropriate lifestyle measures. People were encouraged to limit total 
sugar intake, salt intake, alcohol intake, reduce portion sizes and reduce intake of high sugar  
and fatty foods such as fried and processed foods, soft drinks and sweets. People were 
encouraged to eat low fat and sugar alternatives like whole wheat bread, fruit and vegetables 
and low sugar diet soft drinks.  Physical activity and exercise were also encouraged. This was 
seen as part of achieving their appropriate BMI and waist circumference, by promoting loss of fat 
tissue and limiting the amount of muscle tissue lost during dieting. It was advised as part of the 
overall management of HTN and DM. 
 Any amount of exercise was considered beneficial, but where possible people were 
encouraged to do at least 30minutes, moderate intensity exercise daily. This should have been 
done on most days of the week but could be 10-15min at a time, accumulated to a maximum of 
2.5 hrs per week. Exercise prescribed ranged from home maintenance, gardening, and house 
work to brisk walking and running. PHCNs and HW were encouraged to use the CDOP 
education booklet and government obesity guidelines which included tools for evaluation and 
advice regarding readiness for physical activity and weight reduction. 
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‘Routine’ investigations 
Blood tests (full blood count and platelets, urea and electrolytes, random serum 
cholesterol, Haemoglobin A1c, random serum glucose) were done yearly, at the baseline and at 
yearly follow up visits.  The urine testing for ACR (albumin creatinine ratio) or PCR (protein 
creatinine ratio) was taken at the in-between, six monthly ‘Follow Up’ visit. Blood and urine tests 
were done as indicated, unless otherwise requested by a specialist or the nurse program 
coordinators at a specialist’s request. All blood tests and urine investigations were routine for 
patients with HTN and DM, according to the essential drug list (EDL) or National Society 
guidelines. Blood pressure measurements, a urine dipstick and finger prick haemoglucotest 
(HGT), were considered part of the standard clinical examination. 
 
‘Special’ investigations 
Any patient referred for investigations to the renal outpatient department (ROPD) at Chris 
Hani Baragwanath Hospital may have had additional investigations at the discretion of the 
managing physician, and this may have included kidney ultrasound, urine microscopy, 
echocardiography and even kidney biopsy. These investigations were not included in the 
analysis at the end of the study. 
 
Outcome Measures and CDOP Simplified Clinical Targets 
The study’s outcome measures and clinical targets were again determined by national and 
international society guidelines. They were based on existing resources and the ability of the 
PHCN to monitor them. 
 
The primary measures to be evaluated were  
1. Weight reduction (measured by BMI and waist circumference measurements) 
2. Blood pressure (Systolic Blood Pressure and Diastolic Blood Pressure) 
3. Glucose and HbA1c (if diabetic) 
4. Random Serum Cholesterol measurement  
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5. Proteinuria  
6. GFR changes (Cockcroft-Gault and MDRD methods) 
 
The secondary measures included 
1. Referral and reasons for referral  
2. Death 
3. Chronic Kidney Disease stage  
4. Heart failure 
5. Stroke  
6. Other information e.g. haemoglobin 
 
The CDOP simplified targets were as follows (Figure 23) 
1. Blood pressure <120/70 mmHg 
2. Blood glucose <8mmol/L and HbA1c < 8% 
3. Proteinuria < 1g/24hours (ACR PCR<0.1g/mmol) or a decline from the baseline reading. 
4. Reduction in weight and cholesterol through Lifestyle Measures 
 
Figure 23 CDOP Simplified Treatment Target 
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CDOP and Health System Evaluation – Process Review  
As already explained, a population intervention strategy was implemented by enrolling 
high risk participants with diabetes and hypertension onto an observational cohort study and to 
follow them for 2 years. The program included primary, secondary and tertiary prevention 
strategies and it was implemented in a vertical manner, with the intention that screening 
methods for CKD and CVD would be incorporated into clinic policy. The evaluation of CDOP 
comprised of quantitative and qualitative components and was based on the ability to implement 
a program designed around the Wagner CICM to manage chronic disease in Soweto. Achieving 
control of CVD and CKD risk factors and the diseases associated with these risk factors formed 
the cornerstone of the quantitative evaluation. It included progression of disease, appropriate 
referral, and the patients needing dialysis. Morbidity and mortality information about CVD and 
CKD was included in the clinical outcomes. The functional outcomes included the challenges of 
implementation and scaling up the program. The health care team comprised predominantly of 
the PHCNs who focused on whether the program was implemented as planned and what had 
changed with the ‘delivery design system’ in the clinic and Outreach Program as a result of 
CDOP.  Again, focusing using the CICM the model, I evaluated whether the clinic PHCN teams 
were ‘prepared and proactive’. This included PHCNs ability to supply healthcare and to 
determine their knowledge and understanding of the use of current guidelines and protocols for 
DM and HTN. The information gathered was used to assess how such chronic disease 
programs should be implemented, and what had been its successes and failures. Here the 
randomisation, observational cohort study and research methodologies were assessed as 
mechanisms to implement and scale up chronic disease programs. The qualitative components 
were gathered from the diary recordings and the questionnaire. Cross referencing of quantitative 
with the qualitative methodology allowed the investigators to focus on the processes and 
evaluate whether the outcomes were achieved or failed. The clinical data, diary recordings and 
questionnaire (including health worker motivation and knowledge) was evaluated through a 
process of triangulation (Lacey and Luff, 2001) . Findings gathered from both quantitative and 
qualitative components, were ‘triangulated’ to ensure a complete evaluation of the program 
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(Figure 24). The triangulation process was seen as critical to evaluate the complex nature of a 
public health program like CDOP.  
 
Figure 24. Triangulation of Data 
Note: CDOP involved the integration of quantitative and qualitative data. The focus groups, diary 
recordings and questionnaire was used to evaluate health systems, CDOP integration and health worker 
knowledge and motivation 
 
 
Methods for gathering qualitative data 
Information was gathered in CDOP diaries by the nurse program coordinators and the 
program director/doctor. Thematic analysis was carried out from the diary recording sources of 
the nurse program coordinators and program doctor (author). Analysis was also taken from an 
open ended section in the questionnaire which was used to evaluate clinicians’ knowledge and 
motivation. 
The diaries recorded all information gathered during the general meetings and focus group 
meetings with clinic PHCNs, which also sometimes included the clinic doctors, administrators 
and on one occasion clinic patients. 
The data collected in these semi-structured focus group meetings provided additional and 
different insights into the program. Where additional information was gleaned to be important, 
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this resulted in the investigation of additional information found to be relevant to the study e.g. 
PHCN turnover in each clinic and total number of patients seen monthly at each clinic (see 
results section). This additional information included the creation of a program timeline, 
methodology timelines, patient follow up and enrolment statistics at each clinic. 
At the end of the study, an exit questionnaire was to be given to all the PHCNs and 
nurses working in the clinics i.e. n=162. For this questionnaire, a consent form was filled in by 
the participants (Appendix 7 – Nurses Consent Form). 
The questionnaire (Appendix 8a) comprised four components (i) Demographic information (ii) 
Questions to evaluate PCCs knowledge and (iii) Questions to evaluate PCCs motivation (iv) 
Questions to evaluate CDOP and (v) An open ended question which was included in the 
thematic analysis. 
 
Diary Recording Thematic Content Analysis 
  Five key diary recording sources were used.  They included the CDOP clinician 
questionnaire which included an ‘Open ended comment section’;  the Report Back’ meeting 
notes taking during the meetings with PCCs and Johannesburg Metropolitan Health Department 
(JMHD) management; a 1st nurse program coordinator’s (NPC) diary recordings and clinic 
reviews; a 2nd nurse program coordinator’s diary recordings and clinic reviews and the program 
director/doctor diary recordings. The notes in diaries were summarised at the time of the focus 
groups and were then transcribed into ‘Word’ document format to allow analysis (Appendix 9). 
The diaries were collected in the ‘raw’ format when the nurse program coordinators and or the 
program doctor/director visited the clinics. The reasons for visiting included CDOP training, 
collection of Baseline-Annual and Follow up clinical forms, when delivering ‘feedback reports’, 
during PHCN follow up training on protocols and when visiting the clinics for ‘formal’ focus group 
meetings.  Notes were also taken during management planning meetings and program review 
meetings and the ‘report back meetings’ with the PHCNs and the JMHD management team. 
Information relevant to the program was generally recorded into the diaries and it 
became clear that a ‘recurring’ theme of information emerged. The NCOs and PD had an 
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‘implicit’ sense of the recurring material and what parts were relevant and should remain in the 
Word document transcripts. 
The analysis undertaken was ‘thematic analysis’ only and no ‘discourse analysis’ 
occurred. Recordings were coded according to ‘what’ was said and not ‘how’ it was said. The 
aim of this analysis was to present the PHCNs views and challenges during their running of a 
chronic illness care service. However, the primary focus was their views and challenges of 
working with the CDOP. The diaries were then all included in a process of vertical analysis, 
using Atlas.ti software. Thereafter horizontal analysis took place across all the diaries and text. 
The common features were analysed using Atlas.ti version 5.2.0 software package and codes 
were developed from the pieces of text. At the time of creating codes, memos were also created 
from the text using the Atlas.ti software. 
 
Diary Recording Sources 
1. Primary health care clinicians questionnaire – Open ended comment section 
2. ‘Report Back’ meeting notes to PCCs and Johannesburg Metro Health Management  
3. 1st Program Nurse Coordinators Diary Recordings and Clinic Reviews 
4. 2nd Program Nurse Coordinators Diary Recordings and Clinic Reviews 
5. Program Doctor/Director’s Diary Recordings 
 
Health Worker Knowledge and Motivation Assessment 
A questionnaire was developed to evaluate the impact of the program on both knowledge 
and motivation. The basis of this evaluation was based on the fact that policy implementation 
and protocols for chronic illness management required an ‘informed, prepared, and motivated’ 
health care team (Wagner, 2004, World Health Organization, 2002a). In the case of the program 
and chronic illnesses in general this rested on the shoulders of the primary health care clinicians 
(PHCNs and doctors) in the clinics. A conceptual model previously used by the Centre for Health 
Policy of the University of the Witwatersrand and adapted from this work and that of Franco et al 
was used to develop questions for sections 3 (Franco et al., 2004, Penn-Kekana et al., 2005) 
(Figure 25 and Appendix 10a) .   
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Figure 25. Conceptual Model of Health Worker Motivation 
Org – organizational; HR – human resources; Mx – management; J ob   job; Att chnge – attitude change 
Adapted from Franco Social Science and Medicine 2004 & Penn-Kekana models 2005 
Note: Full figure can be viewed in Appendix 10a 
 
 
Health Worker Knowledge Assessment 
PHCN knowledge was assessed by various means. Clinical data were evaluated during 
the course of the program and where clinical risk factor treatment targets were not being 
achieved, this was noted in the diary recordings .e.g. HbA1c target levels not known or guideline 
knowledge for blood pressure targets were not current. This type of information was also 
gathered during focus group meetings with PHCNs.  
Section four of the questionnaire comprised of questions focusing on the outreach 
program itself and its value to the nurses. It included an evaluation of implementation, clinic 
systems, clinics medications and equipment (Appendix 8a). The questionnaire also had sections 
evaluating PHCN knowledge, health worker motivation, and continuing medical education and 
supervisor support. These are presented in the results chapter (see also Appendix 8b). 
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Knowledge was also assessed in part one of the questionnaire, which included four 
clinical scenarios, and these clinical scenarios were similar to conditions that a PHCN would see 
at the clinic (Appendix 8a). They were asked to read the scenario and then answer ten questions 
about clinical management and risk factor targets; each statement required the PHCN to take a 
clinical action, and nurses were required to tick or circle ‘yes’, or ‘no’ or indicate if ‘not sure’. 
Where a PHCN indicated ‘not sure’, this was taken as a negative result when the answers were 
analysed. Each question was scored separately and an overall score was calculated. 
Comparisons were made between clinics and between PHCNs who participated in CDOP (CD) 
and those who did not participate in the program (NC). The questionnaire covered the topics of 
HTN, DM and HIV management, with particular reference to CKD and CVD complications. It 
also evaluated PHCNs knowledge of guideline targets for these diseases e.g. HbA1c, BMI and 
blood pressure targets. 
 
Health Worker Motivation Assessment 
A conceptual model of the outcomes and determinants of motivation was developed for 
this component of the study (appendix 10a and 10b, figure 25), drawing on the work of Franco 
and Penn-Kekana (Franco et al., 2004, Penn-Kekana et al., 2005). The chronic illness program 
described in this thesis offered an opportunity to further validate the model, to identify the 
motivational determinants that may be important for primary health care nurses, and to ascertain 
if these methodologies are relevant in this particular sector of public health management. In 
order to evaluate the chronic disease models of Wagner and the WHO, it was necessary to 
identify the kinds of interventions and strategies that should be built into a health care system to 
facilitate health worker motivation for managing chronic illnesses. More generically, the aim of 
using this conceptual model was to improve both clinical and functional outcomes for people with 
chronic diseases, to understand how workers motivation could impact on these outcomes. 
Worker motivation is an important determinant of worker behaviour and performance, and 
should be an important consideration in the design of micro- and macro-level organizational 
reforms and for developing specific interventions like a chronic disease outreach program. 
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This questionnaire was the main method for evaluating health worker knowledge and 
motivation. 
Section 1 gathered demographic and background information about the PCCs and 
nurses working in the clinics.  Section 2 of the questionnaire assessed health worker knowledge 
by using a number of ‘clinical scenarios’ which covered HTN and DM management, as well as 
level of knowledge about existing guideline treatment targets. Section 3 used a conceptual 
model to develop questions to assess health worker motivation, used by Pen-Kekana and 
originally by Franco et al (Franco et al., 2004, Penn-Kekana et al., 2005).  This conceptual 
framework was used to define various domains of interest for motivation, outcomes of motivation 
and related factors influencing motivation (see Appendix 10a and 10b – figure 25). Section 3, 
also covered questions selected from the above studies but included additional questions 
developed to cover the domains of interest to evaluate PHCNs motivation but also a CDOP and 
clinic pharmacy and equipment resources evaluation. Section 4 evaluated PCCs and nurses’ 
previous education and training support received for managing chronic illnesses. 
The conceptual framework was used to define 22 domains of interest for the motivational survey, 
1 for CDOP (Extrinsic Characteristic) and 1 for Equipment and Medication (Working 
Environment). Nine concerned the outcomes of motivation and 13 related to factors influencing 
motivation. Seventy-five questions were selected, some from existing organizational survey tools 
(Price, 1997, Franco et al., 2004) used by Penn-Kekana and others were developed to cover the 
domains of interest (Appendix 10a and 10b).  
To assess motivational outcomes, self-assessment scales were employed. Work 
behaviour referred to general work actions, manner, and conduct that reflected diligence in work 
and consideration in the work environment. Respondents were required to identify how strongly 
they agreed or disagreed with each statement, using a 5-point Likert scale. Scales were adapted 
(and occasionally developed) for use in this project and around managing chronic illnesses. The 
questions were developed to ensure it was appropriate for the context of the study, through 
discussions with the local outreach team, and on the basis of information gathered during the 
phases of the study. 
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Questionnaire data were analysed using Analyse-ti and Statistica software. The internal 
consistency of the questions in each domain was measured calculating Cronbach’s alpha 
scoring. The clusters of loadings were marked and those clusters determined the oblique factors 
for hierarchical analysis. The marked loadings had scores that were greater than >0.45 or 0.55. 
The internal consistency of the question for each domain, assessing the correlation between 
scores within this domain, was measured by calculating Cronbach’s alpha score. The internal 
consistency scores were considered ideal if they exceeded 0.8, but were acceptable if above 
0.5. Questions were also evaluated using factor analysis. This was used to evaluate whether or 
not the identified domains were valid and separate constructs.  
 For the questionnaire the variables were analyzed using the original Likert coding 
(ordinal analysis) and recoded as binary categorical variables (agree compared to not sure and 
disagree), and then also as numerical indices derived from the Factor Analysis.  Chi-square 
testing for categorical data will be used. Factor Analysis was used to evaluate whether or not the 
identified domains were valid and separate constructs. Subsequent analysis explored bivariate 
and multivariate relationships between motivational outcomes and determinants using different 
coding and responses. The results obtained from these different methods were very similar. The 
PHCNs were surveyed at the end of the program i.e. when 2 year follow up period had been 
completed. PHCN participating in the program were compared with those who did not. 
The ‘open ended’ narrative data from the last section of the questionnaire was 
transposed to a Word document and thematically analysed using Atlast.ti software. 
 
Coding of Diary Recordings for Thematic Analysis 
In order for the diary recordings to be analysed, codes needed to be developed to 
analyse the text using Analyse-it Software (see Appendix 11). 
The codes or common text analysis were developed from three sources.  
1. The Health Worker Motivation tool –discussed above 
2. Wagner Chronic Illness Care Model (Wagner CCM) 
3. Innovative Care for Chronic Conditions Framework (WHO ICCC) 
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From the CCM, ICCC and the Health Worker motivation models codes were generated with 
broad classifications. Under these codes the diary recording were analysed and quotes 
extracted based on these codes.   
The ‘memos’ were classified into five categories; 1) memo 2) commentary 3) methodology 4) 
program evolution and 5) theory. These memos were then used to create ‘timelines’, various 
tables and evaluations. Some of the conceptual model outcomes and determinants of motivation 
domain definitions and questions were used for this component of the study (see below).They 
were concerned with outcomes of motivation and included 6 codes covering ‘Worker Affect and 
Cognition’ and six codes covering ‘Worker Behaviour and Performance’.  The latter ‘area’ was 
not evaluated by the questionnaire. Additional data were gathered by the nurse program 
coordinators from the clinic records and directly from PHCNs. 
The thematic analysis evaluation did not include a comprehensive use of all previous 
domains coding as was used for the questionnaire (see below). The diary recordings were used 
to complement the questionnaire and clinical data and reinforce the triangulation process. In 
some instances, certain themes may not have been analysed in the questionnaire or clinical 
analysis e.g. Worker Behaviour and Performance and Positive Policy Environment. These two 
domains were only analysed from the diary recordings (see results section). 
Horizontal analysis of the information was then fashioned across the diary text at two levels. 
Firstly, across the diaries without using scientific literature (see Results Chapter and 
Appendices) and secondly, referencing various experts (see Discussion Chapter). 
 A total of 74 different codes were generated under the nine different classifications and 
this resulted in quotes being extracted from the diary recording and questionnaire’s open ended 
comments (Appendix 9). In order to determine the program’s evolution and the methodological 
changes which occurred during follow-up, a further 200 memos were created during the 
analysis. The self administered questionnaire was completed by the PHCNs from the clinics 
(Appendix 8a and 8b) at the end of the phase II of the program. The questionnaire included an 
open ended question which was analysed using thematic analysis.  
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Statistical Analysis  
Statistical analysis was conducted with Analyse-it for Microsoft Excel (Analyse-it 
Software, Ltd, Leeds, United Kingdom) and Statistica release 6 (StatSoft, Inc, Tulsa, OK). The 
thematic analysis was analysed using ATLAS.ti's version 5.2.0. The clinical data was analysed 
using the Shapiro-Wilk test was used to test for normality. Continuous data variables were 
expressed as mean ± SD if parametric and median (IQR) if non parametric. Student t-test was 
used when data had symmetrical distribution and both paired dependent testing was performed 
on patients enrolled and then at 2years after follow up.  
 
Determination of Sample Size 
The sample size was calculated based on the change in HTN and DM control and their 
CVD risk factors, required to achieve significant results. Patient enrolment was based on the 
required number for a p value <0.05. This was also based on comparisons between a treatment 
and control group. It was calculated that if a 10% change in control group occurred then a 20% 
change was required in the treatment group. This would ensure a 10% difference between the 
groups and then 780 people needed to be enrolled. If a 5% change in control group was 
required or achieved then a 25% change was required in the treatment group and the program 
would need to enrol 203 people. For a 5% change in control group and 15% in treatment group 
then need 566 people were needed. This was taken for a follow up period of 24 months. If those 
enrolled were evaluated against their baseline risk factors then similar differences would be 
required, as compared to a control group, for significance to be achieved. 
The sample size for evaluating nurses’ knowledge and motivation was based on ensuring an 
80% response rate to the questionnaire, from the total of PHCNs working at participating clinics. 
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5 RESULTS 
The results are presented in the following order. The functional and clinical data are 
presented first, and includes ‘functional’ outcomes in the form of enrolment process and follow 
up challenges, followed by the baseline clinical information of the cohort and clinical follow up 
data. The outcomes include those patients referred and followed in the specialist centre for two 
years. The results are also presented using the structure provided by the chronic disease 
management models, described in the earlier chapters (figures 4 and 5).  The next section 
covers program implementation and the health care organization. It includes an evaluation of 
delivery system design, decision support and clinical information systems, and is followed by an 
evaluation of current health policy. The questionnaire focuses more specifically on the evaluation 
of the health care team, with a specific focus on evaluating clinician knowledge and motivation. 
This latter section also draws on the ‘conceptual model of health worker motivation’, (figure 25), 
to provide results on health worker motivational outcomes, motivational determinants and worker 
behaviour and performance. This completes the triangulation process of evaluation outlined in 
the chapter 4. All evaluation includes the integration of information gathered from the diary 
recordings, focus group meetings and questionnaire. 
 
Functional and Clinical Outcomes 
Enrolment and follow-up of Cohort 
From February 2004 to February 2006, 618 ‘high risk’ patients (61% females, 39% 
males) were enrolled into CDOP by the PHCNs, from an estimated pool of 38 000 HTN and DM 
patients at 20 clinics. The focus of CDOP was on patients with uncontrolled HTN and DM. 
Extrapolating from previous surveys of DM and HTN control in the Soweto clinics (Mohammed 
and Mthombeni, 2000), the pool of eligible HTN and DM patients for CDOP was half to two thirds 
of the total  number of patients i.e. 19 000-26000. The mean age of those selected at baseline 
was 60+11years. Patients were enrolled randomly, but according to the PHCNs’ judgement of 
whether they met the inclusion criteria, and this may have been influenced by whether  the 
PHCN needed management support or believed the person required referral to a specialist.    
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They were guided by the inclusion and specialist referral criteria. The cohort of patients enrolled 
was followed for two years.  
Of the 618 patients enrolled onto the program, 68.7% (n=425) were lost to follow within 
six months. The survival or attrition rate of the cohort from baseline, excluding those patients 
who completed follow up in the clinic, partial follow up (>18months but <24months), moved, died 
or were referred, is shown in figure 26. 
 
Figure 26. Cohort Survival by Follow up Visit Number in the clinic 
Note: Includes patient visits over 24 months at 6 monthly intervals and excludes those referred patients 
and those who moved or died. 
0 = baseline visit; 1st visit = 6month visit; 2nd Visit=12month visit; 3= 18 month visit; 4 = 24month visit 
 
 
Those patients not followed on the program were able to be differentiated on the basis of 
whether they were still attending the PHC clinic but chose not to participate in CDOP, labelled 
‘Not followed in the clinic’ group and included 213 (34.4%) patients, whereas 123 (20%) were 
truly lost to follow up and outcome was not known, hence labelled ‘Outcome not known’ group. 
There were 24 (4%) patients who were found to have moved to another clinic, area or province. 
None of these “lost” patients required specialist referral. This was determined as we had their 
baseline clinical data, and could determine if they had met the ‘’specialist referral criteria’ at the 
time of being enrolment. The one percent (n=6) who died and those referred to another 
specialist clinic, obviously could not be referred to the kidney clinic. Only 27 (4.3%) patients were 
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lost to follow up who should have been referred.  Again this is because we kept data of each visit 
and could evaluate at what stage a patient would have required referral. Of the 27 lost who 
should have been referred, 23 would have been referred at baseline and only four patients at the 
final visit. Sixty nine (11.1%) were actually referred and arrived at the specialist clinic (Figure 
27). Of these, 47 (68%) were referred from baseline, 5 (7%) at the 6 month visit, 6 (9%) at 1 
year, 4 (6%) at 18 months and 7 (10%) at final 2 year visit. In summary, evaluating the referral 
outcomes of patients enrolled, 82.2% (n=515) were not referred from the PHC clinic.  Of the 
17.8% (n=104) referred to the specialist clinic, 11% (n=69) arrived and were followed for 2 years, 
4.3% (n=27) did not arrive at the referral hospital and 1% (n=6) died during the 2 years of follow-
up, i.e. two-thirds arrived and were followed for two years. 
 
Figure 27. Referral Outcomes from Baseline CDOP Group 
Note: 104 patients referred and 69 arrived at specialist clinic and 6 others referred directly to cardiac 
outpatient clinic i.e. 27 patients lost to follow up at specialist kidney clinic 
* Referred but not arrive indicates patients who did not arrive at kidney clinic (ROPD) 
 
 
Of the 35 patients who did not arrive at the renal outpatient specialist clinic, eight were 
referred with cardiac problems directly to the cardiac outpatient clinic and two were referred back 
to the renal outpatient clinic as kidney disease was the primary problem. The cardiac clinic 
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joined the direct referral system of CDOP during the course of the program (see program 
evolution figure 37 below). Considering that 72 out of 104 patients who were referred to the 
specialist clinics arrived at a clinic and 69 were known to be followed up at the kidney clinic 
(renal outpatient clinic – ROPD), the success of following patients in a specialist setting was 
significantly better at 69.2% and 71.2% compared with the PHC clinic at only 7.9%; n=40. Only 
four clinics were able to complete a full 2 year of follow up.  Some PHC clinics were significantly 
better at following-up and referring patients compared with others (Figure 28). The reasons for 
this are investigated more closely from the diary recording and open ended section of the 
questionnaire and are described below.  
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Figure 28. Referral of Patients according to PHC Clinic 
* Note: Each clinic was assigned a number in order to maintain confidentiality ** Number in brackets 
denotes total number of patients enrolled at this clinic 
 
Of the 618 patients enrolled, only 23% (n=141) completed 2 years of follow up, 104 of whom 
were referred to a specialist and the remaining few were followed up at PHC level. Most were 
unable to be followed by the PHCNs in the clinics 54% (n=336) i.e. remained at clinic but lost to 
follow up or their outcome was never known. Only 4% (n=24) were known to have moved to 
another area or clinic, and 1% (n=6) were known to have died (Figure 29). We were able to 
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differentiate the ‘Outcome not known’ group from the ‘Not followed in PHC clinic’ group. This 
was done when going back to the clinics at the end of the program to assess the reason why the 
‘Lost to follow up group’ was so large. Nurse program coordinators tracked each patient by using 
health promoters working in chronic disease clinics and clinic clerks. Those known to still be 
attending the clinic were classified as ‘Not followed in clinic’, and those patients whose 
whereabouts remain unknown were labelled ‘Outcome not known’. It was felt important to see if 
patients had left the clinic or just left the program. 
 
Figure 29. CDOP Patients Outcomes  
* 69 patients referred to specialist completed a full 2 years of follow up, ** 6% of patients in clinic 
completed 2 years of follow up (Note therefore 23% of patients enrolled from baseline completed 2 years 
of follow up) 
Note: 46 patients were supposed to be referred but were not referred as they were lost to follow up or 
never received a ‘feedback report’ indicating they should be referred to a specialist 
 
Of the 104 patients requiring specialist referral, most were sent to the kidney clinic 
(15.5%; n=96), with only a few to the cardiac clinic (1.3%; n=8). Most people enrolled at baseline 
did not have an indication for immediate referral (82.2%; n=502). There were therefore 27 (4.3%) 
patients who required referral to the specialist kidney clinic but never arrived or were not 
contacted to go to the specialist clinic. Of the 110 patients who required referral, 70 (11.3%) met 
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the referral criteria at the time of baseline screening and a further 40 patients (6.5%) met the 
criteria during the 24 month follow up period (See Table 10 for indications).  
Of the 104 (17.8%) patients who the program was able to refer to the specialist centre, 
69 (71.8%) arrived at the kidney clinic and were then followed until the end of the study period. A 
breakdown of indications for referral is summarized in Table 7. More than half of the patients 
were referred with significant CKD or proteinuria, 3% required lipid lowering medication, and 
equal proportions were referred for insulin initiation, significant proteinuria or to the cardiac clinic. 
 
Table 7. Indications for Referral to Specialist Centre  
 
Reasons for referral n Percent 
No Referral Needed 508 82.2 
Stage 3 CKD* 54 8.7 
Stage 4 CKD* 3 0.5 
Stage 5 CKD* 4 0.6 
Suspected Cardiac Disease** 8 1.3 
Significant Proteinuria*** 8 1.3 
Diabetes needing insulin# 8 1.3 
Cholesterol requiring medication$ 19 3.1 
Total Referred 104 17.8 
Died 6 1.0 
* CKD with a eGFR <60ml/min/m2; ** Suspected Cardiac Disease – chest pain, abnormal 
electrocardiogram; ***Significant Proteinuria - nephrotic range proteinuria ACR>200mg/mol or PCR 
>0.20g/mmol; # HbA1c>10 and on maximum oral hypoglycaemic medication; $ cholesterol >7mmol/L  
 
Six patients were known to have died, three from ‘heart failure’, and two from a ‘stroke’ 
and in one the cause was unknown. Of the 6 patients who died, four were known to have an 
eGFR<60ml/min, one had uncontrolled diabetes (random glucose 10.1mmol/L) and HTN (BP 
178/85mmgHg), and one nephrotic range proteinuria (ACR 690 mg/mol). The causes of death 
were not confirmed but were based on a report from the clinic. An overview of the groups by 
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chronic disease diagnosis (DM or HTN), total number and gender distribution is summarized 
according to follow up from baseline to 2 years in figure 30.  
 
 
Figure  30. Overview of CDOP Baseline Enrolment and Follow up by Diabetes (DM) or 
Hypertension (HT) Diagnosis 
 
 
 
Baseline and Follow-up Clinical Evaluation 
Amongst those enrolled at baseline, fifty-eight percent (349) had uncontrolled HTN, and 
42% (257) DM with HTN and/or proteinuria. Patients enrolled with diabetes (DM) had type 2 DM 
with 20.1% of these patients using insulin. Table 8 demonstrates that at baseline, those patients 
enrolled met the criteria of ‘high risk’, having uncontrolled blood pressure or diabetes and 
significant risk factors for CVD and CKD (see also section on screening below). 
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Table 8. Baseline Demographics and Risk Factors 
Parameters Men Women All 
 n 
Mean 
(SD/%) n 
Mean 
(SD/%) n Mean (SD/%)
Age  (yrs)** 188 62+11 422 59+11 610 60+11 
Diabetics 80 31% 177 69% 257 42% 
Hypertensive 107 31% 242 69% 349 58% 
Smokers** 35 6.6% 22 4.2% 57 11% 
Waist cm* 138 100+16 317 103 +16 455 102+16 
BMI *kg/m2 * 162 28+7 344 33 + 8 506 32 + 8 
SBP * (mmHg) 186 153 424 153 610 153 + 23 
DBP * (mmHg) 186 93+11 424 94 + 13 610 94 + 12 
GFR(ml/m2) 133 69+ 21 311 72 + 26 444 71 + 25 
ACR mg/mmol* 108 60+143 311 58+217 377 59+199 
Note: Data are mean (SD) or proportions; ** Significant difference by gender * Indicates risk factor higher 
than ‘normal’ – see text and inclusion criteria Table 10.  
 
 
Focusing on the baseline group, CDOP Baseline (n=618) (Table 12), the ratio of women 
was significantly higher than men (M: F; 31%, 69%). Eleven percent were smokers and a 
significant difference existed between genders (M: F 6.6% and 4.2%; p<0.0001). On evaluation 
of obesity and CVD risk, measuring waist circumference, women were significantly more likely to 
be have a waist circumference in the high risk zone (p<0.0001); 84.5% of women; (>88cm), and 
36.2% of men (>103cm) (Figure 31). The BMI patterns were similar, where women were 
significantly more likely to be obese (BMI 30-39.9kg/m2), (F: M; 44.8%: 29%) or morbidly obese 
(BMI >40kg/m2), (F: M; 21.8%: 5.6%). Men were more likely to be overweight (BMI 25-
29.9kg/m2) rather than obese or morbidly obese as compared to women (F: M; 18.9%: 35.8%; 
p<0.001) (Figure 32).  
 
The results were similar when all overweight groups were combined, with 85.5% of 
women and 70.4% of men overweight or obese. Women and men were more likely to be 
overweight, obese or morbidly obese if they had DM compared with the HTN group. 
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Figure 31. Waist Circumference at Baseline 
Note: *Significant difference between genders p<0.001 
  
 
Figure 32. Body Mass Index (BMI) at Baseline 
Note: *Significant difference between genders p<0.0001 
 
In the evaluation of patients’ lifestyles at baseline, 86% (n=531) admitted to doing no 
exercise and 3% (n=19) exercised 3 or more times per week. Seventy nine percent (n=483) of 
people enrolled admitted to eating ‘fatty foods’ more than four times per week and only three 
patients to eating no fatty foods at all. 
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At baseline, evaluating BP control, only 25.4% of patients were controlled (<140/90mmHg) 
(Figure 33), and of those with diabetes, only 15.4% achieved current guideline target BP 
(<130/80mmHg).  
 
Figure 33. Blood Pressure Control at Baseline 
Note: No gender differences existed 
 
The mean serum cholesterol for all patients was 5.03 +1.31mmol/L, and women were 
more likely to have higher cholesterol than men, (F: M; 5.14mmol/L: 4.77mmol/L; p <0.008), and 
more likely to have levels which required referral for medication i.e. >6.5mmol/L; (F: M; 14.9%: 
7.2%), (Table 9). The mean serum cholesterol for all DM patients was 5.07 +1.46mmol/L, and 
women were more likely to have higher cholesterol than men, (F: M; 5.21+1.44: 4.78+1.47; p 
<0.05). However again, the women with diabetes were more likely to have levels which required 
referral for oral anti-lipid medication i.e. >6.5mmol/L; (F: M; 18%:7%), compared with men. This 
was similar for non-diabetic (Baseline HTN group) men and women, (F: M; 5.12+1.17: 
4.74+1.14; p <0.05), but total levels requiring referral were much lower in this baseline HTN 
group, i.e. >6.5mmol/L; (F: M; 11%:6%). Evaluation of the burden of kidney disease in this 
cohort included assessing the amount of proteinuria and an estimated GFR (eGFR) using the 
modified diet in renal disease formula (MDRD). 
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Table 9. Total Cholesterol at Baseline 
Total Cholesterol Women (n=276) Men (n=125) Total 
Target Range 
mmol/L 
Percent 
% 
Percent 
% n 
Percent 
% 
<5.2 53.6 62.4 226 56.4 
5.2-6.4 31.5 30.4 125 31.2 
6.5-6.9 6.2 2.4 20 5 
>7$ 8.7 4.8 30 7.5 
Mean (SD) 5.14 +1.31@ 4.77 +1.29@ 401 5.03 +1.31 
$ Specialist Referral Criterion; @ t-test total serum cholesterol (mmol/L) by gender p <0.008; **Total 
Cholesterol (non-fasting 2hr post-prandial) 
 
On evaluation of proteinuria in the group, overall 28.3% had an albuminuria >30mg/mol, 
which is a significant risk factor for CVD. The mean urine albumin-creatinine-ratio (ACR) was 
59+199mg/mol, and 6.9% of the patients met the referral criterion for nephrotic range proteinuria 
(>0.20mg/mol), indicating both CKD and a high risk for CVD (Figure 34). A higher number of 
patients with DM compared with those with HTN, had albuminuria >30mg/mol; 33%. No 
significant gender differences existed for urine albuminuria.  
Using the estimated glomerular filtration rate (eGFR), MDRD formula not corrected for 
the population group, i.e. appropriate ethnicity factor 6, it was found that 12% of patients with 
advanced stages of CKD (eGFR<60ml/min) required referral. Those patients with DM were more 
likely to have advanced CKD or low eGFR (<60mls/min), compared with the baseline HTN group 
(30% vs. 17%; p=NS) (Figure 35). Twelve percent of patients (n= 53) had advanced CKD 
requiring referral i.e. GFR <60mls/min, and 1.6% (n=10) patients had ESRD (i.e. 
eGFR<15mls/min) requiring dialysis. Only 70% of patients had a baseline eGFR calculated, 
                                               
 
 
 
6
 This was not possible as the research to determine an ethnicity factor for black South Africans had not yet been 
completed at the time of initiating and evaluating this study. This study was only recently published using some of the 
information from this study. The reference for this study is H.E. van Deventer, J. George, J. Paiker, P. Becker, I. Katz. 
Estimating Glomerular Filtration Rate in Black South Africans by use of the Modification of Diet in Renal Disease 
(MDRD) and Cockcroft-Gault equations. Clinical Chemistry. 2008;54;7:1197-1202.  
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because the availability of serum creatinine levels enabled calculation.  This possibly 
underestimated the true burden of kidney disease in this group. 
 
Figure 34. Spot Urine Albumin Creatinine Ratio at Baseline 
*ACR – albumin creatinine ratio; ** No gender difference between ACR level; Baseline CDOP Group 
(n=618) for Women (n=428) and Men (n=190) 
 
 
Finally evaluating baseline diabetes control and medication use, eight patients (1.3%) 
were referred for insulin as no doctor or PHCN was able to prescribe insulin at the clinic. All of 
these patients met the criteria for specialist referral due to uncontrolled DM or HTN or significant 
risk factors. The level of DM control was poor overall, with only 31% of patients having optimal 
control i.e., HbA1c <7%., with a mean HbA1c of 9+3% (Table 10). Only 20.1% of DM patients 
were on insulin and only 39% were on an angiotensin converting enzyme inhibitor (ACEi). The 
use of ACEi amongst HTN patients was much higher (84.2%) than in people with diabetes 
(Table 11). 
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Figure 35. CKD Staging at Baseline 
* CKD – chronic kidney disease; Note – staging calculated using an estimated glomerular filtration rate 
with the modified diet in renal disease (MDRD) formula and not corrected for ethnicity 
 
Table 10. HbA1c level Amongst the Baseline Diabetes Group 
Diabetes Control for 
HbA1c 
n 
  
HbA1c 
% 
Percent 
% 
Optimal 45 <7 31 
Acceptable 20 7  to 8  14 
Additional Action 81 >8 55 
Mean (Std Dev) 146 9 +3   
 
 
In general, there was a low use of HTN medication other than hydrochlorothiazide 
(HCTZ) and ACEi. The use of this combination in diabetes occurred in <50% of patients. It 
should be noted that not all classes of HTN medication are available in the clinics. HTN 
medications not available in PHC clinics but at hospital level include alpha blockers, angiotensin 
receptor blocker (ARB) and minoxidil.  Other classes of medication unavailable in most clinics 
were anti-lipid medication, i.e. simvastatin – HMGCoA enzyme inhibitor.  Less than one percent 
of patients were on anti-lipid medication at baseline, despite elevated cholesterol levels. An anti-
lipid agent was only available at one of the twenty clinics. 
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Table 11. Medication Prescription at Baseline 
Medication Diabetics Hypertensive 
 N 257 N 349 
HCTZ 120 47% 310 89% 
Furosemide 4 2% 38 11% 
ACEi 100 39% 294 84% 
CCB 27 11% 38 11% 
N-CCB 12 5% 44 13% 
Beta Blocker 6 2% 58 17% 
Aldomet 11 4% 69 20% 
Gliclazide 98 70.5% - - 
Metformin 86 61.9% - - 
Insulin 28 20.1% - - 
 HCTZ – hydrochlorothiazide; ACEi – angiotensin converting enzyme inhibitor; CCB – calcium channel 
blocker; N-CCB – non-dihydropyridine calcium channel blocker.  
 
 
Specialist Referral Group Clinical Data 
As noted above, two-thirds (n=104, 17%) of the patients required referral, at baseline and 
during follow-up, but only 69 (11%) were those followed at the specialist renal outpatient clinic 
and this group of ‘Specialist Referral’ patients was followed for a full 2 years (see figure 27 and 
29). The remaining 40 (6%) patients, who completed 2 years of follow up, were from the PHC 
clinics and did not require referral (Figure 33 and 34).  The data at baseline and at 2 years, for 
the specialist referred group only, is summarized in Table 12 as the ‘Two-year-specialist group 
at baseline and 2 years’. The Two-year clinic group (n=108) was not considered for analysis as 
there were statistically significant differences in ages between the Two-year-clinic group (n=39) 
and Two-year-specialist group (n=69) (67.2yrs vs. 61.4yrs; p<0.01). There were also differences 
in the chronic disease distribution between the groups. The clinic group had a greater HTN to 
DM patient ratio at 2 years (27:12) compared with the specialist group which comprised of more 
people with diabetes (29:40) (p<0.01), indicating that a greater number of patients with diabetes 
required referral and were referred to a specialist. The Two-year-clinic group could have been a 
self selected group, as the reasons for their completing follow up, compared with those who 
were lost to follow up is unknown.  Therefore analysis of follow up could only be carried out for 
the specialist group, as these patients were not self selected (see paragraph above). 
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Table 12. Risk Factors in the Two-year-Specialist Group at Baseline and 2years 
Parameters Baseline (n=69) 2 years (n=69) p 
Age 69 61 +10 69 62 + 9 - 
Gender 29 Males 42% 40 Females 58% - 
Diabetes 40 58% 40 58% - 
Hypertension 29 42% 29 42% - 
BMI (men)  11 28+4  11 28 + 5  NS 
BMI (women)  35 35+5 22 35+5 NS 
Cholesterol* 51 5.8 +1.6 51 5.3 + 1.4 0.0005 
Glucose (mmol/L)** 15 10.1 + 5 15 8.8 + 4 NS 
HbA1c (%)** 23 9.5 + 3 23 7.6 + 2 <0.01 
SBP  66 155 + 22 66 142 + 22 0.0002 
DBP * 66 92 + 12 66 80 + 13 <0.0001 
ACR, mg/mmol * 47 149 + 287 - - - 
Urine protein >3+* 62 13 60 14 NS 
GFR (MDRD)*** 38 56 55 50 NS 
Note: Data are Mean (SD) or proportions; * Significant difference p<0.05; Student t-test used for 
continuous variables and Pearson Chi-squared for categorical variables; @CVD – cardiovascular; #CKD – 
chronic kidney disease;** Evaluated for diabetes patients only: *** Median; MDRD – mls/min 
 
Participating in the program for 2 years showed no benefit in reducing the patients’ body 
mass indices (BMI) i.e. men remained on average overweight and women remained obese. 
There was however a significant difference achieved with risk factor control in the specialist 
group with respect to the serum cholesterol levels, diabetes control measured by blood HbA1c 
levels and systolic and diastolic blood pressure (see Table 12).  The ‘specialist clinic’ was unable 
to collect adequate data to analyse differences in proteinuria by albumin-creatinine ratio, but on 
urine dipsticks there was no difference from baseline. There was also no significant decline in 
glomerular filtration rate from baseline in this group of patients. Regression analysis of baseline 
variables which affected GFR at 2 years included male gender (p<0.05), serum cholesterol 
(p<0.01) and serum haemoglobin (p< 0.01). Systolic and diastolic blood pressure, body mass 
index and HbA1c were not significant factors affecting GFR decline. 
There were significant changes in medication prescription over the 2 year period and this 
is summarised in Table 13. There was a high use of ACEi in this group at baseline and at 2 
years, and significantly more calcium channel blockers (CCB), minoxidil alpha-blockers and 
angiotensin receptor blockers (ARB) used for hypertension compared with at the clinics. More 
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furosemide was used instead of hydrochlorothiazide and more statins were prescribed in the 
specialist clinic. There was also more insulin used in the patients with diabetes, compared with 
those at baseline in the PHC sector.  
Table 13. Changes in Medication use over 2-year Follow-up 
Medications % Baseline % After 2-years 
HCTZ 84 61 
Furosemide 8.3 35.2 
ACEi 75.0 71.3 
CCB 19 54 
N-CCB 14.8 9.3 
Beta-blocker 8 34 
Methyldopa 15.7 1.9 
Minoxidil** 0.0 5.6 
Alpha-blocker** 0 36.1 
ARB** 0 11.1 
Statin** 2 16 
Gliclazide or Glycomin $ 71 50 
Metformin$ 62 50 
Insulin$ 20 35 
HCTZ – hydrochlorothiazide, ACEi – angiotensin converting enzyme inhibitor, CCB- calcium channel 
blocker, N-CCB – non-hydropyridine calcium channel blocker, ARB – angiotensin receptor blocker 
* Denotes drug not available at primary health care clinic; ** Denotes drug with limited availability in one 
PHC clinic $ Includes only patients with diabetes (n-257) and percentages calculated using a lower 
denominator. 
 
 
 
Success of CDOP and PHCN Screening  
 Enrolment depended on patients meeting the inclusion criteria but also if the PHCN 
chose to enrol the patient for decision support or if they thought the patient needed referral. In 
order to assess if the PHCNs accurately ‘diagnosed’ those patients at ‘high risk’ for CVD and 
CKD, and appropriately referred the patients to the hospital, their ‘screening’ ability or the 
‘criterion-related’ validity was measured. The ‘measuring instrument’ in this case was the PHCN 
in the clinic and this was evaluated against the patients’ clinic data at baseline and at the time of 
referral. The aim was to determine how many patients were correctly enrolled and referred. The 
validity of their ‘diagnostic’ ability was evaluated in terms of sensitivity, specificity and predictive 
values.  
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Appropriate screening and enrolment onto the program by the PHCNs was based on 
whether the patients met the inclusion criteria of uncontrolled HTN (BP>140/90mmHg), 
uncontrolled DM (random glucose >11mmol/L or HbA1c>8) and uncontrolled HTN, DM and 
proteinuria (trace protein on dipsticks or ACR>2.2g/mmol) or proteinuria alone.  
Unfortunately nurses did not collect the data for all patients they screened or they 
considered enrolling, and therefore the sensitivity and specificity or predictive value for PHCNs 
for appropriate program enrolment could not be calculated. Correct enrolment was therefore 
measured by comparing the numbers enrolled and who had met the inclusion criteria, against 
those enrolled who did not. The results are shown in figure 36. From this information, the 
PHCNs showed a 90.4% success in enrolling the correct and appropriate patients for the 
program. 
The data were available for assessing appropriate or correct specialist referral and 
appropriate referral was considered if patients met the ‘specialist referral criteria’ (Table 10). For 
analysis, this was taken as a GFR<60mls/min, proteinuria >200 g/mol, uncontrolled blood 
pressure >140/90mmHg after visit 2 (1 year) of the program, glucose or haemoglucotest 
>11mmol/L and uncontrolled blood pressure and HbA1c >8% after visit 2 (1 year), a serum 
cholesterol >7mmol/L or HbA1c >10% alone at any time.  
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Figure 36. Evaluation of 'Correct' Enrolment onto Outreach Program 
Note: Correct enrolment was measured against patients meeting the inclusion criteria for the outreach 
program 
 
The ‘measuring instrument’ in this case was the ability of the ‘Outreach Program’ to 
detect those who needed referral. The validity of the program’s ‘diagnostic’ ability was evaluated 
in terms of sensitivity, specificity and predictive values. This was evaluated against those 
patients who were actually referred by the PHCNs and CDOP and who arrived at the specialist 
clinic (graduated). The aims were to determine the program and nurses ability to correctly refer 
all patients who required referral and to determine if all those requiring referral arrived at the 
specialist. The sensitivity and specificity of referral decisions by PHCNs are outlined in Table 14 
and 15. 
 
Table 14. Sensitivity and Specificity of Referral Decisions  
 
Were 
referred by 
PHCN or 
CDOP 
Required referral 
 Yes No Total 
Yes 104 (true +ve) 0 104 
No 6* 508 (true –ve) 514 
Total 110** 508 618 
Note:* This refers to patients who required referral and were referred but did not arrive  ** Patients being 
referred to cardiac clinic or who died were included in analysis 
   
The sensitivity according to those patients meeting the criteria for referral and who actually were 
referred was 95% (Sensitivity = % = 104/110 = 94.5%), and specificity for those who didn’t need 
Incorrectly Enrolled
n=58, 9%
Correctly Enrolled
 n=560, 91%Correctly Enrolled
N=560 (90.6%)
Incorrectly Enrolled
N=5  (9.4%)
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referral and were not referred was 100% (Specificity = % = 508/508= 100%).  The positive 
predictive value for the program’s ability to refer patients appropriately was overwhelmingly 
positive at 100%, with a negative predictive value of 98.8% i.e. 508/514.  
 
Table 15. Sensitivity and Specificity of Referral Process 
 
Arrived at  
Specialist 
Clinic  
Required referral 
 Yes No Total 
Yes 83 (true +ve) 0 83 
No 27 508 (true –ve) 535 
Total 110 508 618 
Note: Patients being referred to cardiac clinic or who died were included in analysis 
 
 
The specificity for referring the most appropriate patients was high, as all those referred 
did qualify for referral i.e. Specificity = 508/508 = 100%.  
 
Summary of Clinical and Functional Outcomes 
In summary, the follow up in the PHC clinics was extremely poor after baseline 
enrolment, although some clinics performed better than others. However, once patients were 
referred to the specialist clinic, the ability to follow these patients was much better, and led to 
improved control of some risk factors for CVD and CKD i.e. cholesterol, HbA1c, systolic and 
diastolic blood pressure. Decline in kidney function, measured by GFR and proteinuria, was 
minimal in this specialist clinic group followed over 2 years. However, very little impact was seen 
with weight control. The PHC nurses were successful at enrolling patients who could be 
considered ‘high risk’ for CVD and CKD, and the program systems were able to detect those 
patients who required specialist referral with advanced disease or who required medications 
unavailable at the clinics. However, not all patients had the required laboratory investigations at 
baseline. Although the rates of measurement of the risk factors were more than 70% for all 
measurements, this was not the case for kidney function measurements GFR and ACR where 
rates of measurement were, 61% and 62% respectively. This could indicate an underestimation 
of those patients with advanced disease who required referral, and indicates another limitation of 
the program. 
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5.  
NCOs start using Govt transport & treatment 
authorization begins & 1st PHC Report Back 
Meeting (May 04) 
 
Program Implementation and Health Systems Evaluation 
Figure 37. Program Evolution Timeline 
 
Note: Program Evolution timeline was developed from the diary recordings 
# NPC – Nurse Program Coordinator, * CDOP – Chronic Disease Outreach Program; PHCN – Primary Health Care 
Nurse; HIV CKD – HIV chronic kidney disease 
January 04 
December 04 
January 05 
December 05 
February 06 
July 04 
July 05 
Phase 1 – Pilot Program 
Phase 3 – Web Based Phase 
1.  
Australian NPCs arrive to 
train and help develop SA 
CDOP 2.  
1st SA NPC joins CDOP 3. 
Enrolment begins and protocols 
and standard operation 
procedures developed 
4. 
Recognise need for 2nd NPC  
6. 
2nd CDOP NCO joins 
7. 
NCO computer training begins 
8. 
Australian NCOs return home & 
Australian High Commission sponsors 
CDOP Office and Educational Manual 
9.  
1st Jhb Metro Managements ‘Report 
Back’ Meeting (July 04) 
10.  
PHC School Joins CDOP Network 
(October 04) 
Cardiology Unit joins CDOP Network  
November 04) 12.  
CDOP Wins Premiers Service Excellence 
Award &  
Phase 3 Web Development Begins 
13.   
- CDOP recognizes need to train PHCNs 
to initiate insulin – organises training 
- Start use of ‘CDOP stickers to improve 
Follow up & Purchases 2 cars for NCOs 
- Recognise focus on HIV CKD 
14.  
2nd Jhb Metro Health Report Back &  
3rd PHCs Feedback Meetings    
                                       (February 05) 
 
15.  
NKF brokers Rotary Sponsorship of 
PHC training in Australia 
16. 
- Encourage focus on HIV and proteinuria 
- CDOP assists with health system  
   monitoring e.g. medication shortage alert 
- Assistance with Awareness campaigns and   
       Support Groups 
- Ass 
17. 
Push value of the ‘Truscott Chronic 
Disease Stamp’ for detection of poor 
risk factor control and patients 
eligibility to enroll onto CDOP  
18. 
‘Traffic light’ risk factor approach to assist 
up referral & to assist with poor follow up 
challenge 
    19. 
 Assist Health Dept with Obesity 
 Education - CDOP recognises obesity 
challenge & Audit of clinical data 
20.  
Poor patient follow up continues  
- focus on stickers and log books to track 
patients 
- focus on developing local clinic CDOP 
coordinators instead of focus on all PHCs 
- NCOs in Australia for training 
21.  
-  Close new enrolment (August) 
-  Endocrine Diabetes unit joins program 
– 4th PHC “Report Back” Meeting (Sept) 
22.  
CDOP becomes ‘Referral Only’ 
program until phase 2 closes – 
PHCNs to detect on ‘Red Referrals’ 
or use CDOP for decisions support 
23.  
Active planning and development 
for CDOP web phase with analysis 
of phase 2 challenges, failings and 
successes 
- Change management seminar  
24.  
CDOP wins Khanyisa Award – grant 
used for web development and 
computer training center 
Final ‘Phase 2’ Combined PHC and 
Management Meeting & presentation 
of program to Provincial Executive 
Management Committee 
 
25. 
-  Questionnaire given to PHCs  
- Web based module training  
   Begins 
- 2 pilot web collection sites     
    established 
11. 
CDOP Educational Manual Developed  
& 2nd PHC ‘Report Back Meeting’ (Sept 04) 
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Figure 38. Program Methodological Timeline 
 
Note: Methodology timeline was developed from the diary recordings 
# NPC – Nurse Program Coordinator, * CDOP – Chronic Disease Outreach Program; PHCN – Primary 
Health Care Nurse;  
 
January 04 
December 04 
January 05 
December 05 
February 05 
July 04 
July 05 
Phase 1 – Pilot Program 
Phase 3 – Web Based Phase 
                 Begins 
2. 
-Australian Protocols Adapted  
-20 clinics – 10 per NPC 
-Follow up methods & Role of NPC 
-Team structure in clinics 
-Treatment (Rx) targets developed 
-Lifestyle modification focus 
-Std Operational manual developed 
1.  
- Wagner Chronic Illness Care Model Adopted    
3.  
- 4 monthly fup of patients’ clinical data 
- Randomisation – Standard Clinic Protocols  
   (Control) vs. CDOP protocols (intervention) 
- Focus Groups and Diary Recording to be  
   collected at all clinic visits and meetings and addition of 
post focus group case study education for nurses 
6. 
- CDOP Education folder is    
   developed for PHCNs and 
Health     
   Promoters (August 04) 7. 
- Cardiac unit joins CDOP to    
  accept referrals (October 04) 
8. 
- ‘Traffic light’ triage system starts to develop & 
Endocrine unit becomes involved in CDOP 
10. 
- Follow up challenge proves to be too difficult 
- 6 monthly follow up adopted, with 2 month  
   leeway on either side  
- Motivational incentives needed – to use Australia  
  PHC development visit as CDOP incentive 
 
9. 
- Rotary Group sponsors PHCN        
   Training in Australia 
- To be used as an incentive for  
   PHCs (enrollment and follow up) 
11. 
- ‘Truscott’ Chronic Stamp developed to  
     assist PHCNs to assess risk factor control  
     and qualification for CDOP 
- Its use is encouraged through first 6 months 
- Link and value to CDOP is communicated  
12. 
- Challenge of communicating   
   methodology  
 
15. 
-  ‘Traffic light’ triage initiated together with   
     Truscott stamp to assist PHCs in selecting  
      patients for enrolment 
13.  
- Enrolments to Phase 2 closed (August 05) 14. 
- Program moves to ‘Referral   
   Program’ Phase’ before web  
    based CDOP begins 
-  Due to poor follow up but  
    good high risk detection and  
    specialist referral  capabilities 
 - Endocrine Diabetes Unit joins      
    program 
     
5. 
- Reviewed randomization into ‘control’    
   and CDOP groups 
- Randomisation dropped in August due  
   PHCs not supporting this methodology 
- No ‘value’ seen in this to PHCNs 
- Participatory Action Research Methodology  
   is adopted for future program development 
 
4. 
- Remote Consultant approval  
   authorization via letter 
16. 
-  Questionnaire to assess 
    program 
- Assess clinician knowledge 
- Assess clinician motivation 
17. 
- Web based CDOP computer training   
   begins 
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The program’s implementation and existing clinic systems were evaluated using the results 
from the clinical and functional outcomes data, described above. This evaluation was 
strengthened with triangulation of results obtained during group meetings and program planning 
meetings in the CDOP, nurse program coordinators’ and program doctor/director’s diary 
recordings, and the questionnaire.  The diary recordings, questions and comments from nurses 
in the questionnaire resulted in information which explained reasons for CDOP’s successes and 
failings, and its ability to integrate into the existing clinic systems (Figures 37 and 38). During 50 
focus group meetings, which took place at the 20 clinic sites, the discussion was recorded in 
diaries. The focus group meetings were primarily conducted with the primary health care nurses 
(PHCNs), but on some occasions were also attended by the clinic doctor. Focus groups were 
conducted using a similar structure, comprising of a review of the program to date, nurses’ 
challenges running the program, and then at least one case review of a patient participating on 
the program at that clinic. Discussions were also recorded during 5 ‘Feedback Meetings’ with all 
the 20 PHC clinic nurses at the specialist referral hospital, and a further three meetings with the 
Johannesburg metropolitan regional health department management team.  In addition, 
discussions of a meeting to discuss future funding and plans for the program with the Gauteng 
Health Department Executive committee, comprising all department directors, and regional 
directors, were diarised. Finally, diary recordings were also kept at 23 program 
management/planning meetings, which included meetings with specialist departments involved 
in the program, i.e. primary health care nursing school, cardiac and diabetes/endocrine 
departments. Recordings were also made of all phone calls to the CDOP office at the specialist 
hospital and when nurse program coordinators visited clinics. Organization 
The evaluation of the program, where possible, has been presented using the main headings 
from these models. The results have focused on and relate to health system context factors, the 
chronic disease outreach program (CDOP) and to clinic factors. 
Thematic content analysis with Atlas.ti was carried using 9 overriding classifications and their 
codes which were developed from the above models (Table 16 and 17). 
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Table 16. Thematic Analysis Classifications  
Classification 
 1. Motivational Outcomes - Worker Affect & Cognition 
 2. Motivational Outcomes - Worker Behaviour & Performance 
 3. Perceived Contextual Factors – Health Worker Motivation 
 4. CDOP Evaluation – Extrinsic Characteristics – Health Worker Motivation 
 5. Wagner CICM Model*- Health System -Delivery System Design / 
Decision Support / Clinical Information Systems 
 6. Wagner CICM & WHO ICCC** Models - Prepared Motivated Proactive 
Health Care Team 
 7. Wagner CICM & WHO ICCC Models - Patient Prepared, Informed and 
Activated 
 8. WHO ICCC - Health Care Organization  
 9. WHO ICC - Positive Policy Environment 
* WHO - World Health Organization Innovative Care for Chronic Conditions Framework (ICCC) 
** Wagner – Wagner Chronic Illness Care Model (CICM) 
 
 
Table 17. Example of Thematic Analysis Classification and Coding 
CDOP Evaluation – Perceived Contextual Factors - Extrinsic Characteristics 
_____________________________________________________________________ 
Codes (11): number of quotes in each code follows in the brackets 
CDOP - ‘Research’ vs. Audit & Pay for Research Issue (11)** 
CDOP - Added Value - Better Quality Treatment- Better use Resources (68) 
CDOP - Doctor - Not Involved with CDOP (17) 
CDOP - Failed to Train or Orientate or Involve all HCW (18) 
CDOP - Management does not 'fully' support CDOP (17) 
CDOP - Provided Expertise, Organization or Equipment (14) 
CDOP - Staff Education, Development & Training (48) 
CDOP - Staff shortages & Work load impacting on Enrolment (59-2) 
CDOP - Turnover of Staff affects Enrolment/ Delivery of Program / Fup (14) 
CDOP - Value and Credibility Questioned (42) 
CDOP -Too Time Consuming to Enrol and Capture Data of Patients (24) 
 
Note: This table is referred to in the section evaluating the program. **Indicates number of quotes from 
this code 
 
Program Evolution and Methodology Timelines  
The development of the program is documented in figures 37 and 38 above. Figure 37 is 
a timeline which documents the programs evolutionary changes and both figures outline the 
major events as they evolved over the 2 years of the program.  
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In figure 38, the factual occurrences are documented and the timelines reflect the 
changes adopted during the program.  The figures document the changes which occurred as a 
result of the need to provide a ‘real life’ service for clinicians, and which would be acceptable to 
them and add value to their job. It documents the major program developments, including when 
the program nurse coordinators started and were trained. This included all PHCN training and 
education changes. Also outlined are the times of major report back meetings, new 
developments including when the program began and closed enrolments, and when phase 3, 
the web based phase, began. In the centre of this figure is a timeline dating these occurrences. 
Figure 38 documents the methodological changes that occurred during the study. Here the 
models adopted and the timing of protocol developments and major changes in program 
methodology are documented. These changes are measured against a central timeline outlining 
the month when a change occurred. The challenges which resulted in methodology changes are 
also documented in figure 38. Some inevitable crossover of facts exists between these two 
timelines. 
 The significant positive and negative evolutionary changes which influenced the program, 
and the methodology changes, are summarised in these figures, but some important issues 
need highlighting. Major methodological changes included moving from randomisation of 
patients to PHCN enrolment based on the patient meeting inclusion criteria and the nurse 
requiring decision support. From the diary recordings, it was noted that PHCNs wanted to offer 
the program to any patient agreeing to participate and on whom they required advice (decision 
support). The PHCNs wanted the program to add value to their service and did not support and 
could not implement randomisation of patients onto the outreach program. Some PHCNs 
believed the random enrolment would compromise their patients. Considering that the programs 
overriding aim was to mimic a ‘real life situation’, this meant that it was necessary that nurse 
clinicians were able to influence the enrolment approach but not inclusion criteria. Therefore, the 
initial approach to enrol every 4th or 8th person at the clinic failed and PHCNs failed to see the 
value of this approach. As a result of the early implementation of the review process or PAR 
methodology, the enrolment process was changed in keeping with clinicians’ needs.  The PAR 
process also drove other changes and initiatives. Any patient with whom a PHCN required 
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assistance with management or decision support, or who had serious risk factors, was enrolled 
onto the study as long as they met the program’s inclusion criteria.  It was felt this move was in 
keeping with the Wagner model of establishing improved health systems and an effective 
‘prepared and proactive team’. A ‘standard treatment’ arm was also started initially but 
abandoned a few months after program initiation. Patients were therefore enrolled as a ‘high 
risk’ clinical cohort into a single management stream after 6 months. PHCNs were 
uncomfortable with a standard treatment arm as they felt all patients should have equal access 
to ‘better care’ and they were concerned about missing serious complications or simply wanted 
advice. 
Additional health system changes consisted of the development of a ‘traffic light’ triage 
and decision support system and the initiation of a chronic disease stamp (Figure 39), by the 
PHC School, through its interaction with CDOP.  The ‘traffic light’ triage system focused on those 
patients who were controlled, those at high risk and those who required referral. The stamp was 
used to simplify patient notes and integrate essential chronic disease risk factors and treatment 
targets. 
  Diabetes Asthma Hypertension Epilepsy Control 
Date Urinalysis Blood 
Sugar 
PF Meter BP Failure: 
Yes/No 
No. of fits Yes/No 
        
        
        
        
Figure 39.  Chronic Disease Stamp 
*PF – peak flow meter; BP – Blood Pressure; No - number 
 
Changes in health delivery systems included remote treatment authorization from the 
specialist hospital for certain medication and especially for direct referral to specialist clinic. 
CDOP was also utilised to detect any medication and equipment shortages in the clinics, and to 
report this to management. CDOP was therefore used as a method of monitoring problems in 
the clinics and to improve efficiency by providing a quick link between nurses in the clinics and 
management at the central Johannesburg head office. The problem of patient follow-up in the 
clinics was recognised as a major limitation of the program and numerous attempts were made 
to try and correct this weakness. This incorporated the development of stickers to track patients 
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when they returned for follow up, and to prevent cohort patients from becoming lost into the 
general clinic population. After enrolment was closed, to allow the appropriate follow up period, 
the program became a ‘referral only’ program for patients meeting specialist referral criteria (see 
Table 10). This removed the need for follow up and nurses were encouraged to keep track of 
‘orange’ high risk patients only who were potentially for referral at a later date. Follow up 
challenges influenced the web based clinical information system developed at the end of the 
study and these developments are not included in this project. 
 HIV patients were not included in the program, although they are at risk of CKD. What is 
also acknowledged in the timelines was the need to develop a more comprehensive network, 
which should include primary health care specialists, cardiac disease and diabetes experts. This 
was necessary in order to strengthen CDOP capacity and its ability to integrate all diseases 
affected by the risk factors and chronic illnesses being targeted. Although CKD was targeted, 
when previously it had not been, the aim was not to create a kidney specific program. The need 
was to create a ‘prepared, proactive and motivated’ health care team to manage all chronic 
illnesses, including CKD. For this reason, insulin initiation training, obesity education, case study 
education sessions with focus groups and computer training, were included as part of the CDOP 
‘package’. Other motivational developments included sponsorship for elective training in chronic 
disease management with the Australian Outreach Program nurses, official training in computer 
and organizational skills, and ‘change management’ workshops for the nurses.  
The progress of the program was regularly presented to both the nurses participating on the 
program, managers at the Johannesburg Metropolitan Health Department, responsible for the 
region, and to senior executives in provincial management. These meetings offered an 
opportunity to review and re-design the program in keeping with the adopted participatory action 
methodology. 
These and other issues describing the program and health system factors documented in 
the diary recording and questionnaire are described in greater detail below. 
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Evaluation of the Chronic Disease Outreach Program  
Eighty nine percent (89%) of PHCNs’ on direct questioning found the program made a 
significant difference to their work. It had assisted them with decision support, patient 
management (91%) and with patient referral to a specialist (84%). The presence of Chronic 
Disease Outreach Program also emerged as an ‘extrinsic’ motivational determinant.  Seventy six 
percent (76%) of nurses felt CDOP had ‘added value’ to their job, 21% were unsure and only 3% 
said it had no value (Appendix 8a and 8b). However, there were many factors that impacted on 
CDOP uptake and success, including its ability to be integrated in the clinic’s chronic illness 
management system. These are summarised in the thematic analysis codes from the diary 
recordings evaluating CDOP in Figure 40 and Table 22. The program provided expertise in the 
form of specialised chronic disease nurse program coordinators and specialist visits, including 
providing protocols for managing chronic illness. The program also provided ongoing training 
and development in various forms, such as updated guidelines, equipment e.g. glucose 
monitoring machines, tape measures, patient educational manuals (Appendix 2) and a link 
between the Johannesburg Metro (provincial) Health management structures and the clinicians 
on the ground.  
 
Figure 40. Diary Recordings Evaluation of CDOP 
-ve – denotes diary recording noted  this as a negative factor on CDOP ; +ve – denotes diary recording 
noted this as a positive factor in favour of CDOP; Codes – denotes thematic code used for evaluation and 
for collecting quotes from diary recordings. 
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At first enrolment was hampered by PHCNs being unsure of the program’s credibility and 
they were unsure of the value it would add to their practice. The credibility and value related to 
the program being implemented vertically from the renal department, albeit with the support of 
the Johannesburg Metropolitan Health Department. The program was not trusted by the PHCNs, 
as they were used to changes in clinical guidelines being instituted from their PHC School 
instructors during ‘in-service training’, and this was whom they trusted. This was partly solved by 
involving their instructors from the Soweto Primary Health Care School, but this improved over 
time through their personal experience and from the value gained from being involved with the 
program. The PHCNs could initially also see no value in the program as an audit or monitoring 
tool of their clinical practice and the health system.  
 
A challenge to enrolling was the lack of motivation from the clinicians and the belief that 
CDOP is an audit and research program (PHCN, clinic 7). 
 
Nurses had previously been paid for research enrolment and this affected how they viewed the 
outreach program:   
 
If the CDOP uses patients, then if it can assist us nurses in getting paid when conducting 
the research (PHCN, clinic 9).  
 
The nurses did acknowledge that CDOP had improved quality of care for patients, added 
value to patient management and their work and improved the use of existing resources, such 
as noting better control of patients on the program, easier referral and consultation with a 
specialist and improved use of laboratory investigations all members of the clinic team. 
Managers in the clinics, at the regional head office and in the provincial government all 
expressed support and this was documented in the diary recordings during ‘feedback report 
meetings’. At the presentation to the Gauteng Healt
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point 24 on figure 37), there was unanimous support for the program to be supported financially 
and be assisted with development in its current region and then to other regions. 
 
CDOP has helped so much with the chronic patient (PHCN, clinic 20).  
It (CDOP) provides effective nursing management and allows early referrals to the 
relevant department (PHCN, clinic 1). 
 
On direct questioning, time constraints were not considered a factor affecting enrolment 
and follow up. However, from the diary recordings and again from the questionnaire under 
domains ‘CDOP as an extrinsic characteristic’, 60% of PHCNs acknowledged that if enrolment 
was quicker, they would have enrolled more patients (Appendix 8a and 8b). 
 
The CDOP program is a good tool to use for the sake of treating patients, provided that 
the clinicians are given enough time to spend with the patient in order to get the patients 
consent and then provide the best treatment (PHCN, clinic 8)  
(PHCNs) complained of no time to enrol patients and to do follow up checks (PHCN, 
clinic 15). 
 
In the motivational survey, PHCNs either agreed (59%) or were unsure (81%) if the 
program was too time consuming or had impacted on their ability to enrol more patients. 
Unfortunately doctors in the clinics failed to endorse the program, seeing it as a nurses program. 
This influenced uptake and integration. In addition, doctors and nurses were suspicious of the 
program and there was poor support from local clinic management to integrate the program.  
The poor integration was a result of a breakdown of communication between ‘head office’ and 
‘clinic managers’. The ‘senior’ head office managers were unable to provide the necessary 
support to implement this integration. This would have required visiting the in-service education 
meetings, made a personal effort to be seen supporting CDOP and sent clear directives through 
the assistant directors to the clinic coordinators and nurses. All these issues affected CDOP’s 
ability to integrate into the clinic service as ‘a standard’ method for chronic care. 
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Local clinic doctor seemed to appreciate program, but reluctant to commit involvement 
….program not able to work without general support and integration into clinic by 
management… and (CDOP) is seen as 'special program (PHCNs, clinic 14). 
 
Many nurses and managers during report back meetings expressed the value for 
integrating a CDOP system into the clinic and, especially, including it for managing HIV. In the 
questionnaire, again evaluating CDOP as an ‘extrinsic’ motivational factor, 90% felt positive 
about the CDOP system and would like it as the ‘standard’ method for specialist referral. A 
further 88% of PHCNs indicated they would appreciate having more nurse program coordinators 
linking them to a specialist centre for easier referral (Appendix 8a and 8b).  
 
The CDOP program is very interesting and supports us…. I wish this could be the 
standardized practice in our province to manage chronic diseases (PHCN, clinic 1) 
This (CDOP) should also include the HIV treatment side (PHCN, clinic 9). 
 
However, three related factors had a major negative impact on the ability to enrol 
patients, integrate the program, change the ‘delivery system design’ and carry out follow up 
effectively. These were the work load, staff shortages and nursing staff turnover in the clinics. 
The latter fact was well recognised by the PHCNs and was a recurrent issue discussed at 
CDOPs focus groups and planning meetings. As the program progressed, it had become clear 
that PHCNs were being trained by the CDOP nurse program coordinators to run the program in 
their clinic, and then were resigning.  Reasons for resignation included dissatisfaction with 
working conditions and not receiving a ‘scarce skills grant’, known as the “occupation specific 
dispensation” policy,  poor pay compared to local clinics and better opportunities working for 
NGOs or in the private health sector.  For these reasons, clinic staff turnover was evaluated by 
the nurse program coordinators at the end of the program (Table 18).  
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Table 18. Primary Health Care Nurse Turnover 
 
Clinics No PHCNs Start* Resigned& 
Retired# 
PHCNs 
End$ 
% Lost 
15 12 7 5 58 
9 13 3 10 23 
10 13 2 11 15 
18 12 3 9 25 
20 16 7 9 44 
5 5 3 2 60 
14 3 0 3 0 
17 12 7 5 58 
19 3 0 3 0 
2 12 4 8 33 
1 12 9 8 75 
3 7 1 6 14 
4 12 7 7 58 
12 12 2 12 17 
13 6 4 5 67 
11 11 2 11 18 
6 5 1 4 20 
7 7 1 6 14 
8 6 0 6 0 
16 7 3 5 43 
Total 186 66 135 51** 
Average/clinic 9 3 7 32 
 
*PHCNs Start – primary health care nurses at clinic at start of program; # Resigned & Retired – numbers 
of PHCNs who resigned or retired during program; $ PHCN End – PHCN at clinic at the end of the 
program; *% percent lost over the two years of the program; ** Total nurses lost over 2 years 
 
Continuous staff turnover impacted not only on staff morale but also on commitment to 
the program. It also affected our ability to train PHCNs in the detection of patients with high risk 
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CVD and CKD and the outreach program functioning i.e. enrolment and referral, this was 
documented in the diary recordings: 
 
High turnover of PHCNs was affecting program. Every time one PHCN showed interest 
she would leave and nurse program coordinators would have to train a new person” 
(CDOP Planning Meeting, diary recording)  
Introduction and retraining of CDOP to the clinics again since there are new members 
who joined the PHCN staff; it becomes difficult for the old staff to explain to us about 
CDOP (PHCN, clinic11)  
At the facility where I work it was started (CDOP) but due to people resigning it just died 
a natural death (PHCN, clinic 1).  
 
The staff reduction ratio was 27.4%, and there was a total loss of 51 PHCN staff 
members over 2 years, (i.e. Total PHCNs pre-program – Total PHCN post program divided by 
Total PHCNs pre-program) 
 
Many clinicians complained that the patient load affected their ability to enrol onto the 
program and this was aggravated by the constant staff shortages and high turnover. Fewer staff 
members meant nurses had less time to enrol patients and see them at follow up.  
 
The problem with our clinic is that nurses are unable to adopt programs that are valuable 
because of staff shortage (PHCN, clinic 13) 
The problem is that it (CDOP) cannot be adequately practiced as the clinic has a very 
high number of patients and the nurse clinician is still expected to see the same number 
of patients and enrol them and see them again later  (PHCN, clinic 8). 
 
Documentation of the challenge resulting from staff turnover is well described from these 
three excerpts and they explain some of the reasons for loss of follow up. 
 
  
The enthusiastic health promoter has since retired and patients come to the clinic and do 
not know where to go (PHCN, clinic 4) 
The local authority established new clinics in the new houses and informal settlement 
around this clinic and a lot of patients started attending these clinics (PHCN, clinic 6)
High turnover problem - one nurse left for TB coordination, three joined the local 
authority, one left for the HIV research centre (Program NCO, diary recording).
 
Factors documented from the diaries around staff turnover included nurses resigning to 
private health care, moving to local city council clinics, or to NGOs or moving overseas, and the 
inability to constantly retrain staff about enrolment and following up patients on the program.
Considering that the program was established to provide a mechanism to improve patient care 
and referral, evaluating the program in the questionnaire to assess its value for
an important component of the overall evaluation. Despite the challenges outlined above, 
41 still demonstrated the positive value the program had on PHCNs, especially for those 
choosing to remain involved in the program, and with regar
specialist referral. 
Figure 41. Health Worker Survey 
Note: Answers to questions from Health Worker Motivation Conceptual model 
-Motivation Determinants - CDOP Questions 
NC-PHCN – non-CDOP primary health care nurses group; CD
 
 the PHCN was 
d to management decisions and 
- CDOP Evaluation  
– Domain Perceived Contextual Factors 
– Extrinsic Characteristics 
-PHCN – CDOP primary health care nurse group
 
 
 
Figure 
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Evaluation of Health Care Organization and Policies 
This section focuses on the investigation of factors impacting on implementation relating 
to the existing health care policies and organization of the primary health sector, and its 
interaction with the tertiary health care service in Soweto. The factors explaining the outreach 
programs success and failings against these issues are outlined in this section.  
 
Health Care Organization and CDOP 
As outlined above, a major concern for the CDOP organisers was the loss of follow up of 
patients on the program. Some of the issues are covered in the section above, but those factors 
pertaining to health system issues and policies are discussed in this section. These include 
challenges such as PHC nurses not being available for the CDOP patients at their follow up 
visits. Reasons included issues such as being assigned to work in areas in the clinic other than 
the ‘chronic’ clinic e.g. tuberculosis, family planning or STI (sexually transmitted infection) clinics. 
This demonstrates a lack of integration of CDOP by managers, but also relates to problems 
within the clinic systems where competing demands impacted on delivery. Nurse clinicians 
regularly documented that they were sent to relieve or work at other clinics as part of their 
‘normal duties’, or because other clinics had staff shortages. PHCNs had to rotate within their 
own clinic between different sections. Sections such as the tuberculosis clinic or ‘acute problem’ 
clinic are seen as separate entities, and here nurses do not move around once allocated for the 
day or month. This included the ‘chronic section’ responsible for HTN and DM patients which 
was part of the program. The nurses and clinic did not function as a single team, like a ‘family 
practice’ should work, with all nurses being responsible to see any patient who arrived at the 
clinic on a particular day. The clinic rather functioned as individual and separate clinics, with 
almost separate staff for each clinic e.g. TB clinic or HTN clinic 
 
Friday 28-01-05 Reported at (clinic 1) to find clinician doing CDOP gone to help at (clinic 
20) (NCO diary recording during follow up visit to clinic 1). 
  
159 
The clinicians who had enrolled patients also had to change and rotate e.g.: look after T 
B patients, work in casualty. The change caused the patients to be lost when coming to 
the clinic for follow up (NCO diary recording during follow up visit to clinic 3). 
 
Follow up challenges included patients being frustrated with lack of continuity of care in 
the clinic, especially with CDOP. Patients chose not to participate in CDOP any longer, although 
they continued to come to clinic. This issue was demonstrated in the ‘clinical and functional 
outcomes’ section in figure 29, as those patients ‘not followed in the clinic and lost to follow up’.  
 
When the motivated clinician was off duty, patients would have no one to look after them, 
making them to be discouraged (NCO diary recording during follow up visit to clinic 16). 
 
There was also regular documentation in diaries about PHCNs who were ill or on leave, 
and who were not replaced or accounted for by managers. Staff shortages meant that commonly 
no other nurse was able or prepared to see the CDOP patients. 
 
The patients would have no one to look after them when the (program clinic coordinator) 
was not at work i.e. on leave or off duty (NCO diary recording at follow up visit clinic 11). 
 
NCO and PHCNs highlighted the problem that clinic managers accept many ‘special 
programs’ in the clinics, and this issue further impacted on their ability to effectively track 
patients on the outreach program. This issue was validated in the motivational questionnaire 
domains evaluating clinicians working and organizational environment in figure 42. The 
questionnaire returns confirmed that the organizational environment was chaotic, and nurses felt 
isolated from management, overworked and were impotent in decisions that impacted on their 
work environment. This is further confirmed by the diary recording extracted during thematic 
  
analysis around the domains of organization
Figure 42. Policy Factors impacting on Staff Motivation
Note: Questions from the motivational survey section ‘motivational determinants’, perceived contextual 
factors – ‘Job’, ‘Organizational Environment’ and ‘Work Environment’
NC-PHCN – non-CDOP primary health care nurses group; CD
group 
 
The organization around the program is very poor… (there is) no team work, (it) seems 
each (PHCN is) doing their own thing. Also the original nurses involved in program have 
left (PHCN, clinic 1) 
Found only three PHCNs during visit to check patients overdue for four monthly follow 
up… 
Challenges were patients do come for follow up but the nurse is unable to follow them up 
as she is allocated to other departments e.g. STI and HIV clinic 
follow up visit clinic 11) 
Follow up is not so good (and this is) due to PHCNs having to rotate to other parts (of the 
clinic) e.g. STI, TB etc… (there is) also problems tracking results 
(coming back) and (nurses) miss patients (Focus Group, clinic 4)
 
al environment and working environment (
 
 
-PHCN – CDOP primary health care nurse 
(NCO diary recording at 
- delay in NHLS results 
 
Figure 25)
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The last quote highlighted the need for team work and integration of responsibility, and 
noted that lack of the efficient collection of results and delays impacted on patient enrolment and 
follow up. The reliance on the ‘National Health Laboratory Service’, as the preferred provider for 
laboratory and pathological investigations was another policy and organizational problem 
documented during focus groups and clinic visits. 
 
CDOP is done in our clinic I suggest that every PHC nurse to be given a chance so that 
we all know about it and what to do to the patient and everybody is involved (PHCN, 
clinic 20) 
 CDOP should be for all nurses not just PHCNs, this may improve team work (PHCN, 
clinic 13) 
Currently we are experiencing problems with the NHLS otherwise the results are not 
reflected to make it possible for us to enrol patients on CDOP; they are late or never 
arrive at all (PHNC, clinic 1). 
 
Some patients were not identified when they returned for visits. This was another reason 
for patients ‘not being followed in the clinic and lost to follow up’, prompting nurses to suggest: 
  
(CDOP managers must make) use of stickers to identify CDOP patients for clinic staff to 
know the patients (PHCN, clinic 13) 
Patients disappeared into the clinic. Many do not want to wait. Also (here is) no real 
system and no way of identifying CDOP patients (PHCN clinic 16). 
 
The program had no mechanism initially for tracking these patients and responded, in 
keeping with the action research methodology, to attempt to mark CDOP patient files with 
stickers. The aim was to improve follow up as there was no means of identifying CDOP patient 
when they returned to the clinic, especially if the CDOP PHCN was not there. These problems 
impacting on follow up were also highlighted and confirmed from the thematic analysis coding of 
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the diary recordings, as shown in Figure 43. The issues outlined above are complicated and 
multiple factors are implicated in the functioning of the clinics and the CDOP.  
 
 
Figure 43. Health Care Organization Issues 
Note: Figure outlines the quotes coded in the thematic analysis as being related to health care 
organization i.e. WHO Health Care Organization code 
 
 
Other issues of health care organization which effected patient enrolment and follow up 
included claims by nurses that patients were 'migrants' coming from distant areas or patients 
had moved to other areas or to a different clinic. The comments that migrant issue was 
perceived as larger by PHCNs and may have reflected prejudice rather than the truth This issue 
appeared to be a relatively small factor, affecting only 24 patients (4%), and has been 
documented earlier (see figure 29). However, diary recordings indicate that this issue was larger 
than suggested in the clinical and functional outcome evaluation.  
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The people in this clinic are highly rural, sometimes they would go to Limpopo for more 
than 6 months, nurses would then lose follow up times, (NCO, diary recording during 
training visit at clinic 1). 
Some (patients) said they do not reside here but came to visit, others said they would 
have problems with their employers about visiting the clinic monthly as they are domestic 
workers (NCO, diary recording during training visit at clinic 8) 
 
There were also delays in follow up forms arriving at central data collection point for 
capture and analysis. This would have caused delays in notifying patients who required referral 
to specialist clinic. The delays in ‘feedback forms’ also related to the fact that they were being 
typed by only two nurse program coordinators, who had other program administrative 
responsibilities. The issue of delayed results from the national laboratory (NHLS) would have 
been a compounding factor too. These challenges highlighted the call for more nurse program 
coordinators to support the program and clinic nurses.  
   
Also delays in (laboratory) results getting to PHCs. Noted delays also with forms often 
means patient gets lost if  do not get feedback report at (the patients) next clinic visit. Not 
achieving a two week turnaround time. Nurse program coordinators have too much work 
- typing feedbacks and doing follow up tracking (CDOP Planning meeting notes) 
Complained about (blood and urine) laboratory results not received on time - often wait 
two weeks for delivery as cannot phone for result (no clinic phone), by this time have lost 
patient and cannot find them (Focus Group, Clinic 11). 
 
Included in the evaluation was the ‘organizational environment’, a code derived from the 
health worker motivation model. Factors associated with the clinic organization were assessed 
under these codes in the diary recording. The aims were to ascertain whether the program and 
clinic environment supported the program and provided an enabling environment.  
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I would like that the program be cascaded (spread) to other health workers even if they 
are not directly involved in managing patients (PHCN, clinic 11) 
No team work, admin clerks were not involved and did not help with data collection 
especially the demographic information, this made it difficult for PHCNs to do it alone 
(CDOP Planning Meeting). 
 
The success of CDOP also depended on a well functioning clinic, with management 
support at both the local clinic level and ‘senior’ regional and provincial levels (Figure 44). The 
lack of implementation or ability to scale up the program was limited by management support. 
Poor functioning systems included the lack of provision of adequate supply of appropriate 
medication and equipment. This was evaluated in the thematic diary recordings and the 
questionnaire (Figure 45).  
 
Management seems completely unaware of the problems and challenges in the clinics 
(CDOP Feedback Meeting, program director diary recording) 
Pharmacists are needed at the clinics and drugs for decreasing cholesterol should be 
made available (PHCN, clinic 7) 
I wish our clinics could be better equipped with modern equipment and computers and 
medication made more available at all times for patient (PHCN, clinic 10) 
 Another big problem was no pharmacist at the clinic … often short of drugs (such as) 
perindopril (ACE inhibitor)… No glucophage for past 3 months (NCO diary recording 
follow up visit clinic 17) 
  
Figure 44. Gauteng Health Department Management Structure
$- CEO – Chief Executive Officer; ** GHD 
Metropolitan Health Department * Nurse 
PHCNs; @ - There are few Regional Head Offices in the Gaut
Note: has been simplified 
Figure 45. Questionnaire Working Environment Evaluation 
Note: These answers are from the ‘motivational determinants’ evaluated in the health worker motivation 
questionnaire under ‘perceived contextual factors 
impacting on health worker motivation (see f
NC-PHCN – non-CDOP primary health care nurses group; CD
group  
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These include shortages of medication - regularly run out of some medications and 
patients do not come back to collect them at a later date (Focus Group, clinic 4). 
Challenges are drug shortages…. No urine dipsticks…. No strips for haemoglucotest 
(glucose recording) machines (Focus Group, clinic 12). 
 
The above diary excerpts and question answers in figure 45, confirm the fact that PHCN 
felt isolated from their ‘senior’ management and frustrated with medication and equipment 
shortages. Follow up challenges can be summarized as CDOP nurses not being available to 
follow up the cohort patients for numerous reasons which included: nurses working in another 
area of the clinic or being ill, and no other PHCN prepared to see program patients. Other 
challenges included PHCNs being sent to relieve or work at other clinics as indicated above. The 
resultant problems included  patients who were frustrated with delays and left without being 
seen, were 'migrants' and returned home, or moved to another area in Soweto. The CDOP ‘high 
risk’ patients were not 'flagged' or referred, and delays in follow up forms arriving at the central 
data collection point for capture and analysis further impacted on organization of the program. 
Loss to follow up may also have been affected by delays in ‘feedback forms’ being typed by 
nurse program coordinators and delays of results arriving from the laboratory in time when the 
patient returned for their next clinic visit (see figure 46). Finally there was a lack of 
communication between ‘senior’ regional management and PHCN clinicians, with nurses being 
frustrated and concerned with their working environment. 
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Delivery System Design, Decision Support and Clinical Information Systems 
 
Figure 46. Thematic Analysis of Health System  
*CDOP – Chronic Disease Outreach program as standard method of managing chronic care; 
**Communication 1 to 3 – communication primary to tertiary health care, *** IT Systems – Information 
Technology Systems; NCO – Nurse Program Coordinator; NHLS – National Health Laboratory Service 
Note: See texts for additional explanation of each code 
 
Thematic analysis involved using the Wagner model themes to guide the program and 
health system evaluation. A good example of a positive initiative arising from the program was 
the development of a ‘chronic disease stamp’ to assist nurses. However, its difficulty with 
implementation is also highlighted by the fact that nurses ran out of ink to use the stamp.  
 
Discussed the ‘chronic stamp’ that PHC school had designed…. the stamp was to reduce 
workload of PHCN and…. reflect all the patients’ problems in one place (CDOP Planning 
Meeting) 
We have difficulty using stamp because there is no ink for it at all clinics or clinics run out 
of ink (CDOP Planning meeting, diary recording). 
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Evaluation of the ‘delivery system design’ included the evaluation of primary care to 
specialist care communication and specialist or program support. It also incorporated the referral 
challenges which nurses faced.  All of these themes related to the issue of ‘decision support’. 
PHCNs noted the importance of being able to communicate with specialists for support, and 
pointed out the value of having CDOP nurse program coordinators to act as a liaison between 
primary care and specialist care. Communication improved as PHCNs and NCO could 
communicate more easily, e.g. by direct phone calls to CDOP NCO office, and they received 
feedback about patients who were referred. 
 
We need to be able to communicate with specialists easily in case of problems we 
encounter with regard to patients (PHCN, clinic 20) 
CDOP trained nurses it will allow us to communicate with the CDOP (NCO) sisters more 
easily (PHCN, clinic 15) 
They (PHCNs) see value in the program for they get decision and support, feedback on 
how are they doing, easy consultation and access to doctors at tertiary hospital level 
(Focus Group, clinic 18) 
 
Thirty two quotes (see figure 46) were documented in the diaries which indicated 
improved ability to refer patients to a specialist and the value of specialist outreach to the PHC 
clinic. Nurses indicated that CDOP improved referral to a specialist through ‘decision support’ 
systems: 
 
CDOP will also help with completely treating and managing chronic patients directly and 
without having them lost somewhere in the system before reaching the right people in the 
hospital (PHNC, clinic 15) 
Blood pressure has been controlled with decision support and due to fast up-scaling of 
medication through CDOP (Focus Group, clinic 4) 
Did appreciate having CDOP for referral and many patients appreciated this aspect of 
CDOP. Referring was easy and patients appreciated going directly to specialist clinic. 
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This helped with enrolment and PHCs often focused on pts who they thought would need 
a specialist opinion (Focus Group clinic 17) 
 
Many clinicians indicated that a CDOP method of organizing the health system should be 
adopted as a 'standard' method of managing and referring patients reflecting not only the value 
of the program discussed earlier but the improvement to ‘delivery system design’.  
 
(CDOP) must be done by all PHC sisters in the clinics, so as to have a clear 
understanding of all patients and how to refer them appropriately (PHCN, clinic 10) 
 
Over 65 quotes commentated on the value of ‘decision support’ that was provided or 
improved through the program (see figure 46). This included the ‘patient feedback reports’ 
delivered by CDOP nurse program coordinators (Appendix 5), and included nurses receiving 
letters of authority from CDOP allowing medication prescriptions for HTN medication and insulin. 
In fact, some PHCNs documented their skills development in chronic illnesses management, 
which was valued by other nurses at their clinics. 
 
If we are not sure then we have the opportunity to discuss the patients’ conditions with 
the CDOP nurse coordinators and doctor. This will avoid unnecessary referrals and 
patients being sent from pillar to post and therefore unnecessary travel (PHCN, clinic 15). 
Sister phoned worried about abnormal blood results of CDOP patient. GFR calculated 
and found to be low and the patient was referred to ROPD (NCO Diary recording, phone 
call) 
I now know when to refer patients to hospital for management and when to manage 
patients at the primary care level (PHCN, clinic 13) 
(CDOP) letters of authority and new protocols delivered to the clinicians and the (clinic 
program) coordinator (NCO diary recording). 
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Follow up challenges could also be considered under ‘delivery system design’, although already 
described in the section above. On a positive note, the nurse program coordinators proved to be 
a valuable resource for providing quick efficient ‘decision support’, via phone calls from the 
nurses in the clinics (see figure 46). 
 
Received two phone calls one from ….... clinic PHCN enquiring about a patient…. a 
second call was from (clinic) PHCN (who) was having a patient that reacted from Adalat 
(nifedipine – calcium channel blocker) and needed support and management from the 
specialist (NCO diary recording). 
 
The use or failure of clinical information systems to support both PHCNs and the 
program was assessed. This theme code indicated the need for an information system, when a 
clinician found CDOP’s data information evaluations and system to be valuable. 
  
The feedback recommendations from CDOP take too much time…..  Also to have the 
documents sent to CDOP takes time... this can be resolved with computers and better 
equipment e.g. fax….but I would like to thank the CDOP team for accepting my patients 
without hesitation or refusal and managing them well (PHCN, clinic 8). 
PHCs also complained about delay in NHLS bloods coming to clinic or not at clinics 
when wanting to enrol … nurses discussed computer process of direct deposit of results 
into CDOP (data base) (Focus Group, clinic 8). 
 
Thematic analysis diary of recordings of ‘delivery system design’, ‘decision support’ and 
‘information systems’ are summarised in figure 46 above.  
 
Health System Policy Factors 
A positive policy environment, as outlined by the WHO, remains a key determinant of the 
success of a chronic illness management model (see figure 5). Policy factors are not 
acknowledged in the Wagner model, but in keeping with the WHO ICCC they were considered a 
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very important component impacting on the outreach program. These policy factors impacting on 
CDOP were evaluated during the thematic analysis and the appropriate codes were created and 
quotes from diaries were counted (figure 47 and Table 19). A positive policy environment 
impacts on the willingness of health workers to be motivated to deliver health care and 
especially to volunteer for a ‘special program’ like CDOP. 
 
Figure 47. Positive Policy Environment Evaluation 
 
 
 
Table 19. WHO ICCC Framework - Positive Policy Environment 
_____________________________________________________________________ 
Codes (10):  
1. Funding Inconsistent - WHO - PPE (9 quotes) 
2. Guideline and Training Uniformity - Integrate Policies - WHO - PPE (27 quotes) 
3. In-Service - Clinic vs. Centralised - HW Education/Knowledge - PPE WHO (9 quotes) 
4. Medication - Inconsistent Policies e.g. EDL/ACE/Insulin - Integrate Policies - PPE (18 
quotes) 
5. Pharmacist shortage- Develop & Allocate Human Resources - WHO - PPE (8  quotes) 
6. PHCs - Need Support through Legislation for Clinicians - Support Legislative 
Frameworks - PPE (15 quotes) 
7. Quality Care vs. Cost Efficiency - Promote consistent financing - WHO - PPE (22 quotes) 
8. Resources - CDOP Develop and Allocate Human Resources - WHO - PPE (9 quotes) 
9. Strengthening of Partnerships - Chronic Illness Network - WHO - PPE (24 quotes) 
10. Turnover - Local Authority clinics - Consistent financing - WHO - PPE (10-quotes) 
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Evaluating the program nurses’ environment, and assessing the promotion of consistent 
funding revealed discrepancies in salaries between provincial and local government nurses, and 
even between different programs. A recent initiative of a 'scarce skills payment' for specialist 
nurses, known as the occupation specific dispensation (OSD), did not include primary health 
care trained nurses, but only hospital based nurses e.g. maternity, ICU nurses. This amounted 
to ‘inconsistent funding’ for the primary clinics’ nurses compared to hospital based nurses and 
with regard to the supply of medication. For example, anti-lipid medication was available only in 
certain clinics and at the specialist referral hospital. 
 
Clinic X Time: 09h00 - Found 2 PHCNs (and) clinic full. Other PHCNs on go slow strike for 
scarce skills allowance (NCO, diary recording at follow up visit) 
Also discussed up and down referral and that patients are referred for high cholesterol only - 
to investigate cholesterol testing and medication being more available and on CDOP request 
- seemed like only Clinic L allowed to do cholesterol testing or does it routinely (Focus 
Group, clinic 7 and Feedback Meeting Johannesburg Metro Health Dept managers) 
Problems again with doing ‘routine’ blood tests e.g. HbA1c. More concern from management 
about money than quality of service (Focus Group, clinic 12) 
High turnover-one nurse left for TB coordination, three joined the local authority, one left for 
the HIV research centre (Focus Group, clinic 4). 
 
Assessing ‘policy integration’ and the integration of disease management guidelines and 
training policies revealed a number of discrepancies (28 quotes). It was noted that PHCNs’ used 
multiple different guidelines, and most often used guidelines from their Soweto PHC School, and 
regularly consulted the National ‘Essential Drug List’ manual, and very rarely or almost never 
consulted  guidelines issued by specialist societies .e.g. endocrine or nephrology. There was no 
simplification of treatment targets and policy was not unified or standardised. 
 
  
173 
Some nurses can start insulin others not……. not sure whether PHCs get to read new 
guidelines…. seem to use guideline originally learned (most follow PHC school 
guidelines), some EDL - none look at specialist society guidelines (Focus Group, clinic 
20) 
The clinicians’ in-service training should run chronic disease management in-services so 
as to ensure uniformity in treatments (PHCN, clinic 15) 
Nurses complained of no support and no authority to give medication or even increase 
dose of perindopril from 4mg to 8mg without doctor (Focus Group, clinic 19) 
 
The ‘development and allocation of human resources’ was evaluated in the 
questionnaire, but thematic analysis from diary recordings revealed problems with the allocation 
of human resources and the establishment of referral processes. Nurse clinicians complained 
about the challenge of seeing patients, then dispensing medication and doing other 
administrative tasks. This was a result of no pharmacists being available in most clinics. 
 
The local authority (health service) established new clinics in the new houses and 
informal settlement around this clinic and a lot of patients started attending this clinic 
(NCO diary recording follow up visit) 
Another big problem for patients being lost was that Helen Joseph and Leratong 
Hospitals are often the closer hospital for their patients and Bara is too far away and 
therefore did not want to go there (Focus Group, clinic 3) 
PHCs complained they also have to dispense drugs besides just seeing patient (Focus 
Group, clinic 1) 
(PHCNs) have difficulties attending continuing medical education training at (CDOP)  
clinic because  transport not always supplied and cannot leave clinic due to patients 
waiting for treatment (Diary Recording NCO follow up clinic visit) 
 
A ‘supportive legislative environment’ was one of the policies evaluated, and was 
necessary to empower nurses to implement and run the program. This issue became a problem 
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when nurses were supposed to act on decision support advice from CDOP ‘feedback reports’. 
PHCNs were not empowered to prescribe the appropriate medication or make management 
decisions. Some PHCNs could not prescribe insulin or couldn’t make dose changes. Nurses 
were not allowed to refer patients without approval from a doctor in some clinics.   Existing 
legislation did not allow ‘lower level’ health workers, such as PHCNs, to dispense medication 
unless they had been on a dispensing course. This proved completely impractical, as most 
nurses could not attend training and many PHCNs continued to examine and dispense 
medication themselves. This dual role lengthened patient consultations. They were not allowed 
to initiate or increase dosing of some anti-HTN medication e.g. calcium channel blocker and 
ACE inhibitors. It was for this reason that a letter of authorisation allowing PHCNs’ to initiate and 
increase certain common medications was developed by CDOP, as long as the patient was 
enrolled on the program. 
 
Nurses complained of no support and no authority to give medication or even increase 
dose of perindopril to 8mg without doctor, but clinic has no doctor (Focus Group, clinic 6) 
There was concern about the initiation of insulin by the clinicians and some guidance 
was given about the initiation of insulin, but clinicians are a bit scared to initiate without 
the authority of a doctor or CDOP. It was noted some PHCNs do initiate insulin at other 
clinics (Focus Group, clinic 19) 
(Nurses had) limitations to prescribing drugs…. Need a letter (of authorization from 
CDOP) to prescribe, even though CCB (calcium channel blockers) are part of established 
protocols i.e. nifedipine XL – PHCNs unable to increase from 30mg to higher dose (Diary 
recordings, Johannesburg Metro Health Feedback meeting) 
 
On a positive note, there was much documentation that CDOP provided both ‘the 
development and allocation of human resources’ for PHCNs in the clinics and it ‘strengthened 
partnerships’. 
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(CDOP) told nurses about the growth of program. Cardiology department coming on 
board and the computer training program for nurses is due to start in March 2005 (Focus 
Group, clinic 15) 
(CDOP) was to try and include diabetes clinic (doctor) in the program (CDOP Planning 
Meeting diary recording) 
Also resolved to involve PHC School as much as possible as this will add credibility to 
CDOP and get nurses to see (program)  is not only for research (CDOP Planning 
meeting) 
Visited clinic with National Kidney Foundation and Rotary Club (who are thinking of 
sponsoring visits for nurse clinician training in Australia) (NCO diary recording, clinic 18) 
 
Evaluating the Prepared, Motivated and Proactive Health Team 
A ‘prepared, motivated and proactive’ health care team is one of the two key factors 
considered critical for chronic illness management (Wagner, 2004, World Health Organization, 
2002a) (see figure 4 and 5). In this study, the predominant research focus was on the health 
care team i.e. the nurses and doctors, although some aspects of the patient care and their 
involvement and attitude to their care was evaluated. However, this was evaluated through the 
PHCN perspective.  It was the Primary Health Care Nurses who were responsible for the 
delivery of CDOP and they were the group evaluated using thematic analysis, diary recordings 
and health worker motivation. The nurses’ existing knowledge was assessed by using three 
clinical scenario questions and one risk factor and knowledge question. Section 4 also evaluated 
the continuing medical education and clinical support environment of the PHCNs (Appendix 8a). 
The motivation component, (Franco et al., 2002, Penn-Kekana et al., 2005), was also included in 
this section (Figure 25).  Results from the various assessment tools are presented below not 
necessarily in the order that they were assessed. The models, i.e. chronic disease and health 
worker motivation models provided the structure for this assessment.  
The questionnaire was completed by 140 PHCNs in the clinics, a 75% participation rate 
from baseline PHCNs (n=186). Table 20 describes the demographic characteristics of the 
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professional nurses sampled from the clinics. The mean age was 47 years, with some variation, 
and the majority of these nurses (88%) were trained at the same school i.e. Primary Health Care 
School in Soweto, Lillian Ngoyi Community Health Centre 
In view of the fact that 55% of nurses claimed to have participated in CDOP (CD) and 45% not to 
have participated in the program, some parts of the analysis consisted of comparisons between 
those nurses who voluntarily participated in the program and these primary health care nurses 
are divided into the  CDOP PHCNs (CD-PHCN) and non-CDOP PHCNs (NC-PHCN) groups. CD 
nurses were those who voluntarily participated in the program and NC-PHCN nurses were those 
who chose not to participate. 
Table 20. Questionnaire - PHCN Demographic Information 
Questionnaire Demographics n % 
Nurses  140  
Facilities involved 20  
CDOP PHCNs (***CD-PHCN) 75 55% 
Non-CDOP PHCNs (**NC-PHCN) 63 45% 
Gender – Females 139 99% 
                 Males 1 1% 
Working in ‘chronic disease’ clinics 125 89% 
Trained as PHCs 133 95% 
Trained at Central Wits PHC 
School* 
123 88% 
 Mean SD 
Mean Age 47.4 +7.25 
Years working in clinic 9.84 +6.27 
Years Qualified 7.3 +5.7 
* Central Wits primary health care school is situated at Lillian Ngoyi community health care centre and 
was one of the sites involved in the outreach program 
**NC-PHCN – non-CDOP primary health care nurses group; ***CD-PHCN – CDOP primary health care 
nurse group  
 
 
Clinical Scenarios and Health Worker Knowledge 
Four different clinical scenarios were given to the nurses to complete during the self-
administrated questionnaire (Appendix 8a). The clinical scenarios covered clinical problems 
including patients with uncontrolled HTN, uncontrolled DM and proteinuria, and included a case 
study of a patient with HIV and proteinuria. An analysis of the health worker questionnaire 
revealed better knowledge and management scores for these clinical scenarios amongst CD-
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PHCNs compared with NC-PHCNs (25+7pts (CD) vs. 22+5pts (NC); ANOVA; p<0.0034). A 
comparison of the means, differences and variance for the total score for the clinical scenario 
questions between CDOP (CD-PHCN) and Non-CDOP (NC-PHCN) Primary Health Care Nurses 
is shown in Table 21. A comparison of the means/difference for the total score for the clinical 
scenario questions a-d between CDOP (CD) and Non-CDOP (NC) PHCNs, using independent t-
testing was equivalent to ANOVA, p = 0.0034; 25+5.4 vs. 22+7.1. 
 
Table 21. Clinical Scenario Scores CDOP (CD-PHCN) vs. Non-CDOP PHCNs (NC-PHCN) 
 
      
Total Questions a-d by 
CDOP participation  
n Mean SD SE  
(Non-CDOP – NC-PHCN) 
0  
63 22.1 7.103 0.89  
 (CDOP –CD-PHCN) 1  75 25.3 5.415 0.63  
Source of variation  SSq DF MSq F p 
CDOP participation 346.7 1 346.7 8.90 0.003 
Within cells  5297.7 136 38.9   
Total  5644.5 137    
Note: One-way Analysis of variance (ANOVA) between CDOP (CD) and Non-CDOP PHCNs comparing 
the means and difference for the Total Score for Clinical Scenarios.  
NC-PHCN – non-CDOP primary health care nurses group; CD-PHCN – CDOP primary health care nurse 
group  
 
 
In all the questions a-d, evaluated individually, the CD-PHCNs scored better, but this was 
only statistically significant for the HTN and DM clinical scenarios, i.e. questions a and c; 
p<0.002 (see Table 22, see Appendix 8b).  
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Table 22. Clinical Scenario Example – Question C  
 
An elderly woman of 64yrs presents to the clinic with a blood pressure of 160/76 and proteinuria+++ and 
glucosuria. Her HGT is 9.9mmol/L and HbA1c is 10 and ACR 150mg/mmol . She has been at the clinic for 
the last 8 years. She is on Gliclazide 160mg bd, Metformin 850mg bd, Nifedipine XL 60mg daily and 
HCTZ 12.5mg daily.  What would be your assessment and management?  Please read each statement 
and indicate whether you would take the action. Tick or circle Yes, or No or indicate if you are Not sure. 
 
Clinical scenario scores showed no correlation with enrolment or follow up in the clinics. 
Regression analysis looking at factors which may have impacted on the clinical score, such as 
age of the nurse, years qualified, the facility or years of experience, were not found to be 
significant. In the analysis of the direct questions in section 4, PHCNs were asked who they 
would ask for advice if they needed help with patient who had HTN or DM. The nurses 
expressed a higher likelihood of consulting a colleague, and many preferred asking a PHCN who 
had participated with CDOP and managed these patients, compared with a doctor or contacting 
their referral hospital (see question 14, section 4 – Appendix 8a and 8b).  
 
Health Worker Knowledge and Continuing Medical Education 
The questions which addressed issues of PHCN knowledge, and continuing medical 
education (CME) and clinical support, found that 95% of nurses had participated in a learning 
activity over the past month. Most (41%) had participated in in-service training provided by the 
PHC School, 30% had been on a ‘training course’, 4% were registered for a higher 
degree/diploma or said they undertook ‘self-study’. CDOP provided CME to 16% of PHCNs via 
clinical case teaching during focus groups and from education provided by the CDOP nurse 
program coordinators. Most PHCNs used the National Essential Drug Listing (EDL) HTN 
guideline (67%), 65% also used their own PHC School guideline and only 9% the South African 
Hypertension Society guideline for managing patients with high blood pressure. Eight percent 
said they used the guidelines provided by the CDOP team.   The nurses were then asked when 
had they learned their latest guideline and from who had they learned it. The ranges were broad 
for both chronic diseases, but most (49%) indicated they had learned their HTN guideline within 
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the last 3 years. However, when asked what the ‘ideal’ blood pressure or glucose target for HTN 
and DM, the findings were quite different (Figure 48 and Figure 49). 
Eighty seven percent (87%) of nurses were much more likely to know a target which 
would be considered ‘controlled’ for HTN management i.e. <140/90mmHg compared with only 
60% of nurses knowing the glucose target for diabetes management i.e. glucose <8mmol/L. On 
evaluating the last guideline learned for diabetes control, 51% had read the last published DM 
guidelines. 
 
Figure 48. ‘Ideal’ Blood Pressure targets of PHCNs 
Note: ‘Ideal’ target is that blood pressure at which the PHCN would consider a patient to have a controlled 
blood pressure 
 
1% 12%
20%
25%
42%
Unsure <160/90mmHg <120/70mmHg
<130/80mmHg <140/90mmHg
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Figure 49.The ‘Ideal’ Glucose Targets of the PHCNs 
Note: Glucose rather than HbA1c was used as a target because nurses did not use HbA1c for diabetes 
control in the clinics. HbA1c was used for the first time by most nurses when participating on CDOP and 
therefore could not be used as a comparison. 
 
 
  A quarter of the PHCNs last read a DM guideline more than 5 years ago. The majority of 
PHCNs (67%) relied on the EDL guideline and 60% on the PHC School to provide the latest 
diabetes management education. A further 41% relied on in-service training to up-date their 
knowledge, 30% from training courses and only 1% were self taught. A further 10% said they 
relied on CDOP for this education. From a clinical scenario question, it was found that CDOP 
PHCNs (CD) were more likely to know about an HbA1c test and how it was used, and the 
appropriate targets for glucose control, compared to NC PHCNs (Chi-square; p<0.05). In general 
a target glucose level of <8mmol/L was used by nurses as a clinical target for glucose control. 
A code in the thematic analysis evaluating ‘organizational justice’ revealed nurse 
frustrated with some aspects of ‘In-Service Education’ and training opportunities. PHCNs 
expressed an inability to attend CME due to staff shortages, patient load and transport problems. 
There were some complaints that management did not prioritise staff development. Some of 
these issues are discussed further in the ‘Health Worker Motivation’ section below. 
 
17%
43%7%
33%
<6mmol/L 7-8mmol/L 9-10mmol/L >10mmol/L
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Need to focus more on looking after staff (PHCNs) and developing them as individuals” 
and “nurses felt ignored and often feel as if management does not care, and managers 
promised they would support nurses  and try to get access to computer lab (Diary 
Recording, Management Report Back Meeting). 
 
Analysis of Primary Health Care Nurse Motivation 
Health worker (HW) motivation was evaluated from the diary recordings, open ended 
response section of the questionnaire and the questionnaire motivational survey. The conceptual 
framework defined 22 domains of interest for the motivational survey and some of the more 
relevant results are described below.  Seventy-five questions were selected from existing 
organization tools (Price, 1997) and the Penn-Kekana study, or developed to cover the domains 
of interest (Appendix 8a and 8b or 10a and 10b, Figure 25). The results presented in this section 
are from the 75 motivational determinate and outcome questions that were included in the self-
administered questionnaire, which was completed by the nurses working in the clinics 
participating on the program being evaluated. A complete list of questions distributed according 
to their domains, including the number of that question, is listed in Appendix 8b.  
 
Motivational Outcomes 
There were 9 domains concerned with the outcomes of motivation, worker affect and 
cognition, but the latter two evaluating ‘worker behaviour and performance’ were evaluated from 
the diary recordings only.  Eighteen questions appeared to represent the domains interrogating 
the theme of ‘Worker Affect and Cognition’. The picture portrayed was one of great difficulties 
faced by nurses, including a large patient workload and a management structure not 
understanding their predicament.  This had impacted on nurses’ morale. From a positive 
perspective, PHCNs remain ready to support their institution and deliver on its goals, as 
evidenced by the responses to selected questions evaluating nurses’ motivation i.e. ready to be 
‘activated and motivated’ (Figure 50). 
  
Figure 50. Selected Motivational Responses of nurses in CDOP
NC-PHCN – non-CDOP primary health care nurses group; CD
group  
 
Motivational Outcomes – Worker Affect and Cognition Domain loaded to Factor 1 (Varimax normalized) 
Marked loadings are >0.45. None of these que
 
 
Figure 50 shows that 90% of nurses felt their job gave them a feeling of achievement and 
accomplishment and 57% were still
proud to be working in a clinic”, and just over half still felt they shared similar values with the 
clinic or health department. There were significant differences in some of these questions 
between the CD and NC PHCN, with the latter group less likely to be satisfied o
working in the clinic. However, when evaluating nurses “intention to leave”, this did suggest 
problems with PHCN morale. Over fifty percent of nurses were potentially considering leaving 
their job, with 31% considering working overseas in the
than half the PHCNs supported the possibility of leaving their clinic in the future (
 
 
 
 Clinics 
-PHCN – CDOP primary health care nurse 
stions were excluded after Cronbach alpha correction
 very satisfied with their job.  A further 80% agreed that “I am 
r proud to be 
 future and 32% were still unsure. More 
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 51).  
  
Figure 51. Evaluation of PHCNs Intention to Leave their Job
Worker Affect and Cognition Questions loading on Factor 3 according to factor analysis (Varimax 
normalized) - Marked loadings are >0.45.
NC-PHCN – non-CDOP primary health care nurses group; CD
group  
 
 
This correlated with the evidence which show
the clinics which impacted on the ability to implement CDOP, as described earlier (
also has serious implication for any programs planning to tackle chronic illnesses like DM, HTN 
and HIV in Soweto in the future. These indicators of low motivation were of concern, especially 
as nurses appeared to be suffering from burnt out (
 
 
-PHCN – CDOP primary health care nurse 
ed a significant staff and nurse turnover in 
Figure 52). 
 
Table 22). It 
  
Figure 52. Evaluation of Burnout amongst PHCNs
Note: These questions evaluating burn out
NC-PHCN – non-CDOP primary health care nurses group; CD
group  
 
The thematic analysis of the domains from diary recording supported the findings 
outlined above, as seen from figure
Figure 53. Diary Recordings Worker Affect and Cognition
*Thematic codes comprising of quotes extracted from the diary recordings evaluating motivational 
outcomes of health worker motivation 
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These thematic codes in figure 53 documented when a health worker expressed being 
unmotivated or showed low morale. It also documented the frustration felt by clinicians, or when 
clinicians expressed a desire to leave the PHC service.  
 
PHCs not very motivated, also do not seem to be that interested in patients with chronic 
diseases…. and (CDOP is) seen as a bit of a hassle, not seeing any value (in program) 
(Focus Group, clinic 1). 
The clinic staff are generally dissatisfied about the running of the services, and most are 
suffering from burn-out.  There is nothing to boost their morale (Focus Group, clinic 6) 
Working conditions need to be improved as well as better remuneration (pay)….There 
are staff shortages and many leave to go overseas and this could be stopped by the 
motivation of better money (pay)….Nurses and doctors should be recognised for their 
hard work and good work that they are doing for their communities (PHCN, clinic 10). 
 
The thematic codes specifically covered the attitude of clinicians to patients, although this 
was better covered in the questionnaire. In the questionnaire, nurses overwhelmingly expressed 
a positive attitude to patients and indicated their willingness to carry out tasks and do more than 
was asked of them. Eighty three percent of nurses felt that they “do more than what my job 
requires” and 67% believed that they “still care for patients like they used to”. This probably 
reflects what was described earlier as a positive willingness, to deliver of the goals of the health 
organization, or nurses were ready to be ‘activated and motivated’. 
 
Individual Motivational Determinants 
The individual characteristic domains, evaluated as part of the motivational determinants, 
again showed a nursing team willing and ready to be ‘activated and motivated’ (Figure 54), 
although only 55% of nurses could see themselves continuing to work as a nurse in the future. 
There were no differences between CD and NC nurses.  These questions covered the domains 
of ‘work ethic’, ‘job involvement’, ‘locus of control’, ‘job choice’ and ‘attitude to change’ 
 
  
Figure 54. Motivational Determinants 
Note: All these questions were loaded on factor 1 and cover the domains evaluating ‘wo
involvement’, ‘locus of control’, ‘job choice’ and ‘attitude to change’
NC-PHCN – non-CDOP primary health care nurses group; CD
group  
 
 
In general all nurses, both NC and CD, believed they were hard wo
job made them feel worthwhile”. They were also confident that they were hard working and their 
work was of high quality. These domains were however contradicted in domains assessing 
‘worker behaviour and performance’.  As expressed e
nurses overwhelming felt that their job did not offer “adequate pay compared with similar jobs”. 
Interestingly there was a significant difference in the answer between NC and CD, with CD 
nurses being happier with their pay; p<0.05 by chi
either “in control of things which affect my work” or unsure, more than 70% felt “there had been 
too many changes in their clinic in the past few years”. This reflecting their being frustrate
out of control with decisions being made by senior management (Johannesburg Metro Regional 
Health Department), discussed earlier. 
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Worker Behaviour and Performance 
These domains were evaluated from the diary recordings as there were no questions 
covering these in the health worker motivational survey (Figure 55). This was also assessed in 
the clinical scenarios and direct questions evaluating knowledge (see sections ‘clinical scenarios 
and health worker knowledge’) and ‘health worker knowledge and continuing medical 
education’..  
 
Figure 55. Worker Behaviour and Performance 
*Thematic codes of quotes coded from the diary recordings evaluating motivational outcomes of health 
worker motivation; ** See text for explanation of ‘Bara Syndrome’, ‘work quality – data capture’ and ‘quality 
vs. quantity care 
 
 
 
These codes investigated knowledge deficiency but also failure in the guideline to 
provide this knowledge.  It included evaluating clinicians’ existing knowledge and information 
relating to the latest protocols for chronic disease management of HTN and diabetes and their 
confidence to carry out tasks and make decisions. It also relates the PHCs’ knowledge of what is 
'high risk' and why such people should be enrolled into the program and follow up well. This 
issue was evaluated from the clinical data by doing sensitivity and specificity testing (see Tables 
19 and 20). 
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An example of knowledge deficiency pertaining specifically to screening for proteinuria is 
documented in this recording by one of the PHCNs. 
  
Routine urinalysis in chronic patients is a problem as patients urine is not tested regularly 
making it difficult to identify problems like proteinuria, blood (haematuria) etc.  The only 
time when urine is tested is when a patient presents with symptoms like BOM (burning 
on micturition), and it is only then that urinalysis is done (PHCN, clinic 11). 
 
A major concern related to both confidence and knowledge deficiency was that of nurses 
not initiating insulin, a problem already documented earlier. This also reflected the almost 
complete absence of nurses to evaluate diabetes control by using HbA1c measurements. It also 
reflects the complete absence of CKD evaluation as part of chronic disease management. 
 
Concern about initiation of Insulin by the clinicians discussed and short guidance re 
initiation of Insulin given, clinicians a bit scared to initiate (Focus Group, clinic 19) 
Discussed nurse training and education around the existing CDOP and specialist society 
protocols … need to also educate about HbA1c… unbelievably this is left out and nurses 
are not expected to do this test to follow diabetics - major problem related to poor 
control…the challenge of calculating GFR was also discussed … need to teach concept 
(CDOP Planning Meeting, diary recording). 
 
Issues of work quality were covered by a few codes, one referred to as ‘Bara syndrome’. 
This code reflected the loss of work quality by clinicians when overwhelmed with service 
responsibilities, who failed to deliver any form of a reasonable quality service, and was named 
after the tertiary referral hospital thought to be suffering from a similar problem.  
 
It appears that they (nurses) are overwhelmed with the potential screening problems. 
One nurse mentioned that since testing albumin-creatinine-ratios (ACR), they are finding 
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that too many patients have proteinuria. PHCNs just cannot cope! (Focus Group, clinic 
15) 
There is too much overloading of the (clinics) and then one cannot expect good results 
(PHCN, clinic 14) 
 
Work quality may have reflected on both training and the motivation to carry out tasks. 
However the desire not to carry out any audit of work and the difficulties that nurses’ experience 
in capturing data both reflects and causes poor motivation. One of the most critical problems 
documented with achieving good quality was the failure of clinicians to spend quality time with 
patients. This arises from managements’ failure to emphasize not placing an emphasis on 
quality and nurses being pressurised by numbers of patients they must examine each day. 
 
Also discussed problems of missing data and that they must write information - seems to 
be poor attitude to collecting information…tried to discuss value of audit (Focus Group, 
clinic 8). 
At the end of the day you give quantity care and not quality care (PHCN, clinic 10) 
(We) need to attend to these chronic patients with more patience, instead of us pushing 
the queues that are too long. (PHCN, clinic 6) 
 
Worker absenteeism and the high turnover, discussed earlier (Table 23), reflect a major 
factor impacting on ability to implement CDOP but also on underlying PHCN motivation. This as 
discussed above impacted on the implementation of the program. Absenteeism was discussed 
rarely by clinic nurses, probably because we did not ask about this problem and nurses did not 
want to discuss it, whereas turnover was seen as an issue which could be discussed openly by 
the nurse clinicians. 
 
Challenges to enrolling and follow-up - too few PHCs, often sick or absent from work, too 
many patients, other clinic demands - is a big CHC (Focus Group, clinic 1) 
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Motivational Determinants 
Nine domains were concerned with the outcomes of motivation and thirteen related to factors 
influencing motivation 
Health Working Motivation - Perceived Contextual Factors 
The diary recordings and questionnaires had codes and domains covering the motivational 
determinants impacting on health worker motivation (Table 23). Here, the ‘perceived contextual 
factors’ impacting on health worker motivation and specifically their ‘working environment’ were 
evaluated (see figure 25 for overview).  
 
Table 23. Perceived Contextual Factors of Health Worker Motivation 
Codes (12): (number of quotes) 
1. Work Load too much - PCF - Job - Workload (34)* 
2. Staff Shortages - PCF - Job - Stress (35-2) 
3. PHC Training Opportunities and Staff Development - PCF - Organizational Justice (12) 
4. PHCs - Value and Skills not Recognised - PCF - Organizational Justice (29) 
5. Management - Supportive - PCF - Management Support -Organization Environment (8) 
6. Management - No Consultation - PCF- Policy Change - Organizational Environment (6) 
7. Team Work & Share Skills Lacking - PCF - Organizational Citizenship (45) 
8. Management Ineffective - PCF - Supervision & Support- Working Environment (8) 
9. Management Lacks Understanding of Working Conditions - PCF - Support & Supervision 
- Working Environment (15) 
10. Doctors not Part of Clinic Team PCF - Work Environment - Colleague (5) 
11. Working Conditions - Need Improvement -Work Environment (7) 
12. Living Conditions - PCF - Home & Social Environment (17) 
Note: *Indicates the number of quotes extracted from the diary recordings 
 
The results discussed here are those domains pertaining to the organizational and working 
environment impacting on PHCNs motivation. They include the ‘perceived contextual factors’ 
domains; organizational justice, management support, the policy environment, organizational 
citizenship, supervision and support, including support from PHCN colleagues and doctors. 
Some of these challenges have been discussed earlier.  The diary records’ were used to reflect 
the health care system functioning and how it related to CDOP implementation. In this section,  
the context  is that of worker motivation and is reflected by evaluating a working environment 
short of equipment and medication have specific impact on health worker motivation. There were 
29 quotes highlighted in the diary records indicating how ‘organizational justice’ had impacted on 
health worker motivation.  Nurses felt that their value and skills in the organization were not 
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recognised. There were numerous comments by clinician nurses, that they felt other workers 
and managers with whom they worked, perceived them to be '2nd class citizens' in the health 
organization.  This was evidenced by their exclusion from the 'occupation specific dispensation' 
grant, which included a monthly bonus payment to 'specialised nurses' with scarce skills.  
 
(We) are not remunerated well or appreciated by management and yet (we) are the 
backbone of PHC service delivery with skills and competence compared to doctors working 
in the clinics (PHCN, clinic 1). 
(CDOP) needs to develop more authority for PHCs…. These issues are linked to nurses 
being seen as 2nd class citizens despite that they are doing most of the work and being at 
coalface of our health service (CDOP Planning Meeting notes). 
 
Many nurses complained that ‘management’, referring the management hierarchy outside the 
PHC clinic, were not providing opportunities for development and training:  
 
(PHCNs) complained of no career growth and feeling of stagnation…. PHCNs felt that 
their working conditions were poor and they received no recognition (Focus Group, clinic 
4). 
 
This quote above was contrary to the findings in the motivational survey where 70% of 
nurses felt they had sufficient opportunities for training and development, but only 29% believed 
the ‘clinic’ cared for their well-being. This was also despite the fact most nurses indicated that 
they had good support from their immediate supervisors in the clinics. However, some clinicians 
expressed frustration with the management, outside of their local clinic structure, and this was 
captured in the diary recordings. In general, the references to management refer to managers 
outside of the PHC clinic at Johannesburg Metro Health Department, or Gauteng Health 
Department and are reflected in the diary recordings below as ‘top management’. This was a 
way that PHCNs’ generalised about managers, as opposed to the people with whom they 
worked in their clinic. 
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Management do not know anything about the programs we are involved in….. they can 
hardly solve some problems at clinic level. (PHC, clinic 6) 
Management seem(s) completely unaware of the problems and challenges 
(Management Feedback Meeting, diary recording) 
 
This problem was also reflected in a thematic code evaluating the organizational 
environment, which investigated ‘management showing lack of understanding of work 
conditions’.  
 
There is a great feeling of isolation for each clinic and lack of real support from 
management… (We) never really have visits from ‘top’ management (Focus Group, clinic 
5). 
 
This issue of management not understanding the working environment of clinicians was 
commonly expressed in the diary recordings and the questionnaire (see figure 42). The thematic 
code from the diary recordings reflected nurses’ frustration and its impact on their motivation. 
 
One feels useless when you have to examine patients and then treat them without 
having the medications to give to patients (PHCN, clinic 10). 
“I am sick and tired of telling patients that we do not have a single pain killer and cough 
mixture ….. yet patients are coming to the clinic because of pain!  How do we help a 
patient in this case? (PHCN, clinic 12) 
 
These expressions of frustrations really highlight the plight of clinicians. The reasons for the 
shortages of medication were not documented in the diary recordings. The problem of 
medication shortages could have been related to financial problems of administration not paying 
for medication, problems with procurement of medication or problems with supply to the stores 
  
193 
at clinics, or it may have been all of these issues. The lack of understanding between clinicians 
and management is further highlighted by this excerpt from a diary recording. 
 
Management was complaining that nurses did not want to work rather than there being 
an issue being overworked due to their workload despite (CDOP) explaining the issues of 
patient numbers, workload, poor systems, lack of medication and adequate equipment 
(Management Feedback Meeting, Diary Recording). 
 
The evidence supporting one existing problem is reflected in this statement, which also had an 
effect on staff turnover, documented earlier (see Table 23). 
 
PHCNs also complained of a lack of career structure and a feeling of stagnation…. PHCs 
felt that their working conditions were poor and they received no recognition….. We then 
discussed nurses leaving and they told us one nurse was leaving for local clinic due to 
better salary and conditions compared with government clinics (Focus Group, clinic 4). 
 
PHCNs did express the positive feeling that their co-workers willingly shared their 
expertise and skills with them, and although this feeling of organization citizenship, reflected by 
good team work and was expressed as being positive in the questionnaire (Figure 56), problems 
were detected in the diary recordings, seen below. The negative aspects of team work related to 
the poor integration of programs when adopted by management.  
  
Figure 56. Organizational Citizenship
Note: These questions did not load on the same factor suggesting that this area of questioning lacked 
depth 
NC-PHCN – non-CDOP primary health care nurses group; CD
group  
 
 
 
Clinic not enrolling very well…. Seems to be no real commitment to CDOP and no team 
work at all in this clinic…. All (PHCNs) do their own thing (Focus Group, clinic 3)
CDOP is done in our clinic I suggest that every PHC nurse to be given a chance so that 
we all know about it and what to do to the patient (everybody to be involved) (PHCN, 
clinic 20). 
 
PHCNs, however highlighted the challenges of implementing programs, discussed 
earlier, where policy and programs supported by management were implemented without 
consultation. This may have impacted on cooperation, both team work and team spirit, i.e. 
shared workplace values, and the clinic staff expressed the need to be consulted about 
decisions affecting their work environment. This included starting special programs such as 
CDOP. 
 
 
-PHCN – CDOP primary health care nurse 
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There is too much overloading of the CHCs and then one cannot expect good results. 
(PHCN, clinic 5) 
They should improve good communication from our managers and not just dictate what 
must be done (PHCN, clinic 10). 
 
A major disappointment of the program was the documented non-participation of doctors 
and their isolation, by their own volition, from the rest of the primary health care team. Some of 
the diary recordings suggested this was partly  arrogance, whist other recordings suggested that 
doctors were nervous about their own knowledge and may therefore not have wanted to be 
involved,  in case they were shown up by nurses. Nurses were found to be very good at 
following protocols, whereas doctors showed a reluctance to be ‘tied down’. What remains clear 
is that doctors did not participate as part of the team, in most clinics, and especially with CDOP. 
 
A nurse complained that doctors do not appreciate their work and so they are de-
motivated and want to leave the service to better places where their service will be 
appreciated (Focus Group, clinic 16). 
Doctors and nurses do not seem to work as a team. Seem to work in different streams 
(Focus Group, clinic 3). 
 
Finally an evaluation of ‘living conditions’ and ‘working conditions’ as part of the 
motivational determinants impacting on the nurses, this statement from a nurse highlights the 
degree of frustration which existed at the time of this evaluation. 
 
There is no way that I can even talk about the pathetic salary which we poor “supposed 
to be nurse clinicians” are getting! Our salaries are really appalling! Nurses should be 
paid what they deserve as they are actually the ones who are running the clinics, without 
doctors (PHCN, clinic 12). 
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The Department of Health should consider the influx of patients in our clinic.  We see 
large numbers and we are not coping.  They should improve working conditions for 
nurses and improve salaries to a living wage - not hand to mouth (PHCN, clinic 5). 
 
Comparison of Health Workers Motivation  
The health worker motivational survey included many of the components of the health 
system in the motivational determinants, and ‘perceived contextual factors’, as well as factors 
directly impacting on the health care team i.e. motivational outcomes. All the domains were 
scored together and a comparison between CDOP PHCNs (CD) and non-CDOP PHCNs (NC) 
was made using independent t-test and Analysis of Variance (ANOVA). Although the 
comparison was not statistically significant, CD nurses had higher motivational scores overall for 
all domains evaluated by t-test (CD 92+42 vs. NC 84+40; p=NS). When converting the score for 
each domain to reflect a ‘positive’ motivation affect before analysis, both groups of nurses had a 
similar score (CD 15+9 vs. NC 15+9; p=NS). When comparing other motivational questions, CD 
PHCNs proved to be ‘more satisfied with their job’ than the non-CDOP PHCNs (NC); p<0.05. 
Motivational scores were also compared between clinics having better follow up and those which 
did not, but this was not significant. Scores were also given to each clinic for their organization, 
and included an in depth evaluation of all factors which may have influenced enrolment, follow 
up and patient care. Although there were significant differences in the scores between clinics, 
this did not necessarily correlate with better enrolment, follow up or management (Table 24).  
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Table 24. CDOP Clinic Organization Score 
 
Clinic Drs Twork Tot 
PHCs 
CDOP 
clins 
FupS RefS EquipS MedS Mx 
SupS 
OrgzS Total 
Os 
1 0 2 12 2 2 1 2 2 1 2 12 
2 0 2 3 3 2 2 2 2 2 2 14 
3 8 2 10 2 2 1 2 2 1 2 12 
4 0 2 11 0 2 1 2 2 2 2 13 
5 0 2 3 3 2 1 2 2 1 1 11 
6 0 3 12 2 1 1 2 2 1 2 12 
7 0 2 5 1 2 1 2 2 1 2 12 
8 0 1 10 10 1 1 2 2 1 1 9 
9 0 1 3 3 2 2 1 2 1 2 11 
10 1 2 9 3 1 1 2 2 1 2 11 
11 3 2 8 2 2 1 2 2 2 2 13 
12 3 -2 6 1 -2 -2 2 2 -1 0 -3 
13 2 2 7 12 2 1 1 -2 2 1 7 
14 0 0 4 0 -2 0 1 1 0 -1 -1 
15 2 1 6 1 -2 2 2 2 1 0 6 
16 2 1 6 1 2 1 1 1 2 1 9 
17 1 0 11 1 -1 -1 1 -1 2 0 0 
18 2 1 12 1 2 1 1 2 1 2 10 
19 0 2 5 1 2 1 2 2 1 2 12 
20 0 2 5 1 2 1 2 2 1 2 12 
Drs - number of doctors in the clinic; Twork - score for team work +2 = Very good / +1 Good / 0 = Average 
/ -1 = poor / -2 very poor; TotPHCs - total PHCNs at clinic; CDOPclins - number of PHCNs who did CDOP 
work out of total of PHCNs; FupS - follow up score +2 = Very good / +1 Good / 0 = Average / -1 = poor / -2 
very poor; RefS - Referral score +2 = Very good / +1 Good / 0 = Average / -1 = poor / -2 very poor; EquipS 
- state of equipment and upkeep score +2 = Very good / +1 Good / 0 = Average / -1 = poor / -2 very poor; 
MedS - State of medicine supplies and stocks score +2 = Very good / +1 Good / 0 = Average / -1 = poor / -
2 very poor; MxSupS - Management Support score +2 = Very good / +1 Good / 0 = Average / -1 = poor / -
2 very poor; OrgzS - Organization Score around CDOP score +2 = Very good / +1 Good / 0 = Average / -1 
= poor / -2 very poor; TotalOs = Total organization score adding up all scores 
 
 
The motivational scores were evaluated against the clinical scenario scores, in order to 
determine if more motivated nurses were also more knowledgeable, and whilst there was a trend 
between higher motivation and better scores this was not significant.   
The one domain which did show significantly better scores by CD vs. NC nurses, was for the 
questions evaluating the Outreach Program. Here, the CD PHCNs who had worked on the 
program, scored much better (Figure 57). The questions of this domain are shown in Table 25. 
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Figure 57. Comparison of Motivational Determinant Domain for Outreach Program 
NC – Non CDOP PHCNs; CD – CDOP PHCNs compared using independent t-testing for Motivational 
Determinant domains – Perceived Contextual Factors – Extrinsic Characteristics – Outreach Program 
 
 
 
 
 
Table 25. Motivational Determinants Domain Questions for Outreach Program 
 
An Outreach Program (CDOPPP) has helped me with decision support regarding patient 
clinical care? (11) 
An Outreach program (PPP) has helped me with referring patients to the  hospital (14) 
I feel that I have a clearer understanding of who should be referred to hospital due to my 
involvement with CDOPPP (21) 
The CDOPPP was NOT too time consuming for me to enrol patients in it? (35) 
CDOPPP had added value for me in my job as a PHCN (41) 
I find getting involved in programs like PPP worthwhile (43) 
I would like to have more nurse coordinators helping with managing chronic conditions (48) 
I would participate in CDOPPP even if it was not quicker to enrol patients (55) 
There should be more many special programs, like PPP  in our clinics? (59) 
CDOPPP made a difference to patient care (70) 
I would like to see PPP became a standard way of managing and referring  patients in the 
primary care clinics (74) 
Note: Includes the question and its number in the questionnaire for domains perceived contextual factors, 
extrinsic characteristics ‘outreach program” 
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Patient Factors impacting on Outreach Program 
 A patient informed about their disease, and now activated to take control and 
participate in their care, together with the community are factors important for managing people 
with chronic illnesses. This component of the Wagner CICM and WHO ICCC models was not 
evaluated extensively, due to time constraints and in the interest of focusing in greater depth on 
the primary health care worker. It should therefore be noted that patients were not involved or 
integrated into the evaluation and that any patient factors mentioned reflect the opinions of the 
PHCN only and not of the patients themselves. Failure to evaluate the patient issues in greater 
depth does not reflect the importance which I place on this component of the chronic illness 
management models. It was simply as a result of lack of time and to ensure a better and more 
comprehensive evaluation of one component of the model. The evaluation of patient factors 
should be viewed in the context of a large dropout rate. This probably reflects the poor overall 
education and motivation which was provided by both the clinic and CDOP. However, the results 
from the diary recordings and questionnaire, reflecting patient factors which may have impacted 
on the ability to implement CDOP are still discussed below (Figure 58). 
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Figure 58. Prepared Informed and Activated Patient 
*Thematic codes comprising of quotes extracted from the diary recordings evaluating chronic disease 
models ‘Prepared Informed and Activated Patient’; ** The ‘via syndrome’ reflects patients frustration with 
system delays, shortages of medication and a lack of education (see text) 
 
The code, evaluating patient ‘adherence’, reflects on the difficulty of the program to 
impact on patients’ ability to lose weight and modify CVD and CKD risk factors. Although a 
number of issues impacting on follow-up were outlined earlier, factors improving outcomes are 
also dependent on health worker and patient interactions (see figure 4). Patient factors affecting 
follow up included their failing to turn up for clinic on the medication ‘repeat day’ and then failure 
to see the program PHCN. Patients were also documented to have moved to different areas and 
clinics, this included following their PHCN who had moved to a ‘local authority’ (city council) 
clinic. This could have been driven by patients going to these clinics as the waiting lines for 
medication and evaluation were shorter and quicker. However, it may also reflect the desire for 
patients to be treated by a health worker with whom they had developed a rapport. Public health 
clinic working hours also do not allow patients in employment to attend, as clinics are usually in 
the mornings only. In some clinics PHCNs do start early to allow those employed to attend 
before work. 
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An employed patients may not be able to come back to get tablets that were not 
available on the day of a check-up and this leads to shopping around and being lost to 
follow up (NCO follow up visit diary recording). 
(PHCNs) Claim that patients are going to the 'Local Authority' City Council clinics and do 
not come to Dobsonville clinic any longer (Focus Group, clinic 4). 
A PHCN challenge outlined was that a patient started job and now cannot attend clinic 
during week (therefore to follow up), also claim patients are moving away from the area 
(Focus Group, clinic 13). 
 
A thematic code, the 'Via' Syndrome, further explained the challenge to provide quality 
care in general and through CDOP. This code describes patients’ inability or refusal to embrace 
improvements in care, and therefore reflects both a lack of patient education and motivation. It 
may also indicate a lack of motivation to endure an inefficient primary health care system.  
Patients commonly did not want to participate in CDOP because routine investigations are 
requested and are seen as 'additional' investigations rather than routine, e.g.. blood glucose 
HbA1c and urine tests. These tests would prolong their clinic visits. Three factors affected 
patients enrolling; firstly resistance to ‘additional’ tests; secondly, these tests resulted in  longer 
waiting times and thirdly, patients may have been concerned that delays could impact on their 
receiving medication that day. Patients failed to recognise that additional investigations to 
assess their risk were of value.  Instead they saw this as a 'waste of time' in their endeavour to 
go 'via' the clinic to do their daily activities.  Patients only wanted to see clinicians and receive 
medication as quickly as possible. This ‘Via Syndrome’ code also reflects the delays and 
challenges endured by patients in the clinic waiting lines and when medications ran out at the 
clinic. 
 
Nurses worried about patients not wanting to wait - via syndrome. Do not seem to see 
value for waiting for tests…. Patients are not willing to be kept long at the clinic… (they) 
disappear into the clinic (PHCN, clinic 18) 
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I work with a difficult community who verbally abuse staff and reports us if they are 
waiting for a long period of time to be attended to, even though you explain what you are 
doing (PHCN, clinic 5) 
(Patients) are lost to follow up.  Reasons outlined included patient moving or (they) do 
not want to wait too long for test results or to see PHCN….they do not see the value in 
waiting (via syndrome)… this frustrates the patients (Focus Group, clinic 15). 
 
Another issue aggravating the ‘Via Syndrome’ appeared to relate to issues of patient 
education. Although many patients and PHCNs appreciated the role the Outreach Program 
played in education, it was not always carried out in the clinic and some patients saw it as 
another delay. Thematic analysis, in general, documented the poorly developed patient 
education systems. Clinics use passive education through posters, but also use the well 
supported, ‘patient support groups’ as the predominant system of education. Unfortunately ‘one 
on one’ patient education through the health promoters, PHCNs and CDOP nurse coordinators 
was limited. PHCNs claimed it was due to patient load and time constraints, but education during 
consultations is not encouraged. Patients often also require permission from their partner to be 
treated and participate in programs like CDOP. This demonstrates the complexity involved in 
enrolment and adherence.  Diary recordings demonstrating these issues are outlined in these 
few quotes. 
 
Patients also arriving at (Tertiary Hospital) and do not know what is wrong with them… 
very poor patient education and PHCN not teaching patients…. PHCNs saying they have 
no time to educate patients and assess risk factors (CDOP Planning Meeting, diary 
recording) 
 This community seemed scared to give consent and said they would like to discuss with 
their spouses first (Focus Group, clinic 8) 
 
On a positive note, and contrary to some of the diary recordings documented above, the 
program was shown to have a positive impact on patients being informed and educated about 
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their disease. This was found in some of the patients when referred to the specialist clinic. 
CDOP nurse program coordinators also participated actively in patient support groups for DM 
and HTN at the clinics and during support group education days.  
 
CDOP team was invited by the clinic to sit in when commencing a support group for 
hypertensive patients as they have been motivated by a DM support group leader on the 
program (NCO diary recording, clinic 16 follow up visit). 
 
Summary of the Program Evaluation  
Improving functional and clinical outcomes for patients are the goals of the Wagner and 
WHO chronic illness management models. The results described above are an evaluation of 
outcomes and health system factors which impacted on the establishment of a chronic disease 
management program. They also highlight the challenges and successes of the Outreach 
Program which aimed to link and improve care for patients with HTN and DM in the primary 
health setting and its referral hospital. Health systems are complex and the success of a 
program requiring ‘voluntary’ participation by nurses makes it even more complicated.  
Both positive and negative findings are outlined in this chapter.  A summary of some of 
these findings according to its strengths and weaknesses are outlined in Table 26. The program 
did enrol the appropriate patients who were at high risk for CKD and CVD, although the selection 
of these patients was not random. The implementation was not as planned. However, the 
program aimed to replicate the ‘real world’ and not an experimental one, and so, CDOP adopted 
the participatory action research model. There were multiple implementation constraints and 
these have been discussed in detail above and are summarised in Table 26. Patient follow up or 
return visits, requiring repeat evaluation of their clinical progress on the program, was a definite 
problem in the primary health care setting, but those with advanced disease requiring a 
specialist were detected. Most of those requiring referral were referred correctly, and were 
followed up with successful improvement in the majority of their risk factors. The program had no 
impact on improving weight control, but importantly the GFR and proteinuria did not worsen.  
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Nurses who were involved in the program showed better motivation, and improved 
knowledge as evidenced by better scores in many of the motivational and outcome and 
determinant domains. The knowledge of the primary health care nurses who participated 
showed a statistically better score in the patient clinical scenario (see Table 21), which aimed to 
assess nurses’ chronic illness management knowledge and skills. The results highlight how 
policy affects health care implementation and the problems in existing health organization, 
including the continuing medical education and development of nurses. The question of whether 
it was successful or not and if it improved their health status will be discussed in greater detail in 
the next chapter. 
 
Table 26 . Program and Health system Strengths and Weaknesses  
 
Program Component Strengths Weaknesses 
Positive Policy 
Environment 
• Development of a regional chronic 
illness network with government 
and NGOs e.g. ‘senior 
management’, specialist and PHC 
clinics, groups responsible for 
chronic illness care 
• CDOP improves patient 
management through authorisation 
of management, medication 
prescription and referral 
• CDOP detects weakness in policy 
and guideline implementation e.g. 
improved HbA1c testing, insulin 
initiation training and use of eGFR 
proteinuria and for CKD detection 
• Assistance with the development 
and training e.g. obesity 
management training, computer 
skills 
• Development and Allocation of staff 
through program e.g. use of health 
promoters for patient tracking 
• Sub-specialisation of PHCN skills 
e.g. development of NPCO and 
chronic illness skills  
• Decentralised clinic staff CME 
 
• Inability to become ‘fully’ integrated 
into chronic illness health care 
systems 
• ‘Champion’ driven program therefore 
sustainability questioned 
• Introduction of ‘new’ CDOP 
guidelines instead of strengthening 
existing guideline implementation 
e.g. no HbA1c testing 
• Inability to improve more efficient 
laboratory results and authorisation 
of laboratory investigations 
• ‘Vertical aspect’ to program with a 
focus on kidney disease 
• Failure to implement good audit and 
research philosophy 
• No legislation to support nurses with 
treatment prescription and increasing 
medication dosing 
• Health promoter poorly utilised by 
nursing staff to provide link with 
patients 
• Inconsistent funding of primary 
health care nurses compared to 
hospital based ‘specialist nurses’ 
• Nurses given ‘responsibility without 
authority’ to manage illness 
 
Health Systems and 
Organization 
• CDOP was able to provide an 
alternative integrated model for 
HTN and DM management 
• Program nurse coordinators 
(NPCs) assist with patient 
management coordination and 
continuity of care 
• Improved focus on quality of care 
• Poor overall patient follow up 
• Low skilled tasks not assigned to 
health promoters or non-professional 
nurses or clerks 
• Further aggravates competing 
demands of nurses by starting a 
‘new program’ 
• Failure to integrate into ‘chronic’ 
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versus quantity of care 
• Provides new equipment for patient 
management e.g. glucometers 
• Assessment of existing 
infrastructure for regional 
management 
• Provided research and audit of 
health care system 
• Link between primary care 
clinicians and management 
• Improvement of team work in some 
clinics 
 
clinics and get full management 
support 
• Initial lack of credibility amongst 
PHCNs 
• Limited impact on improving team 
work 
• Shortages of medication and 
equipment 
• Competing demands placed on 
PHCNs in the clinic 
 
Delivery System 
Design 
• Improved integration of chronic 
illness management  
• Link and improved communication 
between primary and tertiary care 
• Provided expertise for chronic 
illness management  
• Nurse coordinators (NCO) provide 
link between nurses and specialists 
and development of ‘chronic illness 
specialist’ 
 
• Failure to integrate CDOP as 
standard method of referral for 
chronic diseases  
• CDOP too time consuming to enrol 
patients 
• PHCNs clinics in PHC sector function 
in vertical design and no horizontal 
integration 
• No ability to ‘step down’ patients from 
hospital to PHC once referred i.e. 
ensure continuation of medication 
(anti-lipid) 
 
Decision Support • CDOP improves patient 
management through authorisation 
of management, medication 
prescription and referral 
• NCO phone call support 
• ‘Feedback Support’ 
• CDOP provides some 
‘simplification’ of management 
guidelines 
 
 
 
 
• PHC clinic doctors not functioning as 
part the PHC team  
• Not all clinics have doctor for 
decisions support 
• Patients have to travel long distances 
for decision support and if not 
enrolled on outreach program 
• No guideline uniformity 
 
Clinical Information 
System 
• Provides an information system 
data base and structure to support 
decision making and referral 
• Tracking system to follow trends of 
patient care and detect 
management weaknesses 
• NPCs ensure data quality capturing 
is correct 
• No electronic information system to 
capture patient information 
• No laboratory computers to access 
laboratory investigations 
• Slow turnaround time of patient 
laboratory results 
• Poor quality of data capture by 
PHCNs 
Prepared, Motivated 
and Proactive Health 
Team 
• Empowering clinicians through 
education, authorisation of 
medications and referral.  
• Clinicians found to be ‘willing’ and 
potentially enthusiastic. 
 
• Failure to involve all PHCNs in 
CDOP  
• Failure to improve team work 
• PHCN feel isolated and 
disempowered and like ‘2nd class 
citizens’ 
Health Worker 
Knowledge 
• Improved health worker knowledge 
through ‘outreach education’ and 
support 
• Provides evidence of link between 
knowledge and motivation 
• Poor existing knowledge of diabetes 
management 
• Limited access to new guidelines 
 
Health Worker 
Motivation 
• ‘Added value’ to PHCN work 
environment 
• Provides incentives through 
• Failure to get doctors to participate 
on program  
• Shortages of staff in clinics 
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workshops and overseas chronic 
disease training 
• Non-statistical improvement in 
primary care nurse motivation  
• Large patient workloads 
 
Informed Activated 
Patient and 
Community 
• Limited engagement of patients on 
the program 
• Good explanation and support 
education when referred to 
specialist 
• Improved waiting times at specialist 
clinic  
• Weak focus on patient and 
community issues impacting on 
chronic disease management 
• Increase of patient time in clinic 
 
Self Management 
Support 
 • Failure to address adherence issues 
• Failure to improve weight loss or 
reduction in BMI 
Patient Education • Support of existing structures for 
self management support e.g. 
support groups 
• Provides patient education through 
development of education manual 
 
• Failure to implement patient 
education and especially kidney 
function testing 
• Failure to educate patients about 
‘value’ of waiting for quality of care 
• Failure of CDOP to improve patient 
waiting times at the clinic 
Productive 
Interaction - Linking 
of health team and 
community 
• Improved use of health promoters 
• Good primary to tertiary care 
interaction.  
• Development of traffic light system 
to help patients recognise urgency 
of disease 
• CDOP became involved in with 
‘patient support groups 
• Limited involvement in improving 
patient health worker interaction.  
• Poor implementation of ‘traffic light’ 
triage system 
• Poor control of patients with diabetes 
and utilisation of support groups 
 
Improved Functional 
and Clinical 
Outcomes 
• Improved clinical outcomes in 
specialist referral group 
• Good screening of high risk 
patients and detection of patients 
requiring referral 
• Improvement of clinicians 
knowledge  
• Able to harness ‘enthusiasm’ of 
motivated nurses 
• Unable to determine clinical 
outcomes for all patients enrolled 
• Limited impact on patients followed in 
primary care setting 
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6 DISCUSSION 
Health systems are complex, and changing existing health systems and health workers’ 
attitudes and knowledge proved to be a challenging exercise. This discussion focuses on the 
three components of evaluation, derived from the Wagner Chronic Illness Care Model (CICM) 
and WHO Improved Care for Chronic Conditions Framework (ICCC), and includes an 
assessment of the i) the program’s implementation and existing health systems; ii) clinical and 
functional outcomes; and iii) the ‘prepared’ and ‘motivated’ health care team. A comprehensive 
evaluation of these components, again using the chronic illness models, was carried out using a 
‘triangulation’ process which linked the clinical and functional data with the information gathered 
from the diary recordings and questionnaire (see figure 25). This comprehensive evaluation 
process allowed for and provided clearer answers about the successes and failings of the 
chronic disease outreach program (CDOP), and its ability to integrate into existing chronic 
disease PHC services.  
 
Program Implementation 
The chronic disease outreach program was a success and a failure as an intervention. 
CDOP was able to successfully implement a vertically independent outreach program using the 
Wagner Chronic Illness Care Model (CICM) and the WHO Improved Care for Chronic Conditions 
Framework (ICCC) in 20 clinics. It established an alternative system for assisting primary care 
health nurses (PHCNs) with the secondary prevention of CVD and CKD, and with the detection 
and management of patients with hypertension (HTN) and diabetes (DM). These advantages 
were similar to programs which used these chronic care models in the United States. CICM 
proved able to be incorporated with relative ease, and was implemented into family practices 
(Nutting et al., 2007, Glasgow et al., 2001), and was used to run a similar chronic illness 
program for American Indian and Alaska native populations, suffering from DM and HTN, in the 
United States (Narva, 2008). The CICM and ICCC models had not been used before in an 
African setting as a mechanism to improve management of chronic conditions. To a very limited 
extent the program was able to integrate into chron
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to assist some PHCNs with decision making and referral. It provided expertise and training 
through the development of its ‘specialist’ chronic disease nurses, the nurse program 
coordinators (NPC). These specialised nurses provided a new referral link between the primary 
care sector and its regional referral hospital. Many of the nurses, especially those who had 
participated in the program, felt that the program had added value to their job, and assisted them 
with ‘decision support’ and referral. Collaborative care has been used to guide efforts to improve 
the quality of chronic illness care in many different healthcare settings (Von Korff et al., 2002), 
and this was achieved in a limited way in the Soweto setting.  
There were many difficulties and shortfalls of the CDOP. Some PHC clinicians, especially 
the PHC doctors working in the clinics, resisted integration, and this was a great disappointment 
and a limitation of the study. The responsibility of this falls both on the doctors and us, as 
implementers of the program. We failed to spend enough time to involve doctors. This limitation 
of the program was that it lacked diverting and spending more time and resources to involve 
more doctors. However, there were other factors. Firstly, many clinics did not have doctors and 
secondly doctors operated independently of the PHCNs and also perceived the program to be a 
‘nurses’ program. This made it difficult to include them in the program.  
The Johannesburg Metropolitan Health Region managers, i.e. at director and deputy 
director level (see figure 44), allowed the program and did support it enthusiastically at ‘head 
office’ level, and allocated two nurse program coordinators to help run the program. However, 
there was an inability of managers at the ‘assistant director’ level, who provided the support at 
the PHC clinics to get involved practically and assist with local systems at each clinic.  Some of 
the  blame again must lie with CDOP not spending enough time and effort to involve and 
educate this tier of manager, but also because it was seen as another ‘vertical program’ in the 
clinic which would run independently of their involvement. Assistant directors needed to support 
the program actively and practically as a ‘standard’ method of chronic disease management at 
clinic level and they needed to share the final vision, of integrating the important components of 
CKD and CVD detection into clinical practice. Unfortunately this vision was not achieved, and 
the responsibility must partly lie with the way the program was implemented and run. The issue 
of an integrated program for chronic illnesses remains an important issue which needs to be 
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addressed. This integration could assist with developing health systems horizontally across 
sectors and this will have a positive affect for all chronic illnesses. In the end the assistant 
directors viewed the program as a vertical independent program, not requiring their assistance. 
At the chief director level, where funding and policy were needed, and which could have assisted 
the programs development in the future, no support was forthcoming.  At this ‘director and chief 
director level,  they either supported the program ‘verbally’ in meetings, or else claimed that they 
had better systems which they were ‘planning in the future’, and did not value the experience of 
a program implemented and run at ‘grass roots’ level. Although it was acknowledged as 
evidenced by the awards it received. This challenge has been experienced by others such 
initiatives and where leadership and advocacy were necessary for the implementation of other 
programs like that of the WHO ICCC, the leadership and management were absent (World 
Health Organization, 2002a, Kotter, 1990). This was especially noted in this regional health care 
setting of Soweto.  The implementation of CDOP was left predominantly to CDOP’s three staff 
members, and the chronic disease regional assistant director, to orientate and inform all 
managers and clinicians about the Outreach Program. This was despite the fact that many 
nurses documented that they would like to see the program implemented as the ‘standard’ 
referral process and wished to see greater links with their referral hospital. This problem of poor 
communication, and extremely hierarchical management structure, was an indication of 
management’s inefficiency and bureaucracy, and resulted in its isolation and lack of direct 
involvement with the PHCNs at the clinic level. Perhaps CDOP should have focussed on smaller 
components for integration into clinics like improved systems of up and down referral, or 
ensuring chronic disease patients with HTN or DM were screened for CKD. Smaller ‘bite sized’ 
initiatives may have been easier to integrate. This would have been focussing on longer term 
health service problems, which may if implemented, have had a permanent institutional 
influence. This approach has been suggested by De Maeseneer (2008) and colleagues. In 
conclusion it must be noted that a major limitation of CDOP was the vertical implementation 
strategy which was adopted. The CDOP initiative in fact resulted in a duplication of disease 
control, creating its own bureaucracy and increased demands on the PHCNs looking after 
patients with chronic diseases. This duplication as a vertical program added to the ineffective 
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utilisation by the recipients, who were the PHC clinicians (doctors and nurses) and patients. The 
major constraints documented by nurses included large patient workloads and staff shortages. 
These issues in turn impacted on patient enrolment onto the outreach program. A particular 
problem, noted by nursing staff and the CDOP nurse program coordinators, was the high 
turnover of staff in each clinic with over a third of the workforce changing in the clinics over 2 
years. A major reason for the high turnover appears to be better working conditions and better 
salary scales elsewhere in most cases. In some cases, the “upskilling” of nurses involved with 
CDOP, may even have made them more likely to get jobs with other NGOs or the private sector. 
This problem is well documented in developing countries where staff retention challenges are 
widespread and the movement of health workers to ‘better’ and more well paid jobs is a serious 
problem (Hongoro and McPake, 2003, Van Lerberghe et al., 2002). The problems of staff 
retention, an overwhelming patient burden, poor pay and working conditions and especially 
dysfunctional health systems have been described in the implementation of HIV antiretroviral 
programs in South Africa (van Rensburg et al., 2008 , Schneider et al., 2006). This was also a 
problem and a setback of CDOP. Many programs that are implemented in a vertical manner 
draw staff away from general activities of the clinic to the ‘special programs’. This was the case 
for CDOP, as the program further diverted the PHCNs skills from the tasks at hand. CDOP, a 
vertically organised program, also potentially resulted in staff moving from one section to the 
next, or at least diverting their attention from the ‘general’ HTN and DM clinic patient and this 
raises concerns regarding equity of care. This problem has been highlighted before (De 
Maeseneer et al., 2007), and results in an internal ‘brain drain’, which can undermine PHC 
chronic disease services. Although CDOP fell into the trap of establishing a vertical program, it 
was not its intention to focus on a narrow band of chronic illnesses that were linked to a 
particular special interest in a tertiary hospital. It was started, because it wanted to reduce the 
burden of a chronic disease which has important implications for CKD and CVD and because 
CKD is completely unacknowledged as a chronic illnesses. It also based this focus on very 
strong evidence that CKD is an unrecognised public health problem (Levey et al., 2007a, Coresh 
et al., 2007, Schoolwerth et al., 2006, El Nahas and Bello, 2005, de Zeeuw et al., 2005, Chen et 
al., 2005 , Hallan et al., 2006b, Chadban et al., 2003, Iseki et al., 2007),  that it has clear strong 
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links with CVD (Go et al., 2004, de Zeeuw et al., 2005, Parikh et al., 2006), and that addressing 
these issues at the PHC level is critical (Hoy et al., 2005b, Katz et al., 2006a, Tollman et al., 
2008, Coovadia and Bland, 2008). Its aims were to see it integrated as part of the chronic illness 
CVD initiatives which are made at PHC level and not as an exclusive chronic illness which 
requires special attention. 
Vertically developed programs together with health worker migration, and staff shortages 
all place a greater burden on the other clinic workers who remain working in ‘specialised HTN or 
DM clinics’. These factors cause clinics not to have the necessary skills mix to handle 
specialised problems. This places further demands on the remaining PHCNs and affects the 
efficiency of service delivery. The problem of competing demands and vertical program 
implementation also affected the outreach program’s ability to detect those patients with HIV at 
high risk for CKD. Despite efforts to enrol patients with proteinuria from any cause (HIV, DM and 
HTN), this proved not possible because the HIV patients were shifted into a specific ‘specialised’ 
HIV only program. A recent study strongly criticised the fact that HIV programs fall outside of the 
clinic chronic disease system (Tollman et al., 2008). This highlights the need to avoid the 
development of vertically structured programs or focus on chronic illnesses as individual entities 
(Beavers and World Health Organization, 2003), in favour of primary care clinicians, both nurses 
and doctors, seeing all types of acute and chronic illness patients together in a single clinic, just 
as a family practitioner would do. Tollman and colleagues have restated the need to invest in 
strengthening the existing ‘comprehensive but generally weak delivery platforms’ that are 
common to the public-health sector (Tollman et al., 2008). Integrating chronic disease care by 
linking CVD and CKD with infectious diseases, through horizontal rather than vertical programs 
in the primary health care setting is necessary. This demonstrates the need to understand and 
contextualise these diseases in each community and focus on diseases as chronic illnesses 
which require sustainable disease control (Manderson, 2008).Through effective PHC, it is quite 
possible to respond to both ‘chronic’ infectious and chronic non-communicable diseases (e.g. 
HIV, TB, HTN and DM)  by treating adults with such illnesses as requiring a single method of 
management. All chronic illnesses should be included e.g. chronic respiratory illnesses, epilepsy 
and part of the integrated approach. The Soweto clinics need to run like ‘family practices’, where 
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PHC clinicians see all patients and all diseases. There may be a practical need for running 
clinics for chronic illnesses which have similar challenges and overlapping risk factors e.g. HTN, 
DM and HIV. There may also be a role for sub-specialisation by PHC clinicians, allowing some 
PHC clinicians may have more knowledge about a single chronic illness. However, the approach 
should still be to tackle these diseases through a ‘horizontal’ approach and not in the way that 
CDOP was implemented. The CDOP, chronic care type of model approach, needs to be broader 
and also need not rely solely on doctors or specialists. It has to be recognised that non-specialist 
health workers, such as primary health care nurses (PHCNs), can reliably evaluate and manage 
risks of chronic disease in settings without doctors (Bodenheimer et al., 2005, Oakeshott et al., 
2003, Epping-Jordan, 2001). 
Other factors impacting on implementation included nurses complaining of little time to 
enrol patients, although there were some conflicting opinions about this, implying that the 
problem may be due to other issues like motivation. There was also a distinct difference in the 
way some of the clinics worked, enrolled and followed their patients. This also highlights the 
importance of team work, ‘organizational citizenship’ and the individual systems which were put 
in place in the different clinics. Nurses do not recognise the value and importance of audit or 
research in their environment. Initially, CDOP was seen as a research project and for this the 
credibility of the program was placed in question. This highlights the inability of health workers to 
see the value of information systems and continuous monitoring of their work environment. The 
way this problem was corrected was through persistence and by developing a good relationship 
with nurses through their training school. CDOP, recognised the value of working with all role 
players involved in health care delivery in the region, and this included the Soweto PHC School. 
The School, which trained and had credibility with clinicians, provided an opportunity for a 
successful approach to correcting this problem. CDOPs links with the school and its team 
proved to be a turning point for its credibility. However, this relationship highlighted the 
importance of establishing a chronic illness network, comprising all organizations responsible for 
managing chronic diseases in the region. It highlighted the importance of strengthening 
partnerships, as identified in the WHO ICCC framework model (World Health Organization, 
2002a). 
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Program Enrolment  
PHCNs perceived random enrolment to be unsuitable, even unethical, and that this 
would compromise their patients care. Therefore, although participants’ were supposed to be 
chosen randomly by PHCNs, it is possible that choice of enrolment was influenced by PHCNs. 
They may have entered patients whom they deemed to be at ‘high risk’ and because they 
wanted and expected clinical advice through the ‘feedback decision support’ reports. 
Considering that the programs aims were to reflect the ‘real’ clinical situation as much as 
possible, this may have been interpreted to mean that PHCNs could influence enrolment. They 
had also participated in the CDOP pilot phase and had experienced the value of quick specialist 
referral.  
The study thus remained as an observational study, following a cohort of high risk DM 
and HTN patients, and this in itself could viewed as confounding and biasing the study. In 
defence of these actions, selection bias can be an insurmountable problem in any health care 
evaluation, because people are selected according to the severity of their disease (Bachmann, 
2007).  However, the  process resulted in an evaluation that took place in a ‘realistic 
environment’, and ensured that PHC clinicians felt that they were not under ‘trial’ conditions 
(Bachmann, 2007).. As the follow up of the cohort was over 2 years, and consisted of multiple 
methods of evaluation, there is some confidence in attributing the findings and changes to the 
intervention.  
 
Health Policy Factors and Implementation 
Other health policy issues impacting on implementation include the structure of primary 
health care facilities in the region. They comprise two separate systems of health care delivery, 
one being the local city council7 and the other the provincial government clinics, where the 
                                               
 
 
 
7
 Local City Council clinics are funded by the Johannesburg City Council. There predominant focus is on 
immunisation and family planning, but more recently have become involved in chronic disease 
management, i.e. HTN and DM. These clinics are funded by the City of Johannesburg, whereas the 
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program was implemented. The clinics are often close to each other and patients may move 
between them depending on the waiting times for treatment or if a nurse they preferred or with 
whom they had developed a rapport had moved. Related to this dual system of health provision, 
different salary structures existed between local and government clinics and between clinic 
nurses and hospital nurses. The local City Council clinics paid higher salaries. Both these issues 
affected staff morale. Primary health care nurses were not included in the OSD allowance and 
this had a particular negative impact on the program’s functioning. PHCNs were often engaged 
on ‘go slow’ protests against this policy and were loathe to extend themselves for any ‘special 
program’ in view of their being dissatisfied with salaries and lack of recognition of their skill and 
contribution to the health system. This affected both patient enrolment and follow up and also 
their efforts to get laboratory results or fill in the CDOP follow up forms. 
The policy of not making available certain medications in the primary care sector, i.e. 
anti-lipid medication and some hypertension drugs, together with the policy of not allowing or 
training nurses to initiate insulin, impacted on program implementation and patients’ diabetes 
and blood pressure control. Nurse clinicians could not increase the doses of certain ‘basic’ HTN 
medication. This aggravated our ability to control risk factors as planned, and explained the poor 
baseline control of blood pressure and serum glucose. PHCNs are expected to manage people 
with chronic illnesses but are not given the appropriate skills or authority to act. If politicians and 
health managers expect nurses to take up the call to manage the growing chronic diseases 
burden, then they have to be provided with the necessary skills to carry out these tasks. Nurse 
practitioners need to  be supported with legislation which would protect and support them, and 
allow them to act appropriately and in their patients best interests.  
The development of staff and appropriate allocation of human resources was an issue, 
with PHCN taking on the roles of pharmacist, clerk and clinician. Pharmacist shortages meant 
that PHCNs had to evaluate, prescribe and dispense medication. This aggravated their sense of 
being overburdened with responsibilities. These are tasks which could be given to trained ‘non-
                                                                                                                                                        
 
 
 
provincial government clinics are funded through the provincial government and specifically the province 
of Gauteng Health Department.  
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professionals’, and would free clinicians to deliver a better quality service. This issue together 
with the fact that nurses were not allowed to refer patients without approval from a doctor in 
some clinics add to the inefficiencies of the health service.   Existing legislation does not allow 
‘lower level’ health workers, such as PHCNs, to dispense medication unless they have been on 
a dispensing course. This type of policy in a developing world stetting is impractical, as most 
nurses could not attend training and many PHCNs continued to examine and dispense 
medication themselves as they had no choice. Having no pharmacists and the fact that they 
have to examine and dispense themselves makes for lengthened patient consultations. In fact a 
strong argument exists for allowing more ‘unskilled’ people to participate in these types of 
services (McPake and Kwadwo, 2008). 
Existing staff development policies are not very well developed, mostly occurring around 
the centralized ‘in-service’ education system. Very little effort is given to staff development and, 
in some cases, nurses expressed that CDOP was one of the only opportunities they had had for 
development and training.  
Developing and strengthening partnerships was not a priority of clinic and regional 
managers. Although the National Health Laboratory Service (NHLS) is responsible for delivering 
a laboratory service, providing quick results and supporting PHC clinicians, with access to 
pathology services and specialist expertise, and efficient service and specialist support did not 
occur in the clinics. This inefficient and ineffective support service impacted on both patient 
enrolment and follow up. Delays in laboratory results caused patients qualifying for the program 
to not be included on the program, and many ‘disappeared’ into the ‘mainstream’ clinic 
environment, often unhappy with waiting for results or delays to be initiated onto the program. 
This highlights another factor that affected the implementation of the program, the lack of a 
clinical and management computerized information system. Nurses do not have quick access to 
patients’ results, and cannot use computerised systems to keep and track their patients’ clinical 
outcomes. PHC clinicians often do not even have easy access to telephones to call the 
laboratory for results on patients. This adds time to each consultation and additional pressure to 
nurses’ restricted time.  
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According to AbouZahr and Boerma (2005), poor health information systems result in 
fragmentation of the health sectors, inability to monitor diseases, and assess quality of care. 
They conclude their review by stating “It is not because countries are poor that they cannot 
afford good health information; it is because they are poor that they cannot afford to be without 
it” (page 582). CDOP was able to provide a basic information system which determined 
shortfalls in patient care, and was a major ‘value added’ service which nurses appreciated. The 
delivery of typed ‘feedback reports’ was truly unique in this environment, although common in 
developed world settings. The CDOP data tracking system provided a surveillance of 
management, allowed for detection of those who needed referral, and improved efficiency when 
patients were referred (see figure 24). It allowed for regular assessment of the progress of the 
program, and was used during ‘feedback meetings’ to evaluate the outreach program. This type 
of system has not previously been described in the South African PHC system.  
Other positive policy factors initiated by CDOP included the strengthening of 
partnerships, the most important of which was the links of tertiary and primary health care. 
However, it did develop the beginnings of a ‘chronic disease network’, by involving regional 
health management structures, the Soweto Primary Health Care School, the division of 
cardiology and later the division of endocrinology. It played an active role in linking and receiving 
sponsorship for nurse training from non-governmental organizations (see figure 40), and also 
provided training in computer skills and ‘change management’ workshops for all PHCNs in the 
clinics. However, although these links were started, this cannot be seen as a true ‘chronic 
disease network’, which would require many more role players and much broader involvement 
e.g. HIV services, asthma services etc. 
Many of the policy concerns highlighted above explain why nurses indicated in the motivational 
survey that they felt misunderstood, overworked and impotent in the decision making of their 
clinics. Although management did support the program through a single regional manager who 
recognised its value and helped with its implementation, the program and its specific 
components were was not taken on as an essential requirement to improve quality of chronic 
care. A lobby was made to broaden the program to include HIV, asthma and general diabetes 
care through the development of new ‘modules’ supporting these chronic illnesses, this was not 
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achieved. This was despite efforts to lobby the regional chief director, and then with his support, 
the Outreach Program was presented to the Gauteng Health Department Executive Committee8 
(see Figure 44 and Figure 37; point no. 24). Although this committee in principle supported the 
development and broadening of the program and promised funding and support, it never 
materialised. The failure to provide this support was a result of resources and personnel at head 
office to support its implementation. It was also affected by the lack of authority which resided in 
those people who were assigned to help with implementation and scaling up of the program.  
There was also suspicion that this funding was being used to fund the research for academic 
reasons alone. Furthermore, managers always needed to consult their ‘senior managers’ or 
were hampered by poor communication and integration of activities between departments. This 
is evidenced by the fact that HIV programs are funded and managed completely independently 
of non communicable disease programs. The challenges of integration and scaling up the 
program reflected on the ‘top-down’ management style which exists in the health service. 
Regional and provincial managers appear helpless to implement existing policies and to deal 
with problems such as shortages of human resources, medications and broken equipment. 
There has to be an improvement in management skills, and communication between the 
management levels and genuine support at integrating chronic illnesses, before real long term 
improvements will be noticed. Despite these problems with a small amount of effort and support, 
many aspects of the program could be implemented. This requires that the proposed models are 
implemented and regularly evaluated, which would include assessing local feasibility and cost 
effectiveness. Many of the human and infrastructure resource challenged could be addressed 
during practical implementation. Resource issues will further be addressed through the 
strengthening of health systems in the clinics by integrating services of all chronic illnesses e.g. 
clinics for chronic NCDs and chronic infectious diseases. This would also include computerising 
data capture which would provide NCD epidemiological surveillance so as to establish the 
                                               
 
 
 
8
  In order to present CDOP to the Provincial Executive Management Committee, which reports to the 
MEC for Health for the province, it required the hierarchical support, endorsement and motivation of all the 
management structures. These structures are outlined in Figure 44, page 166.   
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population-level burden of NCDs and assess the proportion of cases detected and managed by 
the health system. The CDOP provided a good indication that only between 10-15% would 
require specialist referral. This information helps plan future initiatives and what the scaling up of 
similar programs would entail. It also indicates that continued surveillance would provide more 
information about the likely load of the problem. Aspects which were successfully implemented 
like decision support and referral systems could easily be implemented with minimal resources, 
as is shown in this study. Unfortunately information about useful life years gained from the 
program could not be determined with such poor follow up, and this type of information is still 
needed in the future. 
  
Patient Factors 
This study did not specifically focus on components of the Wagner Model relating to the 
community and patient, and this was a major shortfall of the program. This was because it was 
not feasible. CDOP did not have the resources and easy access to patients to focus on the 
entire ‘comprehensive’ chronic illness model. However, two major patient factors arose from the 
diary recordings which impacted on patient enrolment and follow up. These issues of adherence 
are well described problems in chronic disease management (Ingersoll and Cohen, 2008). 
Adherence factors and factors extending the time for patients to wait for service were included in 
the diary recording analysis, and were described in the results as the ‘via syndrome’. There were 
instances of patients not arriving for follow up, who were documented as having moved out of 
the area or presenting to the local council clinic because of shorter waiting lines. The ‘via 
syndrome’ reflected patients not wanting to be delayed in the clinic and the fact that patients 
endure long waiting periods before being seen by a clinicians. It also reflects the lack of insight 
and involvement by patients in their healthcare as waiting for ‘additional’ investigations was 
perceived as a hassle, rather than an an improvement in quality of care. Patients did not 
appreciate, recognise or value the aim of CDOP, which was to improve the quality of care they 
would receive. Poor diabetes control could be attributed to adherence but could equally be the 
result of poor knowledge of PHC clinicians and poor electronic monitoring systems tracking 
glucose control (Cramer, 2004). Few studies adequately quantify adherence to diabetes 
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medication and much fewer look at compliance in chronic illnesses (Cramer, 2004, Ingersoll and 
Cohen, 2008). Unfortunately the lack of adherence evaluation was a major limitation of this 
study.  
Adherence issues remain complex, and patient factors form only one aspect of this 
challenging problem (Ingersoll and Cohen, 2008). In the diary recordings, patients were regularly 
blamed for poor management and risk factor control, and nurses took no responsibility for this 
problem. Clinician roles, such as clear communication and time spent educating patients about 
their diseases, were either not considered important or nurses were just too busy to provide this 
service. The patient–clinician relationship factors such as trust were also not investigated. A 
number of diary recordings reflected ‘patient frustration’, as well as of nurses not being available 
at follow up, long delays waiting to see PHCNs and patients needing to return the next day 
because medication was not available and had run out. All these factors indicate that adherence 
issues were not well addressed at the clinics. Health care delivery factors also played a 
significant role in non-adherence. Even if one criticizes patients for not wanting to wait for 
appropriate laboratory investigations or to be seen by nurses trying to offer ‘better quality care’, 
these actions should be taken in the context of the clinic system. The inefficiencies, delays and 
lack of emphasis on quality explain the reasons for patients’ actions and therefore one cannot 
blame health system failings on the patient alone. Therefore, community factors, and patient 
adherence factors in the Soweto primary health care setting are components of care which are 
emphasized in the Wagner and WHO chronic disease models, and definitely require further 
investigation and attention in the future. The program failed to support or addresses the real 
issues which face patients who receive chronic illness care. It also must be reinforced that the 
issues of patient care was viewed from the biased perspective of the health workers, through the 
diary recordings, and that patients were not included as part of the comprehensive evaluation of 
health services in this study. 
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CDOP as a Screening Program 
Two components of care provided by CDOP required evaluation; i) Were the correct 
patients screened and enrolled onto the program? ii) Was there accurate referral to a specialist? 
The Outreach Program follow up was evaluated in several ways. Firstly, it evaluated the PHCNs’ 
ability to enrol the correct patients onto the study according to the inclusion criteria, i.e. those 
patients at high risk for CKD and CVD. Second, their ability to follow-up these patients’ at their 
follow up clinic visits, assess their progress and carry out appropriate investigations. The third 
question was to assess whether nurses had referred the correct patients to the specialist clinic.  
The factors affecting poor follow up and the inability to achieve DM and HTN control, 
were similar to the enrolment issues, and included the poor existing health systems in the clinics 
and competing demands on the PHCNs, by CDOP and other existing ‘special programs’ e.g. 
HIV and TB. This was aggravated by the problem of staff shortages and high turnover, 
especially amongst PHCNs working in the clinics. PHCNs were overwhelmed and frustrated with 
the number of patients they needed to see, and the shortages of equipment and medication to 
evaluate and treat patients. They complained that their current primary health care clinical skills 
were not recognised and acknowledged, and they remained concerned about litigation, as 
decisions to up-scale medication did not have official support unless endorsed by CDOP. 
PHCNs criticized the fact that they had responsibility without the authority to act. Current 
protocols did not allow nurses to increase dosages or prescribe some of the HTN or DM 
medications. Staff shortages made it difficult for some of them to attend continuing education 
seminars at a central venue, so they did not have access to the latest knowledge and program 
changes. Many nurses complained CDOP was not integrated formally, but was, rather, an 
optional vertical ‘special program’, this affected its potential impact as it was not endorsed or 
encouraged as the primary method for assisting nurses with managing patients with difficult HTN 
and DM control or if they needed hospital referral. Nurses were unaware of formulae to measure 
GFR or the reasons for measuring albuminuria. ‘Quantity of care’ was favoured over ‘quality of 
care’, with PHCNs complaining they had no time to evaluate patients, by doing ‘additional’ blood 
tests or urine investigations. Nurses highlighted the need for better training, integrating care, and 
even sub-specialization in chronic disease management. The question which arises is whether 
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CDOP provided them with ‘special skills’. It appears as if it did on some levels and this included 
the ability to prescribe higher medication dosages for disease control, speed up the referral 
process to a specialist, and in some cases gains more knowledge about CKD screening, and 
DM and HTN control. However, on a broader level, it did not provide the skills of overall chronic 
illness management and an ability to transform the management of a health facility around 
chronic illness. This deficiency was as a result of CDOP not providing these generic skills to all 
PHC clinicians and because it was developed in vertical manner focussing only on CKD and 
CVD.  
 Some novel systems were developed and adopted by the nurses in the clinics, as a 
result of the Outreach Program. Tollman et al have highlighted the need to improve our primary 
health-care systems which have mainly evolved in a pre-transitional era and have adapted little 
to the growing demand for continuous, long-term care (Tollman et al., 2008).The CDOP 
stimulated developments, included the  ‘chronic stamp’ developed by the PHC School, to help 
focus clinicians’ on the key CVD and CKD risk factors which required close attention. It also 
resulted in the development of a ‘traffic light’ triage system to help make decisions about who 
needed ‘special’ focused care and who should be referred. Stickers were also used to try 
improve follow up by helping to locate the enrolled high risk ‘patients quickly and prevent them 
becoming lost in the mainstream clinic system, although from the results the latter initiative did 
not work.  
Despite the bias which may have developed during the enrolment process, the clinic 
nurses, with the assistance of nurse program coordinators (NPCs), were still able to accurately 
screen and enrol ‘high risk’ patients. Less than ten percent of patients enrolled did not fit the 
inclusion criteria. The enrolment process required nurses to capture the data themselves and 
relay the clinical information to the data centre through the nurse program coordinators. The 
slow process of capturing the information, transferring the data from the clinic to our central data 
capture point, analysing it  and delivering feedback reports, contributed to the lack of specificity 
of CDOP. There were often poor quality data captured by nurses, and this included missing 
variables and illegible writing. This resulted in a small number of incorrect inclusions. However, 
in a program aiming to capture those at risk, a higher sensitivity resulting in the inclusion of a few 
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patients at lower risk would be considered acceptable. It is better to have false positives than 
false negatives, because these can be sorted out by the specialist, the “gold standard”. It could 
have also been related to nurses’ attitudes towards data audit as they were never demonstrated 
the value of capturing information. It was seen by nurses as a chore. However, clinical time 
demands and large patient loads also contributed to poor data quality.  It was for this reason that 
nurse program coordinators were used as a mechanism to ensure quality control, as they 
checked all the patient data sheets. This highlights the value of computerised systems, which 
could have prevented this problem by ensuring that nurses enrol the correct patients by instant 
computer assisted evaluation of the inclusion criteria. A electronic information system will also 
prevent ‘missing’ data., PHCNs worked under pressure and, at times, the slow turnaround of 
laboratory results, also contributed to patients not being enrolled or evaluated at their next follow 
up clinic visit. Delays also occurred on the part of the outreach program nurse program 
coordinators, as with only two program coordinators to evaluate and write ‘feedback reports’ 
(see Appendix 5), this resulted in delays to inform nurses about patients who were incorrectly 
enrolled.  
The ability of ‘the program’ to refer the correct patients to the specialist clinics was much 
better. The specificity of detecting the correct patient according to the specialist referral criteria 
was 100% (see Table 10). The failure in the system was making sure that they arrived at the 
clinic. In the case of referral to the ‘renal outpatient clinic’ (ROPD), the success of referral was 
lower at 75%. In principle, it is more important for a screening test (in this case the referral 
process) to be sensitive than specific, i.e. for PHC nurses to refer inappropriate cases rather 
than miss those who should have been referred.  In our case, we had excellent specificity, but at 
the cost of sensitivity (cases were missed). This reflects the resource strapped nature of the 
PHC as well as the referral system, where implicitly, rationing is being applied (limiting time on 
assessing and referring patients). Factors which affected a patient’s ability to arrive at the 
specialist clinic included the many factors already discussed which explained poor follow up. 
Importantly, no patient who needed referral at baseline was lost to follow up, indicating the 
success of the program as a screening tool for ‘red’ high risk patients needing specialist 
evaluation and care.  
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Clinical and Functional Outcomes 
Related to health care organization and to the assessment of ‘functional outcomes’ of a 
chronic illness program, the aims of this CDOP evaluation were to establish if those high risk 
patients had arrived at the specialist clinic, they had been referred, and to establish if they had 
been followed up and treated correctly at the hospital based clinic. These questions are 
addressed in this section.  
 
Baseline Characteristics 
The numbers enrolled were slightly lower than the original target, with more patients with 
hypertension (HTN) than diabetes (DM). This reflects the attendance at the ‘chronic’ clinics in 
the region. Women were also more likely to be enrolled than men, which is in keeping with the 
gender distribution of attendance at primary care clinics nationally (Levitt et al., 1997) and from 
previous Soweto audits (Mohammed and Mthombeni, 2000). The baseline clinical data reflect a 
‘high risk’ group as targeted, with patients having both uncontrolled HTN and DM together with 
significant risk factors. Only one quarter of patients had a controlled blood pressure, only slightly 
better than that demonstrated by the South African Demographic Health Survey (SADHS) (Steyn 
et al., 2001), and worse than international data (Chobanian et al., 2003). This problem remains 
despite the availability of many effective, cost-effective and well-tolerated drugs in primary care, 
indicating that factors other than availability of medication determine control. The problem of 
HTN control in DM patients is even more of a concern, as less than 16% of patients had blood 
pressures meeting the current recommended guideline criteria, i.e. <130/85mmgHg. This is 
much worse than international figures, which are themselves also poor (Hajjar and Kotchen, 
2003, Hyman and Pavlik, 2001, Wong et al., 2007). Obesity demonstrated by both BMI and 
waist circumference was found to be a significant problem in the cohort, with women affected 
more than men. This has been shown in other communities in South Africa and demonstrates 
that lifestyle modification issues are a problem in this community (Vorster, 2002, Puoane et al., 
2002). Cultural factors impacting on obesity in women includes an inaccurate perception of body 
weight and being overweight also has many positive connotations in the African community in 
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South Africa. It reflects both affluence and happiness, and in women indicates the ability of the 
husband to care for his wife and family, and related to HIV/AIDS, being overweight  reflects 
being both healthy and HIV free (Mvo et al., 1999, Clark et al., 1999). The cohort was slightly 
older and the obesity rates were in keeping with findings that increased age, and higher levels of 
obesity are found in urban African women (Puoane et al., 2002). Lifestyle factors included little 
exercise, high intake of fatty foods, smoking and high levels of cholesterol amongst patients 
enrolled onto the program.  
Dyslipidaemia is a particular problem, as 12.5% of patients required a lipid lowering 
agents according to national guidelines and this medication is not available in the primary care 
clinics. Again, women had levels that were higher than men and were more likely to require 
referral for raised cholesterol. The cholesterol problem was also more likely to occur amongst 
patients with diabetes, and women with diabetes were most likely to have this problem. 
Considering that referral to the specialist clinic for high cholesterol is a clinical issue, and that not 
all patients had baseline serum cholesterol measurements, these figures may under represent 
this problem. If one considers that the use of lipid lowering therapy has been clearly 
demonstrated to reduce the risk of cardiovascular morbidity and mortality in subjects with CVD 
or type 2 DM and also for primary CVD prevention (Baigent et al., 2005, Colhoun et al., 2004, 
Sever et al., 2005, Collaborators, 2008), then treatment for dyslipidaemia needs to be given a 
high priority of attention in the future. The use of lipid modifying drugs like the statins are 
considered too costly in South Africa, and so the emphasis is on lifestyle modification, but clearly 
neither of these goals of weight control or dyslipidaemia management are being achieved 
(Seedat et al., 2006), and this was demonstrated in this study. This is not unique to South Africa, 
as currently only one third of people with dyslipidaemia’s in general are receiving treatment, 
even in well resourced settings (Fox et al., 2004b, Stacy and Egger, 2006). Patients specifically 
with CKD and ESRD should be targeted (Expert Panel on Detection, 2001, Nogueira and Weir, 
2007).  
There is no evidence of the extent of the burden of CKD in South Africa, and this study is 
one of the first showing significant proteinuria and CKD in people with DM and HTN. Considering 
that CVD and CKD are commonly associated with these chronic diseases, it was no surprise.  
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Levels of proteinuria are not better detected and reported since the tools for clinical diagnosis of 
CKD have become simplified, as there is still a failure of clinicians to check urine for protein.  
This is despite the fact that current recommendations suggest yearly testing and monitoring of 
people with DM, HTN or HIV (de Zeeuw et al., 2005, Gupta et al., 2005).The mean albumin-
creatinine ratio was 59mg/mol, with over 25% of patients having levels >30mg/mol, and which 
are levels strongly associated with CVD disease (de Jong and Brenner, 2004). Patients with DM 
were again at higher risk of having levels >30mg/mol and overall under 10% required referral for 
significant albuminuria of >200mg/mol. The albuminuria referral level was much higher than 
suggested in guidelines (>100mg/mol) (International Society of Nephrology, 2005), but this level 
was used to avoid overwhelming the specialist clinic. Many patients with significant proteinuria 
also had a low GFR and they did not qualify for dialytic support and were therefore not referred. 
In some cases, it was felt they could be managed with decision support and follow up as per 
guidelines  (K/DOQI, 2002).  
In South Africa in patients with type 2 DM, CKD is most likely a major cause of death, but 
the extent of the problem remains undetermined. Twelve percent of patients had an estimated 
GFR (eGFR) <60mls/min/m2. Patients with diabetes were much more likely to have a low eGFR 
or have end stage renal disease (ESRD).  Higher rates of CKD occurred amongst diabetes 
patients, together with poorer blood pressure control, and higher cholesterol and albuminuria 
levels, indicating that focussing on people with diabetes is particularly important in the PHC 
sector and also an area of great concern. Women also appear to be at higher risk, so requiring 
special support. The levels of albuminuria and the eGFR were appropriately high if one 
considers this was a ‘high risk’ group compared with data from general population screening 
(Coresh et al., 2003, Lamiere et al., 2005), and were in the region of 2 to 4 times higher than the 
general population data available in the international studies. A comparison with the general SA 
population is not available.  Assessing risk in patients with HTN and DM should include an eGFR 
and determining the level of albuminuria, and especially considering that patients in all stages of 
CKD are a high risk of CVD (Menon et al., 2005, Go et al., 2004). Further studies are needed to 
determine the general population risk of CKD and ESRD. Linking risk factors like obesity, 
dyslipidaemia, HTN and DM with the determination of serum creatinine level and a spot urine 
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sample for albumin–creatinine ratio (ACR) are sufficient to detect CKD and evaluate risk for CVD 
(K/DOQI, 2002, de Jong et al., 2003, de Zeeuw et al., 2005) and should therefore be carried out 
in all patients. The observations in this study do have limitations, including basing prevalence 
estimates on single serum creatinine measurements, which are subject to variations owing to 
differences in calibration systems between laboratories (Clase, 2006, Levey et al., 2007b, 
Coresh et al., 2002). Another limitation was that only 70% of patients had serum creatinine 
testing, which was needed to calculate the eGFR, and a population specific GFR calculation has 
only recently been determined (van Deventer et al., 2008). 
 
Baseline Medication Prescription 
Considering the strong evidence for using an angiotensin converting enzyme inhibitor 
(ACEi) to treat individuals who are identified from screening as having microalbuminuria, or are 
at risk for CVD (Asselbergs et al., 2004, ADVANCE, 2007), it was disappointing to see such low 
rates of use of these agents for patients with diabetes. Only 39% of these patients were using an 
ACEi, whereas ACEi use in HTN was significantly higher. This is in keeping with international 
data which shows sub-optimal use in many patients with DM and or CKD (McClellan et al., 1997, 
Kausz et al., 2001, Nissenson et al., 2001, Cooke and Fatodu, 2006). However, the problem in 
this study was linked to the poor knowledge and understanding of diabetes management and 
specifically treatment targets, and the fact that nurses had not been exposed to the recent 
diabetes guidelines. It is also related to the incorrect, confusing and convoluted algorithms which 
they are taught at the Soweto PHC School and appears in their PHCN training Manual (Pein et 
al., 1999) (see Appendix 13). The fact that blood pressure for those with HTN and DM was 
generally so poor, could be explained by the manual and PHC School guidelines and the limited 
use of ACEi, Calcium channel blockers (CCB) and multiple drug combination therapies. A factor 
underlying this low level of use could be the lack of authorisation and support provided for 
nurses to prescribe these agents, prior to CDOP, and a lack of confidence and knowledge. The 
same reasons explain the low use of insulin at baseline despite very poor diabetes control, 
although this was surprisingly similar to data from the United States (Koro et al., 2004, Turner et 
al., 1999, American Diabetes Association, 2008). The American Diabetes Association (2008) 
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has highlighted that there is a need for improving health care professionals’ standards of 
education regarding standards of care, simplifying and ensuring access to latest guidelines, 
improving systems and patient tracking systems as well as improving quality of care. These 
system changes are incorporated in the Wagner and WHO chronic care guidelines and were 
instituted by CDOP. 
 
Cohort Follow-up 
Overall, the cohort follow up was poor and this was a very disappointing aspect of this 
study. A major limitation and concern was the high attrition rate after enrolment (68.7%) and the 
20% of patients whose outcomes remain unknown. Fortunately, at baseline none of those 
patients lost to follow up needed referral, but this is not to say they would not have required 
referral later. The results, and in depth evaluation of the clinic systems, highlight the reality faced 
by PHC clinicians. Tracking people at high risk over time is an important feature of chronic care 
management, encouraging movement by physicians away from the ‘find and fix it’ models 
(Epping-Jordan, 2005)..  
On the positive side, the program was able to detect those who needed referral and refer 
them to the specialist clinic (see Table 19 and Table 20), and most (71.8%) arrived at this clinic. 
Importantly, only ‘high risk’ patients screened required referral, indicating that with the correct 
support and available medication, most patients can be managed in the primary care setting. Of 
those who arrived at the specialist clinic, there was a full 2 years of follow up. This reflected 
positively on the specialist centre and its systems. It also reflects well on the programs’ success 
of detecting those patients with advanced disease, being able to refer them and follow them well 
once referred.. This evaluation further demonstrates the ability of the PHCNs to use the program 
effectively.  There was a problem with the program, because although the specificity was 
perfect, this was at the cost of sensitivity, and not all patients who should have been referred to 
a specialist arrived. CDOP was able to correctly detect people with disease but this was 
dependent on the health and program systems being intact, hence the lower sensitivity. 
Although this was a small group compared with the total enrolled. The study was a sober reality 
check of what is possible to achieve in the existing primary health care system. The findings 
  
228 
suggest that long term cohort follow up should be considered very carefully in the current 
Soweto PHC environment, and the focus should be placed on regular screening and detection 
rather than prolonged follow up. This is not because follow up studies are not ideal or better but 
because the primary care facilities do not have the capacity to handle complex follow up 
processes at this stage. Intermittent comprehensive screening at individual clinics would counter 
some of the existing health system limitations, and this should be a consideration for the future. 
 
Specialist Referral Group 
Despite the weaknesses in follow-up in the clinics, outcomes on the specialist referral 
group revealed some interesting and positive findings. The program had no ability to impact on 
weight control, despite great efforts at training nurses about obesity management. This is 
relevant to chronic illness management worldwide (Stevens et al., 2001).  Even if achieved, 
weight loss is seldom maintained and considerable effort and resources are required to achieve 
and maintain weight loss (Stevens et al., 2001, Lindstrom et al., 2003, Diabetes Prevention 
Program Research, 2002). It appears that, even though the benefits of weight reduction are 
known, the chances of achieving weight loss remain a major challenge.  With rates of diabetes 
and obesity rising, the development and delivery of interventions that promote weight loss and 
increased physical activity among people at high risk for diabetes or with diabetes are needed 
(Center for Disease Control, 2008). Public health interventions, including environmental and 
policy changes which encourage a healthy lifestyle (e.g., creating or enhancing parks, walking 
trails, and access to healthier foods) and maintenance of healthy weight, have been suggested 
(Center for Disease Control, 2008). The question needs to be asked if this is a possible reality in 
South Africa. However, there does need to be a greater emphasis placed on exercise and 
lifestyle in the PHC clinics. From personal experience there is no evidence of such activities.  
Support groups often focus on education, provision of food and social interaction rather than 
exercise. Perhaps, exercise and lifestyle classes could become a focus at PHC clinics. 
The Outreach Program demonstrated, at least in this very small sub-group, that access 
to appropriate medication and aggressive treatment can control many risk factors. Improvements 
were seen with blood pressure, diabetes control and cholesterol reduction. The fact that ‘ideal 
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targets’ for DM control were not achieved in the specialist clinic setting indicates that controlling 
DM in the best settings is a challenge and that specialists also need the same systems and 
support as PHC systems. This study highlighted the importance of utilizing support services for 
DM control, at any level of service and especially in clinics like kidney clinics where a major 
proportion of patients have DM. Neither proteinuria nor eGFR declined over the two year follow 
up. This was despite the fact those patients referred were the worst of the ‘high risk group’ and 
these patients are usually considered to be a challenge to manage (Hoy et al., 2005b). This was 
a small group however and conclusions from this sub-group should be guarded. Of concern was 
the inability of the specialist clinic to carry out spot urine albuminuria measurements, although it 
has been demonstrated that urine dipsticks are a useful surrogate when resources are 
constrained and prevalence is high (Hoy and McDonald, 2004, de Jong and Brenner, 2004). 
Those patients who died all required referral, but died in the PHC setting before they were 
referred. This highlights another limitation and disappointment of the study, our inability to 
determine the morbidity and mortality overall in this cohort due to the overall poor follow up.  
 
Specialist Group Medication Prescription 
This group showed a much higher use of ACEi at both baseline enrolment and two years, 
reflecting the more advanced disease present in this group. There was also greater use of loop 
diuretics (furosemide) compared with thiazide diuretics (hydrochlorothiazide). This is partly 
explained by the poorer kidney function in the group and thiazide diuretics are ineffective with a 
low GFR. However, the better control of blood pressure, glucose and cholesterol control is best 
explained by the greater use and availability of anti-hypertensive, anti-lipid and insulin 
medication. There was also a greater range of anti-hypertensive medication available in the 
specialist setting.  
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Clinicians Knowledge and CME Support 
The results from the evaluation of primary health care nurses’ knowledge, continuing 
medical education support and the motivation survey (discussed in the next section) draw 
attention to both the challenges and successful components of the outreach program. 
The 75% response rate from PHCNs for completing the survey, and the homogeneity of 
the nurses evaluated, makes this component of the program evaluation very meaningful. The 
clinicians were also both experienced and committed, as evidenced by their work experience 
and years qualified. A very exciting finding was the better scores achieved by the CDOP PHCNs 
(CD) compared with the non-CDOP PHCNs (NC) for the clinical scenarios. This strongly 
supports the value of the program in improving clinical knowledge and patient management. The 
advantage of the CD-PHCNs was particularly obvious in the scenario evaluating both HTN and 
DM care, where these CD-PHCN nurses scored significantly better scores. However, the 
meaning and benefit of this significance needs to be evaluated in greater depth. Clinic nurses 
are more likely to consult a colleague, when faced with a clinical problem, rather than a doctor in 
the clinic or contact the referring hospital specialist. Many nurses indicated that they would 
prefer to ask a PHCN who had been participating on the outreach program i.e. CD-PHCN, rather 
than a nurse who had not. This highlights the importance of PHC nurses in managing chronic 
conditions,  with the appropriate knowledge to management and refer (Yawn, 2000, 
Bodenheimer et al., 2005).  
However, PHCN knowledge varied, which was reflected in the poor baseline HTN and 
DM control in the cohort and from the answers in the questionnaire. Most nurses had 
participated in a learning activity over the past month, but most relied on the ‘in-service’ 
education for their CME, where issues clarifying HTN, DM and CKD management were not 
necessarily covered. A broad array of guidelines was being used for patient management and a 
number of nurses had not consulted the latest guidelines on DM and HTN. Many of the 
guidelines and especially the PHC School Training Manual were overly complex and 
management algorithms convoluted. This fact, together with the number of guidelines used, 
highlights the need for simplification of guidelines as well as the clinical targets. Treatment 
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decisions should be simplified and expedited using a restricted number of drugs in each class, 
but systems ensuring fast scaling up medication must also be implemented (Hoy and 
Kondalsamy-Chennakesavan, 2004, Ho et al., 2008).This is supported by the better knowledge 
of the HTN blood pressure target compared with the diabetes target mentioned earlier. The fact 
that DM treatment, serum glucose and HbA1c targets are not well known by PHCNs, together 
with little knowledge of ‘compelling indication targets’, such as those with HTN and DM (Seedat 
et al., 2006), probably explains poor diabetes and risk factor control overall and limited use of 
insulin. However, these findings are not dissimilar to findings from other studies (Hajjar and 
Kotchen, 2003), suggesting that this may be a universal problem (Berlowitz et al., 1998, Hajjar 
and Kotchen, 2003, Wong et al., 2007).  
The CD-PHCN nurses were much more likely to know about HbA1c as a method used 
for managing diabetes, again highlighting the value of the program. However, knowledge 
deficiencies were evident during the evaluation of worker behaviour and performance in the 
thematic analysis. Analysis highlighted nurses’ lack of knowledge about HbA1c, initiating insulin, 
doing urine testing for proteinuria, and calculating an estimated GFR. This highlighted the 
particular problem of poor knowledge of CKD, and difficulties in addressing the growing burden 
of CKD in the primary health care setting to prevent end stage kidney failure (El Nahas and 
Bello, 2005). 
The last question is how continuing education should be delivered in the PHC 
environment. There is great pressure on nurses to deliver a service, and together with staff 
shortages and patient loads, the area of staff development and education is important (Chen et 
al., 2004, Padarath et al., 2003). Greater support and commitment by health managers to 
support nurses’ training needs to be provided, especially as many PHCNs complained they were 
unable to participate in the CME and were not provided with transport to access the training. 
Educating nurses about improving chronic illness through CME is an important mechanism to 
impart knowledge about the management of diabetes and especially about CKD as a public 
health issue. 
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Role of Primary Health Care Nurses in Chronic Illness Care 
The delivery of health care in the PHC setting is heavily dependent of functioning primary 
health care nurses (PHCNs). Ensuring that nurses are informed and motivated to deliver teh 
best possible care is critical to achieving these goals. It is for this reason that evaluation of the 
nurses’ motivation was only carried out in the primary care setting using the health motivation 
survey and diary recordings. The comprehensive evaluation of nurses confirmed the crisis which 
nurses face with respect to large patient workloads and staff shortages. Nurses clearly indicated 
that they were unhappy with management and that management did not appear to understand 
their predicament.  Human forces drive health-system performance (Chen et al., 2004, Franco et 
al., 2002), and the crises in workforce numbers, poor knowledge and inadequate training is 
undermining the health system in many developing countries (Liese et al., 2003, Hongoro and 
McPake, 2003, Padarath et al., 2003). In the Johannesburg Metropolitan Health Region B 
clinics, there was evidence of low staff morale amongst the nurses, although many PHCNs still 
appeared ready and willing to be ‘activated and motivated’. An overwhelming number of nurses 
were still proud to be a nurse and work in the clinics. Most expressed a sense of achievement 
and satisfaction from their job. Nurses still showed they shared the values of the health service.  
There was clear inconsistency between the domains which involved self evaluation i.e. 
‘motivational determinants (individual characteristics)’ and that which involved evaluation 
through diary recordings i.e. ‘worker behaviour and performance’. Most nurses, CD-PHCNs and 
NC-PHCNs felt they were hard working and “doing their job made them feel worthwhile”. They 
were also confident that they were hard working and their work was of high quality. These 
domains were however contradicted in domains assessing ‘worker behaviour and performance’, 
most of which of this information was obtained from diary recordings. The contradiction between 
these domains reflects a difference between how the nurses see themselves and how they are 
seen from the outside, in this case by the CDOP team. A domain should not contradict a domain 
to this extent, but this difference is explained by an evaluation from different perspectives and is 
a result of the triangulation of data. This reflects an advantage of using triangulation of data as 
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part of the evaluation. The one domain was evaluated by nurses themselves whereas the other 
was evaluated by the CDOP team. 
Low staff morale and quality of patient management can be closely related to workload 
(Penn-Kekana et al., 2005), and low levels of staff morale do not create an environment 
conducive to policy interventions. However, there was lack of concordance with what the nurses 
“would do” for CDOP or the clinic and with what they “were able to do” i.e. their personal 
resources which they possessed to achieve these goals (Franco et al., 2004). Compared to NC-
PHCN nurses, CD-PHCN nurses had better scores for the motivational outcome domains. The 
latter were more personally motivated to achieve the program’s goals, policy goals of the clinic 
and their managers’ goals. This may have been a contributing factor for their choosing to 
participate on the program, i.e. the results may indicate a self selection of the most motivated 
nurses, rather than that the program influenced motivation (a problem of reverse causality).  
The evaluation of the ‘intention to leave’ domain reflected high mobility of nurses; this 
was confirmed by a nearly one third reduction of PHCNs over the 2 years of the program and 
high staff turnover shown in the results. This demonstrated that the nursing staff in Soweto and 
Region B shared similar sentiments expressed by other South African nurses previously 
evaluated by a similar motivational survey (Penn-Kekana et al., 2005). In that study, it was also 
not discussed where nurses intended to go to, although it was known that some moved to local 
clinics and others overseas or to better paid local jobs. That study, like ours, demonstrated a 
need for more work to be done to better understand the reasons for nurses leaving their jobs 
and what action needs to be taken to prevent this (Penn-Kekana et al., 2005, Hongoro and 
McPake, 2003). Migration and high nursing staff turnover was a strong factor which could have 
impacted on the implementation and success of the program. A greater focus is required on the 
issue of human resources in health care, especially in relation to the increasing requirement for 
nurses to help provide the platform to support chronic illness management. 
The PHCNs in the clinics were unmotivated, frustrated and intended to leave, but equally 
disturbing, the nurses working in the clinics were also demoralised and suffering burn-out. This 
impacted not only on their commitment to provide quality care in the clinics but on their 
commitment to work on the outreach program, and might explain why those nurses who did 
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choose to participate had better motivational scores in many of the domains evaluated. Burnout, 
and particularly emotional exhaustion is strongly related to job dissatisfaction (Piko, 2006). The 
majority of nurses were still pleased that they had chosen the vocation of nursing, but this 
domain was not evaluated with the same depth as in the Penn-Kekana study (Penn-Kekana et 
al., 2005). The lack of depth to the domains in general in this study, as demonstrated by the 
factor analysis, may be another study limitation. 
The questionnaire did find nurses to be confident in their ability and the majority of 
nurses perceived themselves to be hard working. Nurses universally claimed to still have a good 
attitude towards patients and their job, and were not affected by the increased number of HIV 
patients. These findings were again found to be conflicting with those of poor worker behaviour 
and performance in the thematic analysis.  
A more complete evaluation of determinants of motivation would have been possible if all 
components of the Wagner and WHO models had been investigated i.e. the patient and 
community together with health workers. Perhaps a more inclusive study might have revealed 
patient unhappiness with the health service and their clinicians’ skills, as in other studies in 
similar environments (Gilson et al., 1994). This problem was alluded to in the ‘patient evaluation’ 
and adherence codes in the thematic analysis, but was not adequately assessed in this study. 
Amongst the questions evaluating the individual characteristics of motivation, 
dissatisfaction with pay and the exclusion of the PHC nurse clinicians of the scarce skill, 
occupations specific dispensation allowance (OSD), allowance were again highlighted. This 
exclusion from the scarce skill allowance affected staff morale and did not create an 
environment conducive for policy interventions or ‘external programs’ like CDOP.  It was both a 
blatant mistake and lack of insight on the part of government not to recognise the value of the 
PHCN, and their role that they as nurse practitioners played in South Africa. The PHCNs are 
central health care in Soweto (Health Systems Trust et al., 1999), and the ‘slap in the face’ by 
government policy was a major blow for nurses. This is especially in view of findings that the 
nurse practitioner, in our case the PHCN, has an important role in managing chronic illnesses 
(Laurant et al., 2005, Peters and Davidson, 1998, Aubert et al., 1998a, Bodenheimer et al., 
2005). This issue also emphasized  the need for managers to pay greater attention to their staff 
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when introducing reforms, new policies and programs (Penn-Kekana et al., 2005). This type of 
policy creates resentment and bad feeling in the workforce and was evident by the fact that 
nurses, during this ‘scarce skill allowance’ confrontation with management, refused to enrol and 
see patients on the outreach program. 
The knowledge demonstrated by nurses in the clinical scenario appeared to correlate 
with the nurses’ motivational score from the questionnaire. This is an area requiring further 
investigation. The PHCNs’ conscientiousness and work quality did have an impact on the 
program, as errors in the data captured by nurses required follow up and correction and missing 
baseline data affected some of the analysis. The doctors and some of the PHCNs reluctance to 
participate on the program also reflected motivational problems relating to worker behaviour and 
performance. A major problem noted was the PHCNs’ inability to find solutions to their existing 
health system challenges. This problem was coded as the ‘Bara syndrome’, reflecting apathy 
when confronted with large workloads, where health workers abandoned quality and preferred to 
offer a 'quick fix service' or nothing at all. In circumstances like those experienced in the PHC 
clinics, work quality seems to be lost when health workers are overwhelmed. This is another 
area within the clinic where action research methods may be able to play a role. Increasing 
efficiency and productivity at a clinic could be enhanced with improving and developing nurses 
‘time management’ skills and their ability to apply ‘lean thinking’ mechanisms to address health 
system problems (Young et al., 2004). It might be possible to identify better pathways to improve 
nurses’ ability to cope with patient workloads and lower staff numbers by ‘working smarter’ and 
‘eliminating waste’ in the clinic processes. Providing health workers and managers with skills to 
tackle their work challenges, by teaching them to measure or identify ‘process defects’ analyse 
these problems and make corrective changes, may be an answer for some the health system 
and motivation problems (Young et al., 2004, Kelly, 2005). It could also empower nurses and 
give them a sense of autonomy in the work place. 
Closely related to empowerment of staff were the managers’ needs to create a positive 
working environment in the clinics. Nurses were frustrated with too many changes, and they felt 
‘out of control’ with their ‘senior’ managers’ involvement in the clinic work environment, 
especially related to starting new programs and policy implementation. PHCNs perceived that 
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managers did not understand their working conditions and did not consider the effects of their 
decisions on them. This distrust of management was not unique to this study (Penn-Kekana et 
al., 2005), and managers have to be aware of clinicians when implementing new policy or 
programs (Penn-Kekana et al., 2004).   The working environment, supervision, management and 
collegial support all shaped nurses desires to participate in the program and their desire to 
improve the service. Performance is not only dependent on nurses’ skills, but also on system 
support (Franco et al., 2002). Finding better methods to manage and support staff is an area 
requiring attention.  Providing adequate resources such as medication, supplies, and equipment 
will also go a long way to improving workers motivation and better health care delivery. 
Managers need to be seen as valuing the role that PHCNs play in the health service, and seen 
to acknowledge the importance that nurses’ play in delivery of primary health care. This was not 
the case in ‘outreach’ clinics. Nurses have to be recognised as part of the solution to the 
resource challenges, and to feel that they are critical to the implementation of the health 
department policies and service delivery. The outreach program appeared to have a positive 
effect in this regard, it recognised the role that the nurses played, provided incentives to improve 
service delivery, and conducted workshops on change management. However, despite some of 
these positive aspects, it failed to be adopted or integrated by ‘senior management’. 
 
Additional Issues Arising from this Study 
Role of Specialist in the Primary Health Care 
This study raised some interesting questions about the role of the specialist in the PHC 
setting. There is a growing burden of poorly managed chronic illnesses in ‘transitional’ 
communities like Soweto (Sliwa et al., 2008, Levitt et al., 1999, Bradshaw et al., 2007). 
Specialists are seen as playing a role downstream, at the end of the process, and are supposed 
to rescue people form a long line of health system failings. This project demonstrates another 
more active role that specialists can play, by participating more actively in primary care and 
through enabling mechanisms to link primary and specialist care better. This is not at all to 
suggest that the specialist should take over the role of the primary care clinician, it merely 
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acknowledges the role and value that they can add to the PHC clinician. It is also clear that for 
patients at higher risk of complications or who may require further investigations that the 
increased role of the specialist could be both appropriate and cost effective (Fox, 1996). 
Collaboration is required when it is “necessary for the management of a particular condition” 
(Couper, 2007)(page 8). The evidence is clear that for a condition like CKD, at a particular point 
in the progression of this disease, the role of the PHC clinician is limited. The continued care by 
a PHC clinician is not in the interests of the patient, resulting in increased morbidity and mortality 
and at a greater cost to the health system (Levin, 2000, Roubicek et al., 2000). This is not to say 
that specialist cannot work well with PHC clinicians. Clearer referral guidelines, improved 
communication and decision support can improve outcomes with CKD (Lee and Forbes, 2009) , 
and this approach may be applicable to other specialty areas. The diary recordings documented 
the PHCNs calls for improved outreach from specialists, integration of CDOP methods as the 
‘standard’ method of care for the chronic illnesses and expansion of the program to other 
specialities including HIV. CDOP offered an opportunity for specialists to play a more meaningful 
role in the PHC sector, without affecting the role that they play in their ‘comfortable’ high 
technology environments.  
The role of CDOP in no way suggests that they should replace that of the PHC doctor or 
nurse practitioner. It suggests that they should rather work together as has been shown to be of 
value in a number of studies (Peters and Davidson, 1998, Aubert et al., 1998a, Bodenheimer et 
al., 2005, Nutting et al., 2007). The models proposed strongly support the role of the PHC 
clinician as the primary point of patient management, the use of nurse practitioners where 
resources may be limited and the incorporation of the specialist for decision support and 
collaboration about management. This integrated model should further improve patient care. The 
role of direct referral could also be considered in the system, especially where it can improve 
efficiency and continuity of care. However, it is not an all or nothing phenomenon, but all these 
possible systems need to be considered depending on the environment. ‘Task shifting’ is an 
example where systems were used to transfer clinical responsibility to  health workers in Ghana 
and Mozambique where resources were poor or even absent (McPake and Kwadwo, 2008). This 
may not be applicable for all countries.  
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Role of Guidelines in Chronic Care 
It arose in a number of areas of this study that the guidelines available to clinicians were 
confusing, conflicting and even overwhelming. Some of these issues have been highlighted 
earlier. Many of the guidelines are written by specialist far removed from the primary care 
setting, at meetings sponsored by pharmaceutical companies with agendas which may not 
always be supported by the best evidence. It is for these reasons that the issue of guidelines in 
general, their role and use, as well as the relationship they play in the PHC setting needs to be 
examined. Although standard treatment guidelines exist for all chronic illnesses, and it is not 
necessary to establish new management approaches at PHC level, some flexibility and 
simplification is required (Couper, 2007). There must be a balance between protocol driven care 
and the individual needs of the patient. It is here that we propose a ‘simplification’ or broadening 
of the approach. The Wagner and WHO chronic illness care models demonstrate that managing 
chronic disease requires the involvement of multiple sectors and role players. This approach is 
supported from the findings of the Australian Outreach program, which has documented that 
most people with chronic disease have more than one co-morbidity e.g. hypertension and 
diabetes or diabetes and obesity. It is this overlapping of co-morbidities which justifies an 
integrated rather than disease specific approach (Hoy et al., 2005a).  
Regional and national networks could serve as a mechanism to implement coordinated and 
simplified guidelines. Current clinical guidelines for chronic illnesses require more time than PHC 
clinicians have available (Ostbye et al., 2005), therefore streamlined guidelines and alternative 
methods of service delivery are needed to meet recommended standards for quality health care. 
Considering that similar problems were found in PHCN knowledge regarding diabetes and CKD 
knowledge, it is important to develop clear, simplified and integrated protocols which make 
decision making easier for clinicians managing chronic diseases (Figure 59). 
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Figure 59. Simplifying Management and Referral Protocols 
GFR – glomerular filtration rate measured in mls/min/m2 
Note: A simple ‘traffic light’ approach link primary and tertiary care and assist clinicians with decision 
making 
 
However, it should be noted that guideline implementation and adherence is a major 
challenge in the health sector and multiple interventions to improve guideline or protocol driven 
care are better than one single approach (Weingarten et al., 2002 , 1999). However, a more 
integrated strategy is also required to achieve our goals, especially in view of the complexity of 
protocols for different chronic illnesses, and this will also enable the PHC clinician to follow 
guidelines (Harris and Zwar, 2007a).  
 
Challenges Scaling up 
The increased burden of chronic illnesses requires programs, like CDOP to be scaled up 
to meet the challenge. Health systems in the clinics are functioning in a predominantly curative 
and ‘find it and fix it, framework. A comprehensive and integrated system is needed, such as 
systems that adopt the Wagner and WHO chronic illness methodologies.. The problems with 
scaling up these services relate more to policy and attitude than resource shortages (Schneider 
et al., 2006). This is demonstrated in the success of HIV anti-retroviral programs where 
performance and successful scale up has not related to resources (Van Damme and Kegels, 
➨ GFR >60 = Go on with patient
care in the primary care setting, be seen
less frequently and screen again laterGreen
Orange
➨ GFR <60 = Caution and continue to watch
To develop a system in the 
clinic to provide more regular 
monitoring and refer if progresses 
Or move to green group if becomes 
stable and controlled
Red
➨ GFR <30 = Red for referral 
Refer to specialist clinic to provide 
suitable medications and prepare for
dialysis
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2006). Most studies highlight the need for good policy decisions which improve health systems 
and control the scaling up according to existing resources (Victora et al., 2004). The successful 
aspects of the chronic disease outreach program like decision support, early detection of CKD 
and improved referral systems, failed to be endorsed by policy makers. This was despite the fact 
that these systems were successfully implemented in the challenging Soweto environment. 
There was however,  significant limitations to its ability to scale-up to involve more clinics in 
other regions or the province. CDOP has demonstrated that multiple factors impacted on the 
ability to implement the program in the PHC sector in Soweto. The major limitations include the 
poor existing health systems, the fact that it was ‘driven’ by a single individual or ‘champion’, and 
that it only had two nurse coordinators to drive the process in clinics serving over 40 000 
‘chronic’ patients. There is no substitute for formal health structures (Einterz, 2001), and without 
policy and funding from governments, Einterz argues, even if programs are good, they will not 
be sustained or scaled up. Sustainability and scaling up require government support. 
Chronic disease continuing care must be delivered by a well-functioning team (Epping-
Jordan, 2001), but also within a functional policy and health care organizational environment.  
These components remain as important as adequate funding. The program discussed in this 
thesis, required no specific funding to be implemented and sustained over two years, but it was 
not adequately integrated and was not scaled up to other regions. For true integration and 
scaling up, it would have to be actively incorporated into the formal health structure and have 
genuine management support and financial support. 
Certain basic fundamentals are required for program implementation, integration and 
scaling up, and many of these can be learned from programs which have worked for HIV, TB 
and malaria. The lessons learned from rolling out these programs include the importance of 
gaining political support and developing a strong and workable strategy. It also requires 
implementation of uniform and consistent strategies, and ensuring regular audit and evaluation 
of whether defined targets or outcomes have been achieved. 
 This evaluation demonstrated the importance of chronic disease surveillance, treatment 
and education as essential and major elements of primary care. It highlights the need for 
programs to be adequately funded and staffed over the long term, and that when there are 
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health care resource and staff shortages then activities perceived to be elective, such as chronic 
disease care, are the first to be abandoned (Hoy et al., 2005b). Programs like CDOP require 
good management support and staff who are well trained, well supported and fairly paid. They 
have to feel that they are highly valued and respected for the role that they play and the health 
systems need to provide a supportive and enabling environment (Von Korff et al., 2002, Hongoro 
and McPake, 2003).  
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7 CONCLUSIONS AND RECOMMENDATIONS 
This study has demonstrated that there is a high burden of kidney disease and 
cardiovascular risk factors in patients with uncontrolled DM and HTN in Soweto and its referral 
clinics. Chronic kidney disease satisfies the criteria as a public health issue in that it possible to 
act on the condition at both community and public health levels, thus making a strong case for its 
recognition as part of the continuum of chronic illnesses alongside CVD. It has also shown that 
factors like obesity, dyslipidaemia, and proteinuria are more prevalent than previously 
considered in the community, and that these risk factors remain poorly controlled. There is also 
very poor control of chronic illness risk factors in the primary health care sector with 
improvements when referred to a specialist. It was also demonstrated in this study that many 
patients in the PHC clinics already had advanced CKD and some with ESRD. The majority of 
these did not qualify for dialysis. However, the program only screened a very small number of 
people who are at risk and for those referred, it was often too late. This project was an attempt to 
ensure that CKD is recognised as a more serious public health problem amongst the other 
existing chronic diseases. It is not an attempt to make kidney disease the most important chronic 
disease but rather that it is included in an integrated approach to manage chronic illnesses in the 
PHC setting. Secondary prevention strategies focusing on an individual high-risk approach in 
developing countries could prevent many deaths, but there is a cost and infrastructure 
requirement which needs to be considered. This might involve opportunistic screening and 
treatment with a multi-drug regimen in people with CVD or CKD. 
Additional public health efforts to address CKD are needed, and an effort needs to be 
made to integrate CKD monitoring, education and awareness into the existing structures used to 
manage chronic illnesses like DM, HTN and HIV where the greatest burden of CKD is found 
(Dirks et al., 2006). Unfortunately, the extent to which we have applied this knowledge remains 
disappointing (Zoccali, 2006). Specialists are obsessed with technology and ‘machines that go 
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ping’9, whereas simpler approaches using existing resources but improving health system 
function will have a greater impact than the development of new technology or machines. A 
comprehensive integrated public health system approach is required to effectively address this 
issue.  People with chronic illnesses often present when the disease is advanced. An integrated 
health care system, involving all ‘structures’ including prevention and treatment components, is 
particularly appropriate for the ongoing care of any chronic illnesses, whether tuberculosis, DM 
or HIV (Epping-Jordan, 2005). Prevention strategies would include focusing on those at highest 
risk for disease and utilising a mass strategy of prevention and management to shift the whole 
population distribution of that risk variable (Rose, 1981). However, many questions have yet to 
be answered with regard to health systems and chronic illnesses, such as ensuring the 
availability of low-cost generic drugs for people at high risk of CVD or CKD and ensuring their 
uptake and long-term use without financial burden. Other questions include the identification of 
people at high risk in primary health-care settings and appropriate referral. A simple set of 
indicators for monitoring progress in implementing strategies to manage chronic conditions is 
also needed. Here good information systems play an important  role (Beaglehole et al., 2007). In 
relation to this, there is a strong argument by Couper (2007) that the PHC facility or family 
practice should be better structured to tackle the management of chronic diseases. A framework 
of principles which could inform the future models and health systems for chronic illness 
management has been proposed. If these are implemented with the incorporation of the 
experience of managing HIV, TB and malaria and scaling up such programs, then it may be 
possible to improve quality of patient care and the effectiveness of our health service.  
The implementation of programs like CDOP using chronic illness management models 
like the Wagner and WHO models, offer a potential template and solution for improving the 
standard of care. The relevance of chronic communicable illnesses like HIV/AIDS, tuberculosis 
and malaria, for diseases like CKD, heart disease and asthma, have not yet been fully 
recognised. No attempts have been made to link these two challenges using an integrated 
                                               
 
 
 
9
 Quote from Monty Python’s ‘The Meaning of Life”: Part I, The Miracle of Birth, Written: Graham Chapman, John 
Cleese, Terry Gilliam, Terry Jones, Eric Idle and Michael Palin. A Methuen paperback Humour, ISBN 0413533808 
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response.  Furthermore, chronic diseases which are the major cause of adult illness and death 
in all regions of the world have not been included within the global Millennium Development Goal 
(MDG) targets. Publications on health and the MDGs have recognised this oversight. There is 
scope for considering chronic diseases within existing MDGs, such as Goal 6 incorporating 
HIV/AIDS, malaria and other diseases. Alternatively they could be considered more broadly in 
Goal 1, which aims to eradicate extreme poverty and hunger. This acknowledges that chronic 
illness prevention would contribute towards poverty reduction worldwide (World Health 
Organization, 2005a). It remains important that chronic diseases be included in WHO and 
government programs. 
It is important to link both disease management and prevention. However, the concept 
and understanding of prevention is constantly changing and possibly being distorted. With the 
emergence of risk factors and diseases to be considered as the same entity, we now need to 
critically evaluate what is meant by prevention (Starfield et al., 2008). It has also been suggested 
that we shift the focus on the ‘population’ as a whole rather than the individual with CVD risk 
factors. This needs to be considered when initiating screening and ‘prevention’ programs. 
Furthermore, Starfield (2008) has suggested that population-attributable risk should be the 
priority over individual (relative) risk, and the focus should be on defined populations with strong 
evidence to support an intervention. Interventions should be shown to be cost effective and 
reduce morbidity and not just the ‘disease’. Integrating the therapeutic and prevention roles has 
improved care for obstetricians and paediatricians (Rose, 1981). This has also occurred with HIV 
where integrating treatment and prevention has been shown to have a greater impact on 
outcome (Salomon et al., 2005). Success has been achieved in Australia and the United States 
from the late 1970s where this focus resulted in the reduction of mortality from coronary disease 
(Rose, 1981, Lenfant, 2003). For coronary disease, although both primary and secondary 
prevention and treatment components are necessary to maximise health care, the greatest 
benefit is seen with primary prevention (Unal et al., 2005). This may also be true for other 
chronic diseases.  Essentially, strategies should focus on primary prevention, particularly 
tobacco control and healthier diets and interventions which have a clear population benefit.  
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CDOP and the Soweto Chronic Disease Health System  
In South Africa, chronic disease systems for managing HTN, DM and TB are well 
established, although those for HIV/AIDS are better funded and receive more attention for 
political and emotional reasons. The health system in South Africa requires significant 
strengthening given the epidemics both of non-communicable chronic disease and HIV. 
Research and evaluation of health systems has taken place in developing countries (Joint 
Learning Initiative, 2003, Sanders et al., 2005), and especially with regard to HIV (McCoy et al., 
2005, Schneider et al., 2006) but also non-communicable chronic illnesses (Abegunde et al., 
2007, Epping-Jordan, 2005). Tollman et al. (2008) have warned that PHC systems managing 
chronic diseases like DM, HTN and HIV, need to be strengthened, integrated and scaled up to 
address the growing problem. .      
This thesis examined the integration of an Outreach Program into the PHC clinics for 
improving HTN and DM management and to improve links between the PHC and hospital 
sectors. Despite many of the program’s failures, it achieved some successes, and may 
contribute to the development of future frameworks to tackle many of the chronic illness 
challenges. The data measured at baseline successfully characterized a group of patients with 
hypertension and diabetes in the primary health care clinics in the Soweto region. It 
demonstrated the baseline control of these diseases and their risk factors, and the prescribing 
characteristics of the primary care clinicians. The program proved successful in supporting 
primary health care nurses (PHCNs) working in the clinics which participated in the program. It 
was effectively implemented, but was poorly integrated into the existing chronic clinic system, 
although it did offer an alternative pathway for patient management. There was a perception and 
evidence from the better clinical management scores amongst nurses participating in the 
program that it improved awareness of appropriate referral and efficiency for referral to a 
specialist. The PHCNS indicated that the program did add ‘value’ to the nurse’s clinical practice. 
It assisted PHCN clinicians in their management of patients with chronic illnesses through the 
systems of decision support and patient referral. Certain clinics showed excellent initiatives in 
team work and integration, but this reflected local ‘drivers’ or ‘champions’ and not clinic 
managers. A success of the program was its ability to detect those patients with advanced 
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disease and ensure early referral in the majority of cases. Those referred demonstrated 
improved risk factor control and monitoring at the specialist referral clinic. The program also had 
a positive effect on the existing PHCNs knowledge and motivation, which was most significantly 
demonstrated in those nurses who actively participated on the program. The nurses improved 
knowledge was reflected in their ability to manage chronic disease problems, scoring better in 
the clinical scenarios. There was also evidence of better motivation in those nurses volunteering 
to participate on the program, and this may have related to their improved knowledge. The 
success and failures of the program related to both ‘internal’ CDOP factors and to factors 
‘external’ to CDOP. The program did function, and those PHCN participating did well, although it 
should be noted that this was with a great deal of assistance from the dedicated CDOP nurse 
coordinators. On the basis of the evidence outlined above, this program was not fully integrated 
into the existing clinic system, although it did add value and show certain benefits. 
Many system factors negatively impacted on our ability to implement the program and 
affected its success. Most of the problems related to the poor existing health systems and 
infrastructure. There was poor and inadequate integration into the chronic illness clinics in 
general. Despite an expressed desire by both management and nurses to integrate and scale up 
the program, this was not achieved. It must be noted that only a very small group of patients 
showed improvement and therefore the program would need substantial improvements before it 
can be scaled up and have significant impact.  
Management approved the program and verbally supported it, but did not actively adopt 
it or integrate it into the existing clinic systems. Some of the problems related to poor 
communication between regional, provincial and local clinic managers. The clinicians also were 
not actively consulted on the implementation of new policy and programs. An evaluation of the 
nurses revealed an overworked, poorly supported, frustrated and burnt-out primary health care 
team. These factors resulted in a high turnover of clinic staff. This, together with patient load, 
severely impacted on the ability of the outreach program to enrol and follow up patients, 
integrate into the chronic clinics, and extend it.  Although the PHCNs and nurse program 
coordinators correctly enrolled ‘high risk’ hypertension and diabetes patients’, a major 
shortcoming was that the cohort was not successfully followed.  
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Existing acute and chronic illness services in the clinics are run as vertical services and 
not in an integrated manner. The clinic does not function as a single primary health care unit, as 
would be the case for a private family or general practice. CDOP was also implemented as a 
vertical program and this together with the other ‘vertical’ services and programs that are taking 
place in the clinics resulted in competing demands on the nurses. This impacted on the 
implementation of CDOP. This was a criticism and weakness of the ‘Outreach Program’ and it 
must be noted that a major limitation of the program was the vertical implementation strategy 
which was adopted. It could be argued that the program was an ‘integrating activity’, as the aims 
were for nurses to recognise the commonality of the risk factors (HTN, DM, obesity, 
dyslipidaemia, proteinuria etc.) in relation to CVD and CKD. The implementation strategy 
adopted directly affected the programs’ ability to enrol patients with HIV and possible kidney 
disease. Staff shortages often meant that nurses moved between clinics and programs, and this 
placed an increased demand on these nurses who were unskilled in managing these diseases 
and hampered continuity of patient care. There was a particular problem with nurses’ knowledge 
and ability to recognise the importance of quality care. This was evidenced in their inability to 
manage diabetes, and almost a complete absence of knowledge with regard to kidney disease 
at the outset. Nurses lacked the skills, knowledge and commitment to measure HbA1c levels, 
initiate insulin, measure proteinuria or albuminuria or calculate an estimated GFR. When nurses 
were assigned to work in a ‘specialised clinic’, they were not given the authority or support to 
use all medications. This, together with complicated management protocols, resulted in nurses 
lacking confidence and feeling like ‘second class citizens’ in the health care team. This is despite 
the fact that they are often the only clinicians available to deal with the problems, as not all 
clinics have doctors. It highlights the need to have ‘a positive policy’ environment to ensure the 
goals of the organization are achieved. This also highlights the need for managers to develop 
and allocate their human resources appropriately, as without a well functioning motivated health 
care team, no care can be provided. 
Elements of the Wagner and WHO chronic care models were applied in the clinic health 
care system with CDOP and the program demonstrated that it could provide some of the 
systems and framework to better manage chronic illnesses. What it lacked was the ability to 
 248 
 
implement the models in their entirety and the resources to implement and expand the outreach 
program. This is where some of the principles of Couper (2008), for managing chronic illness at 
a facility and individual level may have been of assistance. Additional models or tools are 
required to establish chronic illness programs in the PHC setting which will draw on past 
experience of programs established for HIV, TB and malaria. This will include better 
identification and management of treatable risk factors, improved screening for common non-
communicable diseases, and the diagnoses, treatment, and follow-up of patients. PHC clinicians 
also need to know when it is necessary refer patients with common standard and simplified 
protocols. 
PHCNs overwhelmingly felt the program had added some value and helped them with 
patient management. There were also numerous limitations, many of which have been 
discussed and are summarized in Table 26. It was effective in determining those patients who 
had advanced disease and who needed referral. It effectively assisted PHCNs with management 
decisions, referral and improving some knowledge about chronic illnesses, but this was in a very 
limited population.  One of the most positive features detected amongst the primary care 
clinicians was that, despite all their personal and work challenges, they remained motivated to 
deliver a better service. What is required is that management develop policy and implement an 
enabling environment to take advantage of this enthusiasm 
This study was an attempt to introduce a program for the management of chronic diseases 
(diabetes, hypertension and chronic kidney disease) in a very difficult environment. Its originality 
lies in the detailed investigation of the working conditions and potential contributions of the 
primary health care workers. Its emphasises the many system problems that face health 
services for ‘transitional societies’ in situations of continuing poverty but is unable to evaluate 
them all in great depth. 
 
Program Strengths and Limitations 
The main value of observational studies like the chronic disease outreach program is its 
effectiveness to provide care for chronic conditions in a realistic situation, instead of in trial 
conditions. Standardising qualitative research is more complex as validity depends on the quality 
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of data and the ability to control for bias and confounding factors. However, this study did have 
limitations.  
The thesis described the CDOP management of high risk CVD/CKD patients with DM 
and HTN, which is potentially more cost effective than usual clinical practice in such an 
environment.  This thesis describes the baseline risk and control of patients with DM, HTN and 
its consequences which included CKD and CVD. The factors affecting good HTN and DM 
control in the clinics were evaluated, as recorded in diary accounts and an administered 
questionnaire. The CPOD served as an effective link between primary and tertiary health care 
systems and provided both clinical and educational support for PHCNs. The ‘program,’ together 
with the PHCNs, proved to be a successful mechanism for detecting and referring high risk 
patients, despite the loss of some patients during the referral process. It documented health 
system weaknesses, including challenges in retaining, supporting and educating PHC clinicians. 
A very important component was the improvement of clinical knowledge and better motivation 
amongst PHC nurses participating in the program.  
The program cohort was small relative to the disease burden, and scaling up such efforts 
will require significant resources. A high number of patients were lost from baseline, and the 
sample was relatively small. This fact did affect the programs ability to compare groups and was 
another study limitation. This together with CDOP’s inability to follow patients successfully, 
meant that I was unable determine the overall morbidity and mortality. This also limited the 
study’s potential to evaluate its impact on clinical outcomes. In addition, we relied on estimated 
GFR equations, which have their limitations; this approach may over diagnose CKD, although 
this is less important in a high risk cohort. Not all patients enrolled had testing carried out and 
estimating kidney function by eGFR was based on single serum creatinine measurements. The 
eGFR equation had not been standardised to this population.Participants were chosen randomly 
by PHCNs, but it is possible that choice of enrolment was influenced by PHCNs. It should be 
noted that detecting advanced disease such as ESRD does not necessarily mean treatment 
access, and issues like these need to be addressed in the future. 
Other limitations included that managers, doctors and some nurses were resistant to 
program integration. CDOP should have invested more time and effort to incorporate all PHC 
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clinicians and managers before and during the process of implementation. The fact that these 
groups of health workers were not questioned more comprehensively, and that these groups 
were not included in the evaluation is a limitation of this study. This problem was affected by the 
large work load, patient numbers and competing demands which exists for PHC clinicians and 
for the researchers. Due to time and resource constraints, it was not feasible to implement or 
investigate all components of the Wagner and WHO chronic illness models. This resulted in an 
inability to adequately evaluate these frameworks for chronic illness management and there was 
only a small focus on the community, patient factors and administrative managerial factors which 
impacted on chronic disease management and the program implementation. Failure to 
investigate these groups more comprehensively and how they impacted on patient outcomes 
and the outreach programs ability to improve health system and adherence factors was a 
weakness of this study. It should also be noted the interpretation of these factors which impacted 
on the program and chronic disease management was that of the nurses or program managers, 
and this is a flaw in this evaluation. The evaluation of the ‘health care team’ was also limited in 
this study and was really an evaluation of primary care nurses.  
The program did have some impact on outcomes, but again this was in a very small 
number of patients, and only in those followed up at the specialist clinic. Patients with advanced 
disease were detected, but this is only a very small number of patients at risk amongst the thirty 
to forty thousand patients with HTN and DM in Soweto. In this small group of patients in which 
clinical risk factors were improved, it should be noted that another major limitation was the lack 
of effectiveness on weight control. Although a limitation, it also reflects the complexity of 
managing chronic illnesses in particular obesity. 
 In relation to the health workers knowledge and motivational survey, the lack of depth to 
the motivational outcome and motivation determinant domains in this study, as demonstrated by 
the factor analysis, reflects another limitation. 
The fact that the program was also implemented in a vertical manner, and did not include 
all chronic illnesses under a single banner, proved to be a limitation. HIV, HTN, DM, chronic 
obstructive airway disease, asthma and epilepsy account for more than 90% of chronic illnesses 
at PHC clinics. There is a strong argument for integrating these illnesses into one stream of 
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care.  This weakness could be attributed to the way the program was implemented and the 
failure of all management structures to support the initiative. The outreach program was also due 
to only a small number of dedicated program staff, funding, and staff limitations in the PHC 
sector in Soweto.  
Due to poor patient follow up, the impact on morbidity and mortality could not be 
determined and the approach to this program may have been too broad. It may have been better 
to focus this ‘pilot’ program in a smaller number (or even a single clinic) with full support from 
management and where an integrated program for chronic disease control could have been 
comprehensively studied..  
Policy factors, poor leadership and advocacy from provincial government managers, 
inconsistent funding and poor allocation of human resources at the PHC clinics may also have 
impacted on the program.  
 
Recommendations 
There is no integrated electronic medical record system in Soweto, and none linking the 
PHC, secondary and tertiary hospital settings. This significantly impacted on the Outreach 
Program’s ability to monitor and track patients. The implementation of such a system should be 
a priority. It would ensure continuity of care, improve cost effectiveness and efficiency and assist 
with clinical audits. Implementation policies and clinical protocols need to be developed in 
partnership with clinicians working ‘on the ground’, including specialist services, and should not 
be instituted in a ‘top down fashion. For example, such systems could immediately ensure the 
provision of anti-lipid agents to patients at high risk in the PHC clinics and develop methods to 
‘refer up’ and ‘refer down’ to and from primary care clinics. The present emphasis is on ‘quantity 
of care’ and not quality of care in the Soweto clinics. There is a great pressure on politicians and 
managers in South Africa to demonstrate that they are delivering health care to all communities. 
There needs to be a greater emphasis placed on health care managers and clinicians to place a 
greater focus on the delivery of quality care and not ‘quantity care’. The measurement of health 
outcomes is critical. This relates to the need for better systems of audit and research. 
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Currently there is only verbal support for better research and audit but this has not been 
actively funded, and no specific resources have been allocated to these challenges. 
Despite the availability of guidelines to address problems of obesity, diabetes and 
hypertension related to lifestyle, there is very little practical ‘action’. It is clear that more active 
and innovative approaches are required which could include incentive driven weight loss 
programs and the establishment of exercise programs at clinics and in departments managing 
chronic diseases e.g. diabetes and hypertension clinics.  
Guidelines and protocols of management provide an effective means to achieve disease 
control and these should be followed for improved management of chronic illnesses. There was 
evidence in this study that guidelines are not being used or are not known to practitioners. There 
is a need to simplify and integrate these protocols for patient management.  
The management of chronic illnesses requires political will to provide a comprehensive 
health system, which includes strengthening the health system through developing strong 
leadership in each PHC facility, resource mobilisation and allocation, policy development and 
implementation. PHC clinicians need to detect and manage those patients with chronic illnesses, 
and refer them on to specialist if the protocols support such referral. Primary health care nurses 
require more support, confidence and reassurance where their management has shown to be 
more efficient and effective.  
The balance between the individual patient care and general population requirements needs 
to be addressed in such systems. Interventions have to focus on population outcomes and not 
always on individual outcomes. Protocols should also be adapted and validated for particular 
settings and populations. Recognizing the existing health system deficiencies in the Soweto 
health region, early detection and management programs should focus more on regular 
comprehensive clinic screening with the aim of detecting patients needing referral and more 
intensive monitoring. This change of emphasis recognizes that current clinic systems in Soweto 
cannot cope with intensive follow up. The results of this study suggest that long term cohort 
follow up should be considered very carefully in the current PHC environment, or at least until 
systems for long term follow up are strengthened. Grant funded cohort follow up remains the 
most likely successful method which can be utilised until health systems are strengthened. 
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In the immediate future, the focus should be placed on regular screening and detection of 
complicated illness rather than intensive follow up. It is also suggested that strategies as 
provided for in figure 59 are used to assist with follow up, by categorising patients according to 
priority. Improved follow up will also be achieved when electronic clinical data is available for 
clinicians and clinical notes become more reliable. These initiatives are generally referred to as 
the strengthening of the health system. 
The limited capacity of the health organization and health systems needs to be taken into 
account. In this regard the interaction and roles of the PHCN or nurse practitioners and doctor 
needs to be clarified. Doctors are needed to support nurse practitioners but the boundaries and 
protocols of interaction need to be clarified.  In this regard there is also a role for the specialist in 
the primary health care sector, and the nature of this role requires further debate and 
investigation. 
Clinical processes have to be supported by the regular and constant supply of medication.  
The regular interruption of treatment as a result of erratic availability of medication leads to poor 
quality care, increased morbidity and a reduction in adherence. The current pharmacy support 
and capacity needs to be strengthened in the primary care setting e.g. private public 
partnerships for medication supply should or could be considered. 
The study indicates that clinicians are not well informed regarding chronic kidney disease 
(CKD). There needs to be a greater emphasis on CKD as part of the chronic disease continuum, 
and more education for the patient/public and health professional on its diagnosis and 
management. Linked to the efforts to highlight CKD is the need, to integrate management of all 
chronic illnesses into a single clinic or ‘stream’ at the primary health care level.  All clinicians in 
the PHC team need to work as part of a single unit, managing chronic illnesses together. Sub-
specialising to develop the skills required for a particular disease e.g. HIV or CKD, should occur 
within this team, so that programs for chronic diseases are integrated horizontally into PHC 
family and community practices and not vertically. . 
In health systems, like in Soweto, where nurses manage most chronic diseases, some need 
to develop ‘specialist’ skills within the team e.g. CKD or HIV. Not all nurses will have the 
knowledge or inclination to specialise in a particular disease, but sub-specialisation will serve to 
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motivate clinicians to develop and focus on developing unique skills for the PHC team. These 
PHCN, could develop as specialist PHC clinicians within the team, and provide a link up with 
specialists’ up-stream in the health system. 
As part of the strengthening of ties between PHC and specialist care, there needs to be a 
development of coordinated ‘outreach programs’ involving all specialties which manage chronic 
illnesses. Hospital specialists need to assist the PHC team and their ‘PHC clinician sub-
specialists’ or chronic disease ‘program nurse coordinators’. These coordinators will provide the 
link between primary and tertiary care e.g. HIV, diabetes, hypertension, CKD, asthma, epilepsy, 
and TB. 
It was evident in this evaluation, that basic skills such as capturing demographic or audit 
information, weighing, measuring blood pressure, blood glucose and urine testing was being 
carried out by highly skilled clinicians such as professional nurses. Managers in PHC facilities, 
regional and provincial offices need to focus on improving team work. This would include utilizing 
non professional nursing staff, or trained community health workers to do non-specialized tasks 
e.g. weighing and blood pressure measurement, recording demographic and data capture.  
The evidence of high turnover of doctors and nursing staff in clinics and hospitals is an 
indication of a serious human resource problem within this health care environment. Managers 
are needed who can take responsibility for providing an organizational environment which 
motivates health workers to achieve the goals of their organization. This would involve the 
acknowledgement and importance of health workers and especially primary health care nurses 
in the PHC system. Improving staff commitment might be achieved by creating incentives, 
providing change management and by developing and training health workers to improve 
motivation and skills to deliver on organization goals i.e. investment in staff by developing skills 
and providing training. As part of the motivation of health workers, managers need to provide 
and ensure the constant supply of appropriate equipment and medication. They also need to 
take a greater interest in the health workers environment, looking at ways to improve efficiency 
and quality of health care.  
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Both this study and other have demonstrated the high turnover and migration of nurses from 
public health facilities. Further investigation is required to better understand the reasons for 
nurse’s ‘migration’ from their jobs and what action needs to be taken to prevent this problem.  
It was demonstrated, in this study, that despite nurses feeling unmotivated and feeling ‘burnt 
out’, they were still willing and wanted to deliver good health care and achieve their 
organizational goals.  It needs to be recognised that health workers in the clinics do not want to 
fail and are enthusiastic to do their job well. Therefore, managers need to take advantage of 
nurse’s pride in their work and capitalise on this situation. This could be achieved by 
acknowledging their important role and providing continuing education and incentives to deliver 
better care. 
Professional bodies and government health departments also need to develop policies which 
empower and authorise nurses to provide the appropriate level of care, e.g. initiating DM insulin 
or scaling up HTN medications and dosages. This empowerment should include appropriate 
skills development and therefore greater effort needs to be placed on continuing medical 
education. 
The loss of motivation amongst health workers is further exacerbated by the failure to 
provide a ‘scarce skills allowance’ in the form of the occupations specific dispensation’ (OSD).  
This issue also resulted in many PHCNs protesting and refusing to work. There was evidence of 
poor staff motivation and burn out in the motivation survey.  This is a serious problem that needs 
to be urgently addressed. 
 The Wagner and WHO chronic illness care models are well researched models and have 
been adopted as a framework for managing chronic illnesses. There was evidence in this study 
that at least some components of these models may be of value in the management of chronic 
illnesses in Soweto. The application in the clinical environment was demonstrated by using 
components of decision support, delivery system design with direct referral and the supply of 
audit information had a direct impact on PHC clinical environment. These types of applications of 
these models were relevant to the individual clinician. In order to see improvement of the health 
system managing chronic illnesses, other chronic illness frameworks or at least some 
components of the Wagner and WHO models should be supported and implemented. 
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This study showed a distinct problem between the communication of regional health 
managers and PHC clinicians. The communication of health policies is an important component 
of health care delivery. Managers and clinic coordinators need to make an effort to improve 
communication between the different levels of care in the health system and also within levels of 
health care. This could be achieved by improving health information systems and providing 
computer literacy skills to all members of the health care i.e. managers and clinicians. The use 
of email would be a simple, accessible method to improve communication. 
Although it was demonstrated that local regions like Soweto, lack the resources and skills to 
follow up patients over long periods, it was also clear that there is inadequate information about 
kidney disease in South Africa. National epidemiological screening programs to determine the 
burden of chronic kidney disease and other chronic illnesses are necessary to determine the 
true chronic disease burden and especially the extent of CKD in the country.  
A limitation of this study was its focus on the ‘health care team’, and more specifically on 
primary health care nurses, and not the patient and their community. It was found that very little 
emphasis and focus is occurring on the community and patient. There is currently a good 
‘support group’ system for diabetes and hypertension, but more effort and research needs to be 
developed to improve existing systems which utilise health promoters and support groups in the 
Soweto clinics. In keeping with this focus more studies are needed to focus on the community 
and patient factors described in the Wagner and WHO chronic care models, but also on ‘task 
shifting’ (McPake and Kwadwo, 2008), where tasks in health-system delivery for chronic 
conditions, are shifted to the least costly health worker capable of doing that task reliably. 
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